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Abstract

THE ROLE OF MATRIX METALLOPROTEINASE 9 AND OSTEOPONTIN IN
SYNAPTOGENESIS AND REINNERVATION OF THE OLFACTORY BULB
FOLLOWING BRAIN INJURY
By Melissa Ashley Powell, B.S.
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of
Philosophy at Virginia Commonwealth University.
Virginia Commonwealth University, 2016
Major Director: Linda L. Phillips, Ph.D.
Professor, Department of Anatomy and Neurobiology

Traumatic brain injury (TBI) is a serious health concern, causing cognitive, motor, and sensory
deficits, including olfactory dysfunction. This dissertation explores the effects of TBI on
synaptic plasticity within the olfactory system, seeking to define mechanisms guiding postinjury
sensory reinnervation. Physical forces induced by TBI can axotomize olfactory receptor neurons
(ORNs), which innervate olfactory bulb (OB). These axons regenerate OB projections after
injury, a process involving growth through a complex extracellular matrix (ECM). As such, we
investigated a potential molecular mechanism capable of modifying local OB ECM to support
postinjury synaptogenesis. Since matrix metalloproteinases (MMPs) and their ECM substrates
are recognized for TBI therapeutic potential, we explored the role of MMP9 and its substrate
osteopontin (OPN) in promoting ORN reinnervation of the OB after mild fluid percussion injury
(FPI). First, we confirmed that FPI deafferented the mouse OB. In Chapter 2, we showed
concurrent activation of neuroglia, elevated spectrin proteolysis and reduction in ORN-specific

xv

olfactory marker protein (OMP). As OMP normalized during regeneration, growth associated
protein-43kD (GAP-43) peaked, marking OB entry of ORN growth cones. Ultrastructural
analysis revealed ongoing ORN axon shrinkage and degeneration, glial phagocytosis of cellular
debris, and a reorganization of synaptic structure. To explore ECM role in mediating postinjury
OB reinnervation, we defined the time course of MMP9 activity and several downstream targets.
Chapter 3 reports biphasic MMP9 activity increase during acute/subacute degeneration,
accompanied by robust generation of 48kD OPN cell signaling peptide. OPN receptor CD44
also increased during the acute/subacute interval, suggesting potential interaction of the two
proteins. Finally, we utilized MMP9 knockout (MMP9KO) mice to confirm MMP9 role in OB
synaptogenesis. In Chapter 4, MMP9KO reversed FPI-induced lysis of 49kD OPN and altered
postinjury expression of ORN axon degeneration marker OMP. Additional ultrastructural
analysis verified delayed recovery of OB synaptic features within the injured MMP9KO.
Overall, we demonstrated that mild FPI elicits ORN axotomy to induce OB reactive
synaptogenesis, and that MMP9 supports reinnervation by processing OPN for activation of local
glia, cells which reorganize the ECM for synapse regeneration.
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CHAPTER 1

INTRODUCTION

1

TRAUMATIC BRAIN INJURY
Impact, Epidemiology, and Classification
Traumatic brain injury (TBI), one of the leading causes of death and disability in children and
adults (Faul et al., 2010), remains a serious public health concern throughout the world. An
average of 200 of every 100,000 people acquire a TBI (Bryan-Hancock and Harrison, 2010),
amounting to over 1.7 million people each year in the United States alone (Faul et al., 2010).
Falls are the most common cause of TBI, followed by motor vehicle accidents, and other blunt
force traumas such as those involving sports or military combat (Langlois et al., 2006).
Although people of any age, gender, or ethnic background may acquire a head injury, some
populations, such as young children 0-4 years of age, adolescents, and older seniors over 75, are
much more susceptible due to the high probability of toddlers and the elderly falling, and young
adults exhibiting reckless behavior. The complexities of head trauma can produce both acute
and chronic effects, with some injuries causing minimal or no loss of consciousness, while others
require long-term rehabilitation (Hyder et al., 2007; Asikainen et al., 1998; Faul et al., 2016;
Weightman et al., 2010). Roughly 52,000 patients with TBI in the United States die each year,
while over 275,000 are hospitalized, and 1.3 million require emergency room visits (RutlandBrown et al., 2006). In addition to the costs of hospitalizations, extensive psychological and
physical therapy coupled with loss of productivity results in annual direct costs over $60 billion
dollars (Langlois et al., 2006; Finkelstein et al., 2006; Rutland-Brown et al., 2006). Estimates for
indirect social and economic costs such as reduced quality of life are much higher, surpassing
$220 billion (Coronado et al., 2012). The emotional, physical, and financial burdens of TBI
demonstrate the need for effective intervention.
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TBI is defined as any mechanical force resulting in temporary or permanent, focal or diffuse,
brain damage after trauma (Silver et al., 2005), including blunt force trauma, penetrating injuries,
and coup-contre-coup (rotational) forces. Historically, TBI has been classified as mild,
moderate, or severe, based on a clinical guide, the Glasgow Coma Scale (GCS). Clinicians
assess patient brain function using the three part scale, divided into functions of eye opening,
verbalization, and motor responses to stimuli. Summation of these scores dictates TBI
classification: mild between 13-15, moderate 9-12, and severe 8 and below (Teasdale and
Jennett, 1974; Teasdale and Jennett, 1976). In addition to the GCS, post-traumatic amnesia
(PTA) and loss of consciousness (LOC) can also be used as measures of injury severity. If PTA
persists for less than a day, the injury is considered mild, while 1 to 7 days is a moderate level
injury, and more than 7 days of amnesia represents a severe TBI. LOC can also represent injury
severity, as patients with mild TBIs exhibit 0-30 minutes of LOC, those with moderate level
injuries experience 30 minutes to 24 hours of LOC, and the most severe cases lose consciousness
for more than a day. Despite these classifications, which are utilized to improve approach to
treating TBI patients, head trauma remains a devastating injury.

In addition to the 1.7 million reported cases, a much larger population is also afflicted by mild
TBIs, such as a concussions, yet often these are not reported, leaving an unknown number of
patients with progressive TBI consequences (Goldstein, 1990; Coburn, 1992), which can involve
memory loss, changes in cognition, movement disorders, and sensory deficits. Although severe
TBIs often result in death and moderate head trauma produces overt, devastating effects, mild
TBI has recently gained increased public recognition for the chronic, delayed problematic
functional deficits, especially in specific populations. Recent studies have focused on the impact
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of TBIs on military combat troops and sports players (Pellman et al., 2006; Phillips and
Woessner, 2015), implicating TBI in prolonged post-traumatic stress disorder (PTSD)
(Benedictus et al., 2010; Greenwald et al., 2012), the development of chronic traumatic
encephalopathy (CTE) (Goldstein et al., 2012; Saulle and Greenwald, 2012; McKee et al., 2009),
and increased risk for neurological diseases later in life, such as epilepsy (Annegers et al., 1998;
Ferguson et al., 2010; Frey, 2003), Parkinson’s (Bower et al., 2003; Goldman et al., 2006) and
Alzheimer’s (Mortimer et al., 1985; Fleminger et al., 2003; Sivanandam and Thakur, 2012)
diseases. Because soldiers can be exposed to multiple blast waves in one or more tours of duty
and dedicated sports players often obtain more than one TBI attributed to prolonged game time,
the additive effect of repetitive TBIs is also being explored as a contributing factor to the
pathologies associated with injury (Goldstein et al., 2012; Saulle and Greenwald, 2012; McKee
et al., 2009). Despite knowledge of the incidence of TBI and classifications that relay degree of
injury, which do assist in helping clinicians with initial approaches for treatment, outcomes for
TBI remain poor due to complexity and heterogeneity of injuries and the low sensitivity and
specificity of the GCS. Fortunately, clinicians and research scientists are exploring the
underlying mechanisms of TBI in order to more effectively address trauma-induced pathologies
in a targeted manner.

Pathophysiology
Whether a TBI produces focal or diffuse damage, or a combination of the two, several
physiological mechanisms are initiated and lead to the functional deficits that persist in patients.
Initial primary injury is the result of a mechanical force applied to the brain in the form of a
striking blow, penetrating object, or rapid acceleration and deceleration of the brain that can
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involve skull fracture, contusion, and hemorrhage (Maas et al., 2007), directly affecting axons,
causing brain damage (Werner and Engelhard, 2007). In mild TBIs, a prevailing mechanism of
injury is rapid acceleration and deceleration, or coup contre-coup forces. This term represents
the directional movement of the brain when the head strikes an immobile object. Momentum of
the brain causes it to impact the skull (coup), the resulting force of which propels the brain to the
side of the cranium opposite the initial blow (contre-coup; Allen, 1896; Goggio, 1941). Despite
degree of TBI, forces inflicted upon injury can stretch, crush, and sever axons throughout the
brain, which immediately compounds signal transduction. When these damaged neurons, which
function as part of larger synaptic circuits, become dysfunctional, the consequences can be
devastating. Additionally, the mechanical loading of primary injury impacts the entire
neurovascular unit, comprised of neurons, blood vessels, and supportive glia, thus leading to
disruption of the blood-brain barrier (BBB), overt vascular injuries, or hemorrhage (Davis,
2000), and increased intracranial pressure (Miller et al., 1977; Treggiari et al., 2007), all of
which contribute to poorer outcomes.

Secondary injury or insult involves downstream effects of primary injury such as reactive
oxygen species (ROS), axonal injury, neurotransmitter (NT) release, inflammation, with cytokine
and chemokine production, and ionic dysregulation (Werner and Engelhard, 2007). These can
collectively and progressively cause the significant chronic problems associated with TBI.
Although mechanical force plays a role in facilitating TBI-induced brain damage, the subsequent
abnormalities are often attributed to secondary injury molecular mechanisms. For example, one
of the most common pathologies associated with TBI is diffuse axonal injury (DAI), which can
result from direct force causing axon damage or in response to cellular ionic imbalances.

5

Secondary processes can cause more extensive physiological damage than primary insult by
several mechanisms, which include but are not limited to persistent inflammatory responses
maintained by neuroexcitation, reactive glia, axonal injury, and aberrant synaptic plasticity, all of
which prevent functional recovery.

Neuroexcitation
Part of the complex secondary injury is pathological neuroexcitation, NT surge as a result of
depolarization and nonspecific NT release (Hayes et al., 1992). Na+, K+, and Ca2+ are
maintained in neurons at concentrations suitable for action potential generation and conduction,
but the initial forces of TBI can alter that balance either by damaging the axolemma, the plasma
membrane of axons, or by causing damage to oligodendrocytes, which hinders saltatory
conduction (Mierzwa et al., 2015). Activation of Ca2+ channels can also lead to calciummediated effects such as cytoskeletal breakdown (Gennarelli and Graham, 1998) and the
activation of some cell death initiating mechanisms with its role in mitochondrial dysfunction
and ROS production (Starkov et al., 2004). In addition to ionic dysregulation, NT release can
also be excitotoxic. For example, in severe TBIs, neurotransmitters are released into the brain
parenchyma due to perforation of the axolemma. Considering NT release is typically tightly
regulated, rapid, robust increases in excitatory or inhibitory NTs can cause serious imbalances in
synaptic circuits, leading to dysfunction (Hayes et al., 1988; Lyeth et al., 1988; Faden et al.,
1989; Miller et al., 1990). For example, release of excitatory NT glutamate can be excitotoxic
(Rothman and Olney, 1986; Rothman and Olney, 1987; Bullock et al., 1998), as subsequent over
activation of NMDA, AMPA, and kainite receptors can lead to increased intracellular calcium
and cell death (Lee et al., 1999; Arundine and Tymianski, 2004). In milder injuries, mechanical
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deformation can also depolarize cells, as extracellular K+ is increased due to altered K+ channels
and membrane breakdown (Hayes et al., 1992). Release of excitatory amino acids (EAAs),
glutamate, aspartate, and acetylcholine, all excitatory neurotransmitters, can lead to excessive,
inappropriate excitatory input (Faden et al., 1989; Hayes et al., 1992; Lyeth et al., 1992) and
altered neuronal function.

Positive and Negative Inflammatory Response to TBI
A physical and metabolic barrier between the periphery and the central nervous system (CNS),
the BBB is an integrated network of endothelial cells and glial cells that maintains the necessary
separation between brain and blood-borne components (Chodobski et al., 2011). Disruption of
this homeostatic divide in the brain upon primary injury, when tight junctions of the BBB are
dismantled, allows blood resident compounds and cells to cross the BBB (Morganti-Kossmann,
2001), prompting a swift and robust inflammatory response. Permeation of the BBB allows
inflammatory cells like leukocytes, including neutrophils, lymphocytes, monocytes, and
macrophages, to infiltrate the brain parenchyma (Chodobski et al., 2011) and migrate to sites of
injury to protect against potential invading pathogens and produce pro-inflammatory cytokines
and chemotactic cytokines, chemokines (Bellander at al., 2001; Fluiter et al., 2014; Lozano et al,
2015). Initial cytokine and chemokine production are critical for increasing BBB permeability
and promoting a sustained inflammatory response (Chodobski et al., 2011). Common proinflammatory cytokines secreted and elevated in head injury paradigms are tumor necrosis factor
α (TNFα), important for injury and repair mechanisms (Hofman et al., 1989; Shohami et al.,
1994), interleukin-1 β (IL-1β), regulating the acute immune response (Rothwell and Luheshi,
2000), IL-6 (Breder et al., 1988; Frugier et al., 2010), IL-12 (Stahel et al., 1998), and interferon γ
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(IFNγ; Frugier et al., 2010) (Hernandez-Ontiveros et al., 2013; Lozano et al., 2015). Proinflammatory cytokines produced in acute phases of TBI have several benefits. Penkowa et al.
(2000) demonstrated that reductions in IL-6 negatively impacted recovery, and eliminating
TNFα did not improve long-term neurocognitive function (Scherbel et al., 1999; Sullivan et al.,
1999). Some matrix molecules, such as osteopontin (OPN), can also act as a cytokine in certain
CNS conditions (Shin, 2012), further enhancing pro-inflammatory cell cascades. Cell signaling
mechanisms initiated with controlled, regulated cytokine release in turn activate transcription
factors that eventually lead to more robust inflammatory responses, cell proliferation,
differentiation, migration, apoptosis, and even phagocytosis of debris after TBI, all of which, in
acute phases after injury, promote a more favorable environment for recovery processes to occur.

In addition to peripheral immune cells, which can invade the CNS in large numbers if BBB
integrity is compromised, resident immune cells of the CNS, microglia and astrocytes, also
produce cytokines, chemokines, and other components to facilitate proper injury repair
mechanisms. Microglia are involved in both normal physiological processes such as embryonic
development (Bilimoria and Stevens, 2015; Fiske and Brunjes, 2000) and normal synaptic
stripping (Blinzinger and Kreutzberg, 1968; Kettenman et al., 2013), as well as pathological
responses, as in a number of neurological diseases and conditions, including TBI. Acutely
neuroprotective (Corps et al., 2015), microglia exhibit distinct phenotypic and marker profiles
directly related to their role in response to TBI. These innate immune cells of the CNS can be
classified, in the most general terms, as resting, surveillant, or ramified microglia, which possess
small cell bodies, and abundant long, fine processes that frequently extend and retract to
“survey” the environment, or activated, reactive microglia, which appear more amoeboid in
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morphology, with large, round cell bodies, and shorter processes. Further, activated invading
and resident macrophages, microglia, can exhibit two distinct marker profiles depending on their
specific function in the inflammatory process, giving them a dual role in TBI pathology and
recovery. For example, classically activated microglia (M1) are immediately responsive to
injury stimuli like bacterial cell membrane component lipopolysaccharide (LPS) and TNFα,
producing high levels of pro-inflammatory cytokines and oxidative metabolites, which are
important for host defense (Ponomarev et al., 2007). Alternatively activated microglia (M2),
which respond to anti-inflammatory cytokines such as IL-4 and IL-13 (Colton et al., 2006) and
express markers associated with reducing the inflammatory response like Arginase-1, are thought
to be involved in processes that promote recovery such as extracellular matrix (ECM)
remodeling and tissue repair (Colton, 2009). Activation of both types of cells is key for
appropriate inflammatory responses, however, it can become pathological and could play a role
in long-term detrimental effects of inflammation (Holmin and Mathiesen, 1999; Bartfai et al.,
2007; Ramlackhansingh et al., 2011). Excessive microglial activation in the CNS, which is
damaging to healthy neurons (Block and Hong, 2005; Ponomarev et al., 2007), is linked to
decreased neurogenesis (Lazarini et al., 2012), initiation of pro-apoptotic pathways (Block and
Hong, 2007), development of auto-immune diseases such as multiple sclerosis (MS; Correale,
2014), and aberrant synaptic stripping (Ziebell et al., 2015), highlighting the duality of microglial
functions in facilitating recovery processes.

Astrocytes, another glial cell important for synaptic function, also become reactive in TBI. This
activation is characterized by elevated intermediate filaments vimentin and glial fibrullary acidic
protein (GFAP), increased cell proliferation, and cell hypertrophy (Herrmann, 2008). These cells
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typically produce and secrete fewer cytokines than microglia, but more growth factors and
extracellular matrix components that contribute to postinjury recovery by supporting neuronal
survival and protecting against cell death (Zhao et al., 2004). For example, brain derived
neurotrophic factor (BDNF), critical to cell survival and axon growth, and chondroitin sulfate
proteoglycans (CSPGs), which help form glial scars upon injury, protecting the site from further
damage (Grumet et al., 1993; Harris et al., 2009; Kumar and Loane, 2012), are secreted by
astrocytes. Another important role for astrocytes is the regulation of glutamate, reducing the
contribution of excess glutamate to neurotoxicity after TBI (Schousboe and Waagepetersen,
2005; Kumar and Loane, 2012). Of note, when astrocyte function is altered or impaired after
injury, neuron dysfunction is exacerbated (Myer et al., 2006). On the other hand, much like over
activation of microglia, excessive astrocyte activation can lead to change in CSPG production,
which can prevent and inhibit axon growth and regeneration (Cafferty et al., 2007).
Alternatively, in genetically modified mice with no vimentin or GFAP genes, axon growth and
repair were improved after CNS injury (Menet et al., 2003; Wilhemsson et al., 2004), suggesting
dichotomous roles for astrocytes after TBI as well.

Although the inflammatory response is a defense mechanism intended to improve the cellular
environment such that further injury is prevented, prolonged secretion of pro-inflammatory
cytokines from reactive glial cells caused by TBI does become neurotoxic, as excessive
production of cytokines like IL-6 can increase neuron cell death (Almolda et al., 2014), and
cytokine INFγ reduces number and length of dendrites, thus inhibiting synapse formation (Kim
et al., 2002). For this reason, a number of studies have investigated anti-inflammatory drugs to
explore their potential to reduce the negative effects associated with TBI and promote recovery.
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While most primary injuries will occur despite preventive measures, some of the molecular
processes of secondary insult, which exacerbate injury, may be preventable. For example,
regulating the production of CSPGs and the formation of a glial scar such that new axons may be
guided to appropriate targets without physical barriers may help restore some physiological
function. Harris and colleagues (2010), for example, increased the number of GAP-43+ axon
sprouts and slightly improved motor function after TBI using chondroitinase ABC, which breaks
down inhibitory CSPGs. In experimental models of head injury, targeting robust proinflammatory cytokine TNFα with reduction resulted in enhanced BBB integrity, reduced edema,
and improved neurological outcomes (Shohami et al., 1997). Additionally, IL-1β neutralization
not only reduced production of pro-inflammatory cytokines but also decreased hippocampal
damage after TBI, thus improving neurological behavior (Kumar and Loane, 2012). Antiinflammatory drugs such as Minocycline, which suppresses production of pro-inflammatory
cytokines, has been reasonably successful inhibiting microglial toxicity and improving
neurological function in TBI studies (Bye et al., 2007; Chan et al., 2014; Kumar and Loane,
2012; Ng et al., 2012). Fortunately, there are also endogenous anti-inflammatory cytokines IL-4,
IL-10 (Colton and Wilcock, 2010), and transforming growth factor β (TGFβ), that dampen the
pro-inflammatory immune response and promote a more appropriate environment for recovery.
For example, several studies have shown that IL-10 is neuroprotective in cases of head injury
(Knoblach and Faden, 1998; Csuka et al., 1999; Kremlev and Palmer, 2005). Despite advances
in understanding the inflammatory responses, preclinical success in the laboratory with
immunosuppressants, steroids, statins (Weitz-Schmidtz, 2002), and treatments like hyperbaric
chambers have largely failed in the clinic (Hellewell et al., 2015; Sanchez-Aguilar et al., 2013;
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Loane and Faden, 2010), leaving the door open for investigators to continue exploration of other
mechanisms to prevent neuropathology induced by TBI.

Similar to inflammatory cytokines/chemokines, ROS generated by infiltrating blood cells or
reactive glia can have devastating effects in brain injury patients. ROS, molecules containing
reactive oxygen atoms, are a normal physiological byproduct of cell metabolism, which include
peroxides, superoxides, and singlet oxygen. Typically, these compounds are maintained in low
concentrations because they are degraded by enzymes like peroxidase or neutralized with
antioxidants. After TBI, antioxidant functions are often impaired (Wang et al., 2014), leading to
an accumulation of ROS (Dasuri et al., 2013), which results in organelle and cellular
dysfunction, and often, cell death (Lewen et al., 2000; Loh et al., 2006). Not only are impaired
antioxidants problematic, but leukocytes such as neutrophils, which migrate into the brain after
BBB breakdown, produce additional ROS as well as matrix metalloproteinases (MMPs),
promoting BBB degradation and cytokine production to enhance inflammatory response (Scholz
et al., 2007; Wang et al., 2014), leading to greater tissue destruction. Post-injury administration
of antioxidants can, however, reduce damage and inflammation in models of brain injury if
administered quickly (Wang et al., 2011; Choi et al., 2012), as in the cases of edaravone (Wang
et al., 2011), apocynin (Choi et al., 2012), and glutathione (Roth et al., 2014).

Cell Death/Axonal Injury
In some cases of TBI, mechanical forces that induce the injury are sufficient to impair
cytoskeletal networks and perforate the cell membrane, leading to influx of neurotoxic
extracellular components, potentially causing cell death (Clark et al., 2000; Pike et al., 1998;
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Yakovlev et al., 1997). Programmed cell death, or apoptosis, occurs when a cell is no longer
required for organ function, while necrosis is a cell death mechanism initiated in response to
infection or injury. Apoptosis is characterized by DNA fragmentation, chromatin condensation,
and cell shrinkage (Zhang et al., 2005), typically induced by two primary mechanisms. Extrinsic
factors contributing to apoptosis involve cleavage and activation of several calcium activated
neutral proteases (caspases), which are responsible for proteolysis of cytoskeletal proteins like
αII-spectrin (Wang, 2000). Intrinsic mechanisms consist of the release of specific factors like
cytochrome C from mitochondria, activating cell death signaling cascades (Zhang et al., 2005).
Cell death after TBI dates back to the 1940’s (Evans and Scheinker, 1944; Evans and Scheinker,
1945) with documented neuronal loss in cortex, hippocampus, cerebellum, and thalamus (Adams
et al., 1985; Kotapka et al., 1993; Ross et al., 1993). Neurons, however, are not the only
populations susceptible to cell death, as vulnerability to apoptosis in CNS cells after injury is
present in most cell types but decreases from neurons to oligodendrocytes to astrocytes, with
microglia least susceptible to apoptosis after injury (Conti et al., 1998). Interestingly, there have
been differences in cell death mechanisms detected after TBI, largely dependent on injury
severity. For example, mild TBI often produces apoptotic cells, which one might expect as a
lower level of injury typically will not cause significant overt cell damage, while severe TBI
promotes necrosis (Du et al., 1996; Charriaut-Marlangue et al., 1996), an expected outcome
given the level of direct cell damage acquired in more robust injuries. Despite injury level, it has
been shown that necrosis occurs first as a result of membrane disruption, metabolic disturbances,
and excitotoxicity (Lenzlinger et al., 2001), while apoptosis is delayed (Liou et al., 2003).
Interestingly, rat TBI studies utilizing caspase 3 inhibitors and transgenic mice overexpressing
Bcl2, two manipulations developed to manipulate apoptosis, suggested 1/3 of postinjury cell
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death was caspase-dependent apoptosis, 1/3 was characterized as caspase-independent apoptosis,
and 1/3 could be attributed to necrosis (Zhang et al., 2005). When assessing extent of cell death,
morphological analyses are often employed. Electron microscopy technology, which utilizes a
high voltage electron beam to resolve intra and extracellular structures, can reveal characteristic
apoptotic morphology of swollen axons with large mitochondria, vacuolated cytoplasm, and
condensed chromatin (Dietrich et al., 1994; Raghupathi et al., 2000; Sutton et al., 1993).
Immunohistochemical analyses, on the other hand, can facilitate the use of terminal
deoxynucleotidyl transferase-mediated dUTP biotin nick end labeling (TUNEL) staining, which
identifies DNA strand breaks in tissue (Gavrieli et al., 1992), an indication of cells undergoing
programmed cell death. Injury-induced cell death is an important feature of TBI that promotes
understanding of trauma-related neuropathology.

Another hallmark pathological feature of TBI is diffuse axonal injury (DAI). This term
encompasses not only widespread damage to axons throughout the brain, but also perturbations
distributed along the axon (Gennarelli et al., 1982, Adams et al., 1982). Previously, investigators
and clinicians believed most axonal damage detected in TBI was caused by the initial mechanical
forces which also induce cell death. It has since been established that this primary mechanism
occurs primarily in severe injuries (Maxwell et al., 1993), and is likely not a major contributor of
axon damage in moderate and mild TBIs. Instead, axon damage that occurs over hours or days
has become accepted as the most accurate mechanism of TBI-induced axonal injury in milder
head traumas (Povlishock and Christman, 1995). This delayed axotomy is a result of primary
injury-induced perturbations of the axon related to local neurofilament change (Povlishock et al.,
1983; Erb and Povlishock, 1988; Yaghmai and Povlishock, 1992). Altered neurofilament
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organization extending from the axon initial segment, through nodes of Ranvier, down the length
of the axon have been documented in several quantitative stereological studies with histological
and transmission electron microscopy analysis, both in human and in experimental animals
(Maxwell, 2015). When these critical cytoskeletal components become misaligned, anterograde
transport is affected, causing accumulation of organelles in axonal swellings, which can later
become retraction bulbs. These changes have been reported even in the absence of axolemma
permeability (Gallant, 1992, Pettus et al., 1994), further highlighting its persistence even with
mild TBIs, in which physical forces may not be sufficient to cause axolemmal damage. One
defining characteristic of the axonal swellings that result is the presence of β-amyloid precursor
protein (βAPP) (Sherriff et al., 1994), which in addition to organelles, accumulates within the
axon (Shigematsu and McGeer, 1992) due to impaired transport, thus serving as a marker of
injury-induced cytoskeletal change (Povlishock and Christman, 1995). Interestingly, injured
axons can exist directly adjacent to uninjured axons (Adams et al., 1989; Mendelow and
Teasdale, 1983; Saatman et al., 2009), further complicating our understanding of the
pathobiology of TBI.

It is important to remember that DAI has several downstream effects. In mild TBI, as organelles
and βAPP accumulate, tension of the growing axonal swelling can cause the axolemma to
eventually pinch, leaving the retraction bulb attached to a proximal axon segment, while the
distal axon segment stands alone and is then subject to Wallerian degradation and phagocytosis
by reactive glia. In addition to intermediate-diameter neurofilaments, larger microtubules and
smaller, actin-composed microfilaments of axons are also affected by TBI (Maxwell, 2015). The
mechanical forces of a head injury can alter Na+ and Na+/Ca2+ exchanger channels (Fehlings and
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Agrawal, 1995; Wolf et al., 2001; Agrawal and Fehlings, 1996), which ultimately disrupts ionic
homeostasis and allows uncontrolled Ca2+ influx. Alpha II-spectrin is a protein that associates
with the actin cytoskeletal components of microfilaments by binding to adhesion and adaptor
molecules of the subaxolemma (Letourneau, 2009). Proteolysis of αII-spectrin is mediated by
calcium-dependent proteases (caspases) or calpains, which become activated from the influx of
Ca2+ upon axonal injury (Tuck and Cavalli, 2010), and studies show that after TBI, expression of
αII-spectrin break down products is increased. The close association of αII-spectrin with the
intact axon prompted investigators to explore αII-spectrin break down products in cerebrospinal
fluid (CSF) of TBI patients (Ringger et al., 2004) as well as CSF and brains of experimental TBI
animals (Pike et al., 2004) as a measure of axonal degradation and injury severity. In some
models of TBI, αII-spectrin break down products were detected in injured tissues within cortical
dendrites and subcortical white matter during acute phases of injury, up to 7 days (Saatman, et
al., 1996; Reeves et al., 2010). To date, αII-spectrin has remained a reliable measure of axonal
injury. Subsequent to DAI, as post-synaptic targets are deafferented, or lose signal input, the cell
soma and proximal axon segment can undergo Wallerian degeneration, and eventually succumb
to cell death (Maxwell, 2015). Considering the dense neuronal network of the brain, each cell is
intimately integrated with others, and as a result, this axotomy and loss of contact between preand post-synaptic cells can strongly impair synaptic circuits, altering output. In addition to
functional deficits as a result of axonal injury and cell death, cell fragments and debris produced
by breakdown of axon terminals and cell bodies can intensify inflammatory processes, further
complicating repair processes.
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NEUROPLASTICITY AFTER TRAUMATIC BRAIN INJURY
Widespread axonal damage induced by primary and secondary injury processes of TBI,
including DAI, leads to retraction of processes undergoing Wallerian degeneration and axotomy.
Subsequent deafferentation results in synaptic disruption and functional deficits (Erb and
Povlishock, 1991; Povlishock and Katz, 2005). While some brain regions such as the cortex,
hippocampus, and thalamus (Adams et al., 1985; Kotapka et al., 1992; Ross et al., 1993), are
more vulnerable than others after traumatic insult, the diffuse nature of most mild TBIs leaves
the entire brain susceptible to damage. Early descriptions of the CNS rejected the possibility of
successful regeneration or repair. Now, it is well understood that the CNS has a strong
propensity for recovery, with evidence of axonal sprouting, niches of stem cells, and the
formation of novel synapses upon the loss of previous connections. Synaptogenesis, the
formation of new synapses between neurons, is a normal process that occurs during embryonic
development, local synaptic plasticity accompanying long-term potentiation or depression, and in
response to trauma. Interestingly, DAI, one of the main underlying pathologies of TBI, also
drives structural synaptic plasticity (Grady et al., 1989; Levin, 1995; Povlishock, 1992), a
process guided by a number of matrix proteins, glial cells, and secreted growth factors. Reactive
synaptogenesis describes the specific process that occurs in response to loss of previously
established synapses, which results from deafferentation caused by disease or trauma.
Reorganization of these synapses occurs over a defined time course with described degenerative,
regenerative, and stability phases (Figure 1).
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Figure 1.1 Phases of Reactive Synaptogenesis
A-B. Deafferentation of normal synapses leads to an acute degenerative period, where damaged
synaptic terminals (d) are removed by reactive glia (gl). C. Degeneration is followed by a
regenerative phase in which new axons emerge (open arrows). D. Nascent synapses then
mature during the stabilization phase. (Steward et al., 1988)

18

19

Normal repair mechanisms are not always sufficient to regain function after TBI, evident in the
persistence of functional deficits described earlier. Consequently, researchers continue to
explore how such endogenous synaptic repair mechanisms might be improved, identifying viable
targets for therapeutic intervention. Defined models of deafferentation and analysis of
subsequent reactive synaptogenesis help clarify some of these recovery processes. Both the
well-characterized synaptic organization and the vulnerability of the hippocampus to TBI have
made it a fundamental brain region for studying TBI-induced synaptogenesis. The unilateral
entorhinal cortex lesion has been a preferred model of deafferentation-induced synaptogenesis
for several decades (Steward, 1989). In the model, the dentate gyrus of the hippocampus is
deafferented of input from the entorhinal cortex, which stimulates axon sprouting and synaptic
reorganization. Using this model, and other models of deafferentation, investigators have
mapped the time course of a defined process of reactive synaptogenesis. During early phases of
the recovery process (1-5 days after injury; Figure 1.1B), damaged axons degenerate and
neuroglia facilitate the removal of cellular debris from the region. In the intermediate repair
phase (6-15 days after injury; Figure 1.1C), nascent terminals are formed as axons begin
sprouting and re-innervating deafferented regions (Lynch et al., 1976; Steward, 1976; Deller et
al., 2007; Frotscher et al., 1997). When 15+ days have passed after injury, the process enters a
period of stabilization (Figure 1.1D), where synapses mature and are both structurally and
functionally strengthened (Steward and Vinsant, 1983). Although this time course is well
established, and the sequence of events is relatively consistent across brain regions, the specific
length of each phase can differ. For example, in the olfactory bulb (OB), the process is slower,
occurring over a more extended period of 2 months (Graziadei et al., 1978; Graziadei et al.,
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1979), rather than 2 weeks, revealing region-specificity and introducing the potential for
exploring efficacy of therapies in brain regions with slightly different recovery periods.

Reactive synaptogenesis evokes several structural, molecular, and cellular changes in
deafferented circuits. In experimental models assessing synaptic plasticity, a number of markers
are often utilized to track the process of reinnervation. Microtubule-associated proteins (MAPs),
for example, can detect morphological changes in synapses, as they are involved in axonal
outgrowth (Gordon-Weeks and Fischer, 2000; Yamanouchi, 2005; Ma et al., 2000; RamonCueto and Avila, 1999) and increase after axonal injury (Book et al., 1996). Pre-synaptic vesicle
docking proteins, such as synaptophysin and synapsins, also change after insult, and can be
measured to assess synaptic plasticity. Several studies have demonstrated reductions in
Synapsin-I after ischemia (Kitagawa, 1992), deafferentation (Chan et al., 2014), and TBI in
hippocampus and cortex (Ansari et al., 2008a, b), indicating loss of pre-synaptic terminals
acutely after brain injury. During later recovery processes, Griesbach et al. (2004) showed
increases in Synapsin-I, indicative of a reemergence of terminals. In addition to tracking the loss
or appearance of physical components of the synapse, several other factors that contribute to
regeneration and synaptogenesis can be assessed. Expression of growth factors like growthassociated protein-43 (GAP-43), which facilitates accumulation of F-actin in the neurite
cytoskeleton (Aigner and Caroni, 1995; Dent and Meiri, 1998) and promotes axonal outgrowth,
increases during plasticity. During critical periods of nervous system development, for example,
GAP-43 expression is high (Shen et al., 2002; Latchney et al., 2014). Additionally, plastic brain
regions with constant neurogenesis and integration of new synapses, such as the hippocampus
and OB, also express high levels of GAP-43 (De la Monte et al., 1989), and increased expression
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has been detected in the OB during regenerative periods (Verhaagen et al., 1993). Interestingly,
change in GAP-43 expression occurs during reactive synaptogenesis as well (Benowitz et al,
1990). In multiple models of brain injury, GAP-43 expression is increased: during axon
regeneration (Sachdeva et al., 2016, Williams et al., 2015; Wang et al., 2014), after SCI (Park et
al., 2013), during regenerative axonal sprouting after stroke (Goto et al., 1994, Carmichael et al.,
2005; Hulsebosch et al., 1998; Stroemer et al, 1993; Gorup et al., 2015), and in injured axons
after TBI (Christman et al., 1997). Clearly, exploring altered post-injury expression of synaptic
components can guide understanding of the processes underlying reactive synaptogenesis.

Inflammation and plasticity
TBI-induced production of pro-inflammatory mediators peaks during acute phases of injury,
within the first 24-48 hours, while anti-inflammatory molecules are produced and secreted later
to help facilitate post-injury recovery. Reactive neuroglia, such as microglia and astrocytes,
respond to stimuli by clearing cellular debris and degenerating synaptic structures (Colton and
Gilbert, 1987; Chao et al., 1992; Ramlackhansingh et al., 2011; Bechade et al., 2013; Bessis et
al., 2007), producing and secreting growth factors, cytokines, and chemokines (Hanisch, 2002),
and migrating through the brain parenchyma to affected brain regions (Carbonell et al., 2005;
Imai et al., 1999). The functions of neuroglia in TBI, however, are not limited to injury
response. Microglia also participate in maintaining the normal synaptic functions of the brain
such as during cortical development, when both microglia and the rate of synaptogenesis are
equally high (Steward and Falk, 1986), and Diniz et al. (2012) have shown that microglia
produce factors like TGFβ to enhance synapse formation. When microglia function as first
responders to sites of injury, after insult such as TBI, they serve beneficial roles, surveying

22

(Lafrenaye et al., 2015), engulfing and eliminating cell debris from the microenvironment and
producing pro- and anti-inflammatory cytokines and growth factors, as discussed earlier.
Further, in TBI specifically, the phagocytic properties of microglia make them critical in the
removal of axonal debris and toxic substances to acquire homeostasis and promote tissue
remodeling (Hanisch and Kettenmann, 2007). Pro-inflammatory cytokines secreted from
microglia, such as TNFα, can also mediate synaptic scaling, or regulation of synaptic activity
(Stellwagen and Malenka, 2006). While important components like bone derived neurotrophic
factor (BDNF), which is involved in synaptic plasticity, are expressed by microglia after TBI
(Nagamoto-Combs et al., 2007) and focal ischemia (Madinier et al., 2009), production of matrix
molecules such as thrombospondin, which plays a role in synaptogenesis, has also been detected
in microglia (Chamak et al., 1995; Moller et al., 1996; Christopherson et al., 2005). Moreover,
studies from Chan et al. (2014) support a positive role for microglia in the process of
synaptogenesis, documenting microglial reactivity and production of cytokine osteopontin,
promoting synaptic organization in hippocampal regions of deafferentation-induced
degeneration. One study showed that altering microglial proteins subsequently altered synaptic
function as well (Bessis et al., 2007), and attenuating microglial response reduced synaptophysin,
GAP-43, and BDNF levels (Madinier et al., 2009), documenting a strong association between
proper microglial function and normal synaptic activity. Alternatively, microglia can also elicit
negative responses during recovery processes (Byrnes et al., 2006; Ekdahl et al., 2009),
particularly since they exhibit different roles in neuronal survival, depending on the
microenvironment. The production of glutamate by microglia, for example, is neurotoxic,
triggering neuronal apoptosis (Piani et al., 1991). In cases of brain injury, however, a certain
level of these toxic stimuli may be beneficial, as death and removal of injured neurons allows

23

space for new terminals to sprout and form synapses. As an example, microglia have been
associated with both neuron death and synaptogenesis after axotomy (Moran and Graeber, 2004),
emphasizing the importance of proper microglial function in all phases of reactive
synaptogenesis induced by TBI.

Prolonged inflammation and neuroexcitation can exacerbate the effects of axotomy, an effect
that has been documented in maladaptive models of TBI (Phillips et al., 1994). Persistent
activation of microglia is one component of TBI-induced inflammation that can also be
detrimental to neuronal survival and synaptic repair. Several clinical and experimental studies
have reported long-term microglial activation after TBI (Johnson et al., 2013; Smith et al., 2013;
Gentleman et al., 2004; Faden, 2011; Engel et al., 2000), even up to 17 years post-injury
(Ramlackhansigh et al., 2011). Continued microglial activation in mice leads to several
detrimental consequences such as lesion expansion and hippocampal neurodegeneration (Loane
et al., 2014). Further, long term microglial activation in models of repetitive TBI produced white
matter degradation and cognitive deficits (Mouzon et al., 2014) as well as behavioral and
electrophysiological changes (Aungst et al., 2014). To combat these effects, some have
employed the use of anti-inflammatory treatments, which have attenuated not only the
inflammatory response, but also associated lesion volume and neuronal loss as well (Byrnes et
al., 2009; Loane et al., 2013). Minocycline, one such anti-inflammatory drug, has been shown to
reduce microglial activation and enhance neurogenesis, thus improving learning and memory
processes (Liu et al., 2007). Others, including Cyclosporin-A (Allessandri et al., 1999;
Allessandri et al., 2002; Colley et al., 2010; Scheff and Sullivan, 1999), Simvastatin (Wang et
al., 2007; Wang et al., 2014; Wu et al., 2010), and FK-506 (Fujita et al., 2011; Marmarou and
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Povlishock, 2006; Oda et al., 2011) have also proven neuroprotective in TBI experimental brain
injury paradigms improving cognition and motor skills, reducing histological damage and
neuronal degeneration, and providing axonal protection, respectively. Recent evidence,
however, points to select agents, such as Cyclosporin-A, producing variable to ineffective results
when applied in several different TBI models (Dixon et al., 2016), yet controlling inflammation
after injury still holds promise for improving functional deficits associated with head trauma.

Much like microglia, which become activated after TBI, astrocytes also adopt a reactive
phenotype, as previously described, characterized by increased intermediate filament expression
and secretion of components such as BDNF and chondroitin sulfate proteoglycans (CSPGs).
BDNF is a prominent promoter of synaptogenesis, while CSPGs can either promote or hinder
synaptic repair. Astrocytes secrete CSPGs to form an important component, the glial scar
(Bignami and Dahl, 1976), to section off the site(s) of injury and prevent spread of the lesion to
adjacent intact tissues (Matthews et al., 1979; Sofroniew, 2005; White and Jakeman, 2008).
Unfortunately, these CSPGs can also be inhibitory for axonal growth (Matthews et al., 1976;
Liuzzi and Lasek, 1987; Silver and Miller, 2004; Goldshmit and Bourne, 2010), thus limiting the
capacity for synaptogenesis. On the contrary, BDNF production is largely beneficial.
Expression of BDNF has been linked to synapse formation (Park and Poo, 2013), dendritic
growth (McAllister et al., 1995), and axon branching (Cohen-Cory and Fraser, 1995), axon
guidance, and neural development (Huang et al., 2001; Lu et al., 2013). The importance of
neurotrophic factors like BDNF during synaptogenesis is represented in experimental models in
which BDNF is absent, reducing synaptic proteins (Pozzo-Miller et al., 1999) and when BDNF is
overexpressed, increasing the number of synapses (Aguado et al., 2003). Even in injury models
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of ischemia and stroke, BDNF proves neuroprotective (Ferrer et al., 2001; Muller et al., 2008),
demonstrating that the effects of some growth factors are indispensable in the process of reactive
synaptogenesis. These analyses show that reactive neuroglia and the inflammatory processes
they promote facilitate the formation of nascent synapses, both in normal conditions and during
periods of synaptic repair, such as following TBI.

EXTRACELLULAR MATRIX
Although the tripartite synapse, which includes perisynaptic glia such as astrocytes, along with
pre- and post-synaptic terminals, has long been accepted as the functional synapse, more
recently, the tetrapartite synapse (Frischknecht and Gundelfinger, 2012; Dityatev et al., 2006;
John et al., 2006; Dityatev et al., 2010) has been introduced, and includes the extracellular matrix
(ECM). This hyaluronic acid-rich space (Frischknecht and Gundelfinger, 2012) between cells is
inhabited by structural proteins, secreted factors, and matrix-shaping enzymes. Through cellmatrix interactions, this composition helps maintain neuronal and synaptic stability. Both glial
cells and neurons produce components of the ECM including CSPGs, laminins, phosphacan,
reelin, thrombsospondins, as well as matrix-shaping enzymes such as proteases and
hyaluronidases (Bandtlow and Zimmerman, 2000; Dityatev and Schachner, 2003;
Christopherson et al., 2005; Dityatev and Fellin, 2008; Frischknecht and Gundelfinger, 2012),
and structural components, which include collagens, proteoglycans, and glycoproteins (Dityatev
and Schachner, 2003). Select ECM molecules can organize to form cartilage-like ECM, known
as perineuronal nets (Fawcett, 2009), which surround cell bodies (Bruckner et al., 1993; Celio et
al., 1998; Yamaguchi, 2000) for synapse stabilization. In normal physiological conditions, the
ECM maintains the homeostasis of the extracellular space, highlighted by the compositional
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maturity of the ECM from a diffuse matrix during embryonic development to a more condensed
perineuronal net in adult brain for promotion of synaptic plasticity (Frischknecht and
Gundelfinger, 2012). Evidence of this function is demonstrated by the presence of ECM
interspersed between neurons and astrocytes (Frischknecht and Gundelfinger, 2012), and tightly
wrapping synapses, with the ECM between synapses differing from the ECM surrounding them.
For example, brevican is perisynaptic (Seidenbecher et al., 1997), while agrin is likely localized
to the synaptic cleft, similar to its position in the neuromuscular junction (Matsumoto-Miyai et
al., 2009). Some components such as hyaluronic acid (HA), serve not only structural purposes,
but also have a direct impact on synaptic plasticity (Kochlamazashvili et al., 2010). Further,
synaptic plasticity is impaired when the ECM is altered. Such is the case when loss of CSPGs
brevican or neurocan leads to impairments in long-term potentiation (LTP; Zhou et al., 2001;
Brakebusch et al., 2002). Similarly, adhesive protein N-cadherin has also been associated with
LTP, as its muted elevation 15d post-injury in a maladaptive recovery model of deafferentation
corresponds with a reduction in LTP (Warren et al., 2012), suggesting N-cadherin may be tightly
associated with functional synaptic plasticity. Moreover, agrin protein is elevated during
adaptive recovery, and reduced in a maladaptive model of synaptic repair (Falo et al., 2008),
highlighting its importance in normal recovery processes. Thrombospondins have also been
identified as critical for synapse development, for example, as interaction with cell adhesion
molecule neuroligin 1 accelerates synaptogenesis (Xu et al., 2010). ECM component neuronal
activity-regulated pentraxin (Narp) is involved in synapse formation and synaptic scaling as well
and is increased at excitatory synapses (Chang et al., 2010; O’Brien et al., 1999). Matrix
enzymes such as MMPs also associate with the process of synaptogenesis by, like other parts of
the ECM, altering the conditions of the immediate environment, making it favorable to permit
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synaptic plasticity. MMP-mediated processing of ECM components can both alter the stability
of matrix structural components as well as produce fragments of important cell-signaling
molecules, both of which can promote synaptogenesis and functional recovery. In pathological
conditions such as TBI, these ECM proteins and enzymes are critical for proper synaptic
reorganization and functional recovery.

Proteoglycans and Cell Adhesion Molecules/Extracellular Matrix Role in TBI
ECM proteoglycans, adhesion proteins such as calcium-based cell adhesion molecules
(cadherins), and matrix receptors, play important roles in promoting synaptogenesis after TBI.
Proteoglycans of the CNS such as brevican, neurocan, aggrecan, phosphacan, agrins, and
tenascins, which are involved in synaptogenesis, are produced by neurons and glial cells
(Bandtlow and Zimmerman, 2000; Heikkinen et al., 2014). CSPGs such as brevican, aggrecan,
versican, and neurocan, are matrix proteins consisting of a protein core and a chondroitin sulfate
side chain, and serve as structural components in tissues that help form glial scars and increase
after injury to promote cellular processes such as cell adhesion, migration, and interaction with
other ECM molecules. After injury, glia such as astrocytes, which secrete CSPGs such as
brevican, versican, tenascin C, and neurocan, can inhibit axon growth (Fitch and Silver, 1997;
Bradbury et al., 2002; Jones et al., 2002; Geissler et al., 2013; Siddiqui et al., 2009).
Phosphacan, an isoform of receptor tyrosine phosphatase β/zeta receptor (Dobbertin et al., 2003),
is one CSPG that has been explored in models of deafferented brain with mRNA expression
peaking when synaptic reorganization is underway and protein localizing to dendrites (Harris, et
al., 2011). This expression and relation to the time course of reactive synaptogenesis suggests a
pro-reconstructive role for phosphacan in the synaptic recovery process. Conversely, inhibiting
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CSPGs can also improve axon sprouting after TBI (Harris et al., 2010) and bone marrow stromal
cell implantation downregulates neurocan, promoting axon growth and synaptophysin expression
after TBI (Mahmood et al., 2014), supporting a dual role for CSPGs after TBI. Heparin sulfate
proteoglycans (HSPGs) consist of 2 or 3 heparin sulfate chains that typically bind to different
ligands to promote biological processes. Interestingly, HSPGs can stimulate synaptogenesis
through interaction with polysialylated neuronal cell adhesion molecule (PSA-NCAM; Dityatev
et al., 2004). The critical astrocyte response to injury may also be mediated by HSPGs through
interaction with fibroblast growth factors, which occurs during neurogenesis and axon guidance
(Yamaguchi, 2001). Interestingly, agrin, an HSPG, (Tsen et al., 1995; Cole and Halfter, 1996) is
expressed in astrocytes, peaking 7d after injury, when axon sprouting in the hippocampus begins,
and localizes with synaptophysin in nascent pre-synaptic terminals (Falo et al., 2008),
demonstrating an association with synaptogenesis. Additionally, HSPG syndecan-2 is involved
in spine maturation (Ethell and Yamaguchi, 1999). Overall, the ratio of permissive HSPGs to
inhibitory CSPGs appears to be important in regulating axon growth (Tselnicker et al., 2014).

In addition to the proteoglycans, cadherins also have strong roles in maintaining cell contacts,
with roles in axon guidance and synapse stabilization (Ranscht, 2000; Gerrow and El-Husseini,
2006). Several investigators have shown that N-cadherin plays a role in synaptogenesis. For
example, it is involved in cell adhesion between neurons, and both N-cadherin and β catenin are
important regulators of spine morphogenesis and synaptogenesis (Togashi et al., 2002; Okuda et
al., 2007; Sagliette et al., 2007). In deafferented brain, N-cadherin increases around 15d postlesion, during the regenerative phase of reactive synaptogenesis (Warren, et al., 2012), an
indication of reestablished contact between neurons. More specifically, Wang et al. (2014)
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showed that the ratio of precursor N-cadherin to mature N-cadherin is critical in regulating
adhesion during synaptogenesis (Reines et al., 2012), as cleavage of the pro-domain is important
for normal N-cadherin cell-cell adhesive functions (Latefi et al., 2009).

Several receptors exposed to the pericellular space also function as important mediators of
matrix processes. Integrins are heterodimeric transmembrane receptor complexes of α and β
subunit isomers, of which there are currently 18 α and 8 β subunits, and 24 known combinations
(Wu and Reddy, 2012), each of which has distinct specificity. For example, the β1 subunit can
participate in at least 10 different combinations with α subunits, and β3 ligands include
fibronectin, fibrinogen, and vitronectin, depending on the paired α subunit (Guell and Bix, 2014).
Integrin receptors are responsible for initiating cell-signaling mechanisms through interaction
with different ligands, many of which occur through an Arginine-Glycine-Aspartate (RGD)
binding sequence, to promote cell adhesion, cell migration, and production of cytokines and
chemokines to further enhance inflammatory response. Interestingly, several matrix enzymes
can unmask the unique binding site on integrin ligands through proteolytic cleavage (Wang et al.,
2008; Michaluk et al., 2009). Integrins serve pivotal roles in epithelial cells throughout the body,
including cerebrovascular endothelial cells (Guell and Bix, 2014; Cousin et al., 1997; Jones,
1996; Grooms et al., 1993; Pinkstaff et al., 1999). Clegg et al. (2003) also demonstrated that
activated integrins on microglia promote adhesion, endocytosis, and phagocytosis, while those
on neurons support neural adhesion and regeneration. Notably, the process of embryogenesis
requires integrins (Bronner-Fraser, 1986, 1994), more specifically, axon guidance,
synaptogenesis, and astrocyte maturation and migration during brain development (Milner et al.,
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2001; Reichardt and Tomaselli, 1991). In the adult brain, integrins, typically expressed on
neurons and glia, have also been implicated in synaptogenesis.

Decreased dendritic spine density, defined by integrin antibody staining, suggests a role for
integrins in synaptogenesis (Nikonenko et al., 2003), while integrin expression on astrocytes has
been linked to axonal sprouting and synaptogenesis after neuronal cell loss (Fasen et al., 2003).
Injury models also promote a functional role for integrins, as αvβ3 increases rapidly in the
ischemic core after middle cerebral artery occlusion (MCAO; Abumiya et al., 1999). In focal
ischemic stroke, αvβ3 interaction with OPN is involved in glial activation, organization, and
repair (Ellison et al., 1999). Although the integrin receptors are composed of 2 subunits, some
studies have explored the role of just one subunit in facilitating cellular processes. For example,
β1 integrin has been implicated in neurovascular remodeling (Lathia et al., 2010), and increases
within nerve lesion models in the vicinity of the lesion, on growth cones and regenerating axons
(Lefcort et al., 1992; Pinkstaff et al., 1998). Interestingly, integrins can also exhibit functions
that contradict known properties, as the use of an α4 integrin antibody reduced infarct size and
lowered neurocognitive deficit scores in a model of brain injury (Becker et al., 2001).

CD44, another receptor involved in several cell-cell and cell-matrix interactions, whose principal
ligand is hyaluronic acid (HA), a core component of the ECM, can also promote processes such
as adhesion, homing, aggregation of lymphocytes, and metastasis (Huet et al., 1989, Denning et
al., 1990; Rothman et al., 1991; Jalkanen et al., 1986; Goodison et al., 1999), all of which can
promote synaptogenesis. In addition to indirectly binding molecules such as HA, collagen,
fibronectin, and laminin through chondroitin (Jalkanen and Jalkanen, 1992), CD44 also binds
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directly to OPN, a matrix molecule with several signaling properties (Rangaswami et al., 2006).
Localized on neurons or glia, CD44 may play a role in repair, as it is expressed after several
different models of nerve transection (Jones et al., 2000), and a stab wound analysis also
implicated CD44 in wound healing (Stylli et al., 2000). On the contrary, Wang et al. (2002)
demonstrated that loss of CD44 resulted in smaller infarct size after MCAO, along with
significant improvement in motor skills and lower pro-inflammatory IL-1β expression,
suggesting CD44 expression may also be detrimental to recovery, under certain conditions.
Interestingly, CD44 and integrins can form complexes for pro-MMP9 to dock (Redondo-Muñoz
et al., 2008) promoting migration of macrophages, an essential part of ECM reorganization.

Matrix Metalloproteinases
Integrin binding can affect MMP activity, influencing membrane signaling and adhesion
properties. The ADAM family of MMPs, classified as a disintegrin and a metalloproteinases,
bind integrins to affect these cell responses and are found throughout the body, including the
brain. Important functions for these ECM molecules have been discovered related to
synaptogenesis, as ADAM21 is active in olfactory receptors neurons (ORNs), where
neurogenesis and synaptogenesis are ongoing (Yang et al., 2005). Moreover, ADAM10 is
expressed during dendritogenesis in the hippocampus (Pokorny and Yamamoto, 1981), while
ADAM9 and ADAM10 mRNA are expressed during injury-induced sprouting after kainic acid
injections (Ortiz et al., 2005). In a model of dentate gyrus deafferentation, the degenerative
phase of reactive synaptogenesis is characterized by an increase in ADAM10 and membranetype 5 matrix metalloproteinase (MT5-MMP; Warren et al., 2012), for which cell adhesion
molecule N-cadherin is a substrate. Lastly, Seipel et al. (2010) showed that MT1-MMP,
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ADAM10, CD44, MMP9, and αvβ3 act in concert to promote migration, an essential function for
reactive glia promoting ECM reorganization. The ADAM and MT-MMP enzymes are members
of a much larger, broader group of enzymes known as MMPs, which have been repeatedly
implicated in TBI and synaptic recovery.

MMPs (Figure 1.2), which modulate the ECM, are zinc-dependent endopeptidases with highly
conserved sequences and domains. Each has an amino-terminal signal peptide, carboxy-terminal
hemopexin domain, propeptide region, which must be cleaved for activation, and a distinct
catalytic domain, specific in each enzyme. Currently, there have been 24 secreted and MTMMPs identified, grouped by substrate specificity (Nagase et al., 2006). Collagenases,
stromelysins, matrilysins, gelatinases, and membrane-type MMPs are the main groups, which
share similarities in catalytic functions, while some others are not strictly categorized. In
general, stromelysins digest a number of ECM components and can activate other MMPs, while
matrilysins lack a hemopexin domain, and membrane-type MMPs have an extra transmembrane
domain to facilitate pericellular proteolytic processes. Collagenases break down collagens,
structural components of meninges, and promote brain development through axon guidance and
synaptogenesis (Fox, 2008; Hubert et al., 2009). Gelatinases (MMPs 2, 9) can also break down
collagens, but further lyse gelatins in the ECM, cerebrospinal fluid, and blood serum (AbdulMuneer et al., 2015). Each of the MMPs has several important physiological functions
throughout the body, some of which also have important roles in the brain including during
embryogenesis, bone remodeling, wound healing, and neurogenesis in normal circumstances,
and BBB disruption, hemorrhage, and neuroinflammation in pathological conditions (Yong,
2005; Abdul-Muneer et al., 2015).

33

Figure 1.2 MMP Family Member Structural Domains
MMPs are zinc-dependent enzymes with highly conserved sequences designating a pro-peptide
zone, hinge region, hemopexin domain, and an enzymatic site. Most of these endopeptidases
can be grouped into families (listed in illustration) that share distinct catalytic functions, while
others remained uncategorized. (Jaoude and Koh, 2016)
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In the brain, MMPs are normally produced and secreted at low levels by neurons and reactive
glia, while the enzymatic activities of MMPs are regulated by growth factors, cytokines, and a
host of endogenous inhibitors. These include α2 macroglobulin and tissue inhibitors of
metalloproteinases (TIMPs), of which there are 4, possessing tissue specificity, that inhibit the
majority of MMPs (Sternlicht and Werb, 2001; Zhang et al., 2010; Abdul-Muneer et al., 2015).
TIMPs 1 and 2 are the primary MMP inhibitors in the brain (Rivera et al., 2010) and maintain a
physiologically relevant ratio with MMPs, such that overexpression of MMPs disrupts the
inhibitor ratio, leading to potentially detrimental effects (Brew et al., 2000). MMP
dysregulation, including aberrant elevation, has been described in several CNS models including
stroke, hemorrhage, Alzheimer’s disease, and TBI (Abdul-Muneer et al., 2015; Van Hove et al.,
2012; Verslegers et al., 2013). When the delicate balance between regulatory molecule and
proteolytic enzyme becomes dysregulated, enzymatic functions can become pathological.

In injury paradigms, MMPs can be synthesized and released by astrocytes (Falo et al., 2006;
Ogier et al., 2006), endothelial cells, oligodendrocytes (Oh et al., 1999; Uhm et al., 1998), and
microglia (Peng et al., 2012) depending on injury type and CNS location (Zhang et al., 2010).
After TBI, when a number of cellular processes are disrupted, MMP function is also altered and
can lead to the progression of neuropathology. For example, high levels of MMPs can promote
increased neuronal and tissue damage (Wang and Lo, 2003; Romanic et al., 1998; Lo et al.,
2002; Yong et al., 2001; Rosenberg, 2002), and MMP8 concentration is associated with
mortality in severe TBI patients (Roberts et al., 2013). Additionally, overactive MMP2, MMP3,
and MMP9 proteolysis can cause BBB disruption, hemorrhage, neuroinflammation, intracranial
pressure, edema, neurodegeneration, and cell death (Abdul-Muneer, et al., 2015; Lotocki et al.,
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2009; Montaner et al., 2001; Pun et al., 2009), all of which promote poorer outcomes after injury.
Moreover, MMPs can accelerate inflammatory processes and activate caspases, which leads to
apoptosis (Abdul-Muneer et al., 2015). MMP1 interaction with integrins can also lead to
apoptosis (Meerovitch et al, 2003), demonstrating that MMPs can attach to MT-MMPs, cell
adhesion molecules, proteoglycans, and integrins (Yong, 2005; Dumin et al., 2001) to promote
different cellular processes critical to recovery.

By redistributing proteins in the ECM, MMPs can promote synaptic plasticity (Phillips et al.,
2014; Abdul-Muneer et al., 2015). Processing of some ECM components alter matrix structure,
while breakdown of others leads to stabilization of synapses, as select MMP substrates can guide
afferent axons during synaptogenesis (Treolar et al., 2009). For example, several proteoglycans
are degraded by MMPs (Pizzi and Crowe, 2007; Hsu et al., 2008; Zuo et al., 1998), such as the
case in MMP3 processing of agrin (Werle and VanSaun, 2003; Falo et al., 2008). MMP3 also
targets other ECM proteins critical for synaptogenesis (Muir et al., 2002; Bejarano et al., 1988;
Imai et al., 1995; Okada et al., 1987; VanSaun and Werle, 2000), and likely contributes to the
process as it is upregulated for weeks after deafferentation and localizes to deafferented zones
(Kim et al., 2005; Falo et al., 2006). After TBI, MMPs 2, 3, and 9, which can regulate extension
of granule cell processes through cerebellar ECM (Vaillant et al., 2003; Luo, 2005), are often
activated, causing ECM degradation, BBB permeability, inflammation, and degeneration, which
can be harmful or beneficial for synaptic plasticity (Phillips et al., 2014; Abdul-Muneer et al.,
2015; Montaner et al., 2001). Several laboratories have shown that MMPs and their substrates
promote reactive synaptogenesis in injured hippocampus (Phillips and Reeves, 2001; Kim et al.,
2005; Falo et al., 2006; Warren et al., 2012; Chan et al., 2014), demonstrating the therapeutic
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potential of targeting MMPs to improve recovery. Particular MMP inhibitors such as GM6001
(Sifringer et al., 2007; Wang and Tsirka, 2005; Warren et al., 2012), FN-439 (Falo et al., 2006;
Kim et al., 2005; Reeves et al., 2003), and SB-3CT (Hadass et al., 2013) have proven useful for
reducing MMP activity and subsequently affecting recovery and brain lesion size in experimental
brain injury paradigms, but consistent and effective control of MMP activity after TBI has
proven difficult because of the complexity of MMP functions and nonspecific effects of some
experimental compounds (Zhang et al., 2010; Abdul-Muneer et al., 2015).

MMPs 2 and 9
Gelatinases A and B, or MMP2 and MMP9, typically localized in neurons, astrocytes,
macrophages, and blood vessels (Yamaguchi et al., 2007; Noble et al., 2002; Hsu et al., 2006),
are specific for both gelatin substrates as well as other ECM components. Gelatinase structure is
similar to other MMPs (Van den Steen et al., 2002), with a signal peptide, pro-peptide for
proteolytic activation, catalytic domain containing a zinc ion, three tandem repeats of fibronectin
type-II inserts within the catalytic domain, proline-rich and heavily glycosylated linker region,
and a hemopexin-like domain (Stute et al., 2003; Dziembowska and Wlodarczyk, 2012). Like
other MMPs, MMP9 is produced as a zymogen and secreted into the ECM for cleavage into its
active form by other MMPs or the plasminogen-plasmin system (Bruno and Cuello, 2006).
Enzymatic activity of MMP9 is regulated by TIMP1 binding at the hemopexin domain (Olson et
al., 1997; Yong, 2005), like other MMPs, as well as by neutrophil gelatinase-associated lipocalin
(NGAL)/Lipocalin-2 (LCN2), which binds and protects MMP9 from degradation, enhancing
enzymatic activity (Yan et al., 2001).
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Several roles for gelatinases in CNS disorders have been uncovered. For example, MMP2
activity in TBI models degrades tight junctions of the BBB, promotes edema, and induces
MMP9 activity (Abdul-Muneer et al., 2013; Jadhav et al., 2008), facilitating further pathological
processes. Additionally, MMP9 activity is elevated in the neurofibrillary tangles and plaque
accumulations associated with Alzheimer’s disease (Asahina et al., 2001) as well as in
hippocampus during seizure/epileptic episodes, as it promotes abnormal recurrent mossy fiber
sprouting and synaptogenesis (Konopka et al., 2013). Interestingly, ROS, which are produced in
numerous pathological CNS conditions, increases both MMP2 and MMP9, and decreases
TIMPS in vitro, altering the delicate ratio between enzyme and regulator (Rajagopalan et al.,
1996; Haorah et al., 2007). Gelatinase activity is also correlated with glial scar formation
(Duchossoy et al., 2001), which is consistent with MMP break down of CSPGs.

In response to spinal cord injury (SCI; Hsu et al., 2006; Hsu et al., 2008), olfactory bulb
deafferentation (Costanzo et al., 2006; Costanzo and Perrino, 2008), TBI (Phillips and Reeves,
2001), and cortical contusion injury (CCI; Wang et al., 2000), gelatinase activity increases
substantially, suggesting a role for their function in neuronal injury and recovery mechanisms.
In the clinic, MMP2 and MMP9 are elevated in blood serum of subarachnoid hemorrhage
patients (Horstmann et al., 2006), while in experimental models of injury, MMP9 activity peaks
early (de Castro et al., 2000; Noble et al., 2002), followed by MMP2 in recovery phases
(Goussev et al., 2003; Zuo et al., 1998; Hsu et al., 2006; Costanzo and Perrino, 2008). These
results suggest that each gelatinase plays an important role in response to brain injury, with
MMP9 potentially a critical mediator of the acute pathophysiological processes preceding
synaptic repair.
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Regarding individual function of MMP9 in TBI, investigators have associated apoptosis
(Chintala et al., 2002; Sifringer et al., 2007; Jia et al., 2010), edema (Homsi et al., 2009; Hirose
et al., 2013; Jadhav et al., 2008), inflammation (Homsi et al., 2009; Ralay Ranaivo et al., 2011;
Suehiro et al., 2004), BBB degradation (Yu et al., 2008; Shigemori et al., 2006; Muradashvili et
al., 2015; Abdul-Muneer et al., 2013; Higashida et al., 2011), and synaptogenesis with MMP9
activity (Chan et al., 2014; Phillips et al., 2014). In synapses, MMP9 mRNA and protein are
localized to dendritic spines (Konopacki et al., 2007; Gawlak et al., 2009; Wilczynski et al.,
2008), while enzymatic activity of MMP9 has also been found in mature synapses (Gawlak et al.,
2009). Additionally, increased MMP9 can lead to spine enlargement (Wang et al., 2008), and
depletion of MMP9 can impair functional synaptic plasticity (Frischknecht and Gundelfinger,
2012). Although normal MMP9 function may benefit synaptic plasticity in injury paradigms,
MMP activity may become aberrantly high, causing synaptic reorganization to be maladaptive
(Falo et al., 2006; Warren et al., 2012; Phillips et al., 2014). For example, assessing MMP9 role
in synaptogenesis after injury, one study showed that post-injury MMP9 inhibition reduced
lesion volume, increased dendritic spines, reduced glial reactivity, and provided enhanced
cognitive and motor recovery (Hadass et al., 2013). Further, in a model of hippocampal
deafferentation, MMP inhibition improved cognition and behavior (Falo et al., 2006; Warren et
al., 2012), suggesting the specific inhibition of aberrant elevation of MMP9 activity after injury
may prove useful. Further, time-dependent inhibition of MMP activity can shift the outcome of
synaptogenesis after deafferentation (Reeves et al., 2003; Falo et al., 2006; Warren et al., 2012),
as acute inhibition of MMP activity proves detrimental to recovery in adaptive models (Phillips
et al., 2014), yet reducing MMP activity later, when pathology drives excessive enzymatic
response, promotes better outcomes.
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OSTEOPONTIN
Structure and Cell Signaling Properties
One important secreted ECM molecule involved in facilitating cellular responses, including
those involved in inflammation, is osteopontin (OPN; Figure 1.3), also known as bone
sialoprotein 1, secreted phosphoprotein 1 (spp1), or early component of type-1 immunity (Eta-1).
Originally discovered as a bone matrix protein involved in bone resorption, and embryonically
associated with bone formation (Nakase et al., 1994; Nomura et al., 1989), OPN is also
expressed in bone, kidney, and epithelial linings (Giachelli and Steitz, 2000), as well as brain
(Shin et al., 1999) of the adult. A multifunctional protein, OPN serves as both a secreted
cytokine and immobilized matricellular protein (Singh et al., 2010; Frangogiannis, 2012; Wolak,
2014; O’Regan et al., 2000), and is a member of the SIBLING protein (small integrin binding
ligand N-linked glycoprotein) family (Smith and Denhardt, 1987; Liaw et al., 1998; Asou et al.,
2001). The size of full length OPN varies based on extent of post-translational modifications,
and has been detected in SDS-PAGE migrating between 30 and 100 kDa (Patarca et al., 1995;
Ashkar et al., 1993; Rodan, 1995; Sodek et al., 2000). Osteopontin is a highly acidic (Oldberg et
al., 1988; Denhardt and Guo et al., 1993), pleiotropic protein with a moderately conserved amino
acid sequence across species. Arginine-Glycine-Aspartate (RGD; 100% conserved), SerineValine-Valine-Tyrosine-Glycine-Leucine-Arginine (SVVYGLR; structurally conserved,
SLAYGLR in mice and rats), and Glutamine-Leucine-Valine-Threonine-AspartatePhenylalanine-Proline-Threonine-Asparatate-Leucine-Proline-Alanine-Threonine-Glutamine
(ELVTDFPTDLPATE; least conserved) sequences within the OPN protein confer binding
capability to integrin receptors (Smith and Giachelli, 1998; Scatena et al., 2007). Cleavage of
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Figure 1.3 Osteopontin Structure and Proteolysis
A. Osteopontin (OPN) structural features key to cell adhesion receptors. Proteolytic processing
exposes integrin receptor binding sequences indicated by color (ELVTDFP: green; RGD: red;
SVVYGLR: blue). Corresponding integrin receptors are listed adjacent to these cell adhesive
regions and sites of peptide phosphorylation (P) along the protein sequence are indicated.
B. MMP and thrombin cleavage sites are identified within the human OPN sequence, notably
the 166 site of MMP proteolysis which generates the N-terminal peptide with exposed RGD
integrin binding residues. C. MMP processing of OPN is shown. A 48kD amino-terminal OPN
fragment containing the RGD integrin binding sequence is generated along with a carboxyterminal 32kD OPN fragment, which is subject to further proteolytic processing. (Scatena et al.,
2007; adapted from Takafuji et al., 2007)
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OPN by matrix proteins including MMPs and thrombin (see again Figure 1.3) exposes the
critical sequences concealed by the tertiary structure of the molecule, so that they may be
uncovered to bind functional receptors and facilitate cellular responses such as chemotaxis, cell
adhesion, metastasis, and immune regulation (Shin, 2012).

Thrombin proteolysis of OPN is well characterized, while the extent of MMP proteolysis of OPN
is still being explored. The thrombin site of cleavage, immediately following the SVVYGLR
sequence, generates amino terminal fragments that bind αvβ3, α4β1, and α9β1 integrin receptors
(Barry et al., 2000; Green et al., 2001; Bayless and Davis, 2001; Bayless et al., 1998), and also
exposes the RGD sequence, which has α v specificity, and ELVTDFPTDLPATE, which binds
α4β1 (Bayless and Davis, 2001). Although some studies propose a single cleavage site for MMPs
within the thrombin cleavage sequence, between the Glycine and Leucine residues (Gao et al.,
2004), additional cleavage sites for MMP2, MMP3, MMP7, MMP9, and MMP12 have also been
uncovered (Lindsey et al., 2015; Hou et al., 2004; Agnihotri et al., 2001). Even though different
matrix enzymes can cleave OPN at unique sites, they all produce OPN fragments with similar
binding properties, even considering that cleavage by certain MMPs may disrupt integrinbinding sequences. This occurs since the proteolytic conformational changes still expose critical
integrin binding loci, one of which is the RGD sequence, which exhibits high affinity binding
after OPN cleavage (Smith et al., 1996; Senger et al., 1994).

RGD, also found in fibronectin and vitronectin, confers cell-binding properties and is involved in
the osteoblast OPN-mediated osteoclast migration process (Oldberg et al., 1986). OPN-receptor
interactions have been addressed extensively in order to better understand the mechanisms
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underlying OPN-mediated cellular functions. Liaw et al. (1995) found that the αvβ3 (vitronectin)
receptor was needed for OPN-mediated migration, while αvβ5 or αvβ1 were sufficient to promote
adhesion properties. Interestingly, αvβ3 is involved in other cell functions including apoptosis,
and is expressed highest in osteoclasts, of which OPN promotes migration during bone matrix
sculpting (Horton, 1996). OPN binding to several other integrin receptors, including α8β1, α4β7,
α4β1, and α9β1, has also been documented (Scatena et al., 2007). While OPN binding to multiple
integrin receptors is prominent, a somewhat unique interaction with hyaluronic acid receptor
CD44 has also been discovered, where dose-dependent binding of OPN to CD44 is not mediated
by chondroitin sulfate (Weber et al., 1996). Both integrin and hyaluronic acid receptors appear
important relative to OPN role in synaptogenesis, as β1 and CD44 antibodies blocked in vitro
OPN-mediated neurite outgrowth (Plantman, 2012). Interestingly, the carboxy terminal
fragment, which lacks integrin binding sites, does not mediate adhesion, as does the amino
terminal fragment, and may actually suppress OPN-mediated adhesion (Smith et al., 1996; Gao
et al., 2004; Maeda et al., 2001). There is also evidence that this smaller carboxy terminal
fragment binds CD44 (Weber et al., 1997; Weber et al., 2002; Takahashi et al., 1998; Weber et
al., 1996). The ability of OPN to bind several different matrix exposed receptors suggests its key
role in mediating autocrine and paracrine response during tissue repair, making it a viable target
for altering aberrant cell interaction throughout this process.

Several years of investigation have implicated OPN in cardiovascular disease (Singh et al.,
2007), lung dysfunction (O’Regan, 2003), cancer (Shevde and Samant, 2014), and inflammation
(Shin, 2012). Because OPN is involved in promoting several protective and pathogenic cellular
responses, including cell proliferation and apoptosis, it has been explored as a therapeutic target
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for several models of disease and injury. For example, as cancerous growth involves
uncontrolled cellular proliferation, OPN has been investigated in several oncology studies. In
preclinical cancer treatment analysis, OPN has been successfully targeted with the commercial
drug Simvastatin (Matsuura et al., 2011), which reduced OPN to both limit cell proliferation and
increase apoptosis of cancer cells, demonstrating OPN could be successfully targeted for
improved recovery.

Role in Inflammation and CNS Disease
Investigators have shown that OPN is consistently upregulated during CNS inflammation
(Ellison et al., 1999; Hashimoto et al., 2007) as well as in neurodegenerative diseases promoted
by inflammation (Maetzler et al., 2007; Comi et al., 2010). In the CNS, OPN has been detected
in microglia (Albertsson et al., 2014; Tambuyzer et al., 2012), macrophages (Gliem et al., 2015),
and astrocytes (Neuman, et al., 2014). When expressed in phagocytic microglia (Choi et al.,
2004), it increases proliferation, while reducing ROS production (Tambuyzer et al., 2012). OPN
is also involved with the promotion of macrophage infiltration (Crawford et al., 1998; Wang et
al., 1996; Weber and Cantor, 1996; Yu et al., 1998). Such macrophages secrete IL-12, which
may be T cell dependent (O’Regan et al., 2000a,b), reducing IL-10 levels and leading to type 1
immunity, often present with inflammatory disease (Ashkar et al., 2000; Weber et al., 1992). In
studies using OPN KO mice, macrophages are less cytotoxic to tumor cells (Bourassa et al.,
2004), suggesting a reduction in important inflammatory processes. Additionally, an incision
model revealed OPN KO mice produced more residual debris, and less matrix reorganization
(Liaw et al., 1998), an indication that OPN signaling is critical for proper macrophage directed
wound healing. On a larger scale, OPN can serve as metric to assay immune-mediated disease,
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indicating the extent of pathogenic effects in irritable bowel disease, hepatic disease, multiple
sclerosis, emphysema, lupus, asthma, and allergies (Rittling and Singh, 2015). For example,
OPN concentrations are elevated in blood plasma of patients with chronic inflammatory
illnesses, such as Crohn’s disease, cancer, autoimmune diseases, and obesity (Scatena et al.,
2007).

Osteopontin has also been associated with the underlying mechanisms of several
neurodegenerative diseases that may include, but are not limited to, inflammation. In the chronic
inflammatory condition multiple sclerosis (MS), a disease characterized by episodes of
neurologic impairment followed by remissions, OPN expression marks the evolution of tissue
pathobiology. Among others, Börnsten et al. (2011), found that OPN concentration was
increased in CSF of MS patients during attacks, while Chabas et al. (2001) detected OPN within
active plaques in MS patient brains, specifically in endothelial cells, microglia, astrocytes, and
macrophages. In the experimental animal model of MS, experimental autoimmune
encephalomyelitis (EAE), OPN expression was localized to T cells, macrophages, activated
microglia, and astrocytes in EAE lesions (Kim et al., 2004), a finding consistent with the clinical
presentation. Additionally, OPN was upregulated in rat brains with EAE, and not present in
those protected from EAE. Near EAE lesions, OPN was largely expressed in microglia, but also
present in neurons, although neuronal expression was exclusive to active disease states, absent in
remission, suggesting the degree of OPN present may correlate with disease severity (Chabas et
al, 2001). Loss of OPN in EAE models reduced the severity of disease (Chabas et al., 2001;
Jansson et al., 2002), while Natalizumab treatment in relapsing remitting patients reduced OPN
and as a result, improved cognitive function and reduced fatigue (Iaffaldano et al., 2014). Such
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integration of OPN and CNS inflammatory disease highlight the importance of the molecule as a
regulator of tissue inflammation, although OPN may influence other cell specific mechanisms in
different CNS pathologies.

One such pathology is Parkinson’s disease (PD), which involves the progressive
neurodegeneration of dopaminergic neurons in the substantia nigra (Bernheimer et al, 1973) and
the distinct presence of intraneuronal Lewy bodies. Several cellular mechanisms can lead to PD
including oxidative and nitrative stress, mitochondrial dysfunction, and excitotoxicity, all of
which promote cell death (Jellinger, 2001). When challenged with LPS or dopaminergic toxin 6hydroxydopamine (6-OHDA) to induce PD-like symptoms, expression of OPN and integrin and
CD44 receptors are upregulated in the substantia nigra, suggesting a neuroprotective response to
promote cell survival mechanisms (Ailane et al., 2013; Iczkiewicz et al., 2005, 2006). Further,
the Iczkiewicz group found that both OPN and an RGD peptide were neuroprotective for neurons
exposed to nigral cell neurotoxin, MPP+, in vitro (Iczkiewicz et al., 2010). Interestingly, OPN
associates with microtubule stability proteins MAP1A and MAP1B in the substantia nigra and
striatum (Long et al., 2012), an interaction that may underlie some of the neuroprotective effects
of OPN in PD. In other PD studies, however, OPN expression was downregulated and exhibited
anti-apoptotic activity (Kim et al., 2006). This is consistent with a report that OPN is localized
within substantia nigra ECM and neurons, and not nigral glia, suggesting that OPN may play a
key role in neuron survival (Iczkiewicz et al., 2006). Contrary to the beneficial effects of OPN,
others have suggested the presence of OPN in PD patient serum and CSF is an indication of
pathology, as OPN levels were highest in those with more severe motor dysfunctions (Maetzler
et al., 2007). This group also found that OPN KO produced more surviving dopaminergic
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neurons after treatment with MPTP, a neurotoxin used to model PD, further supporting the view
of OPN as a pathogenic marker (Maetzler et al., 2007).

In other neurodegenerative diseases, such as HIV-associated dementia and amyotrophic lateral
sclerosis (ALS), OPN expression in Iba-1+ microglia is high, while neurons and astrocytes also
express the protein at lower levels (Silva et al., 2015), further pointing to OPN association with
multiple CNS diseases. Moreover, Alzheimer’s disease (AD), a well-known and devastating
neurodegenerative pathology can also be associated with altered OPN expression. AD is marked
by progressive cognitive decline, as well as the presence of amyloid plaques and intraneuronal
fibrillary tangles of Tau protein. Like PD, OPN is significantly increased in the CSF and serum
of AD patients, however, this increase is associated with lower levels of cognitive decline (Comi
et al., 2010; Sun et al., 2013). Nevertheless, OPN is not only higher in newly diagnosed AD
patients (Sun et al., 2013), but it is also increased in AD pyramidal neurons (Wung et al., 2007),
and OPN expression is significantly positively correlated with increased levels of tangle forming
phospho-Tau (Heywood et al., 2015) as well as high amyloid β protein expression (Wung et al.,
2007). In an experimental AD mouse model APP/PS1KI characterized by axon degeneration
and neuronal loss, OPN was again increased along with other inflammatory mediators (Wirths et
al., 2010). These findings strongly suggest involvement of that OPN could play either
pathological or protective roles in neurodegeneration, depending on disease, disease state, or
other confounding factors.
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Role in CNS Injury and TBI
Studies utilizing different types of CNS injury models have highlighted the prominent, yet
controversial role of OPN after CNS insult. For example, OPN may both enhance repair after
adult brain injury (Doyle et al., 2008; van Velthoven et al., 2011; Chen et al., 2011), but
potentiate injury in neonatal models (Albertsson et al., 2014), suggesting possible age-dependent
effects, possibly attributed to differential integrin receptor expression. Additionally, much like
the neurodegenerative diseases discussed above, OPN levels rise after brain injury (Plantman,
2012). Also, similar to observations in neurodegenerative disease brains, OPN can be expressed
in neurons, such as in a cryolesion model, in which cortical neurons and reactive microglia both
produce OPN (Shin et al., 2005). Exploring this association further, investigators found that
macrophages and microglia produced OPN early after focal stroke, while αvβ3 vitronectin
receptor expression was upregulated later (5-15 days post-injury) in astrocytes (Ellison et al.,
1998). Similarly, Kang et al. (2008) found integrin receptors localized primarily in astrocytes,
but also report that CD44 receptor expression peaked early after forebrain ischemia (2-3 days)
and was localized to reactive microglia. Interestingly, both receptors co-localized with OPN
expression, suggesting equally important roles for OPN within reactive glia during post-injury
recovery processes in the brain. Interestingly, after ischemic stroke, OPN is localized to
infiltrating macrophages, which can cause local astrocyte polarization and activation (Gliem et
al., 2015). When OPN KOs were also subjected to ischemic stroke, animals possessed fewer
reactive, polarized astrocytes. These observations highlight an important role for OPN in
paracrine cell signaling to affect CNS glial response. In another stroke study, OPN was
administered pre- or post-middle cerebral artery occlusion (MCAO), where it reduced lesion size
and cell death, and improved motor recovery (Jin et al., 2014), likely through its RGD binding
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sequence and downstream Akt or MAPK cell signaling pathways (Meller et al., 2005). Further,
nasal administration of OPN through the FAK-PI3K-Akt pathway also reduced edema, cleaved
capsase-3, and neuronal death after subarachnoid hemorrhage (Topkoru et al., 2013), again
demonstrating overall neuroprotective effect of OPN in models of brain injury. Notably, genetic
manipulation of OPN expression (OPN KO) support similar effects on tissue repair in a variety
of injury models, with delayed wound healing (Miyazaki et al., 2008), worsened adaptive
synaptic recovery after hippocampal deafferentation (Chan et al., 2014), and reduced glial
reactivity and subsequently, more extensive histological damage after SCI (Hashimoto et al.,
2007), all suggesting OPN expression and function is important in promoting CNS recovery
processes after injury.

While OPN involvement in CNS injury has been explored, its specific role in TBI is still under
investigation. OPN and one of its receptors, CD44, have been encountered in the perilesional
area following TBI (Günther et al., 2015), localized to activated microglia and macrophages 1-4
days post-injury (von Gertten et al., 2005). Interestingly, it has been suggested that the OPNCD44 interaction leads to poor outcome, while the integrin-OPN interaction is beneficial (von
Gertten et al., 2005). In a model of hippocampal deafferentation, a common pathology occurring
after TBI, OPN expression was highest during degenerative periods, and its transcript localized
to microglia (Chan et al., 2014). The same study showed increased MMP9 lytic activity,
aberrant synaptic protein expression, and altered glial migration within deafferented zones in the
absence of OPN. These results suggest a critical role for OPN in mediating post-injury clearance
of degenerating pre-synaptic axons and modification of synaptic cytoarchitecture during synapse
reformation (Chan et al., 2014).
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OPN Interaction with MMP9
OPN is proteolytically processed by thrombin, several MMPs, plasmin, and cathepsin-D
(Christensen et al., 2010; Denhardt et al., 2001) into amino and carboxy-terminal fragments,
which usually retain functional capabilities. The MMP9-OPN enzyme-substrate relationship,
however, is a particularly important one. Notably, their interaction has been documented in a
plethora of studies, often contributing to pathogenesis of disease. For example, in MS patients
experiencing crises, not only is OPN expression increased (Börnsten et al., 2011), but OPN and
one of its target enzymes, MMP9, are both elevated in CSF of MS patients (Braitch et al., 2008),
an observation that has been correlated with MS disease severity (Romme Christensen et al.,
2013). Increased expression of both MMP9 and OPN has been detected in investigations
crossing numerous disease processes such as prostate cancer progression (Castellano et al., 2008)
and periodontal tissue regeneration (Lima et al., 2008). Co-expression of these molecules is
typically linked to critical cellular processes including cell adhesion (Wang et al., 2014),
suggesting the MMP9/OPN link is important and the implications of this interaction are worth
exploring.

In several studies, the MMP9/OPN relationship is characterized by OPN promoting MMP9
activity and downstream cellular processes. Generally, OPN level regulates MMP9 expression
(Yang et al., 2011), facilitating cell matrix remodeling in muscular dystrophy and asthma disease
models (Dahiya et al., 2011; Simoes et al., 2009). In smooth muscle cells, Liu et al. (2014)
determined that OPN increased MMP9 protein, leading to enhanced smooth muscle functions
such as proliferation and migration, while in an in vitro model of embryogenesis, OPN increased
cellular invasion by influencing MMP9 secretion (Wu et al., 2015). Notably, Lai et al. (2006)
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also demonstrated that the SVVYGLR sequence of OPN, exposed on the amino-terminal
fragment of OPN after processing, can induce pro-MMP9 expression, offering a potential
mechanism for MMP9 induction. Caers and colleagues (2006) suggested OPN interaction with
CD44v isoforms mediated the upregulation of MMP9 and subsequent cell proliferation. A more
exploratory investigation showed that carboxy terminal OPN binds CD44 to promote
chemotaxis, while β3 integrin subunit activation, likely from amino terminal OPN, increases
macrophage activation, pro-inflammatory cytokines, and MMP9 activity (Weber et al., 2002). In
2007, Desai and colleagues conducted a detailed study revealing that surface expression of CD44
was required for MMP9 secretion. They determined that the OPN/receptor interaction,
especially with αvβ3, activates Rho GTPases to increase surface CD44 expression, which then
promotes MMP9 activation, required for migration (Desai et al., 2007). Most impressive, a
majority of studies focused on OPN interaction with one receptor or another, yet this study
integrated understanding of how these are related in the same process.

Evidence of OPN-mediated MMP9 activity warrants discussion of upstream and downstream
mediators of this interaction. Upstream, TNFα appears to play in important role. A significant
positive correlation found among TNFα, OPN, MMP9, and a novel MMP9 regulator, LCN2
(Catalán et al., 2009) indicates interactive processes, while other studies more definitively
elucidate the role of TNFα. For example, in the case of psoriasis, both OPN and MMP9 levels
were enhanced by TNFα and reduced by anti-TNFα treatment (Buommino et al., 2012).
Similarly, in diabetes, TNFα and OPN also enhance MMP9 activity, and loss of OPN abrogates
MMP9 induction (Lai et al., 2006). As TNFα appears to be an upstream regulator several have
also explored the specific pathways involved in OPN-mediated MMP9 increase.
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Amino terminal OPN binding αvβ3 to facilitate activation of downstream CamKII and ERK 1/2
to activate MMP9 (Pagano and Haurani, 2006) was demonstrated in one study, while OPN/αvβ3
interaction promoted MMP9 activation through JNK1 phosphorylation in another (Rangaswami
and Kundu, 2007). Rangaswami et al. (2004) also found that αvβ3 interaction with OPN
promoted NIK-dependent MEK-1 and ERK 1/2 phosphorylations, which activate NFκB, thus
inducing MMP9 activity, and cell migration, which was blocked by MMP9 antibody.
Interestingly, several studies implicate NFκB in MMP9 induction. In the pathogenesis of aortic
aneurysms, for example, OPN upregulates MMPs through NFκB (Mi et al., 2011), while
following similar logic, Liu et al. (2010) found that OPN inhibition reduced MMP9 and MMP2
expression through IKK-2 and NFκB. Several cell-signaling cascades appear to be involved in
the intermediary processes of MMP9 induction.

Further downstream, MMP9 also promotes OPN actions through cleavage. Regardless of the
specific mechanism of MMP9 activation, it is understood that OPN acts in a positive feedback
mechanism, as enhanced MMP9 activity promotes cleavage of OPN to facilitate more OPNmediated functions. Takafuji et al. (2007) explored the enzyme-substrate relationship between
MMP9 and OPN, finding that MMP9 activity produces several OPN fragments, one of which
increased tumor cell invasion, likely mediated by CD44. Similarly, Lindsey et al. (2015)
discovered 9 cleavage sites for MMP9 within the OPN sequence, thus confirming MMP9
proteolysis of OPN. In vitro, MMP9-cleaved OPN increased macrophage migration (Tan et al.,
2013), supporting evidence that MMP9 processing produces functional OPN fragments.
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Despite the breadth of information following the reported positively correlated link between
MMP9 and OPN, some investigational studies have shown conflicting results, particularly in
those utilizing recombinant OPN to promote recovery. As expected, genetic ablation of OPN
reduced MMP9 activity in a deafferentation model of brain injury (Chan et al., 2014). Other
investigators, however, showed that MMP9 secretion was not affected by OPN KO (Koh et al.,
2007), a finding which could suggest the role of OPN upstream MMP9 is to promote activity
over secretion. In a lung injury model, recombinant OPN (rOPN) surprisingly increased TIMP1,
yet did not alter MMP9 expression, attributed to promoting an appropriate regulator/enzyme
ratio for recovery. Additionally, NFκB expression and lesion size were effectively reduced
(Zhang et al., 2014), an indication of ongoing repair mechanisms. Similarly, rOPN also
appeared to operate through this complex mechanism in brain injury models. Administration of
rOPN after intracerebral hemorrhage attenuated increase in MMP9 and ROS and improved
cognitive function (Wu et al., 2011), and pre-treatment with recombinant OPN administration
early after subarachnoid hemorrhage deactivated NFkB and reduced MMP9 activation.
Interestingly, these investigators further suggested that this may only occur in the presence of
pro-inflammatory cytokines (Suzuki et al., 2010), and integrin receptors were likely involved
(Suzuki et al., 2011). Collectively, these studies support a link between OPN and MMP9 both
with OPN-guided MMP9 activity as well as MMP9-mediated cleavage of OPN, both interactions
being critical to key cell functions in pathological and/or recovery conditions.
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MODEL SYSTEM IN PRESENT STUDY: THE OLFACTORY BULB
Cellular Organization
Olfactory deficits are often overlooked in TBI patients, where there is potential for severe
damage to the olfactory nerve, causing incapacitating loss of the sense of smell, or anosmia.
Olfaction, the most primitive sensory system (Brodal et al., 2004), plays an essential role in the
social behaviors of vertebrate animals, such as survival-dependent behaviors like food seeking,
predator evasion, and maternal preference. Although the perception of smell is less keen in
humans than in other mammals (Kandel et al., 2013), it remains extremely sensitive. Scents
detected by this complex system are an essential part of life and can alert an individual to
potential dangers or offer the pleasure to enjoy fragrant aromas. In the olfactory system,
numerous cell types work in cohort to recognize and interpret an array of molecules that animals
eventually perceive as discrete odors. Disease, aging, infection, and injury are some mechanisms
by which olfaction can be impaired in humans (Mesholam et al., 1998; Sumner, 1964; Wilson et
al., 2007), Parkinson’s disease (Doty, 2012) and head injury (Sumner, 1964) being two well
documented examples. Given the low probability of long-term olfactory recovery after injury, it
is important to understand the molecular details of olfactory system damage and address
potential avenues for regaining function.

In general, the olfactory system involves the detection of specific molecules in the nasal cavity,
transmission of signals through olfactory nerves, enhancement of output in the olfactory bulb
(OB), projection through the lateral olfactory tracts, and eventually, interpretation of smell in the
telencephalon. Of these constituents, the OB is a key component, considering a significant
amount of processing in the olfactory system occurs in the OB. Similar to complex brain regions
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and structures such as the neocortex and retina, cytoarchitectural lamination of the OB is crucial
for its proper function. Although olfaction begins in the nasal mucosa, the first part of the
olfactory system, input is refined in the layers of the OB (Figure 1.4A). In order, from the
ventral portion of the OB, these layers include the olfactory nerve layer located just above the
cribriform plate of the ethmoid bone, followed by the glomerular layer, external plexiform layer,
mitral cell body layer, internal plexiform layer, and granule cell layer (Kandel et al., 2013). Each
level possesses unique characteristics contributing to the fine discrimination necessary for
interpreting a wide range of odors.

Pseudostratified columnar epithelia line the interior of the nasal cavity (Morrison and Costanzo,
1992), making up the nasal mucosa. Olfactory epithelia include ORNs, supporting or
sustenacular cells, stem cells, microvillar cells, and Bowman’s glands (Costanzo et al., 2012;
Kandel et al., 2013). Lamination of the OB begins in the olfactory nerve layer (ONL), the
superficial OB region just above the cribriform plate, through which the ONs project to the
glomerular layer (GL). In the GL, which ORN axons do not pass, oval-shaped regions densely
populated with unmyelinated axons, dendrites, and glial processes, or neuropil, contain the axodendritic and dendro-dendritic synapses of various cell types. Chao et al. (1997) noted that these
glomeruli are compartmentalized with sensory synaptic and central synaptic layers (Figure
1.4B). These observations were validated in 2001 when Kosaka et al. (2001) confirmed separate
glomerular regions showing complex interdigitation, with differential cellular components and
molecular characteristics. The sensory synaptic portion of each glomerulus is defined by ORN
axons, which create axo-dendritic synapses with excitatory mitral and tufted cells and inhibitory
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Figure 1.4 Organization of the Olfactory Bulb
A. Several cell types comprise the layers of the OB. Olfactory receptor neurons (ORNs), which
originate in the olfactory epithelium (OE) and cross the cribriform plate, synapse onto mitral,
tufted, and centrifugal cells in the olfactory bulb (OB) glomerular layer (GL). Inhibitory
periglomerular cells surround these synapses with axo-dendritic connections, providing a source
of signal modulation. The external plexiform layer (EPL) contains post-synaptic tufted cells, as
well as dendrites of mitral cell bodies that lie within the mitral cell layer (MCL). Neurons of the
deeper granule cell layer (GCL) offer an additional level of modulation before olfactory signals
are transmitted through the lateral olfactory tract (LOT) to the olfactory cortex. B. Organization
of the GL, densely populated with sensory axons, dendrites of relay (R) and periglomerular (PG)
cells, and glia is shown. This area can be divided based on the specific synapses within each
glomerulus: sensory ORN afferents (ORN) in the outer portion (sensory synaptic; SS), and
centrifugal projections (cFA) localized to the interior regions of the glomerulus, toward the OB
core (central synaptic; CS). The glomerular layer can be further divided by the absence (A-) or
presence (A+) of astrocytes and blood vessels (BV), which are restricted to the CS compartment.
(Chao et al., 1997; Simpson and Sweazey, 2013)
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periglomerular cells. In contrast, the central synaptic layer does not contain the axons of ORNs,
but is comprised of a variety of dendro-dendritic synapses between mitral, tufted, periglomerular,
granule, and short axon cells, as well as axo-dendritic synapses with extrinsic fibers (White,
1965).

Each glomerulus is surrounded by two types of periglomerular (PG) interneurons that facilitate
inter-glomerular communication. Type 1 PG cells are found in both the sensory and central
synaptic layers and express γ–aminobutyric acid (GABA) and tyrosine hydroxylase (TH), the
rate-limiting enzyme for the production of the catecholamine neurotransmitters (Kosaka et al.,
2001). Conversely, type 2 cells only extend into the central synaptic region and express
calbindin d28k and calretinin (Kosaka et al., 2001). Electron microscopic and
immunohistochemical analyses showed that astrocytes are also distributed heterogeneously
throughout the glomerular layer, although most astroglial cell bodies are integrated with
periglomerular cells, delineating the GL from the ONL below and the external plexiform layer
(EPL) above (Valverde and Lopez-Mascaraque, 1991). Astrocytes, which mediate a number of
cellular processes to maintain the microenvironment of the OB, such as neurotransmitter uptake
and ion exchange, extend processes into one or several glomeruli to contact periglomerular cell
bodies, dendrites, and dendro-dendritic synapses (Chao et al., 1997). Interestingly, in the OB,
astrocytes do not form triad synapses with sensory cell axo-dendritic connections as they do in
other CNS structures. Although they are sparse in the sensory synaptic region, astrocytes
comprise about 7% of all cell bodies in the GL (Chao et al., 1997). Information processing
among astrocytes associated with a single glomerulus occurs through extracellular potassium
produced by neuronal activity (Roux et al., 2011). One of the first suggestions for the function
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of astrocytes in the bulb deemed them regulators of ORN axonal growth, as they promoted
growth in the ONL and GL, but also inhibited axonal progression in deeper layers of the OB
(Poston et al., 1991). In addition to these cell types, studies have shown that microglia and
endothelial cells of capillaries are also present within glomeruli, but are likely restricted to the
central synaptic compartment. Evidence suggests that microglia are present in all bulb layers,
but populate non-glomerular layers more densely than the GL (Okere and Kaba, 2000), possibly
playing a role in immune responses as well as non-glomerular synaptic function (Miyamoto et
al., 2013; Murabe and Sano, 1982).

The next layer of the OB, the external plexiform layer (EPL) contains the length of the apical and
secondary dendrites of mitral cells extending into glomeruli and protruding horizontally in the
EPL, respectively (White, 1965). Many cell bodies of the axons that course the EPL are located
in the mitral cell body layer (MCL), the next layer of the OB. Although the main cells in this
layer are mitral cells, tufted and periglomerular cells are also present, and enhance the signals
relayed from the olfactory epithelium to the olfactory cortex. Ezeh et al. (1993) noted two mitral
cell types exist, some extending their dendrites from deep within the EPL, requiring high
intensity input, while others are positioned more superficially, closer to the GL, effectively
responding to lower intensity stimuli, demonstrating cell positioning in the OB is closely
associated with function. Given that tufted cells are typically more superficial than mitral cells,
they often respond more strongly to ON stimulation (Ezeh et al., 1993).

Horizontal axons of a variety of cell types are found in the internal plexiform layer (IPL). This
layer is rich in fibers of tufted, centrifugal, and short axon cells (Shepherd, 1972). Processes of
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granule cells also pass through this layer, but originate in the granule cell layer (GCL), the
deepest layer of the OB. Granule cells, typically clustered the GCL, make reciprocal dendrodendritic synapses on mitral cells. Similar to amacrine cells of the retina, granule cells have no
identifiable primary axon, as all processes resemble dendrites (Shepherd, 1972). In 2002,
granule cells, which have been classified as the most numerous cell type in the bulb (Shepherd,
1972), were confirmed as a prominent source of inhibition in the OB through dendro-dendritic
synapses onto mitral cells, characterized by the release of GABA onto mitral cells, and the
release of glutamate from mitral cells onto granule cells (Urban, 2002). Fibers of other cell types
also appear in the GCL including the axons of mitral, tufted, and short axon cells, which
converge to form the lateral olfactory tract (LOT). Additionally, perforating the GCL are
extrinsic fibers from the telencephalon to the OB such as centrifugal fibers and projections from
brain regions including the anterior olfactory nucleus and anterior commissure (Shepherd, 1972).
The layers of the OB end with the GCL, from which the LOT projects to higher order brain
regions for cognitive processing.

The specialized bipolar sensory cells of the olfactory system, ORNs, are responsible for
detecting odorants and transmitting appropriate information to the OB. Uniquely, these cells are
the only first order sensory neurons that extend from the peripheral nervous system directly to
the brain. At the apical end of ORNs, a single dendritic process bearing abundant cilia
expressing odorant receptors projects into the nasal mucosa, while the basal end is characterized
by a thin, unmyelinated axon that courses the epithelium and terminates in the OB (Morrison and
Costanzo, 1992). In 1991, Richard Axel and Linda Buck revealed the odor detection mechanism
of the olfactory system was similar to the visual system, mediated by G-protein coupled receptor
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(GPCR) signal transduction (Buck and Axel, 1991). These GPCRs, seven transmembrane
domain receptors, are responsible for detection of odor molecules, or odorants, in the nasal
mucosa. Activation of Golf, the specific G protein localized in ORNs, triggers second messenger
adenylyl cyclase III and the subsequent production of cAMP (Menco et al., 1992) to propagate
an action potential through the unmyelinated axon toward the OB, where the signal is relayed to
other cells in glomeruli. Additionally, the ORN to glomerular ratio in the rodent is 2:1, and 16:1
in humans, as ORNs expressing the same receptor types converge on the same glomeruli (de
Castro, 2009). Each ORN expresses a single odorant receptor gene, which can detect one or a
small number of odorant molecules with similar molecular conformation (Buck and Axel, 1991).
Although only one odor receptor type is expressed on each ORN, complex combinations of
odorants result in the perception of distinct smells, termed a combinatorial receptor code (Malnic
et al., 1999). Once odor transduction has begun, signals from the olfactory mucosa are relayed to
the OB to undergo further processing.

Axons of ORNs extending from the olfactory epithelium form bundles of fibers, or fascicles, of
which about fifty form the olfactory nerve (ON), also identified as cranial nerve I. Fascicles are
defined by perineurial fibroblasts, within which lie groups of ORN axons wrapped by a special
glial type, olfactory ensheathing cells (OECs), bound by a basal lamina, and separated by
collagen fibrils (Field et al., 2003). Uniquely, S100+ and P75+ OECs exhibit similarities to both
astrocytes and Schwann cells, but are restricted to the olfactory nerve layer (Ramon-Cueto and
Nieto-Sampedro, 1992). OECs protect the vulnerable unmyelinated axons of ORNs and
facilitate their passage from the peripheral nervous system into the CNS, extending along the
length of the axons until they reach the OB, where astrocytes become the primary glial cell
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(Ramon-Cueto and Nieto-Sampedro, 1992). Furthermore, OECs exhibit phagocytic properties,
produce NFκB, TNFα, IL-1β, IL-6 as well as other inflammatory cytokines, and express
macrophage markers such as toll-like receptors and OX-42 in response to lipopolysaccharide
(LPS), a microglial activator (Su et al., 2013). Also present within each ON fascicle are Iba-1
and annexin A3 immunoreactive cells, likely microglia, the innate immune cells of the CNS,
serving as the first line of defense against CNS invasion of pathogens (Smithson and Kawaja,
2010). Projecting from the olfactory epithelium, the ON pierces the cribriform plate of the
ethmoid bone in the ventral portion of the cranium, and projects superiorly toward the ipsilateral
OB, where ONs undergo terminal ramifications and synapse onto mitral and tufted cells in
glomeruli. Each glomerulus contains numerous axonal arborizations from ONs, as ORNs only
express one receptor type and subsequently only project to one glomerulus, yet several ORNs
can express the same receptor, allowing the axonal endings of multiple ORNs to innervate each
glomerulus (Buck and Axel, 1991). In the OB, ORNs synapse onto dendritic processes of mitral,
tufted, and periglomerular cells. Axons of the mitral and tufted neurons eventually converge to
form the lateral olfactory tracts (LOT), which project to the olfactory cortex.

Synapses of the Glomerular Layer
For many years, the basic cellular composition and synaptic organization among ORN, mitral,
tufted, and periglomerular cells in the GL have been known (Pinching and Powell 1971a, b;
Pinching and Powell 1972a,b; Price and Powell, 1970; Shepherd, 1972; White, 1965). In the
GL, it has been established that olfactory axons terminate in axo-dendritic connections with
characteristic post-synaptic densities, representative of excitatory synapses. Moreover, presynaptic marker synaptophysin colocalizes with olfactory marker protein (OMP), a marker for
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ORNs. Furthermore, glutamate serves as the neurotransmitter relaying signals from ORNs to
mitral, tufted, and periglomerular cells (Berkowicz et al., 1994; Trombley and Shepherd, 1993).
This synaptic turnover is mediated by ionotropic NMDA, AMPA, and kainate receptors as well
as some metabotropic mGluR receptors (Berkowicz et al., 1994; Berkowicz and Trombley,
2000). Most synapses in the GL are between ORNs and mitral or tufted cells. In decreasing
abundance, the remaining synapses are those involving centrifugal fibers, ORNs onto
periglomerular cells, periglomerular cells onto mitral cells, and lastly mitral and tufted cells onto
periglomerular cells. For comparison, the number of periglomerular to mitral and tufted cell
synapses is twice that of mitral and tufted to periglomerular cell synapses, emphasizing the large
degree of inhibition in the GL (Kasowski et al., 1999).

Other important connections in the GL include those involving periglomerular and granule cells.
Inhibition from these interneurons contributes to feature extraction, noise reduction, and contrast
enhancement of olfactory input (Linster and Cleland, 2002). Periglomerular cells are excited by
ORNs or mitral cells, and in turn, inhibit mitral cells in the same glomerulus or in adjacent
glomeruli through lateral axonal projections (Linster and Cleland, 2002). Granule cells have
reciprocal synapses with mitral cells in the EPL, on which mitral cell secondary dendrites excite
and the granule cell dendrites inhibit. Interestingly, periglomerular and mitral cells are activated
by nicotinic acetylcholine receptor agonists, and muscarinic acetylcholine receptor agonists
inhibit granule cells, demonstrating that cholinergic fibers can both increase periglomerular
activity and decreases granule cell inhibition (Linster and Cleland, 2002). The horizontal limb of
the diagonal band of Broca provides a large source of cholinergic innervation and plays a role in
olfactory short-term learning, olfactory habituation, and discrimination of overlapping olfactory
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stimuli (De Rosa et al., 2001; Hunter and Murray, 1989; Ravel et al., 1994). Lesioning the
acetylcholine tract increases perceptual overlap, strengthening the concept that cholinergic inputs
fine-tune olfactory discrimination (Linster and Cleland, 2002).

Considering the OB is the largest dopaminergic system of the forebrain, with about 5% of all
neurons in the olfactory bulb being dopaminergic interneurons (Cave and Baker, 2009), it is
conceivable that dopamine plays a large role in olfaction. Dopaminergic periglomerular cells
receive axo-dendritic inputs and subsequently inhibit other cells of the OB, while nondopaminergic periglomerular cells, expressing calbindin and calretinin, only participate in
dendro-dendritic synapses (Kosaka et al., 1995, Kosaka et al., 1998). About 10-16% of all
periglomerular cells restricted to the glomerular layer are dopaminergic and coexpress GABA
(Kosaka et al., 1995; Lledo et al., 2006; Parrish-Aungst et al., 2007). Hyperpolarizing neurons
by mediating the influx of negatively charged chloride ions or the efflux of positively charged
potassium ions, GABA is an important inhibitory neurotransmitter (Purves et al., 2008).
Together, GABA and dopamine contribute to olfactory discrimination by modifying sensory
information traveling from the bulb, proven by an enhanced responsiveness and inability to
discriminate odors due to olfactory deprivation-mediated decreases in OB dopamine levels
(Lazarini and Lledo, 2011). One purpose of dopamine in the GL is to modulate the release of
glutamate from ORNs (Berkowicz and Trombley, 2000). Evidence of the importance of
dopamine in the olfactory system is highlighted in Parkinson’s disease, in which the
degeneration of dopaminergic neurons often results in a characteristic loss of olfaction (Doty,
2012). Interestingly, dopaminergic modulation of synaptic transmission occurs through presynaptic D2 receptors present on inhibitory neurons (Cave and Baker, 2009; Ennis et al., 2001).
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Activation of these D2 receptors decreases cAMP and inhibits adenylyl cyclase, thus reducing
the number of pre-synaptic vesicles released in the GL. Additionally, concentrations of tyrosine
hydroxylase, dopamine production, GABA release, and glutamate decarboxylase mRNA
expression are all reduced by D2 activation. These reductions result in decreased inhibition of
mitral and tufted cell output, leading to enhanced synaptic transmission (Berkowicz and
Trombley, 2000).

As briefly mentioned, synapsins are the major phosphoproteins localized to nerve terminals
(Johnson et al., 1972), which can serve as functional synaptic markers. Both Synapsin-I and
Synapsin-II form two isoforms that have been detected (Südhof and Jahn, 1991), all having
identical amino terminal regions and variable carboxy-terminals. These synaptic proteins bind to
elements of cytoskeleton including microfilaments, microtubules, and αII-spectrin (Baines and
Bennet, 1985; Baines and Bennet, 1986; Bähler and Greengard, 1987; Petrucci and Morrow,
1987) to control synaptic vesicle release. Functionally, Synapsin-I in the OB is required in
GABAergic interneurons for short-term habituation (Sadanandappa et al., 2013) and early odor
memory formation (Knapek et al., 2010). A role for Synapsin-II has also been uncovered for
pre-synaptic GABA release synchronization (Medrihan et al., 2015) through interaction with presynaptic calcium channels (Medrihan et al., 2013), which facilitates control of neurotransmitter
release at inhibitory synapses. Interestingly, Synapsin-I expression has largely been found in the
OB core, with mRNA mostly found in the MCL and GCL in adult rat (Melloni et al., 1993),
while Synapsin-II has primarily been detected in the GL (Stone et al., 1994), where ORNs
synapse onto their post-synaptic targets. Understanding the anatomical organization, synaptic
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components, and mediators of plasticity of the OB provides a basis for addressing concerns
regarding dysfunction of the olfactory system observed after injury.

Induction of Post-Traumatic Anosmia
Beginning as early as the 19th century, there have been documented cases of post-traumatic loss
of smell, or anosmia, yet all processes underlying olfactory dysfunction and the mechanisms to
restore olfaction remain elusive (Costanzo et al., 2012). Several case studies have been
conducted over the past decades, demonstrating the persistence of TBI related anosmia. An
estimated 15-20% of TBI patients experience anosmia when a cerebral contusion is involved
(Hagan, 1967), along with 31% of patients with severe head injuries experiencing post-traumatic
amnesia for more than 24 hours (Sumner, 1964). The incidence is drastically reduced to 3-8%
for those who sustain injuries with no loss of consciousness or post-traumatic amnesia lasting
less than one hour (Sumner, 1964). Costanzo and Becker (1986) reported that males between the
ages of 15 and 24 make up a substantial percentage of reported cases of post-traumatic anosmia
with most head injuries sustained by motor vehicle accidents. In 1991, Costanzo and Zasler
(1991) reported incidence of post-traumatic anosmia around 25-30% of all severe head injuries,
15-19% of moderate injuries, and 0-16% of mild head injuries, which is in accord with older
reports of olfactory disturbances associated with head trauma (Sumner et al., 1964). These data
indicate a correlation between degree of TBI and the probability of acquiring anosmia. Most
often, TBIs result from strikes to the frontal cortex, but TBIs caused by falls and other events
leading to blows to the occipital lobe present a greater incidence of anosmia (Costanzo et al.,
2012). Patients with occipital impact injuries appear five times more likely to suffer olfactory
impairments than those with frontal head injuries (Sumner, 1964) due to the coup and contre-
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coup forces involved. It has been established that complete loss of smell is often irreversible, but
phenomena such as hyposmia, in which olfaction is diminished, or dysosmia, in which it is
distorted, may resolve over time, indicating that post-injury synaptic plasticity is involved.
Overall, changes in the ability to perceive odors can significantly reduce quality of life for TBI
patients.

Head trauma can induce anosmia by three primary mechanisms. Trauma to the face, resulting in
broken facial bones causes superficial damage to the olfactory epithelium and disruption of the
sinonasal tract (Costanzo et al., 2012). Similar injuries can also follow medical treatments and
processes such as the use of a nasal cannula to assist breathing, which can directly damage nasal
epithelia, and some medications, which can inadvertently impede the function of smell. The
most common mechanism of post-traumatic anosmia, however, may result as a consequence of
the anatomical arrangement of the olfactory nerves, which makes them vulnerable to stretching
and severing (Costanzo et al., 2012). Shearing forces caused by the involuntary rapid
acceleration and deceleration of the brain can damage ORN axons at the point at which they
course through the cribriform plate, leading to partial deafferentation of the OB, altered synaptic
circuitry, and subsequent olfactory dysfunction. Additionally, notable damage to other olfactory
structures in patients presenting with post-traumatic anosmia has been observed, with the most
common sites of injury being the olfactory bulbs and olfactory tracts, followed by the interior
frontal lobes (Yousem et al., 1996). Hagan (1967) showed that damage to the lateral olfactory
tracts and cortical regions can cause disturbances in olfaction, although the incidence is low. As
the OB sits beneath the cortex in the human brain, just superior to the cribriform plate, direct
focal damage directly to the OB is not very common. Moreover, MRI studies have revealed that
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complete anosmia due to cortical injury is unlikely, considering the lack of olfactory impairment
linked to specific higher order brain regions of the olfactory cortex. Although there were no
direct comparisons between TBI patients with and without anosmia in these MRI studies, the
volume of bulbs and tracts in anosmic patients was reduced in comparison to normosmic or
hyposmic patients (Yousem et al., 1996), possibly as a result of synaptic loss.

Development of anosmia following broken facial bones, use of nasal cannula, or medications
may be remedied with surgery, nasal steroid sprays, or ceasing use of medication, respectively
(Costanzo et al., 2012). Post-traumatic anosmia as a result of head injury, however, has a limited
propensity for recovery. Literature suggests spontaneous recovery due to regeneration of
olfactory receptor neurons occurs at a rate of around 30%, with Ikeda et al. reporting 24%,
Costanzo and Becker suggesting 33%, and Doty et al. proposing 36% (Costanzo and Becker,
1986; Doty et al., 1997; Ikeda et al., 1995). Despite the breadth of information implicating posttraumatic anosmia as a pathological result of head injuries, experimental treatments have yet to
prove effective. Clinical studies exploring potential therapeutics for post-traumatic anosmia
have had limited success, but current experimental investigations in rodents show great promise.
In addition to the heterogeneity of head injuries, obtaining human subjects or samples for
experimentation has proven difficult, complicating translation from bench to bedside.

Diagnosis of Anosmia
Diagnosis of anosmia often offers a poor prognosis, although a few cases have reported
functional recovery after long periods of time. Most clinical studies show there is a limited
chance of recovery which typically occurs between twelve weeks and two years after head
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trauma (Reiter et al., 2004; Sumner, 1964), while some have documented patients regaining a
sense of smell five, seven, and even nine years after diagnosis (Mueller and Hummel, 2009;
Sumner et al., 1964; Zusho, 1982).

Odorant identification provides an important avenue for diagnosis of anosmia following head
injury, as odor quality perception is altered following olfactory nerve transection (Yee and
Costanzo, 1998). Unfortunately, subjective olfactory tests can be compromised by cognitive
deficits or other effects of injury. In lieu of these tests, common neuroimaging technologies may
be utilized for assessing olfactory damage. High resolution CT scans are useful diagnostic tools
for evaluating damage caused by bones, while MRIs prove useful for analyzing soft tissue
damage (Costanzo et al., 2012). Recently, Rombaux et al. (2012) revealed OB volume at the
time of diagnosis of olfactory dysfunction may be prognostic in evaluating the likelihood of
recovery from post-traumatic or post-infectious olfactory loss. Gender, age, size of OB,
mechanism of olfactory loss, and specific olfactory dysfunction proved to play a role in the rate
of recovery, as women, young patients, and those with OBs larger than 40mm3, showed that
postinfectious olfactory loss, and hyposmia, rather than anosmia, demonstrated the best chances
of recovery (Rombaux et al., 2012). There are a number of diagnostic methods for identifying
patients with post-traumatic anosmia, but effective treatments for olfactory impairment have yet
to be determined.

One of the most common diagnostic tests employed for post-traumatic anosmia is the University
of Pennsylvania Smell Identification Test (UPSIT), a simple test involving the identification of
forty olfactory cues, for which four different multiple choice options are provided for each
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sample odorant. The number of correct choices determines patients’ scores, which are classified
into one of six categories to confirm overall degree of olfactory deficit (Doty et al., 1984). In
addition to differences found regarding age, race, and smoking habits, there are also slight
differences related to gender, as a score of 34-40 is normal for men, and 35-40 is normal for
women (Doty et al, 1997). Other less extensive smell tests have been developed from the
UPSIT, including the 5-item pocket smell test and the 12-item brief smell identification test
(Costanzo et al., 2012). Tests such as the UPSIT and the University of Connecticut
Chemosensory Clinical Research Center Test are useful, assessing both detection and
identification of odorants, while others only offer a strategy for detection. Some tests, such as
the T&T Olfactometry and Alinamin tests, address recognition thresholds, while others like the
Alberta Smell Test focus on laterality of olfaction (Costanzo et al., 2012). As some assessments
of olfactory performance may be expensive, extensive, and time-consuming, methods such as
Sniffin’ sticks have been developed to decrease time and costs for quick diagnosis (Kobal et al.,
1996).

Post-Traumatic Anosmia and Quality of Life
Despite an understanding of the debilitating consequences of post-traumatic anosmia, few have
detailed the specific ways in which quality of life can be reduced. Drummond et al. (2013)
conducted a study evaluating the impact of anosmia in everyday tasks. Patients reported
enduring a wide range of emotions from embarrassment to loss of identity. Depression has also
been documented as a common consequence of the inability to smell (Atanasova et al., 2008;
Callahan and Hinkenbein, 1999; Negoias et al., 2010). Those with anosmia who hold olfactiondependent occupations such as chefs, florists, chemists, and firefighters are likely to experience a
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greater degree of frustration, considering their lives are strongly based on the proper function of
the olfactory system (Costanzo et al., 2012). Additionally, for those with careers that do not
require a keen sense of smell, quality of life is still severely diminished considering daily
activates involving safety, hygiene, and child care become exponentially more difficult.

OB Plasticity and Approaches for Inducing Repair
Published reports have shown that, even after injury, ORNs maintain and exhibit a clear
regenerative capacity. For example, at 35d post olfactory nerve transection, a deafferentation
model, small ovoid collections in the glomerular layer and smaller glomerular-like structures
throughout the OB indicate ORN regeneration and, albeit distorted, reinnervation of the OB
(Morrison and Costanzo, 1995). Studies injecting the olfactory epithelium with horseradish
peroxidase to label pre- and post-synaptic terminals also suggest these regenerative ORNs are
functional. Focusing more on specific stages of regeneration, Hirata et al. (2008) conducted
studies utilizing sodium dimethyldithiocarbamate, or DDTC, which severely damages the
olfactory epithelium. Electron microscopic analyses showed both recovery of olfactory vesicles
with immature profiles at 3 weeks after DDTC injection, indicating ORN reinnervation of the
OB, and mature, specialized ORN cilia appearing at 6 weeks, representing restoration of
synapses (Hirata et al., 2008). Despite regeneration and extension into the OB, it has been
proven that ORN axons can project to inappropriate OB layers, incorrectly and partially
innervating multiple glomeruli instead of one, likely due to competition among axons to occupy
synapses (Costanzo, 2005). Notably, ORNs must course a long path between the olfactory
epithelium and the glomeruli of the OB, making synaptogenesis difficult and lengthening the
time for recovery. Although ORNs are capable of regeneration into the OB, abnormal synaptic
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connections may underlie the persistence of olfactory impairment after injury, suggesting
mechanisms of this regenerative plasticity should be explored to help facilitate proper synapse
formation to restore function.

As mitral cells are one of the main output cells of the OB projecting to the olfactory cortex, some
recovery studies have focused on their functional repair instead of that served by input fibers.
Olfactory tract transection (OTT) studies revealed 3-4 weeks after OTT, mitral cell numbers
decreased significantly and returned to normal at 5 weeks. In a similar pattern, neurotrophic
factors FGF-2, IGF-1, and BDNF were significantly increased at 2, 5, and 6 weeks after
transection (Mansoor et al., 2012), suggesting these molecules may have a functional role in
restoring cell counts. Mitral cell function after OTT has also been explored
electrophysiologically. At 120 days after transection, structural and functional recovery were
confirmed by synchronized firing between mitral cells and the piriform cortex (Anil et al., 2012),
suggesting restored mitral cell function could be an additional factor in the spontaneous recovery
seen in some anosmic patients.

Although olfactory deficits persist after TBI, the olfactory system has a strong propensity for
regeneration from several sources, including stem cell replacement. Basal cells of the olfactory
epithelium are a major source of stem cells for ORNs throughout life, yet the subventricular zone
(SVZ) along the lateral ventricles contains the largest pool of neural stem cells produced into
adulthood and also provides adult stem cells that eventually integrate into the OB. Neuroblasts
originating in the SVZ travel through the rostral migratory stream (RMS) to the OB where
majority become granule and periglomerular cell interneurons (Carleton et al., 2003; Kishi,
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1987; Luskin, 1993). Many studies have focused on this neurogenesis as a source of functional
recovery, but implications have yet to be fully defined. In models of TBI and stroke,
neurogenesis has been largely examined in the context of SVZ migration into the injured OB
(Kernie and Parent, 2010; Radomski et al., 2013). Increasing new interneurons in the OB
enhances olfactory memory, and a decrease alters olfactory discrimination (Carleton et al.,
2003), showing these cells play an important role in OB plasticity and could contribute to
functional recovery of post-traumatic anosmia. In injury models such as cortical contusion, SVZ
proliferation increased, yet olfactory discrimination deficits persisted at 30d (Radomski et al.,
2013). Interestingly, Thored et al. (2009) found that after focal ischemia, neuroblasts from the
SVZ are redirected from the RMS to the site of injury, therefore reducing the number of new
neurons migrating to the OB, possibly contributing to the persistence of anosmia in TBI cases
with clear vascular pathology. Conversely, others have documented transient expression of
nestin+ radial glial cells after destruction of the olfactory epithelium (Hirata et al., 2008), which
could indicate migration from the subventricular zone to degenerating terminals at the site of
injury (Duggal et al., 1997) to promote recovery mechanisms.

In exploring the mechanism for regulation of OB cell replacement, some investigators have
examined the effects of inflammation during neurogenesis. According to Lazarini et al. (2012),
neuroprotective antibiotic Minocycline decreases inflammation and increases the survival of
adult-born neurons by preventing the phagocytic properties of microglia, including impairment
of neurogenesis. Suggesting the same concept of inflammation-mediated SVZ neuroblast
inhibition, Tepavčević et al. (2011) demonstrated decreased SVZ neuronal supply to the OB in
targeted experimental autoimmune encephalomyelitis (EAE) models of chronic inflammation,
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which induced long term olfactory memory impairment, while short-term memory and odor
discrimination were unaffected. These findings not only demonstrate an inflammation-mediated
reduction of SVZ generated stem cells after injury, but also imply granule and periglomerular
interneurons produced by the migrating SVZ cells could be important factors involved in longterm OB plasticity. While inflammation may play a role in SVZ neurogenesis, conflicting
evidence exists on the effects of reactive glia such as microglia in this process (Sierra et al.,
2010; Thored et al., 2009). Anti-inflammatory drugs have proven to increase survival of strokegenerated neurobalasts (Hoehn et al., 2005), yet chronically activated microglia permitted
positive neuronal differentiation and survival in mouse cultures (Cacci et al., 2008).
Additionally, Yan et al. (2007) noted activated microglia and reactive astrocytes express
monocyte chemoattractant protein-1 (MCP-1), which promotes migration of neuroblasts.
Interestingly, MCP-1 is elevated in areas of the brain vulnerable to TBI (Woodcock and
Morganti-Kossmann, 2013). Although not immediately related to microglial function, the Yan
research group (2006) also reported IGF-1 as an important modulator of neural precursor cell
proliferation in the SVZ, and neural progenitors express IGF-1 receptors, an important find
considering secreted IGF-1 can act as a chemoattractant critical for olfactory nerve innervation
of the OB (Scolnick et al., 2008). Taken together, these studies showing that neurogenesis
affects OB regeneration provide insight as to how neurons and glia interact during restoration of
OB circuitry and function after TBI.

As an alternative approach, some investigators have suggested steroid treatment or the use of
Vitamin A to alleviate olfactory dysfunction after injury, but limited success has been achieved
(Ikeda et al., 1995). In one study, listing trauma as an exclusion factor, anosmic patients given
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combined steroid treatment with systemic prednisolone and topical glucocorticoid fluticasone
propionate demonstrated improved olfactory function (Blomqvist et al., 2003). Conversely, in a
clinical investigation conducted by Jiang et al. (2010), which explored the efficacy of
prednisolone for restoring the sense of smell in patients with head trauma, some cases showed
signs of recovery, but the data were considered inconclusive due to small sample size and the
inability to obtain all appropriate control groups. Additionally, the possibility of spontaneous
recovery, a well-documented phenomenon, was not addressed in these results, and could be
explained by the fact that some participants may have regained olfactory function after circuit
regeneration. Similarly, a double-blind, placebo-controlled, randomized clinical trial assessing
the potential of Vitamin A as a treatment for post-traumatic anosmia revealed no effect when
administered orally (Reden et al., 2012), however, retinoic acid, a byproduct of Vitamin A and
promoted extension of regenerated ORNs in the OB (Luxenhofer et al., 2008). Vitamin A
treatment also improved recovery in an experimental rodent model of trauma, validated by a
decreased latency for finding buried food (Yee and Rawson, 2000).

In another clinical trial, zinc sulfate, a compound which can enhance regeneration, appeared a
more promising treatment for patients with post-traumatic anosmia rather than post-viral
anosmia (Aiba et al., 1998). As post-traumatic anosmia is most often acquired from severance of
select ORN axons and post-viral anosmia involves complete cell loss in the olfactory epithelium,
enhanced regeneration supported by spared basal cells in patients with post-traumatic anosmia is
more probable considering the olfactory epithelium is not completely destroyed. Although a
variety of potential treatments may prove useful for some anosmic patients, many do not seem to
significantly affect anosmia induced by TBI. One explanation is that those which are successful,
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like steroids, act superficially on the nasal epithelium, reducing inflammation to permit
regeneration. This is probably due to the fact that cell-mediated inflammation induced by TBI
indirectly affects the nasal cavities, attenuating regeneration and undermining olfactory
impairment after trauma.

Treatment of Olfactory Dysfunction in Animal Models
Regarding olfactory dysfunction after TBI, animal models present a challenge, as behaviors,
especially those mediated by smell, are not identical to humans. However, experiments in the
laboratory certainly offer invaluable insight for understanding TBI pathology. Considering the
superior sense of smell in other mammals and rodents, similar animal models can in fact be
excellent for testing olfaction. For example, application of steroids has not been particularly
effective in the clinic, however, administration of steroids at early time points after injury have
facilitated functional recovery in the rat (Kobayashi and Costanzo, 2009). Other drug treatments
have also been explored in rodent models in order to facilitate olfactory bulb recovery.
Minocycline, a known neuroprotective anti-inflammatory antibiotic, prevents decrease in bulb
volume after injury (Siopi et al., 2012), suggesting the overall reduction in inflammatory
processes also prevents some neurodegenerative processes. Similarly, Etazolate, an α secretase
activator, also exhibited neuroprotective effects in the rodent OB after TBI by decreasing edema
and IL-1β levels, increasing sAPPα and cAMP, and improving functional recovery (Siopi et al.,
2013). Although administration of drugs seems the most likely treatment for TBI patients, some
studies explore the effects of environmental enrichment in recovery. Johnson et al. (2013) found
that environmental enrichment before TBI protects against functional deficits, increasing spatial
memory and sensory discrimination after TBI. One study conducted by Yee and Costanzo
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(1998) suggested that odor training could enhance olfactory discrimination, revealing that
pharmacological intervention is not necessarily the only treatment mechanism capable of
restoring the sense of smell. Each of these approaches to improve synaptic reorganization in
animal models of TBI are feasible for clinical translation and have potential to serve as therapies
for olfactory dysfunction after brain injury.

OB Synaptogenesis after Injury
Synaptic replacement in the OB is more complex than in most other areas of the CNS. It not
only involves local axonal sprouting at sites of new synapse structure, but requires generation of
new pre-synaptic neurons and growth of their axons over much greater distances to reach new
post-synaptic sites. Basal stem cells of the nasal epithelium regenerate ORNs every month in the
human (Moulton, 1974) – a process which leads to the differentiation of new pre-synaptic
sensory cells and reinnervation of OB synapses. Despite a fairly intact olfactory epithelium after
injury, IHC and ultrastructural analyses of biopsied tissue from patients with post-traumatic
anosmia displayed olfactory epithelia distinctly different from those of control subjects (Jafek et
al., 1989; Kern et al., 2000). Cells in the epithelium were less compact, enlarged, and nuclei
were rearranged. ORNs of these patients bore no cilia for sensory reception, one clear
morphological confirmation that olfaction was inhibited. Additionally, axon tangles appeared in
the epithelium revealing passage of ORNs to the OB was inhibited (Jafek et al., 1989), possibly
due to trauma-induced fibrotic scarring at the base of the cribriform plate, which often occurs if
both the ORN axons and the OB are injured, and could underlie altered mapping of odorant
patterns in the OB after injury (Costanzo, 2005; Kobayashi and Costanzo, 2009). Considering
sensory ciliogenesis and establishment of contact between ORN axons and their post-synaptic
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OB targets are concurrent processes (Cuscheri and Bannister, 1975), the limited reinnervation of
the OB could explain the lack of cilia on the visualized ORNs.

From animal models of OB damage we know that axons of nascent ORNs are capable of
growing into nonspecific target regions and forming synapses (around 20 days after bulbectomy
in the mouse), despite having no appropriate mitral or tufted cell post-synaptic target (Graziadei
et al., 1978). Axonal growth supporting synaptic reinnervation in the OB differs from local
collateral axon sprouting that occurs to replace damaged terminals in other brain regions, as the
olfactory sensory cells must differentiate, mature, extend axons that migrate a considerable
distance to their targets and form synapses. This process takes between 60 and 120 days postdeafferentation in the rodent olfactory system (Graziadei et al., 1978; Graziadei et al., 1979), as
terminal degeneration occurs 1-15 days after axotomy, regeneration between 15-60 days, and
synapse stabilization extends well past 60+ days post-axotomy. Under normal conditions, axons
of these neurons grow and re-innervate the post-synaptic mitral and tufted cell targets in the
glomerular layer (Nagayama et al., 2014) either as part of typical physiological processes or in
response to traumatic injury. Chemical ablation of ORNs with Triton X-100 (Nathan et al.,
2001) and methyl bromide (MeBr; Bakos et al., 2010) has demonstrated that these cells can also
regenerate after complete epithelial loss.

Olfactory nerve transection, which more accurately models the OB deafferentation after TBI, has
also been explored, and functional assays have proven that regeneration can occur as ORNs form
appropriate connections with post-synaptic targets. Early studies in the pigeon documented
regrowth of sensory neurons after ON transection with recovered behavioral and
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electrophysiological responses (Oley et al., 1975), and near normal synaptic organization
manifesting 30-50d after axotomy (Graziadei and Okano, 1979; Morrison and Costanzo, 1995).
Behavioral analyses supported these findings, with first instances of recovery at 19d, but normal
behavior not exhibited until 40d post-transection (Yee and Costanzo, 1995). Similarly, utilizing
horseradish peroxidase (HRP), which is transferred from a pre- to post-synaptic cell in functional
synapses, and electrophysiology, comparing electrical input in pre-synaptic cells to output from
post-synaptic cells, other investigators have shown that ORNs form functional synapses after
injury. For example, following nerve transection, no HRP staining was detected 4d post-lesion
(Morrison and Costanzo, 1995), while HRP was distributed in a uniform pattern much later,
revealing 70% reinnervation by 32d and 100% reconnection by 64 and 96d (Jennings et al.,
1995). Electrophysiology conducted to detect responses to odor stimuli presented to hamsters
with transected ORNs similarly showed that longer recovery periods produced greater responses
to stimuli (Costanzo et al., 1985). Later, Koster and Costanzo (1996) also demonstrated that
negative evoked potentials (NEPs) were detected after transection, but failed to reach control
amplitude, even by 120d post-injury, documenting potential for reconnection but persistent
functional deficits.

Complimenting HRP and electrophysiological analyses of ORN recovery, OMP, a cytoplasmic
protein specific for mature ORNs and integral to normal sensory neuron function, has also been
measured as a marker of synaptogenesis. Reliably, independent of mechanism of denervation,
OMP is reduced in several models of OB injury. Both Triton X-100 and MeBr reduced OMP 7
and 15d post-epithelial ablation, respectively, recovering expression by 40d (Bakos et al., 2010;
Nathan et al., 2001), while complete bulbectomy reduced OMP at 11d, returning to control levels
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by 35-49d after loss of input (Tsukatani et al., 2003; Inamitsu et al., 1990). Nerve transection
models demonstrate the sensitivity of OMP measurements, showing that OMP was lost 3-10d
post-injury (Costanzo et al., 2006; Kobayashi et al., 2013), a quicker reduction and return than
other models, reflecting a deafferentation-dependent and propensity for recovery. Interestingly,
although OMP has been used as a marker of synaptogenesis because of its restricted presence in
ORNs, it has also been associated with another marker of synaptogenesis, GAP-43. Tsukatani et
al. (2003) demonstrated that when OMP was reduced most, GAP-43 levels in the olfactory
epithelium peaked, while Griff and colleagues (2000) suggested a regulatory mechanism
between the two, proposing that OMP downregulates GAP-43 such that when OMP is lost, GAP43 is upregulated, promoting formation of several immature neurons.

Unfortunately, olfactory deficits commonly persist after TBI, despite ORN neurogenesis and
reactive synaptogenesis. For example, reduced olfactory function persisted up to 120 days after
olfactory nerve transection and OB deafferentation in the mouse, documented by negative
evoked potentials, although synapse structure had been restored (Koster and Costanzo, 1996). In
this case, it is likely that the ORNs do extend processes, attempting to form viable synapses, but
part of the connections are inappropriate, lacking functional utility (Costanzo, 2005). While this
process may only be aberrant in a subset of synapses, it still serves as an excellent model to study
persistent maladaptive synaptogenesis and define mechanisms of regeneration that may be
manipulated to improve olfactory outcome. Interestingly, this outcome is consistent with postinjury clinical observations. Despite aberrant connectivity after injury, the basic phases of
reactive synaptogenesis still occur in the OB: terminal degeneration, axon sprouting and synapse
reinnervation, and synapse stabilization (Monti Graziadei and Graziadei, 1979). Thus, a study of
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the processes governing OB reinnervation may also offer additional answers as to which cellular
mechanisms control synaptic plasticity in other brain regions.

Due to secondary injury induced by TBI, a number of molecules are upregulated after insult. As
in other regions of the brain, ECM components, including matrix metalloproteinases have been
implicated in post-injury synaptogenesis in the OB. In particular, gelatinases A and B (MMP2,
9) are robustly upregulated in deafferented OB, suggesting they may be important in post-injury
synaptic reorganization. In nerve transection models, for example, MMP9 peaks at 1d, however,
does remain elevated over controls throughout the entire OB degenerative period, up to 15d after
injury (Costanzo et al., 2006; Kobayashi et al., 2013), while MMP2 expression peaks somewhat
later, at 7d (Costanzo and Perrino, 2008), and returns to control levels more quickly. Olfactory
epithelial loss, on the other hand, causes MMP9 to peak at 5d, slower than ON transection, and
MMP2 to peak at 5d, sooner but less robust than transection (Bakos et al., 2010). The
differential activation of the gelatinases with rapid MMP9 peak and later MMP2 peak, and
MMP9 KO animals confirming that these are independent processes, suggests a degenerative
function for MMP9 and greater role for MMP2 in regeneration and elongation (Costanzo and
Perrino, 2008). Similarly, others have suggested MMP9 is more closely associated with
deafferentation, while MMP2 plays a greater role in recovery (Zuo et al., 1998; Hsu et al., 2006;
Phillips and Reeves, 2001). These rapid MMP peaks are followed by decreased levels of OMP,
suggesting gelatinases may be important in mediating clearance of ORNs. Upregulation of these
molecules, which are also linked to synaptic plasticity of the hippocampus (Dziembowska and
Wlodarczyk, 2012; Phillips et al., 2014), suggests they play a similar role in promoting plasticity
in the OB. Glial cells most likely contribute to this increase in MMPs after injury to the OB, as
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olfactory ensheathing cells expressing MMP2 have been considered necessary for axonal
regeneration in the OB (Pastrana et al., 2006), and microglia and astrocytes have historically
been principal producers of MMPs, especially in injury paradigms. In addition to early
investigations showing that phagocytic cells infiltrate 2-3d after nerve transection (Monti
Graziadei and Graziadei, 1979), Costanzo et al. (2006) found post-knife lesion elevation in
GFAP concurrent with OMP loss, yet surprisingly, the MMP9 peak preceded the GFAP increase
and OMP reduction (Costanzo et al., 2006). These important molecules represent a number of
factors involved in injury progression, and could potentially serve as targets for therapeutic
intervention, as synaptogenesis of the OB may be mediated by these proteases.

MOUSE OB AS A MODEL OF TBI-INDUCED REACTIVE SYNAPTOGENESIS
OB Deafferentation Models
Different cells throughout the brain are axotomized after TBI. ORNs are subject to injury from
head trauma by several mechanisms, one of which includes OB displacement along the
cribriform plate, causing sensory axons traversing through the bony structure to become
stretched and/or severed (Costanzo et al., 2012) at the point at which they cross. As a result,
olfactory function can be severely impaired, as the injured axons often undergo Wallerian
degeneration and subsequently retract synaptic input from the OB. The stem cells of the
olfactory epithelium and the ability of differentiated nascent sensory neurons to innervate the OB
provided the framework for the development of injury models that directly deafferent the OB to
assess molecular processes promoting reinnervation after traumatic axotomy and denervation.
One methodology which mimics ORN damage caused by severe TBI, the ON knife lesion, or
transection, directly axotomizes the cells, as a blade is used to cut the ON just below the
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cribriform plate, thus deafferenting the OB. Interestingly, the composition of the blade can
dictate severity (Kobayashi and Costanzo, 2009), offering the benefit of graded injuries to
distinguish traits of synaptogenesis that may be unique to level of injury. This model can
damage both ORN axons as well as OB structures, modeling clinical aspects of traumatic impact
where several components of the olfactory system are injured. Conversely, chemical ablation of
the olfactory epithelium, which causes widespread ORN death without damaging the OBs
(Bakos et al., 2010; Nathan et al., 2001), offers a more direct analysis of the process of OB
reinnervation without confounding factors related to OB injury, such as glial scar formation.
Recently, Steuer and colleagues (2014) have proposed a rodent model that applies direct impact
force to physically shift the OB perpendicular to ORN input, generating major ORN axon
damage at the cribriform plate and significant loss of ORNs in the OE. While this model may
mimic aspects of olfactory insult in more severe human TBI, the model directly damages the OB
and ORNs, making the study of deafferentation-induced reactive synaptogenesis difficult. By
contrast, the central fluid percussion injury model (FPI), which displaces brain matter using a
fluid pressure pulse, causes a more diffuse, widespread axonal damage without contusional
injury, permitting the assessment of synaptic repair in a variety of brain regions. Adapted from
Dixon et al. (1987), FPI has been successfully modified for mice (Carbonell et al., 1998) and
historically applied to study cortical, hippocampal, thalamic, and optic nerve damage. Our
studies will utilize mild FPI to generate ORN axotomy and olfactory deafferentation without
focal OB damage. We will test whether such FPI induces novel MMP9/OPN mediated cell
reactivity to regulate TBI-induced OB reactive synaptogenesis.
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MMP9 Knockout (KO) Mice, Brain Injury, and Neuroplasticity
Given the implications of MMP9 in CNS development and pathology, several laboratories have
utilized MMP9 KO animals to study the role of MMP9 in CNS pathobiology and the
neuroplasticity it induces. Genetically modified mice in which MMP9 expression is absent, yet
who are phenotypically identical to the WT FVB/NJ background strain, were first generated in
1998 for studies of MMP role in angiogenesis and apoptosis (Vu et al., 1998). More recent
studies have used these KO mice to show MMP role in the evolution of variety of CNS insults.
For example, Mizoguchi et al. (2011) showed that seizure phenotype could be attenuated in
MMP9 KO mice, attributing the effect to a reduced MMP9 processing of pro-brain-derived
neurotrophic factor (BDNF), thereby diminishing abnormal recurrent mossy fiber sprouting in
the hippocampus. Further, sensitivity to pentylenetetrazol (PTZ)-induced epileptogenesis was
likewise decreased in MMP9 KO animals, likely through the same aberrant terminal sprouting
mechanism (Wilczynski et al., 2008). MMP9 KO animals have also been used to confirm the
enzyme’s role in pathogenesis resulting from certain types of brain injury, as well as the extent
of functional deficits produced in these models. For instance, MMP9 KO mice exhibited slightly
better motor skills and reduced lesion size acutely in the controlled cortical impact (CCI) model
of TBI (Wang et al., 2000), and after transient global or focal cerebral ischemia, MMP9 KO
attenuated cerebral damage (Copin et al., 2005; Lee et al., 2004). In these cases, it is likely that
MMP9 KO prevented enzyme-associated disruption of ECM and vascular disorganization,
resulting in more favorable outcomes. Alternatively, MMP9 may act in a positive role to
promote neuroplasticity for improved synaptic function. Axotomy induced by TBI often results
in deafferentation and synaptic loss. In this context, several studies have shown that loss of
MMP9 significantly disrupts critical ECM reorganization necessary for successful synaptic
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plasticity. For example, loss of MMP9 impairs long-term potentiation (Nagy et al., 2006), a
cellular model for synaptic plasticity associated with learning and memory. Sensory deprivation
in the rodent barrel cortex also causes collateral sprouting of spared fibers, a process which is
attenuated in MMP-9 deficient mice (Kaliszewska et al., 2012). As specific mechanisms are still
being explored for MMP9 role in reactive synaptogenesis, genetic models such as MMP9 KOs
offer excellent experimental options for identifying those underlying processes. We propose that
these genetically modified animals will be valuable for exploring the MMP9/OPN role in OB
synaptic recovery.

Summary and Hypothesis for Present Study
The prevalence of head trauma, its persistent deficits and limited therapeutic options have
encouraged decades of study, typically focusing on cortical injury and subsequent memory,
motor, behavioral, and sensory loss. Anosmia is a common post-traumatic sensory dysfunction,
attributed to OB deafferentation caused by both primary and secondary injury mechanisms.
While such impaired olfaction has long been identified as an effect of TBI (Costanzo and Zasler,
1991; Sumner, 1964; Hagan, 1967; Costanzo et al., 2012), the processes underlying persistent
anosmia and specific mechanisms of OB recovery from trauma-induced axotomy and
deafferentation are poorly understood. Studies in both cortical brain regions and OB point to
ECM components, like MMPs, as major mediators of repair following injury. Given that many
aspects of MMP9-mediated plasticity are still unknown, and one of its novel substrates, OPN,
has potential to improve neuronal integrity and function after brain injury, we believe that
MMP9/OPN interaction is worth investigating in a TBI model of OB deafferentation. The
regenerative capacity of the olfactory system, established MMP9 response to OB injury, and
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OPN fragment-mediated glial cell reactivity to trauma all suggest that a MMP9/OPN pathway
may be instrumental for OB synaptic plasticity. We hypothesize that TBI induces timedependent changes in MMP9 activity, producing functional receptor-binding of OPN signaling
fragments in the deafferented OB. Further, we posit that the binding of these fragments to matrix
receptors leads to glial cell response which promotes reorganization of the ECM to facilitate
reactive synaptogenesis.

We will employ the fluid percussion TBI model (FPI) in mice to administer widespread, diffuse
damage to dissect the MMP9/OPN relationship in ORN reinnervation of the OB after a mild
level of injury-induced denervation. In order to first document induction of injury and
subsequent synaptogenesis, we will use Western blot protein analysis to assess axonal
degeneration, as well as the loss and reemergence of several pre-synaptic markers. Additionally,
we will analyze qualitative changes in synaptic and glial morphology using transmission electron
microscopy (TEM) and immunohistochemistry (IHC). Gelatin zymography experiments will
allow us to document the time course of MMP9 activity, which can be correlated with OPN
fragment generation and receptor expression detected by Western blot. OB distribution of
critical proteins in the MMP9/OPN pathway will be mapped with IHC. Our studies will examine
1, 3, 7 and 21d survival intervals, representing specific degenerative/regenerative phases of OB
synaptic repair.

To confirm that TBI-induced synaptic changes and altered ECM protein expression are indeed
dependent upon MMP9, we will probe the same molecular and structural outcome measures in
MMP9 KO mice subjected to FPI and allowed to survive for the same postinjury intervals.

88

Changes in the progression of synaptogenesis will be compared with WT cases to confirm
MMP9 role in OB deafferentation-mediated plasticity. We hypothesize that loss of MMP9 will
significantly alter both the time course of WT synaptic recovery, as well as the OPN and glial
cell changes induced by injury, allowing us to more precisely identify its role in OB reactive
synaptogenesis.
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CHAPTER 2

DIFFUSE FPI LEADS TO OB REACTIVE SYNAPTOGENESIS
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ABSTRACT
Head trauma can cause olfactory disturbances in up to 30% of patients. The OB is a plastic brain
region with strong regenerative capacity, however, olfactory deficits can persist long after TBI.
Previous approaches to understanding injury-induced reactive synaptogenesis have largely
focused on focal axotomy of the sensory ORNs, which is a primary mechanism for posttraumatic loss of smell. Here, we utilized diffuse FPI to induce OB deafferentation and reactive
synaptogenesis. We hypothesized that FPI would damage ORN axons, leading to retraction of
input to OB synapses and initiation of appropriate cellular responses to facilitate repair during a
21d recovery period, when axotomized ORN axons begin to reinnervate the OB. Analysis of OB
protein extracts revealed calpain-cleaved 150kD αII-spectrin breakdown product elevated at 3d
post-injury. This corresponded with a 3d reduction in protein expression and tissue distribution
of a marker of mature ORNs, OMP. Normalization of OMP followed at 7 and 21d postinjury,
during early onset of regeneration. While exploration of Synapsin-I and Synapsin-II did not
show time-dependent injury changes in protein level, robust upregulation of GAP-43 at the 21d
mark indicated initiation of synaptic sprouting. Imunohistochemistry (IHC) was employed to
demonstrate that mild FPI was sufficient to produce an inflammatory response. We found that
morphology of GFAP+ astrocytes and IBA1+ microglia changed most prominently 3d after FPI,
indicative of glial activation. Lastly, we utilized transmission electron microscopy (TEM) to
visualize synaptic morphology and axon cytoarchitecture following TBI and found extensive
ORN axon disorganization, pre-synaptic terminal degeneration, and evidence of glial
phagocytosis at 3 and 7d postinjury. By 21d, post-synaptic densities begin to become more
pronounced, and pre-synaptic ORNs appeared to be shifting into a more normal arrangement.
Together these data confirm a process of sensory neuron damage, clearance of cellular debris,
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and synaptic repair. Overall, we have demonstrated that diffuse FPI can induce reactive
synaptogenesis in the mouse OB, which provides a solid model for exploring mediators of
plasticity in Chapters 3 and 4.

INTRODUCTION
TBI is a serious public health concern and financial burden in the United States. Immediate
consequences of severe TBI can be devastating, but the long-term effects of mild TBIs can also
prove problematic. It is well documented that TBI-induced axotomy will deafferent synaptic
circuits and alter neuronal function (Phillips et al., 2014; Povlishock and Katz, 2005). In
addition to cognitive, motor, and behavioral dysfunctions, sensory systems are also vulnerable to
functional deficits resulting from altered synapses. The prevalence of olfactory dysfunction after
head trauma (Costanzo and Zasler, 1991; Sumner, 1964; Hagan, 1967; Costanzo et al., 2012)
demonstrates the widespread effects a TBI produces. Brain plasticity and the propensity to
recover from multiple types of head trauma have been studied extensively in the hippocampus,
cortex, cerebellum, and thalamus. Further, the plasticity of the OB, a site of constant
neurogenesis, and where regenerating ORNs project new terminals under normal physiological
conditions, has also been investigated in injury paradigms. ORNs, regularly reinnervate mitral
and tufted cell synapses in the OB GL, serving as an excellent model to explore the molecular
mechanism directing synaptic repair induced by TBI deafferentation of the OB. TBI-induced
olfactory dysfunction has been studied in models of total olfactory epithelium ablation and focal
OB deafferentation with olfactory nerve (ON) knife lesions. In several preclinical investigations
of OB deafferentation, ORNs have been shown to reinnervate the OB and reestablish function
once new GL synapses are formed (Graziadei et al., 1978; Koster and Costanzo, 1996; Costanzo,
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1985; Morrison and Costanzo, 1995; Yee and Costanzo, 1995; Oley et al., 1975; Jennings et al.,
1995). Although these studies successfully model OB deafferentation for analysis of subsequent
synaptogenic processes, they do not address the partial axotomy likely produced by diffuse TBI.
We utilized mild central FPI, a less focal, non-contusion TBI model, which does not produce
complete ON axotomy, but rather offers insight to evolution of recovery in the clinical cases
where only a subset of ORN processes are axotomized after a mild head injury.

We chose to explore the molecular pathways involved in TBI-induced reactive synaptogenesis,
focusing on the role of extracellular matrix (ECM) proteins. In order to investigate OB synaptic
reorganization after TBI, it was important to first establish that our FPI model, which injures
cortex, hippocampus, corpus callosum, cerebellum, thalamus, and other brain regions (Sato et al.,
2001), delivers a sufficient injury to the OB to drive reactive synaptogenesis. Utilizing FVB/NJ
mice, we administered a mild level FPI, and collected OB samples at 1, 3, 7, or 21d postinjury or
perfused OB tissue at 3, 7, or 21d after TBI. Based on literature analyses outlining the time
course of OB reinnervation (Graziadei et al., 1978; Graziadei et al., 1979), these time points were
chosen to reflect periods of acute/subacute degeneration (1-7d) and early regeneration (21d).
Western blot technique was the primary assay used to document molecular changes in the OB
after injury. We first demonstrated the extent of injury in the OB by measuring αII-spectrin
fragment generation. Increase of mixed calpain and caspase derived 145-150kD fragments and a
120kD αII-spectrin peptide generated by caspase-3 have been used as benchmarks to confirm
cytoskeletal disruption associated with axonal breakdown. Lysis of αII-spectrin has been a
useful marker to confirm TBI axotomy over multiple injury models and brain regions (Hall et al.,
2005; Newcomb et al., 1997; Park et al., 2007; Reeves et al., 2010; Saatman et al., 2003; Serbest
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et al., 2007), suggesting it would be a valuable tool in our analyses. Early stages of
synaptogenesis also require removal of dying pre-synaptic terminals, achieved through the
induction of reactive gliosis. Although olfactory ensheathing cells (OECs) support the
development and extension of ORN axons, and can engulf cellular debris, as well as produce
important ECM molecules such as MMPs (Gueye et al., 2011; Pastrana et al., 2006; Su et al.,
2013; Yui et al., 2014), OB microglia and astrocytes are more intimately associated with ORN
synaptic sites and likely mediate ongoing synaptic plasticity in the structure. After injury,
endogenous microglia and astrocytes shift from resting to activated forms, clearing degenerating
axon terminals from the area and reorganizing the post-synaptic environment for synaptogenesis.
To document the extent of FPI-induced gliosis in the OB, we employed IHC to detect
morphological changes in microglia and astrocytes after TBI, with the goal of better
understanding their role in both inflammatory cell-mediated processes and induction of synaptic
recovery. As discussed in Chapter 1, primary and secondary injury processes can lead to axonal
perturbations that may not be readily detectable. Ultrastructural examination of OB offers
detailed analysis of cytoskeletal structure, axonal integrity and degeneration. To assess synaptic
changes resulting from injury-evoked axon cytoskeletal destabilization, we employed TEM, to
assay intra and intercellular changes in cytoarchitecture and connectivity of synapses, which will
clarify the extent of OB injury with FPI.

Our qualitative approach for detecting synaptic change on an ultrastructural level warranted
quantitative analyses of synaptic plasticity as well. Four molecular markers of OB
neuroplasticity were used to confirm FPI-induced synaptic reorganization. Initially, we
employed Western blot (WB) technique to assess postinjury generation of functional synapses by
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measuring levels of Synapsin-I and Synapsin-II, synaptic vesicle docking proteins of the presynaptic terminal, which can change after TBI. Reduction in Synapsin proteins typically
indicates a loss of synapses, as the pre-synaptic terminal is dysfunctional without these proteins.
The time course of the disappearance and reemergence of these proteins could also provide
insight to the time-dependent phases of synaptogenesis in the OB subjected to FPI. Both
synapsins are expressed in the OB, but Synapsin-II is more localized to the GL (Stone et al.,
1994). We propose to use this differential expression to our advantage, to hone in on GLspecific synaptic change. Additionally, neuronal markers can be used to evaluate changes in
synaptic integrity. For our OB-specific investigation, we measured changes in OMP expression,
a cytoplasmic protein of mature ORNs that has been used extensively to label pre-synaptic cells
of the GL and track ORN axon regeneration (Bakos et al., 2010; Costanzo et al., 2006; MontiGraziadei et al., 1977; Inamitsu et al., 1990; Kobayashi et al., 2013; Nathan et al., 2001;
Tsukatani et al., 2003). Loss of OMP is detected in OB protein extracts as well as IHC of OB
tissue sections in other models of OB deafferentation, an indication that pre-synaptic input is
lost. Because we are interested in the extent of OB deafferentation after FPI, we measured OMP
protein levels in OB protein samples as well as distribution of OMP expression in the GL during
the defined postinjury time course outlined above. Time-dependent changes in OMP expression
promoted our understanding of GL-specific synaptic changes occurring in response to diffuse
brain injury. In order to more fully understand the process of synapse regeneration in the OB
after FPI, we also identified the extent of successful OB synaptic targeting using GAP-43. This
protein has been routinely used as a marker of axon terminal sprouting, and its presence an
indicator of the formation of new synapses (Benowitz et al, 1990; De la Monte et al., 1989;
Verhaagen et al., 1993; Sachdeva et al., 2016; Williams et al., 2015; Wang et al., 2014; Goto et
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al., 1994; Carmichael et al., 2005; Hulsebosch et al., 1998; Stroemer et al, 1993; Gorup et al.,
2015). Increase in GAP-43 after OB deafferentation suggests successful synaptic targeting of
pre-synaptic neurons to post-synaptic cells. The prevalence of TBI and post-traumatic olfactory
dysfunction coupled with the paucity of information available on OB injury in diffuse models of
TBI support our proposed investigation. We hypothesize that FPI will induce injury in FVB/NJ
mouse OB, deafferent the ORN target GL synapses, and will be confirmed with current,
established methods of injury detection.

METHODS
Experimental Animals
All procedures met national guidelines for care and use of laboratory animals, and all
experimental protocols were approved by the VCU Institutional Animal Care and Use
Committee. FVB/NJ WT adult male mice (The Jackson Laboratory, Bar Harbor, ME) were
housed (4 littermates/cage) under a temperature (22ºC) and humidity controlled environment,
with food and water ad libitum, and subjected to a 12h dark-light cycle. WT mice (20-30g; 8-11
weeks old) were randomly selected and subjected to midline FPI. WT sham-injured cases served
as control. Subsets of FPI and sham-injured groups [WT Sham (n=48), WT FVB TBI (n=53)]
were allowed to survive for either 1, 3, 7 or 21d post-injury prior to molecular or histological
analysis.

Surgery Preparation and Injury
Mice were anesthetized with isoflurane (4% in 100% O2 carrier gas) and maintained on 2.5%
isoflurane in carrier gas delivered by nose cone. Once stabilized in a stereotaxic frame, heads
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were shaved, body temperature maintained at 40ºC by Gaymar T/Pump water pump (Gaymar
Industries Inc., Orchard Park, NY) and heart rate (bpm), arterial oxygen saturation (percent O2),
breath rate (brpm) and pulse/breath distension (µm) monitored by pulse oximetry (MouseOx;
Starr Life Sciences, Oakmont, PA). Mice then received a midline incision and a 2.7 mm
craniectomy prepared over the midline, centered between bregma and lambda. Without
damaging the underlying dura, a Leur-Loc syringe hub was cemented to the skull surrounding
the craniectomy and dental acrylic poured around the hub to stabilize the site. Topical
anesthetic/antibiotic was applied to the incision site and the mice housed in recovery cages.
After one hour of surgical recovery, mice were anesthetized for 4 mins (4% isoflurane, 100%
O2), and subjected to FPI as previously described (Dixon et al., 1987; Reeves et al., 2012). The
device consisted of a 60 x 4.5 cm Plexiglas water filled cylinder, fitted at one end with a piston
mounted on O-rings, with the opposite end housing a pressure transducer (EPN-0300A; Entran
Devices, Inc., Fairfield, NJ). At the time of injury, the Leur-Loc fitting, filled with saline, was
attached to the transducer housing. Injury was produced by a metal pendulum striking the
piston, transiently injecting a small volume of saline into the cranial cavity and briefly deforming
the brain tissue (20 millisecond pulse duration). The resulting pressure pulse was recorded extra
cranially and registered 1.3±0.1 atm pressure. After injury, all mice were promptly ventilated
with room air until spontaneous breathing resumed. The duration of suppression of the righting
reflex (5.0±2.0 mins) was used as an index of traumatic unconsciousness. Once righting reflex
was determined, mice were re-anesthetized for hub removal, scalp suture and topical
anesthetic/antibiotic application. Sham-injured controls received the same surgical preparation,
anesthesia and connection to the injury device, except that the intracranial pressure pulse was not

97

applied. All animals were returned to their home cages and assessed for weight loss, locomotion,
and eye/nose exudate once per day until weights stabilized.

Protein Extraction
WT mice were anaesthetized with 4% isoflurane in carrier gas of 100% O2 for 4 min, then
sacrificed by decapitation at 1, 3, 7 or 21d after FPI or sham injury, with bilateral OBs dissected
(n=4-7/group) for assessment of protein expression. Tissue samples were homogenized on ice in
100 µl of RIPA Lysis Buffer (EMD Millipore, Billerica, MA), and centrifuged at 14,000 x g for
20 min at 4°C. Supernatant was aliquoted and stored at -80°C. Prior to WB analysis, protein
concentration was determined using Pierce BCA Protein Assay Reagent (Thermo-Fisher,
Waltham, MA) and the FLUOstar Optima plate reader (BMG Labtech, Inc., Cary, NC).

Western Blotting
WB analysis was carried out utilizing Bio-Rad products (Hercules, CA). Twenty µg of protein
was prepared in WB XT Sample Buffer and reducing agent (Bio-Rad Laboratories), then
denatured at 95˚C for 5 mins. Samples were electrophoresed on 4-12% or 12% Bis-Tris
Criterion XT gels (200v x 45 min in MOPS running buffer), then protein transferred onto
polyvinylidene fluoride (PVDF) membranes (1h at 100V). Post-blotted gels were stained with
0.1% Coomassie Brilliant Blue (Sigma-Aldrich, St. Louis, MO) in 40%MeOH+10% glacial
acetic acid, then de-stained at RT to confirm protein load and even transfer. Membranes were
rinsed with deionized water and Tris-buffered saline (TBS) before blocking with 5% milk TBSTween (mTBS-T). Blots were then incubated in 5% mTBS-T overnight (4°C) with individual
primary antibodies to αII-spectrin (1:2,000, Enzo, Farmington, NY), Synapsin-I (1:500, Santa
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Cruz, Dallas, TX), Synapsin-II (1:4,000, EMD Millipore, Billerica, MA), olfactory marker
protein (OMP; 1:20,000, Wako, Richmond, VA), and growth associated protein-43 (GAP-43;
1:1,000, Santa Cruz, Dallas, TX). After primary incubation, membranes were washed with
mTBS-T, then incubated with appropriate HRP-linked secondary antibodies [IgG bovine antigoat (1:15,000, Santa Cruz, Dallas, TX), IgG goat anti-mouse (1:15,000, Rockland
Immunochemicals Inc., Limerick, PA)] in mTBS-T for 1h at RT. Finally, blots were washed
with mTBS-T and antibody binding visualized using Super Signal Dura West
chemiluminescence substrate (Thermo-Fisher, Waltham, MA). WB images were captured with
Syngene G:Box and positive band signal subjected to densitometric analysis (relative optical
density, ROD) with Gene Tools software (Syngene, Frederick, MD). Protein data were
expressed as percent change relative to paired WT Sham control cases run on the same
transferred gel. Cyclophillin A (EMD Millipore, Billerica, MA) or beta actin (Sigma-Aldrich,
St. Louis, MO) was used as load controls for signal detection.

Immunohistochemistry
At 3, 7 and 21d post-injury WT injured and WT sham mice (n=4/group) were prepared for
fluorescent IHC analysis according to published protocol (Warren et al., 2012). Animals were
anaesthetized with sodium pentobarbital (400mg/kg, i.p.), transcardially perfused with 0.9%
saline followed by 4% paraformaldehyde in phosphate buffer (0.1M NaHPO4, pH=7.4), after
which brains with attached OBs were extracted and placed in fixative for 24 h before transfer to
0.03% NaN3in 1.0 M phosphate buffered saline (PBS). For IHC, fixed brains were cryoprotected
in 30% sucrose for 3d, sucrose solutions exchanged after each day. Frontal lobes were blocked
and attached bulbs mounted in Tissue Tek media (Thermo-Fisher, Waltham, MA) and stored at -
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80°C. Coronal cryostat OB sections (13µM) were collected using a Cryostar™NX70;
Cryotome™FSE; HM525 NX cryostat (Thermo-Fisher, Waltham, MA) and prepared for
immunofluorescence visualization.
Free floating sections were first permeabilized in 5% peroxidase for 30 mins. After a wash with
PBS, tissues were pre-incubated in blocking buffer (fish gelatin in PBS + 0.05% triton X-100) to
prevent non-specific binding, and then incubated overnight in primary antibody (OMP, 1:20,000,
Wako, Richmond, VA; glial fibrillary acidic protein [GFAP], 1:20,000, Dako; ionized calcium
binding adaptor protein [IBA1] for microglia, 1:300, Wako, Richmond, VA) at 4°C. Sections
were next washed with PBS, placed in blocking buffer for 30 mins, after which they were
incubated with secondary fluorescent antibody (Alexa-Fluor 488 donkey anti-goat, 1:1000 and
Alexa-Fluor 594 donkey anti-rabbit, 1:1000, Thermo-Fisher, Waltham, MA) in Blotto for 1h at
RT. Slices were then PBS washed, equilibrated in phosphate buffer, and mounted on Superfrost
Plus slides (Fisher Scientific, Pittsburgh, PA) with Vectashield + DAPI (Vector Laboratories,
Burlingame, CA). IHC signal was visualized on the Zeiss LSM 700 (Carl Zeiss, Thornwood,
NY) confocal microscope (VCU Microscopy Core).

Transmission Electron Microcopy
Following FPI, WT injured and WT Sham-injured mice were randomly assigned to either 3, 7 or
21d survival groups (n=4/group). At time of sacrifice, mice were anesthetized with sodium
pentobarbital (400mg/kg, i.p.), transcardially perfused with mixed aldehyde fixative (2%
paraformaldehyde and 2.5% glutaraldehyde) in 0.1M phosphate buffer, pH-7.2. Brains were
removed and post-fixed overnight at 4°C. OBs were next blocked in the sagittal plane and
placed in 1% osmium tetroxide (0.1 M cacodylate buffer), and processed for embedment with

100

Epon resin (Embed; Electron Microscopy Sciences, Hatfield, PA). After curing, OB areas
containing glomeruli were mounted and both semi-thin (0.5µm) and ultrathin (silver, 600 Å)
sections were cut with a Leica EM UC6i ultramicrotome (Leica Microsystems, Wetzlar,
Germany). Semi-thin sections were used to guide subsequent ultrastructural sampling. Ultrathin
sections were collected on membrane Formvar-coated slotted grids and observed on a JEOL
JEM-1230 electron microscope (JEOL USA, Inc., Peabody, MA), equipped with a Gatan
UltraScan 4000SP CCD camera (Gatan, Inc., Pleasanton, CA).

Statistics
The effects of injury, and the time postinjury, on protein levels were evaluated using GLM SPSS
v.23 (International Business Machines, Corp., Armonk, NY). These analyses used 2-way
completely randomized ANOVAs. Specific pairwise comparisons were evaluated using the
Duncan Post Hoc Test. Western blot and zymography results are reported as mean +/- SEM. An
alpha level of 0.05 was used in all analyses.

RESULTS
Alpha II-spectrin proteolysis is increased after FPI
Investigation of reactive synaptogenesis in the OB requires that a valid model for induction of
deafferentation injury be established. In order to determine the extent of ORN axonal damage
within WT FVB/NJ mice following FPI, we first examined injury-induced production of αIIspectrin breakdown products, as the profile of these αII-spectrin proteolytic fragments within the
OB after TBI was unknown. We and others have previously used level of αII-spectrin fragments
to characterize extent of axonal injury, revealing increased expression after TBI (Reeves et al.,
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Figure 2.1 OB αII-spectrin expression after FPI
A. Western blot (WB) analysis of αII-spectrin breakdown products in OB extracts. Acute, 1d
expression of the150kD calpain-derived αII-spectrin fragment was reduced by approximately
50%, but the effect was not statistically significant. However, by 3d postinjury, 150kD αIIspectrin was elevated over 3-fold, supporting a peak in FPI induced axon degradation at that
time point. No other change in calpain-derived αII-spectrin proteolytic fragments (either 150 or
145kD) was detected. Post hoc analysis confirmed the time-dependent elevation of 150kD αIIspectrin between 1 and 3d postinjury. Notably, caspase-cleaved 120kD αII-spectrin remained
unchanged across all time points. Results are expressed as percent of sham control relative
optical density (100% dashed line). B. Representative blot images of 150kD, 145kD, and
120kD αII-spectrin lanes, with cyclophilin A and β-actin load controls, are illustrated below.
#p<0.05 day x vs. y, **p<0.01 Sham vs. TBI. N=4-8/group.

102

103

2010; Pike et al., 1998; Buki et al., 1999; Ringger et al., 2004; Thompson et al., 2006). With
WB methods, we examined changes in OB caspase and calpain-mediated αII-spectrin proteolysis
during postinjury intervals of 1, 3, 7, and 21d, a period mapping axon degeneration (1-7d) and
initial synaptic regenerative (21d) phases. Results suggest that mild diffuse FPI does produce
OB axotomy, however, significant change in αII-spectrin proteolytic fragment generation was
limited, and restricted to a large increase the 150kD fragment. For the calpain-derived 150,
145kD peptides, there was a non-significant trend toward reduction at 1d relative to sham
controls (52.68±11.90; 69.83±12.87), but no detectable shift in caspase-derived 120kD αIIspectrin signal (90.00±11.71). By contrast, at 3d we found significant, nearly 4-fold elevation in
postinjury 150kD αII-spectrin relative to sham injured controls (380.77±129.58, p<0.01) (Figure
2.1). Levels of the 3d 145kD fragment (107.02±10.20) and 120kD fragment (104.14±8.18) were
not different from controls. These acute 3d postinjury changes in αII-spectrin proteolysis are
consistent with delayed onset of OB axon degeneration (Costanzo et al., 2006; Graziadei and
Monti Graziadei, 1980) and our observation that ORN axon marker protein OMP shows
significant reduction at the same 3d time point (see Figure 2.6 below). For the later
degenerative (7d) and early regenerative (21d) phases, we found no change in αII-spectrin
fragments at 150kD (130.50±26.46; 107.21±38.98) and 145kD (109.77±25.42; 102.98±16.50),
or at 120kD (119.27±18.85; 101.26±16.44). Post hoc comparison of the different survival time
points did show a significant change in 150kD αII-spectrin expression between 1 and 3d
(p<0.05), but failed to detect time-dependent differences for any other time comparisons. We
conclude that there is at least a 24h delay in expression of the αII-spectrin axon degeneration
marker within the OB after FPI induced axotomy and that the mechanism underlying production
of the 150kD breakdown product is predominant. This later 3d peak of αII-spectrin processing
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could be attributed to the length of ORN axon projections from OE to the OB and the
subsequently delayed/longer time course of synaptic reorganization. Further, no differences in
120kD αII-spectrin were detected, either relative to sham-injured cases or over time postinjury,
suggesting little involvement of caspase-3 in OB cell death and axon terminal breakdown. This
pattern of αII-spectrin proteolysis shows that time-dependent generation of OB axonal damage
does occur in our TBI model. The time frame of this degeneration is consistent with that
reported after complete ON axotomy and olfactory epithelium (OE) sensory neuron ablation
(Costanzo et al., 2006; Costanzo and Perrino, 2008; Bakos et al., 2010; Nathan et al., 2001;
Graziadei and Monti Graziadei, 1980), which follows a pattern of profound degeneration over
the first week post-lesion.

OB glia change morphology in response to FPI
Understanding the time course of αII-spectrin expression leads to questions regarding the cellular
mechanism underlying these degradative processes. Breakdown and accumulation of αIIspectrin, indicative of damaged OB axons, requires a process of removal these axons from the
extracellular matrix (ECM) of affected brain regions before effective terminal sprouting can
begin. In most cases of CNS trauma resulting in axonal injury, degeneration, and local synaptic
deafferentation, reactive glia such as astrocytes and microglia are the principal cells responsible
for ECM clearance to promote plasticity. Focusing on 3, 7, and 21d after injury, we next utilized
IHC to examine cell morphological changes in OB neuroglia after FPI, as they can often
contribute to axon breakdown and debris clearance. Interestingly, astrocytes, labeled with glial
fibrillary acidic protein (GFAP) antibody, were most reactive at 3d postinjury (Figure 2.2A),
exhibiting prominent hypertrophy with extended processes interdigitating deafferented
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Figure 2.2 Immunohistochemistry (IHC) of OB glial phenotypes after diffuse FPI
A. Confocal imaging of sham cases shows GFAP labeled astrocytes principally within the GL,
wrapping and infiltrating synaptic-rich glomeruli. At 3d postinjury, reactive astrocytes are
observed within the deafferented GL, where their cell processes were thick and hypertrophic
(arrows). Over time postinjury, astrocyte reactivity becomes more diffuse, with a less intense
signal (7-21d). B. Sham IBA1 labeled microglial cells displayed a resting ramified morphology
in GL and EPL, with long, thin processes and small cell bodies. At 3d after FPI, both regions
appeared to contain greater numbers of activated microglia with rounded cell bodies and thick,
bushy processes (arrows). At 7d, this microglial response was attenuated, with the reactive cells
having less amoeboid morphology. By 21d postinjury, microglia were more ramified and
resembled those in sham animals. Scale bar = 50µm. N=3-4/group.
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glomeruli. Their processes were long and thick at 3d postinjury, their most reactive phenotype,
gradually reducing over time, as they returned to a less reactive stellate-like appearance by 7d
postinjury. Utilizing ionized calcium-binding adaptor molecule 1 (IBA1) antibody to mark
microglia, we also found that these cells were highly reactive within the 3d injured OB when
compared with paired sham controls (Figure 2.2B). Microglia shifted from a resting, ramified
morphology detected in shams to an activated form, with enlarged, amoeboid cell bodies and
lobular cytoplasmic processes. At 7d postinjury, microglial reactivity was reduced relative to the
3d response, but remained above that of sham-injured animals, possessing slightly longer
processes and smaller cell bodies, as they began to return to a less reactive phenotype. By 21d,
when early synaptic regeneration is reported in other models of OB deafferentation (Graziadei
and Monti-Graziadei, 1980; Cummings et al., 2000), glial phenotypes were not different from
sham cases. Astrocytes, both in sham and injured animals, were primarily localized to the GL,
however, microglial response was not restricted, presenting in all layers of the OB. These results
demonstrate that the predicted activation of endogenous OB glia (Bailey and Shipley, 2003;
Lazarini et al., 2012) occurs in response to FPI axotomy, and suggest that synaptic morphology
changes during the same postinjury intervals.

Expression of ORN marker OMP changes after FPI
To narrow our focus on the investigation of ORN-specific synaptic change, we next probed the
same FVB/NJ OB extracts for change in expression of OMP, a cytoplasmic protein selective for
mature ORNs and their axons (Monti-Graziadei et al., 1977; Cummings et al., 2000; Griff et al.,
2000; Holtmaat et al., 1995; Kasowski et al., 1999; Stone et al., 1994). Taking OMP reduction
as a metric for ORN axon loss (Figure 2.3), we found evidence for onset of axon damage at 3d
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after FPI, consistent with our predicted induction of pathology due to diffuse axotomy, and the
rather delayed time course of ORN degeneration seen in other models of OB deafferentation. At
1d postinjury, OMP protein was equivalent to control levels (100.84±11.17), but by 3d we found
a significant reduction in the 19kD OMP signal to approximately 62% of control (61.84±10.09,
p<0.05). Interestingly, at 7d after injury, OMP protein had returned to near sham control values
(90.76±11.34) and reached a mean slightly higher than controls by 21d onset of the regenerative
phase (108.69±7.54). This 3d reduction in OMP showed time-dependent differences from both
1d (p<0.05) and 21d (p<0.01) values, indicating that the 3d interval was a critical point in the
evolution of OB postinjury axon degeneration. The fact that 7d OMP levels approach sham
controls, but a 3d versus 7d comparison did not show significant temporal differences suggests
that the 3-7d interval is critical for shifting from ORN degeneration to regeneration in our model.
Further, this intriguing result opens the possibility that onset of OB regeneration may be a
function of extent of injury and that more local sprouting could contribute to reinnervation in our
model.

Similarly, IHC showed a detectable loss and later return of OMP in the GL beginning at 3d
postinjury (Figure 2.4), while OMP staining remained strong across time points in the olfactory
nerve layer. These findings suggest a time period of 3d is required for onset of axon
degeneration, and that OMP positive terminals, marking synapse regeneration, could emerge as
early as 7d after FPI. Our results also show that the time course of OMP reduction and
restoration after FPI is similar to that observed during postnatal injury and ORN reinnervation of
OB glomeruli (Gonzalez and Silver, 1994), as well as that described for OB synaptogenesis after
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Figure 2.3 FPI induces OB time-dependent reduction of OMP
A. WB probe of ORN axon marker protein OMP showed significant postinjury reduction in the
OB. While OMP expression did not change at 1d postinjury, by 3d it was significantly reduced
to 60% of sham level. This supports subacute loss of mature ORN axons in the OB after FPI and
is consistent with 3d peak in GL glial reactivity. However, by 7d OB OMP expression had
increased to a level not different from controls. At 21d, predicted onset of OB reinnervation,
OMP protein was slightly higher than sham cases. Post hoc comparison of time points showed
that the 3d OMP reduction was significantly lower than both 1d and 21d protein levels, but not
from 7d values. This result further supports 3d postinjury as the period of peak axon
degeneration. Results are expressed as percent of sham control relative optical density (100%
dashed line). B. Representative blot images of OMP, with cyclophilin A and β-actin load
controls, are illustrated below. #p<0.05 day x vs. y, ##p<0.01 day x vs. y, *p<0.05 Sham vs.
TBI. N=5-6/group.
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Figure 2.4 IHC of OMP distribution in OB after FPI
A. Confocal imaging of OMP in sham controls shows heavy ONL labeling and signal within
pre-synaptic ORN axons innervating OB glomeruli (GL; arrow). B. At 3d postinjury, GL
staining of OMP is reduced, appearing punctate and diffuse, with fewer OMP+ ORN projections
(arrows). This IHC pattern is consistent with 3d OMP reduction in WB experiments, further
supporting injury-induced loss of GL synaptic input. Scale bar = 50µm. N=3/group.
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ORN lesion and OE chemical damage (Costanzo et al., 2006; Cummings et al., 2000; Bakos et
al., 2010).

FPI does not significantly alter Synapsin protein expression
Knowing that FPI induces an injury response in the OB, and GL synapses are affected, we next
explored molecular markers of intact synaptic junctions to define the time course of ORN
reactive synaptogenesis. First, we mapped postinjury expression of two synaptic vesicle
regulatory proteins in FVB/NJ OB tissue extracts. Both Synapsin-I and II have functional roles
related to synaptic vesicle release, particularly in inhibitory GABAergic neurons (Sadanandappa
et al., 2013; Knapek et al., 2010; Medrihan et al., 2015). In several studies, Synapsin-I is altered
in response to injury, and serves as a marker of synaptic plasticity in cortex and hippocampus
(Kitagawa, 1992; Chan et al., 2014; Ansari et al., 2008a,b; Griesbach et al., 2004), suggesting
FPI may alter Synapsin-I in OB as well. Interestingly, the OB contains both proteins, with
Synapsin-I expressed throughout the OB core (Melloni et al., 1993) and Synapsin-II predominant
in the glomerular region (Stone et al., 1994). This provides an opportunity to more specifically
assess pre-synaptic changes in the vulnerable GL. Our WB analyses (Figure 2.5) detected both
isoforms of Synapsin-I (80, 70kD), but revealed that neither showed significant difference from
sham controls over time postinjury. At 1d after FPI, both the 80 and 70kD isoforms remained
near control values (106.66±7.16; 103.26±18.37), as well as the 70kD Synapsin-I signal for 3d
(107.94±17.93). However, we did observe a trend toward increase in the 80kD isoform at 3d
postinjury (122.58±8.88, p=0.076). At the later survival intervals, 7 and 21d, we also failed to
find significant differences in expression of either isoform relative to sham controls. For 80kD
Synapsin-I, values were very close to controls (81.78±9.38; 94.78±5.21), however, the overall
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Figure 2.5 Synapsin-I 80 and 70kD isoform expression in OB following FPI
A. WB analysis of OB Synapsin-I expression after FPI revealed no injury effect on the 80kD
isoform compared to sham controls. However, time-dependent differences were found with post
hoc analysis, showing that 1d 80kD Synapsin-I was higher than 7d expression, and 3d level was
higher than protein levels at both 7 and 21d postinjury time points. These results suggest a trend
toward lower 80kD Synapsin-I production during later postinjury time points. B. OB expression
of 70kD Synapsin-I was not affected by FPI. It did not differ from controls at any time
following injury, nor was time-dependent change in its expression detected by post hoc analysis.
Results are expressed as percent of sham control relative optical density (100% dashed line).
C. Representative blot images of 80kD and 70kD Synapsin-I, with β-actin as a load control, are
illustrated below. #p<0.05 day x vs. y, ##p<0.01 day x vs. y. N=4-7/group.
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Figure 2.6 Synapsin-II 72 and 58kD isoform expression in OB following FPI
A. WB analysis of OB Synapsin-II expression after FPI revealed no injury effect on the either
the 72 or 58kD isoform compared to sham controls. Similarly, results failed to show any
significant differences in isoform expression over time postinjury. B. A trend toward increase
in the 58kD Synapsin-II was observed at 1 and 3d after FPI (150% of shams). Although
reasonable group numbers were used for these experiments, this trend suggests that larger
sample size could yield a significant increase of injured samples over sham controls at the acute
and early subacute time points. Results are expressed as percent of sham control relative optical
density (100% dashed line). C. Representative blot images of 72kD and 58kD Synapsin-II, with
cyclophilin A as a load control, are illustrated below. N=4-6/group.
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pattern for the smaller 70kD isoform suggested a trend toward reduced expression during the late
degeneration/early regeneration transition period (76.28±11.72; 67.19±9.16). When timedependent changes in Synapsin-I expression were probed, we did find several significant
differences in the 80kD isoform profile for the acute 1 and 3d intervals. Both of the early 80kD
expression levels were higher than the 7d signal (p<0.05; p<0.01) and the 3d 80kD isoform was
higher than the 21d level (p<0.05). As the smaller isoform seemed much less affected by FPI, it
is possible that the 80kD Synapsin-I protein possesses a more important function in OB synapse
repair.

Similarly, the two forms of Synapsin-II, expressed within mouse cortical and subcortical regions
(Nesher et al., 2015), and detected in our OB extracts at 72kD and 58kD, were also not
significantly affected by FPI when compared to sham injured animals (Figure 2.6). While
postinjury levels were consistent with controls at 1, 3, 7, and 21d for 72kD Synapsin-II
(108.21±7.33; 104.92±6.85; 90.86±5.55; 87.62±5.84), we did observe an average increase of
about 58% in the 58kD form of Synapsin-II at 1 and 3d postinjury (160.64±46.97;
156.65±34.13), however, group variance was high and the data analysis failed to support these
increases as significant (p=0.078; p=0.130). Similar to the 72kD isoform, the 7 and 21d signal
for 58kD Synapsin-II was not different from sham injured cases (96.71±8.26; 84.57±10.21).
Further, post hoc analysis did not show any significant time-dependent changes in OB SynapsinII protein expression. Together, these results suggest that while OB expression of synaptic
vesicle mobilization proteins are not substantially altered by FPI, subtle time-dependent shifts in
Synapsin-I and II isoform level appear to occur after FPI, potentially marking transitions
between early (1-3d) and later (7d) regenerative phases of OB synaptogenesis.
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GAP-43 increases during regenerative periods
Finally, as a third probe for mapping synaptogenesis, GAP-43 expression was assayed over time
postinjury to correlate our previous findings with a known protein marker of pre-synaptic
sprouting and synapse regeneration. This growth factor is critical to axon growth and extension,
as well as synaptic replacement in the OB (Cizková et al., 1995; Griff et al., 2000). It is also
posited to be regulated by OMP expression (Griff et al., 2000), where, as axons are lost, OMP
levels fall, removing inhibition of GAP-43 production. In our FPI model, we found that
induction of GAP-43 expression was highly correlated with the onset of synaptic replacement at
21d postinjury. As would be predicted for the OB, we saw no significant change in the GAP-43
signal over the 1-7d postinjury period, covering the first week of the degenerative phase (Figure
2.7). In 1 and 7d samples, GAP-43 level was equivalent to sham controls (95.69±24.18;
105.20±10.99). At 3d after FPI, however, we detected a small 36% rise in mean levels of GAP43 protein relative to controls (136.28±9.06), but this change failed to reach significance.
Interestingly, such a shift toward GAP-43 increase would be predicted to accompany the
observed 3d reduction in OMP if, indeed, the two have an inverse regulatory relationship with
respect to expression (see again Figure 2.6). The fact that we did not find
significant rise in GAP-43 associated with major loss of OMP protein could be attributed to the
diffuse, partial extent of OB axotomy with FPI. Most notable was the significant, nearly 3-fold
rise in GAP-43 over controls at 21d after FPI (297.19±58.77, p<0.001), a time interval
corresponding to the onset of ORN axon regeneration after axotomy (Cizková et al., 1995;
Graziadei et al., 1978; Graziadei et al., 1979). Moreover, this significant 21d elevation of GAP43 was also statistically different from 1d (p<0.001), 3d (p<0.01), and 7d (p<0.001) expression,
further supporting the importance of its role during the early regenerative phase of OB synaptic
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Figure 2.7 OB GAP-43 is elevated at onset of synapse regeneration after FPI
A. WB analysis of changes in OB GAP-43 protein expression after FPI showed that the growth
factor was not elevated over sham controls during the degenerative phase, 1, and 7d postinjury.
At 21d, the time point characterized by ORN axon reinnervation and synapse reformation, a
significant 3-fold elevation in GAP-43 was found. Post hoc analysis confirmed that this 21d
change was significantly different from GAP-43 signal at all three of the other time points.
Results are expressed as percent of sham control relative optical density (100% dashed line).
B. Representative blot images of GAP-43, with cyclophilin A and β-actin as a load controls, are
illustrated below. ##p<0.01 day x vs. y, ###p<0.001 day x vs. y, ***p<0.001 Sham vs. TBI.
N=4-6/group.
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repair. Overall, postinjury changes in OMP and GAP-43 as two markers of OB neuroplasticity
provide compelling support for the induction of OB injury and synaptic repair after TBI.
Together, with the structural evidence of damage, these data show that FPI can serve as a good
model for investigating OB reactive synaptogenesis following diffuse TBI.

Ultrastructure reveals axon and synaptic disruption postinjury
Our initial findings of increased αII-spectrin proteolysis and glomerular glial reactivity within
the injured OB warranted a more precise exploration of glomerular synaptic morphology. In
order to establish FPI effects on this morphology, we employed TEM to examine OB glomerular
structure between 3 and 21 d after injury (Figure 2.8). Low magnification imaging of 1µm thick
plastic embedded sections (panel A) revealed the gross organization of OB glomeruli seen in
sham controls, where large groups of electron dense, dark ORN axons interdigitate throughout
each glomerulus. At 7 and 21d after FPI, the low magnification view clearly shows pre-synaptic
axon groups reduced in size relative to control cases. Subsequent ultrastructural analysis of
sham control and 7d cases (panel B) revealed that bundles of ORN axons often encircled a
central grouping of mitral and tufted cell dendrites. At 7d after injury, these ORN axon bundles
were reduced in size and appear collapsed in shape. Higher magnification views of these cases
(panel C) showed that, by 3d after FPI, there exists evidence of disrupted synaptic cytology, with
ORN axon terminals beginning to exhibit early signs of degeneration relative to sham
morphology. At 7d postinjury, ORN axons were visibly shrunken and collapsed, with multiple
sites containing membranous debris reflecting tissue degeneration. Notably, glomerular glial
processes were reactive and contained degenerated cell material at 7d after FPI. While 21d
postinjury glomeruli still contained some areas of tissue degeneration, the normal structure of
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Figure 2.8 Ultrastructure of OB glomeruli show ORN axon damage after FPI
A. Micrographs of semi-thin (0.5µm) sections from OB illustrate sham ORN axons (electron
dense) within a glomerulus (black arrow) and bundled entering GL (white arrow). At 7d after
FPI, these axons appear compressed and their grouping elongated in shape. By 21d, the sham
ORN axon bundle structure begins to reemerge. B. Micrographs of ultrathin sections (600Å)
show ultrastructure of ORN axon groups (ax) within a sham glomerulus, where the pre-synaptic
processes interdigitate to make synapses (arrows) on multiple post-synaptic dendrites (d). By 7d
postinjury, the ORN axon bundles appear irregular, collapsed (white arrows) and contain
evidence of cytoplasmic degeneration (black arrows). C. Glomerular ultrastructure illustrates
postinjury time-dependent change in axo-dendritic cytoarchitectue. Axons (black arrow) in
sham show pre-synaptic vesicles grouped along membranes at synaptic junctions and thick postsynaptic densities (white arrow). At 3d, synaptic organization deteriorates (white arrows), with
early signs of axon degeneration (black arrow). By 7d, ORN axons appear less compressed
(black arrow), but retain poorly organized synaptic junctions (white arrows). Inset: Active
phagocytosis of degenerative debris (black arrow) occurs within 7d reactive astrocytes. At 21d,
glomerular synaptic structure mimics well-developed synaptic structure of controls (black
arrows), even though ORN axons appear less electron dense and processing of degenerating
membranes remains visible (white arrow). Bar in A=10µm; B sham=4µm; B 7d=2µm; C=1µm.
N=2-3/group.
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ORN axons and surrounding dendrites appeared to reemerge. These results are consistent with
the observed 3-21 d IHC increases in OB glial reactivity after FPI and suggest that a protracted
degenerative/clearance phase occurs following diffuse ORN deafferentation in this model. The
delayed time course of axon loss (>3d after insult) matches that reported after knife cut ORN
axotomy (Costanzo et al., 2006) and chemical ORN lesion (Cummings et al., 2000; Bakos et al.,
2010).

DISCUSSION
Clinical presentation of olfactory dysfunction after TBI is well documented, yet the capacity for
diffuse models of TBI to induce synaptic change in the OB is unknown. Although prior studies
have used both hippocampal and OB deafferentation models to investigate time course of
reactive synaptogenesis (Lynch et al., 1976; Steward, 1976; Deller et al., 2007; Frotscher et al.,
1997; Monti Graziadei and Graziadei, 1979; Oley et al., 1975; Graziadei and Okano, 1979;
Morrison and Costanzo, 1995), few studies have examined TBI effects on the OB. These TBI
studies focused on direct impact injury to the OB structure, mapping injury response molecules
in the OB and OE, as well as the time course of functional recovery, including effects of antiinflammatory therapy (Siopi et al., 2012; Steuer et al., 2014). To our knowledge, none have
focused on diffuse OB deafferentation caused by FPI, nor examined the role of MMPs and OPN
cell signaling with OB deafferentation. Here we aimed to show that a mild injury delivered by
central FPI is sufficient to cause damage to the FVB/NJ mouse OB and alter synapses. We
hypothesized that FPI would cause a time-dependent injury-induced reactive synaptogenesis in
the OB, based on changes in αII-spectrin breakdown, induction of glial reactivity, synapto-
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dendritic ultrastructure, synaptic vesicle protein expression, OMP ORN marker protein level and
elevation of GAP-43 with axonal regeneration.

Overall, our results showed that mild FPI does induce OB deafferentation, with a time course of
synaptic reorganization similar to that reported for more severe ORN transection or OE
disruption (Bakos et al., 2010; Costanzo et al., 2006; Cummings et al., 2000; Graziadei et al.,
1978; Graziadei et al., 1979; Graziadei and Okano, 1979; Kobayashi and Costanzo, 2013;
Graziadei and Monti Graziadei, 1980; Morrison and Costanzo, 1995). We examined acute 1d
and subacute (3-7d) degenerative postinjury phases, as well as the early phase of synaptic
reformation (21d). Currently, it is accepted that this process occurs in the OB over a longer time
period than in other cortical brain regions. For example, the degenerative phase in hippocampus
is 1-5d post-injury, the regenerative phase 6-15d and the synapse stabilization phase after the 15d
mark (Lynch et al., 1976; Steward, 1976; Steward and Vinsant, 1978; Deller et al., 2007;
Frotscher et al., 1997). By contrast, in the OB the same process is characterized by a
degenerative phase of 1-15d, regeneration between 15-60d, and synapse stabilization beyond 60d
(Graziadei et al., 1978; Graziadei et al., 1979; Cummings et al., 2000). In the present study,
changes of the selected metrics of OB reactive synaptogenesis were observed after FPI,
occurring along the predicted OB time intervals. Although reduced relative to more severe insult
paradigms, changes in αII-spectrin breakdown fragments were detected. We also documented
reactive glia (astrocytes and microglia) within the deafferented glomeruli and external plexiform
layers of the OB. Molecular markers showing both acute reduction in pre-synaptic vesicle and
OMP proteins, as well as a significant rise in GAP-43 at onset of OB synapse regeneration, all
point to a predicted time course of deafferentation/reinnervation in animals subjected to FPI.
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Thus, our evidence supports induction of OB synaptogenesis after a diffuse TBI, permitting
subsequent exploration of how ECM molecules may regulate synaptic reorganization following
trauma-induced OB deafferentation.

Lysis of αII-spectrin marks subacute degeneration with FPI
We first assessed changes in expression of breakdown products of αII-spectrin protein.
Historically, αII-spectrin has been used as a marker of axonal degradation due to its membrane
stabilizing function. Alpha II-spectrin binds to the cytoskeleton adjacent to the intact plasma
membrane and is processed by Ca2+ activated enzymes calpain and several caspases. TBI leads
to increased axon permeability, signal transduction, excessive neurotransmitter release and
excitotoxicity. Increased [Ca2+]i activates these proteases, thus leading to the lysis of αII-spectrin
and the accumulation of its breakdown products. These products have been used reliably to
estimate extent of cytoskeletal breakdown as a result of TBI-induced axonal injury, where
caspase and calpain proteolytic fragments are increased (Pike et al., 1998; Buki et al., 1999). For
this reason, αII-spectrin expression can serve as a biomarker for tissue injury, such as when
detected in the cerebrospinal fluid of TBI patients (Ringger et al., 2004), as well as for estimates
of axotomy, as in the case of altered time course of αII-spectrin breakdown product expression in
moderate and severe traumatic injuries (Thompson et al., 2006; Reeves et al., 2012).
Interestingly, the level of FPI used in our experiments induced only a mild production of OB αIIspectrin lytic peptides. Significant elevation was observed only for the 150kD calpain fragment
at 3d after injury. This result contrasts with prior reports from our laboratory (Reeves et al.,
2010) and others (Harris and Morrow, 1988; Pike et al., 1998; Buki et al., 1999; Wang et al.,
2000; Ringger et al., 2004; Thompson et al., 2006; Aikman et al., 2006), where animals
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subjected to TBI show major (up to 10-fold higher) elevation of the 150 and 145kD fragments,
as well as minor increases in the caspase 120kD peptide, within other regions of the injured brain
(e.g., cerebral cortex, hippocampus, corpus callosum). Several factors could explain this
difference in OB αII-spectrin proteolysis. Foremost, the rostro-caudal dissipation of injury
forces from a midline, centralized injury site may result in a smaller subset of axotomized cells
for the OB than in other parts of the FPI brain. It is also possible that more robust αII-spectrin
breakdown could occur prior to the first 24hr after FPI, the earliest postinjury interval examined
here. In fact, an earlier study from our laboratory (Reeves et al., 2010) reported significant
increase in 150, 145 and 120kD fragments in the cortex at 3h postinjury. A third factor possibly
responsible for this reduced production of OB αII-spectrin fragments would be that the source of
FPI cytoskeletal proteolysis comes from a source other than ORN axons. As IHC analysis of
αII-spectrin was not conducted in our studies, it is possible that the αII-spectrin breakdown
products could result from cytoskeletal disruption within axons and dendrites of several types of
OB neurons injured with FPI. Mitral and tufted cells, the principal post-synaptic targets of
ORNs, are good candidates for injury sensitivity, as reported for a model of transient ischemia
(Hwang et al., 2008). Further analysis of specific cell damage within the OB will be required to
determine the exact source(s) of our detected αII-spectrin effects. To the best of our knowledge,
this study provides the first documentation of time-dependent αII-spectrin proteolysis in the OB
after diffuse TBI, directly linking deafferentation with a marker of axotomy.

FPI promotes glial reactivity in the OB
It is well documented that TBI generates a rapid and localized glial reactivity, concurrent with
acute induction of inflammatory response (see Chapter 1). In addition to production of
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cytokines, chemokines and reactive oxygen species, the inflammatory response alters glial
function following brain insult. The cell signaling cascades initiated by these molecules are
typically associated with reactive neuroglia, cells whose altered morphology reflects a role in
both degenerative and regenerative phases of recovery. Importantly, these reactive glia are often
associated with deafferented zones. For example, reactive microglia are juxtaposed to
regenerating GAP-43+ axon terminals after auditory sensory deafferentation (Janz and Illing,
2014), and migrate to deafferented regions during reactive synaptogenesis in the hippocampus
(Chan et al., 2014). While, such glial response after TBI has been established for other brain
regions, the time course of OB glial reactivity to diffuse axotomy remained unclear.
Nevertheless, it is established that the OB, like other parts of the CNS, contain responsive
microglia and astrocytes, which often drive the different phases of synaptic plasticity induced by
ORN damage (Bailey and Shipley, 1993; Chang et al., 2003; Lazarini et al., 2012). Our IHC
results confirm FPI activation of both astroglial and microglial cells in the OB. We examined
the same postinjury intervals as for αII-spectrin lysis (1, 3, 7 and 21d), observing a clear
hypertrophy of glomerular astrocytes, and a shift of glomerular/outer plexiform layer microglia
from resting to an activated state. This reactivity was greatest at 3d postinjury, matching the
period when αII-spectrin lysis was detected and reduction of ORN axon marker OMP was
maximal (discussed below). By 7d after FPI, this reactivity was attenuated, with cell
morphology for each glial type returning to normal profile at 21d postinjury.

The time course of FPI glial response is in agreement with that reported by Lazarini et al. (2012)
for OB microglia, where intranasal 2, 6-Dichlorobenzonitrile lesions revealed a peak response at
3d, with reduction of reactivity by 7d postinjury. Close examination of the immunostaining
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patterns for OB astrocytes and microglia revealed additional detail as to their role in response to
FPI. OB astrocytes were mostly confined to the glomerular layer in our model, and for this
reason have been the focus of cellular response in other models of OB deafferentation (Bakos et
al., 2010; Kobayashi et al., 2013). Few astrocytes appear outside this region. Our IHC results
consistently show a postinjury GFAP+ hypertrophy, with larger cytoplasmic projections
wrapping around individual glomeruli and finer processes extending into the surface zones of the
glomeruli. Such a pattern is consistent with detailed ultrastructural studies, which show that
astrocyte processes generate boundary zones between the axo-dendritic synapses of the central
glomerular region and the juxtaglomerular neurons surrounding the core (Chao et al., 1997).
This hypertrophic response to FPI suggests that astrocytes are more intimately involved in the
early stage response to ORN deafferentation (1-3d postinjury) and are sensitive to the changes in
synaptic organization required for OB reactive synaptogenesis. These findings are consistent
with other reports of OB astrocyte response to injury, also showing confinement to the glomeruli
and hypertrophy upon deafferentation. However, the temporal extent of astrocyte response after
mild FPI appears to be attenuated relative to these other models. For example, methyl bromide
exposure, which destroys ORNs, caused a 15d increase in GFAP (Bakos et al., 2010), while full
ORN transection caused a steady increase in GFAP signal over 60d postinjury (Kobayashi and
Costanzo, 2009; Kobayashi et al., 2013; Cummings et al., 2000).

Interestingly, most pro-inflammatory cytokines peak early after FPI, being chiefly produced by
microglia and other invading immune cells. As predicted, we found that OB microglia also
exhibited their most reactive phenotype at 3d post-injury. Such phenotypic change was similar
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to that detected after injury of olfactory epithelium with zinc sulfate (Chang et al., 2003) and
nerve transection induced macrophage reactivity (Bakos and Costanzo, 2011).
In contrast to astrocytes, the activated microglia in our study were not restricted to the
deafferented glomerular layer, but appeared more uniformly distributed in the OB, particularly
among the dendrites of the mitral and tufted neurons of the external plexiform layer. This would
suggest that, under conditions of deafferentation, they may be involved in cell signaling for the
entire OB structure. Acute microglial generation of pro-inflammatory molecules likely
facilitates autocrine and paracrine cell signaling to locally activate other cells, including
glomerular astrocytes (Shin et al., 2005; Doty, 2012). Although prolonged microglial reactivity
has been reported for other brain regions after TBI (Johnson et al., 2013; Smith et al., 2013;
Gentleman et al., 2004; Faden et al., 2011; Engel et al., 2000; Loane et al., 2014;
Ramlackhansigh et al., 2011), we found that microglial morphology was identical to that of sham
controls by 21d postinjury. This suggests a relatively rapid reduction of inflammatory response,
possibly attributed to the reduced level of OB injury in our experiments and distance from injury
site. Reactive glia are critical in altering the environment after injury. Therefore, documenting
that OB microglia and astrocytes are responsive to FPI is imperative and defines the extent to
which these reactive glia are challenged to promote reactive synaptogenesis. Our IHC analyses
provide further insight into the time course of an important secondary injury/recovery
mechanism.

Olfactory marker protein reduction after FPI
In order to determine the extent of glomerular pre-synaptic damage, we next examined the
profile of OMP, a 19kD peptide selectively expressed in ORNs and their axons (Monti-Graziadei
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et al., 1977). Cytoplasmic OMP is specific for mature ORNs, and is conserved across species
(Keller and Margolis, 1976). It has been linked to functional odor responses (Kass et al., 2013),
where OMP KO attenuates response to odor stimuli (Buiakova et al., 1996), reduces odorant
sensitivity (Lee et al., 2011), lowers odor thresholds (Youngentob and Margolis, 1999), and
decreases odor quality perception (Youngentob et al., 2001). While OMP role is still being fully
defined, there is strong evidence to suggest it is involved in maturation of ORN function because
it is not present in immature ORNs. Tracking gain and loss of OMP in models of OB injury and
deafferentation has suggested the protein can be useful as a marker of axon damage and repair.
For example, when glomerular synapses are deafferented by transection lesion, OMP levels drop
significantly compared to controls (Costanzo et al., 2006), a clear indication that axonal input has
been lost. In such cases, OMP expression generally falls anywhere between 3 and 15d after OB
deafferentation as a function of the specific type of lesion (Bakos et al., 2010; Inamitsu et al.,
1990; Kobayashi et al., 2013; Nathan et al., 2001; Tsukatani et al., 2003). Here we found
significant reduction of OMP protein expression at 3d after FPI. In our mild diffuse injury
model axon damage appears to be more limited, as predicted. When examined by WB, OMP
levels did rise toward sham control values at 7d postinjury, but were not significantly different
from 3d levels. By the 21d onset of synaptic regeneration, OMP expression was equal to normal
levels.

In parallel IHC experiments, this 3d OMP reduction was confirmed, clearly associated with
reduced protein localization and evidence of OMP disorganization within affected OB glomeruli.
As expected, this 3d drop in OMP signal revealed time-dependent differences relative to early 1d
postinjury response and the later 21d interval of axon regeneration. We conclude that this OMP
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time course confirms acute ORN axon damage after FPI, likely within a subpopulation of presynaptic olfactory sensory axons.

Overall, our OMP findings are consistent with other OB deafferentation models discussed above,
showing a protracted subacute degenerative period relative to other injured brain regions.
However, OMP expression after FPI does indicate that a shorter degenerative phase may exist
for milder, diffuse OB deafferentation. At 1d postinjury, we did not expect a large OMP
reduction, since a subset of injured axons would not generate a large change in the marker
immediately, but only after secondary injury processes are initiated, as discussed in Chapter 1.
Further, even though OB degeneration in other models can extend through 15d, our data show
initial OMP recovery by 7d. Nevertheless, reduced OMP expression after FPI was temporally
correlated with 3d increase in the 150kD αII-spectrin fragment, which, taken together support
ORN sensory axon degeneration. In addition, the fact that FPI failed to affect the generation of
the calpain-derived 145 and caspase-derived 120kD αII-spectrin peptides, which also fits with a
more diffusely injured axon population.
Another striking finding was the 3d postinjury correlation of OMP reduction and peak glial
reactivity in the affected glomeruli, implicating participation of reactive OB neuroglia in the
clearance of degenerated ORN axonal terminals and promotion of synaptic reorganization. Thus,
3d after FPI represents an important time point for significant ORN damage and the initiation of
glial role in early clearance of axonal debris within the OB.
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Pre-synaptic markers show minimal change after FPI
The loss of ORN axons indicated by our αII-spectrin and OMP data supports FPI induction of
the acute degenerative phase of reactive synaptogenesis. This loss is frequently accompanied by
disruption of synaptic vesicles within pre-synaptic terminals, thereby reducing the level of
proteins which regulate synaptic vesicle movement and membrane fusion. Synapsins I and II are
two such proteins, molecules which bind to and direct neurotransmitter vesicles. While a
downward shift in Synapsin level has been used as an index of CNS synaptic deafferentation
(Chan et al., 2014; Griesbach et al., 2009; Wu et al., 2011), the effect of TBI on its expression is
varied and controversial. In some studies, it increases after injury (Griesbach et al., 2004a,b),
while in others Synapsin expression is no different from controls (Griesbach et al., 2007; Xuan et
al., 2015). Nevertheless, most reports support its acute reduction after brain insults (Wu et al.,
2006; Aiguo et al., 2010; Wu et al., 2011; Shang et al., 2014; Ansari et al., 2008a,b; Chan et al.,
2014). Over time, an increase in pre-synaptic protein markers like Synapsin would be expected
during regenerative or stabilization periods, when reinnervation occurs.

Despite evidence for αII-spectrin lysis, OMP reduction, and synaptic disorganization in the OB
after FPI, we failed to detect injury vs. sham control differences for either Synapsin-I or
Synapsin-II over 1-21d of survival. There was, however, a trend toward reduction of both
Synapsin-I isoforms, and the lower kD form of Synapsin-II. The only significant differences
identified were time-dependent shifts in protein level of 80kD Synapsin-I, with the late
degenerative/early regenerative phases showing reduced expression relative to one another.
While tissue Synapsin level may be a reliable metric for other brain regions and more severe
models of CNS axotomy, it does not appear to serve as robust marker of FPI-induced
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deafferentation within the OB. This result is somewhat surprising since Synapsin-II is highly
expressed within the glomerular layer, co-localizing with OMP (Stone et al., 1994), and
Synapsin-I is found throughout the OB laminae, being less specifically associated with ORN
axon marker OMP (Kasowski et al., 1999). The most likely explanation for our inability to
detect changes in postinjury Synapsin expression would be that diffuse FPI effect was diluted
due to sampling of protein extracts derived from the entire OB. In fact, the study by Stone and
colleagues (1994), which used an intranasal Zn sulfate lesion, inducing a more severe OB insult,
reported significant reduction of local glomerular Synapsin-II and OMP. We posit a smaller
subset of axons are injured in our model, making the proportion of those with Synapsin loss low
relative to the total synaptic content of the entire OB. In order to confirm our present Synapsin
results, additional studies which limit sample dissection to the glomerular layers are needed.

GAP-43 increase marks onset of OB reinnervation after FPI
As a confirmation of successful axon sprouting and synaptic reformation after FPI, we conducted
additional experiments probing for expression of GAP-43. This protein is known to be elevated
over periods of axon growth and extension during development and in CNS regeneration (Shen
et al., 2002; Latchney et al., 2014). Following peripheral nerve crush or transection, GAP-43
expression is upregulated in growth cones and sprouting axons undergoing regeneration
(Knyihár-Csillik et al., 1992). Further, overexpression of GAP-43 has been linked to
spontaneous formation of new synapses and enhanced sprouting after injury (Benowitz and
Routtenberg, 1997). Additionally, Thompson et al. (2006) have demonstrated concurrent
expression of GAP-43 and pre-synaptic synaptophysin, promoting GAP-43 as a marker of
synaptogenesis. Relative to sham control samples, we found increased expression of GAP-43
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restricted to 21d, the period when axon sprouting and synapse regeneration is reported to begin
within the deafferented OB. Moreover, these data are consistent with the stability of αII-spectrin
cytoskeleton at 21d after FPI, also supportive of regenerative processes directed by GAP-43. As
expected, this large elevation in GAP-43 showed significant time-dependent differences between
each of the other time points. Little change was seen in GAP-43 level over the three earlier time
points, however, the protein trends toward increase over controls at 3d postinjury, the same time
period when we see significant reduction of OMP signal. This slight shift is worth noting since
others propose that OMP inversely regulates GAP-43 production (Griff et al., 2000). That study
used OMPKO mice to show that loss of OMP increased ORN axon diameter and the number of
OB sensory axo-dendritic synapses, attributed to dysregulated rise in GAP-43 production. It is
possible that FPI may also alter OMP regulation of GAP-43 during specific phases of OB
reactive synaptogenesis. While our data does not currently show a significant rise in GAP-43 at
3d, more select sampling of glomerular regions could confirm such a relationship between OMP
and GAP-43.

Time-dependent differences in OB GAP-43 expression are clearly consistent with FPI pathology
driving synaptic regeneration in the structure. The significant increase of this growth-regulating
protein at 21d matches onset of synaptic restoration, as nascent terminals are guided to their postsynaptic targets. This period is has been defined as the regenerative phase of OB
synaptogenesis, shown to occur between 15-60d post-injury (Graziadei et al., 1978; Graziadei et
al., 1979). Others have reported that newly formed glomeruli express increased GAP-43,
presumably during axonal re-growth (Cizková et al., 1995), which also supports our
interpretation of the role of elevated GAP-43 in deafferented OB at 21d after FPI. Given that

137

surrounding neuroglia could be responsible for GAP-43 upregulation, it is also interesting that
the increase in this growth protein did not coincide with peak microglial and astrocyte reactivity
identified by IBA-1 and GFAP. One possible explanation for this difference would be that a
second wave of glial activation, not dependent on structural hypertrophy and occurring during a
postinjury interval not sampled here, contributes to the 21d GAP-43 rise during later synapse
regeneration. Alternatively, injury could drive increased expression of GAP-43 within olfactory
ensheathing cells (OECs), typically restricted to ORN layers. One report exploring OEC
transplantation into the cortical injury site of a weight drop model found increased GAP-43
signal in the adjacent tissue, correlating with higher synaptophysin and neurological protection
(Wang et al., 2014). Thus, several lines of evidence show GAP-43 is involved in OB reactive
synaptogenesis, but the specific cellular source(s) remain to be determined.

Axon and synapse integrity within OB glomeruli is compromised after FPI
Given that we observed molecular and IHC evidence for OB synaptic disruption following FPI,
our last set of experiments focused on applying TEM methods to determine if these effects of
diffuse axonal injury could be detected as change in glomerular synapto-dendritic structure.
Overall, qualitative glomerular ultrastructure supported our other outcome measures, showing
that FPI resulted in progressive structural degeneration of ORN sensory synapses over the same
1-7d postinjury interval. TEM revealed a similar series of events: first, axon terminal
degeneration, then synaptic disruption and glial phagocytosis, followed by early stages of
synapse reorganization at 21d. Consistent with other TEM studies of the OB (Chao et al., 1997;
Valverde and Lopez Mascaraque, 1991; Kasowski et al., 1999) controls exhibited electron dense
ORN axon terminals grouped around dendrites of mitral and tufted cells, forming well defined
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synaptic structure. Pre-synaptic vesicles were seen opposed to synaptic membranes, which had
thick post-synaptic densities. This profile was shifted toward a less organized and degenerating
axo-dendritic structure as early as 3d after injury, consistent with the loss of OB OMP and
increased αII-spectrin breakdown at that time. By 7d, acute pathology had evolved to form
shrunken ORN axons with irregular shapes and sites with hypertrophied glial processes
containing phagocytosed tissue debris. We interpret this increase in membranous material within
OB astrocytes to be in line with a reduced expression of GFAP cytoskeletal protein, as the cells
shift to a more phagocytic function at the 7-21d postinjury interval. While the majority of
glomerular glial response appeared to be astrocyte in nature, reactive microglia were observed in
the more peripheral zones, potentially serving as phagocytes within damaged axon bundles as
seen after bulbectomy (Smithson and Kawaja, 2010). Further, since WB data showed 7d OMP
moving toward control levels, although not significantly different from 3d cases, we conclude
that this intermediate time point is a highly transitional period between degeneration and
regeneration for OB reactive synaptogenesis.

Summary
Collectively, these data show that the central FPI delivered to FVB/NJ mice is sufficient to cause
ORN axotomy, induce deafferentation of OB glomeruli and generate overt synaptic
disorganization. Reactive gliosis accompanies this injury sequence, contributing to removal of
degenerative debris, and likely producing molecules which direct synaptic repair. These events
occur despite the diffuse and somewhat mild nature of FPI, as well as the distance of the OB
from injury epicenter. This injury profile is also consistent with the reported olfactory deficits in
clinical TBI. Importantly, it also validates our experimental model for the further studies
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described in Chapters 3 and 4, addressing the interaction between ECM proteins that regulate the
recovery process.
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CHAPTER 3

MMP9/OPN SIGNALING MARKS OB SYNAPTIC REORGANIZATION AFTER FPI
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ABSTRACT
TBI has potential to axotomize ORNs, leading to deafferentation of OB synapses and olfactory
deficits. In the plastic OB, ORNs are capable of OB reinnervation and synapse restoration after
damage. ECM modulators like MMPs are upregulated in the OB after ORN axotomy and
implicated in recovery processes. In Chapter 2, we showed that mild FPI was a viable model to
induce OB injury and cause deafferentation. We posit that MMP9, an acute responder to TBI
and ORN axotomy, mediates OB reinnervation by processing its substrate OPN. Proteolytic
fragments of OPN express amino acid sequences with integrin and CD44 receptor binding
capabilities, through which cell signaling pathways can promote glial migration, proliferation,
and phagocytosis. Here, we profile the postinjury time course of MMP9 activity, OPN
fragmentation, and CD44 receptor expression in order to determine whether MMP9/OPN
interaction plays a role in OB synapse repair. Gelatin zymography analyses revealed significant
elevations in MMP9 at 1 and 7d and MMP2 activity at 7d postinjury, highlighting both 1 and 7d
as a critical periods in ECM modulation. Despite the fact that full length 66kD OPN did not
change after FPI, however, we did observe increases in OB 48kD OPN at 1 and 7d, as well as a
reduction in 32kD OPN at 7d. This result points to a time-dependent correlation between OPN
processing and injury-induced gelatinase activity. IHC revealed that MMP9 was localized to
reactive astrocytes and increased in these cells 7d after FPI, as well as within post-synaptic
neuronal compartments. However, OPN did not co-localize with GFAP+ or IBA1+ cells, but
labeled neurons in the EPL and MCL only. Co-labeling experiments with periglomerular cell
marker tyrosine hydroxylase, supporting selective OPN expression in OB tufted and mitral cells.
Further, IHC failed to show co-localization of neuronal OPN and microtubule associated protein2, suggesting that intracellular OPN isoforms bound to microtubules were not predominant.
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Interestingly, CD44 receptor protein was upregulated at both 3 and 7d, which was consistent
with maximum glial activation observed in Chapter 2. We conclude that MMP9-generated OPN
fragments are critical signals for the temporal progression of OB reactive synaptogenesis
following FPI. Moreover, the generation of these OPN signals is likely sourced within both
deafferented neurons and the ECM, where secreted MMP9 and OPN interact. Mapping of
postinjury CD44 receptor expression suggests that an indirect OPN/CD44 interaction may foster
cell signaling pathways to enhance glial mediation of successful OB synaptic plasticity after TBI.

INTRODUCTION
Adaptive and maladaptive models of synaptic recovery have shown that ECM components like
proteoglycans and MMPs can direct the restoration of synaptic terminals after injury (Phillips
and Reeves, 2001; Kim et al., 2005; Chan et al., 2014; Dityatev et al., 2004; Falo et al., 2008;
Harris, et al., 2011; Harris et al., 2010; Mahmood et al., 2014; Warren, et al., 2012; Yamaguchi,
2001). Reactive synaptogenesis after TBI is a well-documented phenomenon, with stages
representing injury-induced loss of synapses, glial-mediated removal of cellular debris and
degenerating axons, sprouting of new terminals, and stabilization of nascent synaptic
connections. While the process has been confirmed in focal models of deafferentation in
hippocampus (Steward et al., 1988) and OB (Oley et al., 1975), whether synaptic repair could be
induced in the OB following mild diffuse injury was previously unknown. In Chapter 2, we
carefully documented the acute/subacute time course of OB deafferentation and reinnervation
with mild FPI. Next, we aim to explore whether the posited MMP9/OPN interaction may
contribute to successful TBI-induced OB synaptic plasticity. The link between ECM and
plasticity is well documented (Frischknecht and Gundelfinger, 2012; Phillips et al., 2014;
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Wlodarczyk et al., 2011). In particular, several studies have focused on the dual roles of MMPs
in head trauma, being either neuroprotective or causing detrimental consequences (Phillips et al.,
2014). Consistently, time proves to be an important factor in MMP function, as early activation
of MMPs usually promotes degenerative processes to clear injury debris, which are typically
beneficial, but later, prolonged MMP activation can inhibit repair mechanisms. Understanding
time-dependent activity of MMPs has been useful, yet therapeutics aimed at reducing MMP
activity for TBI recovery have had little success in the clinic (Zhang et al., 2010; Abdul-Muneer
et al., 2015). The reason for this outcome is largely considered to have been due to the
pleiotropy and complexity of each enzyme, and limited specificity of MMP inhibitors.
Nonetheless, therapeutic agents that focus on MMP activity remain viable options, given that
appropriate molecular mechanisms are targeted.

As discussed in Chapter 1, gelatinases A and B (MMPs 2, 9) have been explored extensively in
models of brain injury and functional recovery (Bakos et al., 2010; Costanzo et al., 2006;
Costanzo and Perrino, 2008; Hsu et al., 2006; Hsu et al., 2008; Phillips and Reeves, 2001;
Verslegers et al., 2013; Wang et al., 2000). In particular, several investigators have focused on
the role(s) of MMPs 2, 9 in synaptogenesis of the deafferented OB. During the period of early
reactive synaptogenesis (1-15d), following focal models of ORN axotomy, activity of both
gelatinases increases (Bakos et al., 2010; Costanzo et al., 2006; Costanzo and Perrino, 2008).
MMP9 generally peaks strongly and acutely within 5d (Bakos et al., 2010; Costanzo et al.,
2006), emphasizing its importance in degenerative processes. Conversely, MMP2 expression is
also upregulated following OB deafferentation, although its delayed peak suggests a more
prominent role in facilitating later recovery. These differences highlight the importance of
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understanding time course in molecular processes underlying synaptic repair. Injury-induced
MMP9 elevation has consistently been detected in preclinical experiments and clinical trials (de
Castro et al., 2000; Horstmann et al., 2006; Noble et al., 2002) as well as several models of
axotomy (Costanzo et al., 2006; Chan et al., 2014), yet exact gelatinase-mediated mechanisms
guiding synaptic recovery of the OB are still unknown. We posit that defining the time course of
postinjury MMP9 activity in our OB model and testing a candidate substrate which could signal
cell-based GL synaptic repair, will reveal important targets for development of therapeutics to
support recovery of olfactory function.

One novel MMP substrate associated with such cellular signaling is the cytokine OPN.
Interestingly, OPN is a dynamic phosphoprotein expressed in several tissues, with
neuroprotective functions in models of brain injury (Chan et al., 2014; Hashimoto et al., 2007;
Jin et al., 2014; Miyazaki et al., 2008; Topkoru et al., 2013). It is a substrate for several MMPs,
including MMP9 (Lindsey et al., 2015; Takafuji et al., 2007; Tan et al., 2013). OPN is typically
secreted into the ECM, and cleaved by matrix-dwelling enzymes. Upon cleavage, integrin
receptor-binding RGD and SVVYGLR sequences are exposed, giving the OPN fragments
important cell signaling capabilities. Signal transduction through integrin receptors (particularly
the αvβ3 vitronectin receptor) is one of the primary mechanisms by which OPN facilitates its
adhesion, migration, and proliferative properties. Both large and small OPN fragments, which
are produced by MMP9 proteolysis, can be critical to the recovery process after FPI, so it is
important to assess postinjury expression and localization of each. Further, interaction of OPN
with hyaluronic acid receptor CD44 has also been well documented after CNS insult and is
important for some OPN properties, such as migration and paracrine signaling between reactive
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glial cells. While CD44 expression has not been examined during synaptic repair in many TBI
models, the receptor has been reported to increase in tandem with OPN after cortical cryolesion
(Shin et al., 2005), transient forebrain ischemia (Kang et al., 2008), and other central nerve injury
models (Günther et al., 2015). Increased glial reactivity in the OB after FPI-induced axotomy,
documented in Chapter 2, encourages exploration of change in CD44 expression, as altered glial
function can often be mediated by cell surface receptors like CD44.

To determine MMP9-OPN-receptor role in OB reactive synaptogenesis after FPI, we first
measured postinjury change of MMP9 enzyme activity. We then employed WB analyses to
correlate the time course of MMP9 activity with expression of full-length and fragmented OPN,
determining if an enzyme-substrate relationship existed over time postinjury. Additionally, we
utilized IHC to explore OB tissue localization of OPN and MMP9 within in order to identify the
cellular sources of these proteins during synaptogenesis. Lastly, CD44 receptor expression was
also assessed by WB over the same 21d OB synaptic recovery period to determine if OPN
fragmentation tracks with growth factor expression. Our results support a biphasic, timedependent postinjury interaction between MMP9 and OPN, generating critical cell signaling
peptides that show a complex relationship with glial reactivity and expression of CD44 cell
surface receptors. Our analyses in Chapter 3 also revealed relationships between this
MMP9/OPN cell activation mechanism and other markers of ORN axon damage (e.g., αIIspectrin and OMP) identifying, as yet unexplored, pathways potentially regulating
synaptogenesis after FPI.
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METHODS
Experimental Animals
All procedures met national guidelines for care and use of laboratory animals, and all
experimental protocols were approved by the VCU Institutional Animal Care and Use
Committee. FVB/NJ WT adult male mice (The Jackson Laboratory, Bar Harbor, ME) were
housed (4 littermates/cage) under a temperature (22ºC) and humidity controlled environment,
with food and water ad libitum, and subjected to a 12h dark-light cycle. WT mice (20-30g; 8-11
weeks old) were randomly selected and subjected to midline FPI. WT sham-injured cases served
as control. Subsets of FPI and sham-injured groups [WT Sham (n=48), WT FVB TBI (n=53)]
were allowed to survive for either 1, 3, 7 or 21d post-injury prior to molecular or histological
analysis.

Surgery Preparation and Injury
Mice were anesthetized with isoflurane (4% in 100% O2 carrier gas) and maintained on 2.5%
isoflurane in carrier gas delivered through a nose cone. Once stabilized in a stereotaxic frame,
heads were shaved, body temperature maintained at 40ºC by Gaymar T/Pump water pump
(Gaymar Industries Inc, Orchard Park, NY) and heart rate (bpm), arterial oxygen saturation
(percent O2), breath rate (brpm) and pulse/breath distension (µm) monitored by pulse oximetry
(MouseOx; Starr Life Sciences, Oakmont, PA). Mice then received a midline incision and a 2.7
mm craniectomy prepared over the midline, centered between bregma and lambda. Without
damaging the underlying dura, a Leur-Loc syringe hub was cemented to the skull surrounding
the craniectomy and dental acrylic poured around the hub to stabilize the site. Topical
anesthetic/antibiotic was applied to the incision site and the mice housed in recovery cages.
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After one hour of surgical recovery, mice were anesthetized for 4 mins (4% isoflurane, 100%
O2), and subjected to FPI as previously described (Dixon et al., 1987; Reeves et al., 2012). The
device consisted of a 60 x 4.5 cm Plexiglas water filled cylinder, fitted at one end with a piston
mounted on O-rings, with the opposite end housing a pressure transducer (EPN-0300A; Entran
Devices, Inc., Fairfield, NJ). At the time of injury, the Leur-Loc fitting, filled with saline, was
attached to the transducer housing. Injury was produced by a metal pendulum striking the
piston, transiently injecting a small volume of saline into the cranial cavity and briefly deforming
the brain tissue (20 millisecond pulse duration). The resulting pressure pulse was recorded extra
cranially and registered 1.3±0.1 atm pressure. After injury, all mice were promptly ventilated
with room air until spontaneous breathing resumed. The duration of suppression of the righting
reflex (5.0±2.0 mins) was used as an index of traumatic unconsciousness. Once righting reflex
was determined, mice were re-anesthetized for hub removal, scalp suture and topical
anesthetic/antibiotic application. Sham-injured controls received the same surgical preparation,
anesthesia and connection to the injury device, except that the intracranial pressure pulse was not
applied. All animals were returned to their home cages and assessed for weight loss, locomotion,
and eye/nose exudate once per day until weights stabilized.

Protein Extraction
WT mice were anaesthetized with 4% isoflurane in carrier gas of 100% O2 for 4 min, then
sacrificed by decapitation at 1, 3, 7 or 21d after FPI or sham injury, with bilateral OBs dissected
(n=4-7/group) for assessment of protein expression. Tissue samples were homogenized on ice in
100 µl of RIPA Lysis Buffer (EMD Millipore, Billerica, MA), and centrifuged at 14,000 x g for
20 min at 4°C. Supernatant was aliquoted and stored at -80°C. Prior to or zymography analysis,
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protein concentration was determined using Pierce BCA Protein Assay Reagent (Thermo-Fisher,
Waltham, MA) and the FLUOstar Optima plate reader (BMG Labtech, Inc., Cary, NC).

Western Blotting
WB analysis was carried out utilizing Bio-Rad products (Hercules, CA). Twenty µg of protein
was prepared in WB XT Sample Buffer and reducing agent (Bio-Rad Laboratories), then
denatured at 95˚C for 5 mins. Samples were electrophoresed on 4-12% or 12% Bis-Tris
Criterion XT gels (200v x 45 min in MOPS running buffer), then protein transferred onto
polyvinylidene fluoride (PVDF) membranes (1h at 100V). Post-blotted gels were stained with
0.1% Coomassie Brilliant Blue (Sigma-Aldrich, St. Louis, MO) in 40%MeOH+10% glacial
acetic acid, then de-stained at RT to confirm protein load and even transfer. Membranes were
rinsed with deionized water and Tris-buffered saline (TBS) before blocking with 5% milk TBSTween (mTBS-T). Blots were then incubated in 5% mTBS-T overnight (4°C) with individual
primary antibodies to osteopontin (OPN; 1:500, R&D Systems, Minneapolis, MN; 1:500,
Rockland Immunochemicals Inc., Limerick, PA) and CD44 (1:500, BD Biosciences, San Jose,
CA). After primary incubation, membranes were washed with mTBS-T, then incubated with
appropriate HRP-linked secondary antibodies [IgG bovine anti-goat, IgG bovine anti-rabbit
(1:15,000, Santa Cruz, Dallas, TX), IgG goat anti-rat (1:15,000, Rockland Immunochemicals
Inc., Limerick, PA)] in mTBS-T for 1h at RT. Finally, blots were washed with mTBS-T and
antibody binding visualized using Super Signal Dura West chemiluminescence substrate
(Thermo-Fisher, Waltham, MA). WB images were captured with Syngene G:Box and positive
band signal subjected to densitometric analysis (relative optical density, ROD) with Gene Tools
software (Syngene, Frederick, MD). Protein data were expressed as percent change relative to
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paired WT Sham control cases run on the same transferred gel. Cyclophillin A (EMD Millipore,
Billerica, MA) or beta actin (Sigma-Aldrich, St. Louis, MO) was used as load controls for signal
detection.

Immunohistochemistry
At 3, 7 and 21d post-injury WT injured and WT sham mice (n=4/group) were prepared for
fluorescent IHC analysis according to published protocol (Warren et al., 2012). Animals were
anaesthetized with sodium pentobarbital (400mg/kg, i.p.), transcardially perfused with 0.9%
saline followed by 4% paraformaldehyde in phosphate buffer (0.1M NaHPO4, pH=7.4), after
which brains with attached OBs were extracted and placed in fixative for 24 h before transfer to
0.03% NaN3in 1.0 M phosphate buffered saline (PBS). For IHC, fixed brains were cryoprotected
in 30% sucrose for 3d, sucrose solutions exchanged after each day. Frontal lobes were blocked
and attached bulbs mounted in Tissue Tek media (Thermo-Fisher, Waltham, MA) and stored at 80°C. Coronal cryostat OB sections (13µM) were collected using a Cryostar™NX70;
Cryotome™FSE; HM525 NX cryostat (Thermo-Fisher, Waltham, MA) and prepared for
immunofluorescence visualization.

Free floating sections were first permeabilized in 5% peroxidase for 30 mins. After a wash with
PBS, tissues were pre-incubated in blocking buffer (fish gelatin in PBS + 0.05% triton X-100) to
prevent non-specific binding, and then incubated overnight in primary antibody (OPN, 1:40,
R&D Systems, Minneapolis, MN; MMP9, 1:100, R&D Systems, Minneapolis, MN;
microtubule-associated protein 2 [MAP2], 1:500, EMD Millipore, Billerica, MA; tyrosine
hydroxylase [TH], 1:300, EMD Millipore, Billerica, MA; glial fibrillary acidic protein [GFAP],
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1:20,000, Dako; ionized calcium binding adaptor protein [IBA1] for microglia, 1:300, Wako,
Richmond, VA) at 4°C. Sections were next washed with PBS, placed in blocking buffer for 30
mins, after which they were incubated with secondary fluorescent antibody (Alexa-Fluor 488
donkey anti-goat, 1:1000 and Alexa-Fluor 594 donkey anti-rabbit, 1:1000, Thermo-Fisher,
Waltham, MA) in Blotto for 1h at RT. Slices were then PBS washed, equilibrated in phosphate
buffer, and mounted on Superfrost Plus slides (Fisher Scientific, Pittsburgh, PA) with
Vectashield + DAPI (Vector Laboratories, Burlingame, CA). IHC signal was visualized on the
Zeiss LSM 700 (Carl Zeiss, Thornwood, NY) confocal microscope (VCU Microscopy Core).

Gelatin zymography
Zymographic enzyme assay was performed using previously described methods (Chan et al.,
2014). Briefly, 20 µg of protein from OB extracts described above were prepared with 2x Trisglycine SDS sample buffer, then separated by gelatin electrophoresis (at 4°C, 45V for 1.5 h) on
Novex® 10% zymogram gels (Thermo-Fisher, Waltham, MA). Gels were renatured in Novex®
Zymogram Renaturing Buffer (Thermo-Fisher, Waltham, MA) for 30 min at RT before
development in Novex® Zymogram Developing Buffer over 6 d at 37°C. Gelatin lysis was
visualized with Coomassie brilliant blue (Sigma-Aldrich, St. Louis, MO) and purified enzyme
run as positive control. Zymogram signal was captured on Syngene G:BOX, and densitometry
analyzed as ROD with Gene Tools software (Syngene, Frederick, MD). Enzyme activity was
expressed as percent change relative to paired controls run on the same gel.
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Statistics
The effects of injury, and the time postinjury, on protein levels and gelatinase activity were
evaluated using GLM SPSS v.23 (International Business Machines, Corp., Armonk, NY).
These analyses used 2-way completely randomized ANOVAs. Specific pairwise comparisons
were evaluated using the Duncan Post Hoc Test. Western blot and zymography results are
reported as mean +/- SEM. An alpha level of 0.05 was used in all analyses.

RESULTS
MMP2, 9 activity changes in response to FPI
Prior studies in numerous brain injury models have confirmed that secreted MMPs and
inflammatory cytokines are elevated postinjury, contributing to both acute pathophysiology and
chronic repair mechanisms (Rosenberg et al., 2012; Phillips et al., 2014; Woodcock and
Morganti-Kossmann, 2013). Time-dependent increases in OB gelatinases MMPs 2, 9 were
reported during early postinjury intervals of pre-synaptic degeneration induced by either ORN
knife cut axotomy or chemical lesion (Bakos et al., 2010; Costanzo et al., 2006; Costanzo and
Perrino, 2008), however, OB MMP response to FPI has not been determined. Here, we first
assessed whole OB protein extracts with gelatin zymography to determine whether our injury
would increase each gelatinase over the 1-21 postinjury interval. Overall, we found elevated OB
activity for both gelatinases MMP9 and MMP2 at 7d after FPI, with MMP9 also increasing in
the acute postinjury period. At 1d postinjury, FVB/NJ WT mice showed a 2-fold rise in MMP9
activity versus sham controls (236.85±50.71, p<0.01). By contrast, 1d MMP2 lysis was the same
as control values (99.48±10.63) and activity for both gelatinases remained equivalent to that of
sham injured at 3d after FPI (117.40±17.71;107.69±10.89). Interestingly, at 7d after injury, the
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Figure 3.1 FPI induces time-dependent increase of OB gelatinase activity
A. Zymographic assessment of postinjury OB gelatinase activity revealed prominent elevation
of MMP9 relative to sham controls. As seen in other CNS insult models, acute increase of
MMP9 activity occurred at 1d after injury. This effect was normalized by 3d, where enzyme
lysis returned to control level. Surprisingly, we found a second phase of MMP9 activation at 7d
postinjury, nearly 3-fold higher than sham proteolysis. By 21d, activity had again returned to
control values. This biphasic pattern of OB MMP9 activity is novel in the context of diffuse
TBI. Other brain regions and insults show predominant peak MMP9 activity only at the early
postinjury intervals. Post hoc analysis confirmed the 7d peak MMP9 proteolysis to be different
from its bracketed 3 and 21d intervals, where the enzyme was longer activated. B. Increase in
MMP2 activity was also detected, but with two large differences: increase was confined to the
7d postinjury time point and this was only a modest elevation. MMP2 activity was not different
from controls at 1, 3, or 21d postinjury. Results are expressed as percent of sham control
relative optical density (100% dashed line). C. Representative zymogram images of Sham
(left), Injured (right) MMP9, MMP2 are illustrated. #p<0.05 day x vs. y. *p<0.05 Sham vs.
TBI; **p<0.01 Sham vs. TBI. N=4-10/group.
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OB exhibited a significant elevation in both MMP9 (279.54±52.58, p<0.001) and MMP2
(130.75±10.02, p<0.05) (Figure 3.1). At this time point MMP9 activation was predominant
(achieving a maximal rise of nearly 3-fold over sham cases), whereas MMP2 increase in activity
only reached 31% over controls. By 21d, the period marking onset of ORN axon reinnervation,
activity of each gelatinase was not different from baseline sham injured levels (111.79±10.42;
106.43±8.66). Notably, post hoc analysis showed that the MMP9 7d rise was also significantly
increased relative to 3 and 21d postinjury time points (p<0.05), reflecting critical periods of
enzyme activation at 1 and 7d postinjury. We conclude that, while both MMP2 and MMP9 were
elevated at 7d, the differences in their time-dependent expression patterns suggest they may have
unique roles in the recovery process. These findings indicate a critical gelatinase role during the
early degenerative phases of OB reactive synaptogenesis following FPI deafferentation, and
more specifically, a predominant role for MMP9 at days 1 and 7 postinjury.

MMP9 localization supports glial response in deafferented OB
Our molecular analyses suggested that during acute axon degeneration in the OB, secreted
gelatinase MMP9 serves a key role, which likely includes processing intercellular signals for
glial/neuronal reorganization. Prior studies have mapped MMP9 expression to both neuronal
and glial cell types (Phillips et al., 2014). As reactive astrocytes closely associate with
glomerular synapses, we performed IHC for cell specific localization of MMP9 in OB astrocytes
after FPI. Our results showed that GFAP+ astrocytes surrounding glomeruli did contain MMP9,
and that MMP9 was highly elevated within the GL and EPL at 7d postinjury (Figure 3.2). This
not only supports the astrocyte as a primary glial source of elevated MMP9 in deafferented OB,
but also reveals significant MMP9 upregulation within neuronal processes of deafferented GL
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Figure 3.2 IHC of MMP9 protein distribution within OB following FPI
A. Confocal imaging of sham cases shows low level of MMP9 (green) labeling within the GL
and EPL, appearing as punctate signal. Astrocytes labeled with GFAP (red) were localized to
the GL and showed non-reactive phenotype (white arrows). Boxed sham area shown in high
magnification at right, with no detectable MMP9 expression in GL astrocytes (white arrows).
B. MMP9 protein staining intensity was increased within the same OB layers 7d after FPI
(yellow star=GL; red star=EPL) and visible within reactive astrocytes (white arrows). Boxed
7d area shown in high magnification at right, with no MMP9 expression clearly visible within
reactive GL astrocytes (white arrows). These results are consistent with 7d rise in MMP9
activity assessed by gelatin zymography. Bar in A=50 µm; B=20 µm. N=3-4/group.
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and adjacent OB layers. Together these two findings suggest a complex enzyme response to FPI,
where astrocytes likely secrete MMP9 to process matrix proteins, including OPN, driving critical
glial response, and affected neurons either produce and secrete MMP9 or utilize the enzyme
intracellularly to process substrates like OPN.

FPI does not change full length OPN expression
Recent studies in deafferented hippocampus identified OPN as a mediator of synaptic plasticity,
specifically linking its RGD integrin signaling fragment to glial reactivity, degenerative terminal
removal and adaptive synaptic recovery (Chan et al., 2014). The observation that FPI causes OB
glial reactivity (see Chapter 2), possibly induced by integrin signaling pathways, and a clear
elevation of MMP9, which cleaves OPN to generate RGD exposed fragments (Lindsey et al.,
2015; Scatena et al., 2007; Takafuji et al., 2007), lead us to examine full length OPN and OPN
fragment generation in the deafferented OB. FVB/NJ WT OB protein extracts were again used
to conduct WB probe for full length OPN (66kD) (Figure 3.3) and proposed OPN fragments (see
Figure 3.4 below). Despite changes in MMP9 activity at 7d, full length OPN did not change for
any time point after injury when compared with sham injured controls. Surprisingly, levels of
66kD OPN trended higher than sham controls at 1 and 3d postinjury (128.08±21.57;
124.84±10.12), however, these differences failed to reach significance. By contrast, full length
OPN showed the opposite response at both 7 and 21d postinjury, trending lower than control
values (77.33±12.39; 85.64±10.83), but again these changes failed to reach statistical
significance. Nevertheless, post hoc comparison did reveal differences in 66kD OPN expression
over time. The 7d level of this protein was found to be significantly lower than both 1 and 3d
expression (p<0.05). These data suggest the possibility that small changes in full length OPN do
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Figure 3.3 Full length OPN expression in OB is unchanged after FPI
A. WB analysis of full length OPN (66kD) in deafferented OB failed to show injury effect
relative to sham controls. Nevertheless, a trend toward increase at 1 and 3d postinjury and
decrease at 7d, was observed, but each time point failed to reach significance versus shams. Post
hoc time point comparisons did reveal that 1 and 3d 66kD OPN expression was higher than 7d
level. This shift toward 7d reduction is consistent with the significant MMP9 activity and OPN
fragment generation observed at that postinjury time point. Results are expressed as percent of
sham control relative optical density (100% dashed line). B. Representative blot images of
66kD OPN, with β-actin load controls, are illustrated below. #p<0.05 day x vs. y. N=4-7/group.
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occur after FPI, and that a trend toward reduction in this form of the protein is consistent with the
7d interval of maximal MMP9 activation. It is possible that the overall non-significant change in
66kD OPN relative to sham controls occurs commensurate with altered OPN transcription to
compensate for any injury-induced proteolysis, keeping the level of protein stable over time.

OPN fragment expression is altered following FPI
In order to examine the level of OB OPN signaling fragment generation after FPI, we utilized a
commercial OPN antibody that specifically binds to its proteolytic fragments. According to prior
studies (Lindsey et al., 2015; Scatena et al., 2007; Takafuji et al., 2007), MMP lysis of OPN
should contribute to cleavage that exposes the RGD/SVVYGLR region of the protein, generating
two principal signaling fragments: an amino terminal portion with the RGD sequence accessible,
and a carboxy terminal peptide. When probing for OPN fragments, we observed the generation
of these two principal OPN bands at 48 and 32kD (Figure 3.4A). The 48kD integrin signaling
RGD fragment was significantly elevated over control levels at 1d (76%) and 7d (62%) after
injury (176.06±22.81, p<0.01; 161.53±12.76, p<0.05), which was correlated with elevated
MMP9 activity. By contrast, 3 and 21d levels of this fragment were not different from that of
sham injured cases (123.22±18.77; 79.09±4.49). Analysis across the postinjury time intervals
revealed that the low level of 48kD OPN at 21d was significantly different from both 1 and 7d
elevations in the RGD signaling fragment (p<0.01). These findings support a variable, timedependent expression pattern of the 48kD OPN signaling fragment, consistent with MMP9
activity. Further, the early increase in this fragment over 1-7d and subsequent stabilization at
21d, when synaptic regeneration is underway and MMP9 lysis normalized, would also support
principal OPN signaling role during the period of acute degenerative change.
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Figure 3.4 FPI induces time-dependent changes in OB OPN signaling fragments
A. WB analysis of OB 48kD OPN expression showed significant elevation of the RGD
signaling fragment at 1 and 7d after FPI when compared with sham controls. At both 3 and 21d
postinjury, 48kD OPN levels were not different from controls, however, 21d cases showed a
trend toward reduction. Post hoc analysis revealed that the low 48kD OPN signal at 21d was
significantly different from both 1 and 7d measures. This data is consistent with peak MMP9
activity at 1 and 7d after FPI and suggests that acute and subacute OPN RGD signaling is
important for progression of OB synaptic repair. B. Expression the 32kD OPN peptide was not
different from sham controls at 1 and 3d postinjury. By 7d, this fragment was half of sham level,
and no longer different from control by 21d. Post hoc analysis pointed to the 7d 32kD reduction
as significantly lower than both 1 and 3d signal, again consistent with the peak MMP9 activity at
that time interval. Results are expressed as percent of sham control relative optical density
(100% dashed line). C. Representative blot images of 48 and 32kD OPN, with cyclophilin A
and β-actin load controls, are illustrated below. ##p<0.01 day x vs. y, ###p<0.001 day x vs. y,
*p<0.05 Sham vs. TBI, **p<0.01 Sham vs. TBI, #p<0.05 day x vs. y. N=3-6/group.
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In contrast to 48kD OPN, the 32kD carboxy terminal fragment, lacking the RGD integrinbinding sequence, exhibited a different postinjury pattern (Figure 3.4B). Here, the only
significant change from controls was a 53% reduction at 7d (52.52±7.26, p<0.05). While some
variability in expression occurred for the 32kD OPN at 1, 3 and 21d after FPI, none of these
changes were significant (117.90±14.02; 137.61±13.85; 78.11±18.10). Post hoc analysis also
identified time dependent changes in this OPN fragment. Principally, the early 1 and 3d levels
were different from the reduced 32kD OPN at 7d (p<0.01, p<0.001), and the 3d fragment
expression different from that at 21d (p<0.01). Interestingly, the smaller carboxy terminal OPN
peptide showed opposite injury-induced change at 7d versus the 48kD OPN signaling fragment.
This may be due to the fact that increased activity of both gelatinases occurs at 7d, where MMP9
and MMP2 contribute to an elevation in the 48kD RGD-containing fragment, as well as a
progressive proteolysis of the smaller non-RGD carboxy-terminal sequence. This correlation of
postinjury OPN fragment expression with differential MMP activity is also supported by our
observation that acute 1d response to FPI increases the 48kD peptide, but does not change the
32kD form. Such correlates highlight progressive changes in OPN expression during OB
reactive synaptogenesis and a predominant role for 48kD in this model. In order to test whether
48kD OPN fragment generation was associated with OB cell signaling after FPI, we next
mapped postinjury cellular localization of OPN.

OPN localization supports neuronal response in deafferented OB
Gelatin zymography and WB studies revealed time-dependent responses of MMP9 activity and
OPN expression in deafferented OB. Following our detection of MMP9 in OB astrocytes, we
initially performed IHC to assess OPN localization in OB tissue. Interestingly, we found strong,
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selective OPN localization within two neuronal populations, external plexiform tufted and deeper
mitral neurons (Figure 3.5A), two of the same populations reported to selectively contain OPN
mRNA (Shin et al., 1999). These are the principal post-synaptic neurons affected by OB
deafferentation, and their expression of OPN increased over time postinjury, peaking at the 7d
interval and normalizing by 21d. Notably, this antibody binding intensity change matches the
result of 48kD OPN postinjury fragment formation, implicating neurons as the primary source of
OPN. To further substantiate our finding and confirm absence of glial OPN, we performed
double label experiments with OPN and astrocyte and microglial markers GFAP and IBA1,
respectively. Unlike other brain regions deafferented by FPI, we found no appreciable OPN
protein signal within either reactive astrocytes or reactive microglia of the OB (Figure 3.5B).

While OPN signal appeared predominant within the cell bodies of these neurons, it remained
unclear if this neuronal OPN served a secretory-peptide signaling function. Given that a variant
form of OPN was reported to bind to intra-neuronal microtubule associated proteins (Long et al.,
2012), we further probed these tissues to determine if MAP2/OPN co-localization was present in
the processes of tufted and mitral neurons (Figure 3.6A). As predicted, we observed clear
MAP2 labeling within neuronal processes (principally dendritic), however, little OPN colocalization with MAP2 dendritic marker was found, suggesting that its production in the
deafferented OB neurons was more likely directed toward secreted, cell signaling function over
bound intracellular role. In a second cell-based probe, we sought to clarify the identity of the
OPN positive neurons found closely bordering deafferented glomeruli. To do this, OB tissues
were exposed to paired tyrosine hydroxylase (TH) and OPN antibodies, with TH used to

165

Figure 3.5 IHC of OPN protein distribution within OB following FPI
A. Confocal imaging of sham cases shows OPN (green) localized to cells along the border
between the GL and EPL, likely tufted neurons, as well as mitral neurons in the MCL (arrows).
After FPI, OPN signal revealed time-dependent increase in these neurons, a modest rise at 3d and
a robust increase within the neuronal cell bodies and primary dendrites at 7d postinjury. By 21d,
OPN staining intensity was still higher than sham, but appeared reduced relative to the 7d
interval. B. Double label experiments with OPN (green) + GFAP (red) at 3d, and OPN (green)
+ IBA1 (red) at 7d failed to show co-localization of signal, suggesting that OPN was not
detectable in reactive glial cells of the deafferented OB. Scale bar = 50µm. N=3-4/group.
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Figure 3.6 IHC of OPN expression in OB post-synaptic neurons following FPI
A. Confocal imaging showing the absence of interaction between OPN and microtubules
(MAP2 labeled; red) at 7d postinjury. MAP2 signal is present in dendrites (yellow arrows)
throughout the OB, higher within dendrite-rich EPL. OPN (green) did not colocalize with
MAP2, but was restricted to cell soma of tufted and mitral neurons (white arrows). B. OPN was
not found within tyrosine hydroxylase positive (TH; red) inhibitory periglomerular cells. While
TH identified a large population of these cells surrounding glomeruli (yellow arrows), OPN
(green) was not co-localized in them. This result suggests that OPN positive cells at the GL/EPL
border are likely ORN post-synaptic tufted neurons. Scale bar = 50µm. N=3-4/group.
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positively identify periglomerular inhibitory neurons forming boundaries around individual
glomeruli. Results failed to show co-localization of the two proteins, confirming that the OPN
positive cells near OB glomeruli were not TH containing periglomerular cells, but likely local
tufted neurons (Figure 3.6B).

Taken together, our IHC results suggest that OB glia do not produce significant levels of OPN,
but rather, may be targets of OPN signals generated by tufted and mitral neurons affected by
injury. Further, since reactive astrocytes also contain MMP9, we posit that a complex cellular
interaction occurs in the OB after FPI, which includes ECM processing of neuronal secreted
OPN by astrocyte produced MMP9, activating local cellular response at sites of ORN terminal
degeneration, and directing tissue response for reinnervation. Indeed, OB deafferented neurons
may play a more precise role in directing this OPN tissue response than in other cortical regions.

FPI upregulates CD44 receptor expression
As a final approach to understanding the complex OPN-mediated OB cell interactions after FPI,
we decided to probe for time-dependent postinjury expression of the cell surface receptor, CD44,
which can bind OPN signaling fragments. From our observation that FPI induces acute OPN
increase and pronounced glial reactivity within the deafferented OB, we posited that OPN and
the CD44 receptor expression would show temporal correlation. When FVB/NJ WT OB protein
extracts were probed for CD44, we found significant postinjury elevation in the receptor level at
both 3d (364.96±16.96, p<0.001) and 7d (213.71±61.16, p<0.05) when compared to sham
control cases (Figure 3.7). Interestingly, this early 3d rise in OB CD44 was nearly 3-fold over
controls and persisted into the 7d period. We also observed an increase in CD44 protein at 1d
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Figure 3.7 Diffuse FPI induces time-dependent increase of CD44 OPN receptor
A. WB analysis of CD44 protein expression showed significant elevation of the OPN receptor at
3 and 7d after FPI when compared with sham controls. By 3d, CD44 was over 3-fold higher
than sham, and remained 2-fold higher at 7d. At 1d postinjury, CD44 trended toward increase
relative to sham controls, but failed to reach significance, and at 21d, expression equaled control
level. Post hoc analysis revealed significant differences in CD44 receptor protein level across
time, with the 3d rise different from all other time points, and the reduction between days 3 and
7 also different. B. Results are expressed as percent of sham control relative optical density
(100% dashed line). Representative blot images of CD44, with cyclophilin A and β-actin load
controls, are illustrated below. ##p<0.01 day x vs. y, ###p<0.001 day x vs. y, *p<0.05 Sham vs.
TBI, ***p<0.001 Sham vs. TBI. N=3-6/group.
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(190.41±35.52), but this change failed to reach significance when compared with sham injured
cases. By 21d postinjury, CD44 levels were again not different from controls (96.77±19.57).
After post hoc analysis, time-dependent differences were found between 3d CD44 and receptor
levels at all three additional time points (p<0.01 for 3d vs 1and 7d; p<0.001 for 3d vs 21d).
Acute rise in OPN-mediated receptor signaling is consistent with a reported 3d peak in
CD44/OPN elevation after ischemia (Kang et al., 2008), and approximates the temporal rise
documented after cryolesion (Shin et al., 2005). Notably, 48kD OPN fragment increase was
observed at 1d following OB deafferentation, prior to the 3d induction of CD44, and both
proteins are concurrently elevated by the 7d time point. Given that we also detected increase in
MMP9 activity 1d postinjury and maximal enzyme activity at 7d, we posit that a molecular
interaction between MMP9/OPN/CD44 is induced early after FPI to facilitate autocrine/paracrine
cell signaling during the 1-7d degenerative phase of OB injury response.

DISCUSSION
A hallmark of TBI is diffuse axotomy, a pathology resulting in disruption of axon projections
and deafferentation of synaptic circuits. Brain ECM plays an important role in maintaining the
appropriate local environment to support structural integrity and function of these circuits
(Marcoli et al., 2015). After TBI, collagens, proteoglycans and other glycoproteins, as well as
MMPs, modify matrix structure around affected synapses. Further, synaptic repair induced by
TBI deafferentation requires time-dependent adjustment of the surrounding ECM to facilitate
removal of damaged axons, reshape post-synaptic sites and induce sprouting of re-innervating
axon terminals. For example, in deafferented hippocampus, agrin and N-cadherin, matrix
proteins which normally act to stabilize synaptic junctions, are reduced in their expression during
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early periods of synapse deconstruction/reformation, and are subsequently increased during
phases of nascent synapse stabilization (Falo et al., 2008; Warren et al., 2012). Interestingly,
postinjury MMP activation is also correlated with these shifts in ECM protein level and, as such,
is linked to progress of synaptic development and repair mechanisms (Ethell and Ethell, 2007;
Kaliszewska et al., 2012; Verslegers et al., 2013; Phillips et al., 2014; Kelly et al., 2015).
Recently, our laboratory has discovered that OPN, an inflammatory signaling cytokine, is
upregulated in the hippocampal glia after brain injury, and its activation is temporally correlated
with increased proteolysis by local MMPs (Chan et al., 2014). While several studies suggest
OPN may serve as a target for improving postinjury synaptic recovery in cortical brain regions
(Shin et al., 2005; Plantman, 2012), it is not known if OPN plays a role in OB reactive
synaptogenesis following TBI. Here, we investigate time-dependent MMP9 proteolysis and
OPN expression within FVB/NJ mouse OB subjected to mild FPI, an insult which produces
ORN axotomy and reactive synaptogenesis (detailed in Chapter 2). Based upon gelatinase
(MMP2, 9) response to ORN transection in animal models (Costanzo et al., 2006; Costanzo and
Perrino, 2008; Bakos and Costanzo, 2011), and the presence of clinical olfactory deficits after
brain trauma (Costanzo and Becker, 1986; Costanzo and Zasler, 1991), we hypothesized that
olfactory pathology generated by FPI would induce time-dependent increase in MMP2 and
MMP9 activity, leading to OPN signal fragment production, which then directs OB cellular
response during reactive synaptogenesis. We also posited that this OPN response would be
mediated through reactive glial cells in deafferented glomeruli, which we expect to show timedependent change in OPN receptor proteins.
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Overall, our different outcome measures do support the first hypothesis, showing that MMP9 is
the predominant OB gelatinase activated after FPI, and that the OPN RGD receptor binding
fragment serves as a principal cell signal during the acute and subacute postinjury intervals. We
also found MMP9 present in reactive astrocytes, similar to enzyme distribution in deafferented
hippocampus. However, OPN protein localization was different from injured hippocampus, in
that it was not present in reactive glia, but restricted to the deafferented mitral and tufted cells of
the OB. Moreover, this neuronal OPN did not show the predicted association with cytoskeletal
proteins, which characterizes cytoplasmic OPNi isoforms, and failed to co-localize within
periglomerular inhibitory neurons. We conclude that MMP9/OPN/CD44 signaling likely
contributes to OB postinjury synapse degeneration and reinnervation after FPI through ECM
processing of neuronal-derived, secreted OPN protein.

Gelatinase activity shows time-dependent change after FPI
We first assessed MMP2 and MMP9 proteolytic activity in OB protein extracts over the initial
postinjury degenerative phase (1-7d) and at onset of the regenerative phase (21d) using gelatin
zymography. These two MMPs are normally produced by both neurons and glia (Phillips et al.,
2014; Abdul-Muneer et al., 2015), and assist in the redistribution of ECM substrate proteins,
promoting plasticity in brain regions susceptible to axotomy by inducing axon sprouting and
growth during synaptogenesis. While gelatinases can exhibit both pathological and beneficial
properties within the injured CNS (Huntley, 2012), their time-dependent activity is linked to the
success of specific phases of synaptic reorganization. In models of hippocampal deafferentationinduced synaptogenesis, MMP9 activity maximally rises during early degenerative periods,
while MMP2 activity evolves later, during axonal sprouting and synapse reformation (Phillips
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and Reeves, 2001; Phillips et al., 2014). This phase-related pattern has also been reported to
occur for OB gelatinase protein expression following full ORN transection or nasal epithelium
ablation (Costanzo et al., 2006; Costanzo and Perrino, 2008; Bakos et al., 2010).

Our study shows that diffuse FPI ORN axotomy can generate time-dependent change in
gelatinase activity, however, the temporal pattern of this response appears to vary from more
severe OB deafferentation models. Although these other studies assessed MMP9 protein rather
than activity, comparison with our FPI model shows that the pattern of enzyme rise and recovery
to normal activity is altered, and the relative contribution of the two gelatinases is different. Like
FPI, full ORN transection (Costanzo et al., 2006) causes a rapid 1d stimulation of MMP9
protein, followed by reduction at 3d, however, no second peak in MMP9 response occurs with
full nerve lesion as is observed with FPI. Even more interesting are the differences between FPI
and OE ablation (Bakos et al., 2010). In that case, no OB MMP9 reaction to ORN cell death is
detected at1d postinjury, with only one peak in MMP9 protein generation occurring at 5d, more
in line with our second peak in MMP9 activity at 7d. By 21d, we found no difference in MMP9
activity relative to controls, whereas both ORN transection and OE ablation maintain modest
elevation in MMP9 protein during the 15-35d period. Overall, these results suggest multiple,
perhaps distinct, roles for MMP9 throughout the acute/subacute injury process as a function of
injury model. ORN transection and OE ablation are severe; FPI would not cause acute, massive
axon damage. It is also interesting that diffuse OB deafferentation produced by FPI reveals two
MMP9 activation cycles during the period of degeneration, and requires a longer time to
maximally activate MMP9, perhaps due to a retarded rate or extent of axon/synaptic damage. In
contrast to MMP9, we found MMP2 activity increase only at 7d postinjury, and to a much lower
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extent. Again, this is in contrast to the more severe ORN transection, where the magnitude of the
7d peak in MMP2 protein was equal to that of 1d MMP9 (Costanzo and Perrino, 2008). A
distinct difference with diffuse FPI is that 7d MMP9 activity is not equivalent to that of MMP2,
but is elevated nearly 3 fold higher.

In parallel IHC experiments we probed for cellular localization of MMP9 in the OB. FPI not
only caused an increase in enzyme signal within OB glomerular and external plexiform layers,
but also showed clear upregulation within reactive astrocytes surrounding glomeruli. Notably,
these changes were most pronounced 7d after FPI, matching our peak of zymography activity.
This pattern of MMP9 increase is consistent with reported glial production and distribution of
MMPs in and around other cortical synaptic sites deafferented by TBI (Rosenberg, 1995; Wang
et al., 2000; Zhang et al., 2010). As discussed below, MMP9 distribution within reactive
astrocytes surrounding disrupted synapses suggests an enzyme/substrate interaction between
MMP9 and OPN to facilitate OB cell signaling for synaptic repair.

Overall, contrasting MMP9 and MMP2 activity in our FPI model emphasizes the importance of
MMP9 over MMP2 following diffuse deafferentation of the OB. Considering that OB reactive
synaptogenesis occurs over a longer period of time than in other brain regions, elevated
gelatinase activity at both 1 and 7d is consistent with an extended synaptic
degeneration/regeneration cycle occurring after diffuse axotomy. We posit that the 7d MMP9
activity represents peak enzyme targeting of critical cellular and molecular substrates that serve
to facilitate the onset of synaptic repair. Osteopontin is potentially one such target.
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Osteopontin cell signaling fragments increase following FPI
The multiple functions of OPN proteolytic fragments were discussed in Chapter 1, focusing on
integrin and CD44 receptor binding which directs specific cellular responses. Most studies
exploring OPN role after brain injury map such fragment generation, however, reports in several
CNS trauma models do show robust elevation of full length 66kD OPN within 1d postinjury
(Ellison et al., 1998; Hashimoto et al., 2007; Kang et al., 2008; Shin et al., 2011; Chan et al.,
2014). For example, microglia surrounding stroke infarct show increased OPN mRNA well
within 3h after injury (Ellison et al., 1998) and reactive microglia/macrophages exhibit
significant rise in OPN by 4d after cortical cryolesion (Shin et al., 2011). In our laboratory,
Chan et al. (2014) reported a multifold upregulation of both OPN mRNA and 66kD OPN 1-2d
after entorhinal deafferentation of the hippocampus, with reduction to control levels by 7d. The
present OB results do support a similar trend toward increase in full length OPN 1-3d and
reduction at 7d after FPI, however, the overall analysis showed no significant changes relative to
sham controls. This suggests that diffuse FPI insult of the OB fails to induce the multifold
increases in 66kD OPN seen with severe hippocampal deafferentation. Again, we interpret this
lack of significant effect to be a function of reduced axotomy in our model. Post hoc analysis
did, however reveal a time-dependent reduction at 7d compared to 1 and 3d full length OPN,
which fits with maximal MMP9 activity at 7d postinjury and could explain the shift toward less
intact 66kD OPN at that time point.

Lysis of 66kD OPN can be achieved by thrombin and other proteases, including MMPs 3, 7 and
9 (Agnihtori et al., 2001; Lindsey et al., 2015; Scatena et al., 2007; Takafuji et al., 2007).
Primary MMP cleavage occurs at a site near the internal RGD/SVVYGLR sequence, generating

178

a larger amino-terminal fragment (~48kD) containing the exposed RGD integrin binding domain
and a smaller carboxy-terminal fragment (~32kD) with hyaluronan receptor binding
characteristics (Scatena et al., 2007). This 48kD amino-terminal OPN fragment has been
explored in a model of CNS deafferentation, where its elevation has been documented (Chan et
al., 2014) and linked to acute immune activation (Wang and Denhardt, 2008). It binds primarily
to vitronectin (αvβ3 integrin) and other integrin receptor types, as well as inflammatory cell
surface receptors, like the hyaluronan CD44 receptor, directing cell adhesion and migration
(Scatena et al., 2007; Weber et al., 1996). Thus, the 48kD OPN fragment has significant
potential to direct cellular reactivity and mobility after FPI, influencing early phases of reactive
synaptogenesis. Following FPI, we first found a peak of 48kD OPN within the OB at 1d
postinjury, an acute interval also reported to show fragment elevation after other forms of CNS
injury (Chan et al., 2014). Surprisingly, we saw a second, later significant increase in 48kD
fragment generation, coinciding with the peak of OB MMP9 activity at 7d. It became apparent
that the pattern of 48kD OPN generation was temporally correlated with level of MMP9
proteolysis detected. The early elevation in enzyme activity at 1d and maximal peak of activity
at 7d were matched by significant OPN cleavage, while the intervening 3d postinjury period
showed no change in enzyme or 48kD OPN fragment. This suggests that OPN signaling through
RGD integrin binding plays a principal role in the 1d acute and 7d subacute phases of FPI
induced axon degeneration, likely directing inflammatory cell migration for debris removal and
reorganization of local synaptic sites for subsequent onset of regeneration. Interestingly, tandem
MMP9/OPN increase is also reported in multiple sclerosis, where patient CCR2+/CCR5+ T cells
can be stimulated to produce high levels of both proteins (Sato et al., 2012). In our model, such
cell reactivity was no longer visible at 21d, when the regenerative phase was underway,
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apparently no longer requiring generation of OPN fragments by MMP9. Our results confirm this
shift, with significant time-dependent differences between data for 21d and earlier time points.
By contrast, we found that FPI had the opposite effect on OB expression of the 32kD OPN.
Essentially no change was seen during the 1-3d postinjury period, but the fragment showed
significant reduction below controls at 7d, when MMP9 activity was increased 3-fold. These
results indicate a complex processing of this OPN peptide during the acute and subacute
postinjury intervals. Specifically, its overall level is likely maintained early after FPI, with
generation/degradation balanced. By 7d, however, high MMP9 activity appears to drive
additional lysis of this smaller fragment, a recycling process already attributed to the enzyme
(Lindsey et al., 2015; Takafuji et al., 2007). Together, these stages of 32kD processing suggest
its role is more important during the early, acute phases and less significant during the subacute
7d period. Like the 48kD OPN signal, 32kD OPN shows no change from sham controls by the
21d regenerative phase, also supporting the decreased requirement for integrin or CD44 cell
signaling activation.

Our parallel IHC experiments probing for OB cellular localization of OPN revealed rather
unexpected results. Several studies, including those from our laboratory, have shown OPN
protein within both neurons (Shin et al., 2005) and glia (Choi et al., 2007; Ellison et al., 1998;
von Gertten et al., 2005), however, following CNS injury, increased OPN transcript is often
prominent within microglia and elevated OPN protein in both microglia and astrocytes (Chan et
al., 2014). Interestingly, we found no OPN localization within astrocytes and microglia of the
OB glomerular and outer plexiform layers after FPI. Over 3-21d postinjury, OPN upregulation
appeared within two neuronal populations, mitral and tufted cells, suggesting a direct OPN
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response in the specific cells deafferented by FPI. Notably, the strongest neuronal OPN signal
occurred at 7d, matching the peak MMP9 activity and significant increase in 48kD OPN. To our
knowledge, this primary neuronal OPN response is unique to the OB among cortical regions
deafferented by TBI. The majority of OPN signal was seen within the cell bodies of these
neurons, with some protein extending into primary dendrites, presumably associated with ORN
synapses. This result raised the possibility that changes in OPN protein after FPI might be
mediated through cell to cell signaling originating within the actual deafferented neurons (i.e.,
mitral and tufted post-synaptic dendrites). Since a cytoplasmic OPNi has been identified and
associated with microtubule binding proteins of the cytoskeleton (Long et al., 2012), we explored
whether our IHC signal reflected OPNi and not secreted, lysed OPN. Based on the absence of
OPNi and MAP2 signal co-localization, we conclude that OB neuronal OPN exists primarily in a
form which is secreted and cleaved within the ECM. It was also possible that some of the
glomerular-associated neurons positive for OPN might be periglomerular inhibitory neurons,
whose synapses would be indirectly affected by ORN axo-dendritic pathology. However, we
failed to find OPN expression in these cells when co-localization experiments were performed
with their cell marker, tyrosine hydroxylase. From this result, we conclude that the OPN+
neurons responding to FPI at the base of the OB glomerular layer are deafferented post-synaptic
tufted neurons. Taken together, these IHC observations suggest that postinjury OPN signaling
begins within the primary deafferented neurons, a process likely involving increased production
and release of OPN locally. This posited release appears to pair with elevated neuronal and glial
MMP9, generating OPN signaling peptides for critical autocrine/paracrine response to direct
reactive synaptogenesis.
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Elevation of OPN receptor CD44 after FPI
Our results show that time-dependent change in expression of OPN peptide fragments occurs
within the OB after FPI. The two principal fragments we observed (48, 32kD) each have a high
affinity for cell surface receptors which direct inflammatory activation, migration and axon
growth (Plantman, 2012; Scatena et al., 2007; Weber et al., 1996). While 48kD amino terminal
peptide can bind to multiple integrin receptors, including α8β1, α4β7, α4β1, and α9β1, (Scatena et
al., 2007), Liaw et al. (1995) found that the αvβ3 (vitronectin) receptor supported OPN-mediated
migration, while αvβ5 or αvβ1 promoted cell adhesion. There is also evidence that the smaller
carboxy terminal 32kD fragment binds CD44 hyaluronan receptor (Takahashi et al., 1998;
Weber et al., 1996; Weber et al., 1997; Weber et al., 2002). These integrin and CD44 receptors
are most associated with OPN cell signaling in the injured CNS. Moreover, both appear
important relative to OPN role in synaptogenesis, since β1 and CD44 antibodies block OPNmediated neurite outgrowth (Plantman, 2012), and interference with hyaluronan/CD44 signaling
through genetic manipulation of Rac1/PKNƴ alters astrocyte cytoskeleton and cell migration
(Bourguignon et al., 2007). Initially, we sought to probe OB postinjury expression of each
receptor, however, antibodies tested for αvβ3 presented technical concerns, so our focus was
shifted to mapping CD44. This receptor is acutely elevated after CNS injury, suggesting it as a
candidate for OPN cell signaling following OB deafferentation. In addition, CD44 is expressed
over the perilesional area after TBI (Günther et al., 2015) and increases within activated
microglia and macrophages 1-4 days post-injury (von Gertten et al., 2005).

The present profile of OB CD44 expression revealed injury-induced upregulation at subacute
intervals of 3 and 7d, with the greatest increase at 3d. This is striking, since the peak of CD44 is
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early after injury and does not match the 7d peak of 48kD OPN. In fact, we found no change in
the latter fragment at 3d after FPI. Nevertheless, it is possible that the generation of 48kD OPN
at 1d, just prior to the CD44 3d peak expression, might contribute to the rapid upregulation of the
receptor. Indeed, one in vitro study reports increase of CD44 surface membrane expression in
the presence of OPN, and that OPN facilitates formation of specific phosphorylated variants of
CD44 which interact with MMP9 at cell membranes to regulate enzyme activity (Desai et al.,
2009). By contrast, the directional changes in CD44 and 32kD between 1-7d (upward, peak,
downward), while not all significant, do show a consistent pattern of change. This pattern
suggests the possibility that OB CD44 response to FPI may be closely linked to 32kD levels.
Further, it points to CD44 as important for execution of the acute/subacute degeneration phase,
and less so for the 21d reinnervation interval, which is similar to a pattern of CD44 increase
reported after central and peripheral nerve transection (Jones et al., 2000). Interestingly, 32kD
CD44 signaling could operate in tandem with 48kD vitronectin pathways to modulate the timing
or extent of neurite outgrowth, a critical element for successful OB synaptogenesis. It is posited
that the 32kD OPN, lacking integrin binding sites, may actually oppose 48kD OPN-mediated
adhesion (Smith et al., 1996; Gao et al., 2004; Maeda et al., 2001), providing a means to balance
growth at different stages of the degeneration/regeneration cycle. Notably, we observed a
similar temporal pattern for glial reactivity and CD44 response, mapping maximal cell
responsivity to the same 3d phase of the synaptogenic cycle. As stated above, the latter
interpretation fits the post ischemia time sequence proposed by Kang et al. (2008), where early
2-3d microglial activation mediates CD44 glial mobility and cell adhesion. Further IHC studies
mapping CD44 cell localization will be required to clarify whether acute neuronal or glial signals
are responsible for OB CD44 activation after FPI.
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Summary
Taken together, these data provide evidence that time-dependent change in gelatinase activity,
OPN proteolysis and CD44 hyaluronan receptor expression each occur within the deafferented
OB of FVB/NJ mice following central FPI. These changes suggest a temporally cued interaction
between MMP9/OPN/CD44, which likely facilitates the initial degenerative phase of OB
reactive synaptogenesis. Significant 7d elevation of MMP9 activity was correlated with
generation of 48kD integrin binding OPN fragments, potentially signaling a second, critical
cellular response to FPI axotomy. CD44 hyaluronan receptor upregulation occurs earlier at 3d
after injury, revealing a pattern that may be more associated with the non-integrin binding 32kD
OPN fragment. However, it is possible that early 1d rise in 48kD OPN could also underlie
elevated CD44 at 3d postinjury. From additional IHC of MMP9 and OPN, we also found that
FPI induces a unique OB pattern of response, where OPN signal could be generated both within
deafferented post-synaptic neurons and ECM. OPN could be processed by MMPs in
deafferented neurons and signal fragments released, or full length OPN released into the ECM
around affected glomeruli for processing by astrocyte secreted MMP9. Our results support the
hypothesis that MMP9 and OPN cooperate to provide cellular signaling that directs the early
degenerative phase of OB reactive synaptogenesis. In Chapter 4 we will describe results from
experiments which utilize MMP9 KO mice to manipulate this cooperative mechanism, directly
testing its contribution to OB synaptic repair after FPI.
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CHAPTER 4

MMP9 KO ALTERS PROGRESS OF FPI-INDUCED OB SYNAPSE REGENERATION
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ABSTRACT
MMP9 has been implicated as a critical mediator of ORN recovery during axotomy-induced
reactive synaptogenesis in the OB. We have proposed that MMP9 processes one of its
substrates, OPN, generating signaling fragments which promote cellular responses necessary for
synaptic repair. In Chapter 3, we documented postinjury biphasic elevation of MMP9 activity,
which corresponded with increased levels of 48kD OPN peptide. In order to fully assess MMP9
role in postinjury ORN reinnervation of the OB, we subjected MMP9 KO animals to FPI,
assessing the same outcome measures examined in WT mice. While full length 66kD OPN was
similarly unaltered by loss of MMP9, generation of OPN fragments was significantly affected.
Foremost, our WB data revealed that loss of MMP9 eliminated 1 and 7d injury-induced elevation
of the 48kD OPN fragment. Paired IHC of MMP9 KO mice confirmed this result, with a clear
reduction of OPN signal in tufted and mitral neurons at 7d postinjury. Moreover, WT patterns of
OMP expression 3-21d after FPI were reversed by MMP9 loss, specifically showing a delayed
initial loss and a persistent reduction in the protein marker of ORN axons. Together these two
lines of evidence support direct OB MMP9/OPN interaction after FPI, indicating that the
pathway provides critical cell signaling necessary for rapid clearance of injured ORN axon
terminals and onset of reinnervation. Interestingly, the 7d injury-induced reduction of 32kD
OPN in WT animals was attenuated in MMP9 KO cases, further validating the importance of
MMP9/OPN interaction after FPI. Notably, measurement of MMP2 activity in MMP9 KO
animals failed to show strain differences, even though WT 7d elevation was normalized to
control level. This suggests that delayed degeneration associated with low OMP in the MMP9
KO caused attenuation of the 7d rise in MMP2 activity, normally linked to synapse regeneration.

186

As for WT mice, no injury effects on Synapsin-I or Synapsin-II expression were found in the
MMP9 KO. However, small strain effects could be detected at 3d postinjury for Synapsin-I and
at 21d postinjury for Synapsin-II, suggesting that a time-dependent role for MMP9 might exist.
Glial reactivity, CD44 levels, and GAP-43 expression were all unchanged in the absence of
MMP9, indicating that redundant molecular pathways exist for their activation to facilitate OB
synaptogenesis. Finally, TEM analysis of MMP9 KO mice at 21d postinjury revealed persistent
ORN axon degeneration, disorganization of pre-synaptic vesicles and underdeveloped synaptic
junctions. We conclude that MMP9 plays an important role in OB postinjury cell signaling, a
complex process that involves interaction with OPN to support ECM reorganization critical for
ORN reinnervation.

INTRODUCTION
Reactive synaptogenesis is a complex process involving breakdown and clearance of axonal
debris from injured neurons, emergence of nascent terminals, and stabilization of newly formed
synapses. Matrix enzymes like MMP9 have several functions associated with modulating the
ECM for synaptic repair and stabilization of synaptic function (Phillips et al., 2014). In OB
synaptic recovery, however, the exact role(s) and mechanisms underlying their function are still
being uncovered. Elevation of MMP9, a known mediator of synaptogenesis, is associated with
critical stages of synaptic plasticity following FPI-induced OB deafferentation (see Chapter 3).
Our results with diffuse FPI confirm MMP findings reported for focal OB injury models during
reactive synaptogenesis. As with FPI, these other models show that MMP9 response is
upregulated following OB deafferentation, induced by either ON transection (Costanzo et al.,
2006) or chemical OE ablation (Bakos et al., 2010). Collectively, these data provide support for
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the strategy of manipulating MMP9 to affect outcome during synaptic repair following diffuse
brain injury. Thus, it is important to clarify specific properties of MMP9 associated with
synapse reorganization in order to guide development of therapeutic interventions.
Data presented in the previous chapters reveals several time-dependent correlations of molecular
response in the OB subjected to mild FPI: 1) αII-spectrin proteolysis and OMP reduction
marking injury; 2) increased MMP9 activity and OPN fragment generation marking cell
signaling; 3) activated glia and CD44 cell surface receptor upregulation marking
autocrine/paracrine interaction; 4) GAP-43 elevation and OMP normalization marking
reinnervation. Such interesting findings point to complex interaction among these different
molecules within the damaged OB. Increased MMP9 expression or activity across several OB
deafferentation models suggests the enzyme targets and processes a variety of ECM molecules in
the OB, including OPN. Because OPN can be cleaved by several ECM enzymes to facilitate
inter-cellular signaling during synaptogenesis, direct manipulation of MMP9 will determine
whether this enzyme is critical to the production of OPN fragments after FPI and if it affects
CD44 receptor expression for successful ORN synaptic recovery. Typical approaches to
manipulate MMPs employ pharmacological inhibitors (Falo et al., 2006; Hadass et al., 2013; Hsu
et al., 2008; Kim et al., 2005; Reeves et al., 2003; Warren et al., 2012; Zhang et al., 2011) or
genetic knockout of MMP genes (Costanzo and Perrino, 2008; Copin et al., 2005; Hsu et al.,
2008; Kaliszewska et al., 2012; Lee et al., 2004; Mizoguchi et al., 2011; Wang et al., 2000;
Wilczynski et al., 2008; Van Hove et al., 2012; Vu et al., 1998; Zhang et al., 2011). Since MMP
family members are highly homologous, and sites of enzyme inhibition can be non-selective for
MMP type, MMP9 KO mice allow for a more specific test of the enzyme’s role in OB plasticity.
We maintain a colony of MMP9 KO mice, generated on FVB/NJ background, which can be used
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to test the effect of MMP9 loss on the OB synaptic degeneration/regeneration cycle and OPN
expression. In other brain injury models, MMP9 KO reduces the efficacy of both structural
(Kaliszewska et al., 2012) and functional (Nagy et al., 2006) synaptic recovery. The processing
of OPN into key signaling fragments is also reported to be attenuated when MMP activity is
pharmacologically inhibited (Chan et al., 2014; Phillips et al., 2014).

This chapter reports results of studies using MMP9 KO mice subjected to FPI in order to
determine if OB MMP9 loss alters postinjury changes in OPN proteolysis and CD44
upregulation, ORN degeneration marker OMP, as well as expression of Synapsin vesicle
proteins, and regeneration promoter GAP-43. Protein expression was again analyzed with WB
and compared to WT injured cases generated in Chapter 3. IHC was also conducted to confirm
any postinjury differences in glial reactivity, as well as cellular OMP and OPN localization due
to MMP9 KO. To further test if synaptic recovery was altered by loss of MMP9, we also used
TEM to probe for differences between MMP9 KO and WT synaptic reorganization at 21d
postinjury. Based upon our results in Chapters 2 and 3, we hypothesized that MMP9 KO will
significantly reduce OPN fragment generation, alter the pattern of ORN degeneration, as
reflected by change in OMP reduction, and attenuate the expression of proteins linked to glial
reactivity (CD44) and ORN reinnervation (GAP-43) within the OB deafferented by FPI. Our
results clearly showed that postinjury MMP9 activity generates OB OPN fragments as well as
altered the onset and progression of ORN axon degeneration marked by OMP reduction. The
loss of OPN signaling shifted the time course of the early degenerative phase of OB reactive
synaptogenesis, resulting in delayed debris removal from the ECM and poor synaptic
reorganization at the onset of reinnervation. Our analysis in Chapter 4 also revealed that MMP9

189

loss did not affect OB CD44 receptor or GAP-43 expression after FPI, suggesting that redundant
molecular pathways exist for their activation to facilitate OB synaptogenesis.

METHODS
Experimental Animals
All procedures met national guidelines for care and use of laboratory animals, and all
experimental protocols were approved by the VCU Institutional Animal Care and Use
Committee. FVB/NJ WT and matrix metalloproteinase 9 knockout (MMP9 KO) adult male
mice (The Jackson Laboratory, Bar Harbor, ME) were housed (4 littermates/cage) under a
temperature (22ºC) and humidity controlled environment, with food and water ad libitum, and
subjected to a 12h dark-light cycle. WT mice (20-30g; 8-11 weeks old) were randomly selected
and subjected to midline FPI. WT sham-injured cases served as control. Subsets of FPI and
sham-injured groups [WT Sham (n=48), WT FVB TBI (n=53), MMP9 KO TBI (n=36] were
allowed to survive for either 1, 3, 7 or 21d post-injury prior to molecular or histological analysis.

In this study we compared the effect of MMP9 KO on OB response to injury using FVB WT
sham animals as the control group. This design was intentional and based upon several factors.
First, we sought to correlate our findings with published laboratory databases that compared KO
effects relative to WT controls, specifically those focusing on MMP9 and OPN role in other
brain regions following TBI (Chan et al., 2014). The design was also based upon preliminary
profiling of MMP9 KO cases (Appendix C.1) which showed that: 1) glomerular axo-dendritic
cytoarchitecture in the MMP9 KO OB was identical to that of FVB WT control cases, 2) MMP2
gelatinase activity in the OB of MMP9 KO sham mice was not different from that observed in
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FVB WT sham cases, and 3) OPN protein expression in a second white matter tract injured by
FPI (corpus callosum; Reeves et al., 2012) did not differ between FVB WT and MMP9 KO sham
animals.

Surgery Preparation and Injury
Mice were anesthetized with isoflurane (4% in 100% O2 carrier gas) and maintained on 2.5%
isoflurane in carrier gas delivered by nose cone. Once stabilized in a stereotaxic frame, heads
were shaved, body temperature maintained at 40ºC by Gaymar T/Pump water pump (Gaymar
Industries Inc, Orchard Park, NY) and heart rate (bpm), arterial oxygen saturation (percent O2),
breath rate (brpm) and pulse/breath distension (µm) monitored by pulse oximetry (MouseOx;
Starr Life Sciences, Oakmont, PA). Mice then received a midline incision and a 2.7 mm
craniectomy prepared over the midline, centered between bregma and lambda. Without
damaging the underlying dura, a Leur-Loc syringe hub was cemented to the skull surrounding
the craniectomy and dental acrylic poured around the hub to stabilize the site. Topical
anesthetic/antibiotic was applied to the incision site and the mice housed in recovery cages.
After one hour of surgical recovery, mice were anesthetized for 4 mins (4% isoflurane, 100%
O2), and subjected to FPI as previously described (Dixon et al., 1987; Reeves et al., 2012). The
device consisted of a 60 x 4.5 cm Plexiglas water filled cylinder, fitted at one end with a piston
mounted on O-rings, with the opposite end housing a pressure transducer (EPN-0300A; Entran
Devices, Inc., Fairfield, NJ). At the time of injury, the Leur-Loc fitting, filled with saline, was
attached to the transducer housing. Injury was produced by a metal pendulum striking the
piston, transiently injecting a small volume of saline into the cranial cavity and briefly deforming
the brain tissue (20 millisecond pulse duration). The resulting pressure pulse was recorded extra
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cranially and registered 1.3±0.1 atm pressure. After injury, all mice were promptly ventilated
with room air until spontaneous breathing resumed. The duration of suppression of the righting
reflex (5.0±2.0 mins) was used as an index of traumatic unconsciousness. Once righting reflex
was determined, mice were re-anesthetized for hub removal, scalp suture and topical
anesthetic/antibiotic application. Sham-injured controls received the same surgical preparation,
anesthesia and connection to the injury device, except that the intracranial pressure pulse was not
applied. All animals were returned to their home cages and assessed for weight loss, locomotion,
and eye/nose exudate once per day until weights stabilized.

Protein Extraction
WT mice were anaesthetized with 4% isoflurane in carrier gas of 100% O2 for 4 min, then
sacrificed by decapitation at 1, 3, 7 or 21d after FPI or sham injury, with bilateral OBs dissected
(n=4-7/group) for assessment of protein expression. Tissue samples were homogenized on ice in
100 µl of RIPA Lysis Buffer (EMD Millipore, Billerica, MA), and centrifuged at 14,000 x g for
20 min at 4°C. Supernatant was aliquoted and stored at -80°C. Prior to Western blot (WB),
protein concentration was determined using Pierce BCA Protein Assay Reagent (Thermo-Fisher,
Waltham, MA) and the FLUOstar Optima plate reader (BMG Labtech, Inc., Cary, NC).

Western Blotting
WB analysis was carried out utilizing Bio-Rad products (Hercules, CA). Twenty µg of protein
was prepared in WB XT Sample Buffer and reducing agent (Bio-Rad Laboratories), then
denatured at 95˚C for 5 mins. Samples were electrophoresed on 4-12% or 12% Bis-Tris
Criterion XT gels (200v x 45 min in MOPS running buffer), then protein transferred onto
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polyvinylidene fluoride (PVDF) membranes (1h at 100V). Post-blotted gels were stained with
0.1% Coomassie Brilliant Blue (Sigma-Aldrich, St. Louis, MO) in 40%MeOH+10% glacial
acetic acid, then de-stained at RT to confirm protein load and even transfer. Membranes were
rinsed with deionized water and Tris-buffered saline (TBS) before blocking with 5% milk TBSTween (mTBS-T). Blots were then incubated in 5% mTBS-T overnight (4°C) with individual
primary antibodies to Synapsin-I (1:500, Santa Cruz, Dallas, TX), Synapsin-II (1:4,000, EMD
Millipore, Billerica, MA), olfactory marker protein (OMP; 1:20,000, Wako, Richmond, VA),
growth associated protein-43 (GAP-43; 1:1,000, Santa Cruz, Dallas, TX), osteopontin (OPN;
1:500, R&D Systems, Minneapolis, MN; 1:500, Rockland Immunochemicals Inc., Limerick,
PA), and CD44 (1:500, BD Biosciences, San Jose, CA). After primary incubation, membranes
were washed with mTBS-T, then incubated with appropriate HRP-linked secondary antibodies
[IgG bovine anti-goat, IgG bovine anti-rabbit (1:15,000, Santa Cruz, Dallas, TX), IgG goat antimouse, IgG goat anti-rat (1:15,000, Rockland Immunochemicals Inc., Limerick, PA)] in mTBST for 1h at RT. Finally, blots were washed with mTBS-T and antibody binding visualized using
Super Signal Dura West chemiluminescence substrate (Thermo-Fisher, Waltham, MA). WB
images were captured with Syngene G:Box and positive band signal subjected to densitometric
analysis (relative optical density, ROD) with Gene Tools software (Syngene, Frederick, MD).
Protein data were expressed as percent change relative to paired WT Sham control cases run on
the same transferred gel. Cyclophillin A (EMD Millipore, Billerica, MA) or beta actin (SigmaAldrich, St. Louis, MO) were used as load controls for signal detection.
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Gelatin zymography
Zymographic enzyme assay was performed using previously described methods (Chan et al.,
2014). Briefly, 20 µg of protein from OB extracts described above for WT and MMP9 KO cases
were prepared with 2x Tris-glycine SDS sample buffer, then separated by gelatin electrophoresis
(at 4°C, 45V for 1.5 h) on Novex® 10% zymogram gels (Thermo-Fisher, Waltham, MA). Gels
were renatured in Novex® Zymogram Renaturing Buffer (Thermo-Fisher, Waltham, MA) for 30
min at RT before development in Novex® Zymogram Developing Buffer over 6 d at 37°C.
Gelatin lysis was visualized with Coomassie brilliant blue (Sigma-Aldrich, St. Louis, MO) and
purified enzyme run as positive control. Zymogram signal was captured on Syngene G:BOX,
and densitometry analyzed as ROD with Gene Tools software (Syngene, Frederick, MD).
Enzyme activity was expressed as percent change relative to paired controls run on the same gel.

Immunohistochemistry
At 3, 7 and 21d post-injury WT injured and WT sham mice (n=4/group) were prepared for
fluorescent IHC analysis according to published protocol (Warren et al., 2012). Animals were
anaesthetized with sodium pentobarbital (400mg/kg, i.p.), transcardially perfused with 0.9%
saline followed by 4% paraformaldehyde in phosphate buffer (0.1M NaHPO4, pH=7.4), after
which brains with attached OBs were extracted and placed in fixative for 24 h before transfer to
0.03% NaN3in 1.0 M phosphate buffered saline (PBS). For IHC, fixed brains were cryoprotected
in 30% sucrose for 3d, sucrose solutions exchanged after each day. Frontal lobes were blocked
and attached bulbs mounted in Tissue Tek media (Thermo-Fisher, Waltham, MA) and stored at 80°C. Coronal cryostat OB sections (13µM) were collected using a Cryostar™NX70;
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Cryotome™FSE; HM525 NX cryostat (Thermo-Fisher, Waltham, MA) and prepared for
immunofluorescence visualization.

Free floating sections were first permeabilized in 5% peroxidase for 30 mins. After a wash with
PBS, tissues were pre-incubated in blocking buffer (fish gelatin in PBS + 0.05% triton X-100) to
prevent non-specific binding, and then incubated overnight in primary antibody (OMP, 1:20,000,
Wako, Richmond, VA; OPN, 1:40, R&D Systems, Minneapolis, MN; glial fibrillary acidic
protein [GFAP], 1:20,000, Dako; ionized calcium binding adaptor protein [IBA1] for microglia,
1:300, Wako, Richmond, VA) at 4°C. Sections were next washed with PBS, placed in blocking
buffer for 30 mins, after which they were incubated with secondary fluorescent antibody (AlexaFluor 488 donkey anti-goat, 1:1000 and Alexa-Fluor 594 donkey anti-rabbit, 1:1000, ThermoFisher, Waltham, MA) in Blotto for 1h at RT. Slices were then PBS washed, equilibrated in
phosphate buffer, and mounted on Superfrost Plus slides (Fisher Scientific, Pittsburgh, PA) with
Vectashield + DAPI (Vector Laboratories, Burlingame, CA). IHC signal was visualized on the
Zeiss LSM 700 (Carl Zeiss, Thornwood, NY) confocal microscope (VCU Microscopy Core).

Transmission Electron Microcopy
Following FPI, at 21d, select injured WT and MMP9 KO mice (n=4) were anesthetized with
sodium pentobarbital (400mg/kg, i.p.), transcardially perfused with mixed aldehyde fixative (2%
paraformaldehyde and 2.5% glutaraldehyde) in 0.1M phosphate buffer, pH-7.2. Brains were
removed and post-fixed overnight at 4°C. OBs were next blocked in the sagittal plane and
placed in 1% osmium tetroxide (0.1 M cacodylate buffer), and processed for embedment with
Epon resin (Embed; Electron Microscopy Sciences, Hatfield, PA). After curing, OB areas
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containing glomeruli were mounted and both semithin (0.5µm) and ultrathin (silver, 600 Å)
sections were cut with a Leica EM UC6i ultramicrotome (Leica Microsystems, Wetzlar,
Germany). Semithin sections were used to guide subsequent ultrastructural sampling. Ultrathin
sections were collected on membrane Formvar-coated slotted grids and observed on a JEOL
JEM-1230 electron microscope (JEOL USA, Inc., Peabody, MA), equipped with a Gatan
UltraScan 4000SP CCD camera (Gatan, Inc., Pleasanton, CA).

Statistics
The effects of injury and MMP9 KO on protein levels and gelatinase activity were evaluated
using GLM SPSS v.23 (International Business Machines, Corp., Armonk, NY). These analyses
used 2-way completely randomized ANOVAs. Specific pairwise comparisons were evaluated
using the Duncan Post Hoc Test. Western blot and zymography results are reported as mean +/SEM. An alpha level of 0.05 was used in all analyses.

RESULTS
MMP2 elevation is attenuated by MMP9 KO
Time-dependent increases in OB MMP9 activity in both prior studies and ours (see Chapter 3)
suggest critical MMP9 proteolytic functions for mediating ORN repair. In order to define
MMP9 role, we utilized MMP9 KO animals to document consequences of genetically ablated
MMP9 for postinjury OB reinnervation. In our initial MMP9 KO experiments, we measured
MMP2 gelatinase activity to document a potential interaction between the two gelatinases during
reactive synaptogenesis. Prior studies have shown that after ORN axotomy, MMPs 2, 9 exhibit
distinct functions, as MMP2 protein levels are not affected by loss of MMP9 (Costanzo and
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Perrino, 2008). Our model also axotomizes the ON and deafferents the OB (see Chapter 2), thus
we chose to explore this interaction as well and potentially confirm and reproduce those findings.
Similar to the nerve transection model, following TBI, MMP2 activity was not elevated in a
compensatory manner in the absence of MMP9 (Figure 4.1). At 1, 3, 7, and 21d postinjury,
MMP2 lytic activity in the MMP9 KO was no different from sham controls (103.17±9.47;
119.83±12.15; 113.22±11.82; 90.38±7.46). Notably, however, loss of MMP9 did attenuate the
modest 7d increase in MMP2 detected in WT animals. While not significant, this effect suggests
peak 7d MMP9 activity in injured OB indirectly contributes to MMP2 elevation and that loss of
MMP9 impacts timing of MMP2 response during the subacute recovery period. To further
investigate the extent of postinjury consequences attributed to MMP9 loss, we probed for protein
expression of MMP substrate OPN.

MMP9 KO alters FPI-Induced Full Length OPN Expression
We posit that MMP9 elicits critical ECM reorganization for degenerative and regenerative
periods of ORN recovery through OPN. As for WT cases, we first tested whether loss of
enzyme activity with MMP9 KO affects expression of 66kD OPN during FPI-induced OB
synaptogenesis. (Figure 4.2). Overall, no change in FL 66kD OPN was detected with loss of
MMP9, as expression was not different from sham at each postinjury time point (93.23±17.90;
118.59±27.21; 88.25±9.08; 89.99±7.78). Likewise, no strain differences were found. However,
post hoc analysis did show that WT time-dependent differences in 66kD OPN were no longer
detected. This suggests that loss of MMP9 might have an effect on how FL 66kD changes over
time postinjury, but the effect appears to be small and difficult to interpret. As for WT FPI, we
shifted our focus to assay of change in the generation of OPN fragments within MMP9 KOs.
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Figure 4.1 MMP9 KO effect on MMP2 response to FPI
A. Zymographic assessment of postinjury OB gelatinase activity in MMP9 KO mice was
performed to assay whether loss of MMP9 generated a compensatory change of injury-induced
MMP2 response. In WT cases, MMP2 activity showed a significant OB increase at 7d
postinjury relative to sham controls, consistent with predicted role of this gelatinase in OB
synaptic regeneration (WT data replotted for comparison). MMP9 KO did not affect MMP2
activity at 1, 3 or 21d after FPI. At 7d, loss of MMP9 did result in a normalization of MMP2
proteolytic response, making it no longer significantly elevated over controls. Despite this
change, post hoc analysis failed to show strain differences at 7d. These data suggest that the two
gelatinases interact during OB response to deafferentation, and a reduced MMP2 function could
contribute to attenuated synaptic recovery at 21d postinjury (see Figure 4.12 below). B. Results
are expressed as percent of sham control relative optical density (100% dashed line). C.
Representative zymogram images of Sham WT (left) versus MMP9 KO Injured (right) MMP2
are illustrated. *p<0.05 Sham vs. TBI. N=3-8/group.
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Figure 4.2 MMP9 KO does not alter OB expression of full length OPN after FPI
A. WB analysis of full length OPN (66kD) in deafferented OB failed to show MMP9 KO effect
on injury response relative to sham controls. With loss of MMP9, 66kD OPN expression was
not different from control level at any of the four postinjury time points examined. Post hoc
time point comparisons also failed to detect any strain differences between WT and MMP9 KO.
This results indicates that the postinjury expression of full length OPN remains stable whether or
not MMP9 is involved in the injury response. Results are expressed as percent of sham control
relative optical density (100% dashed line). B. Representative blot images of 66kD OPN, with
β-actin load controls, are illustrated below. #p<0.05 day x vs. y. N=4-7/group.
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Loss of MMP9 reduces OPN signaling fragments after FPI
An additional set of experiments probed MMP9 KO effect on FPI induced OPN expression,
testing if generation of OPN signaling peptides can be altered when injury is delivered in the
absence of MMP9. Since WT mice exhibited time-dependent elevation of the 48kD RGD cell
signaling peptide and reduction of the carboxy terminal 32kD sequence, we focused on these two
OPN fragments. In WT animals, generation of the 48kD fragment was correlated with elevated
MMP9 activity at 1 and 7d postinjury (see again Figure 3.4). Here, we showed that loss of
MMP9 reduced the injury-induced increase in 48kD OPN fragment generation at these two time
points (Figure 4.3A), essentially returning expression level to that seen in control cases
(115.21±12.58; 89.64±8.69). Surprisingly, we also found that MMP9 KO significantly reduced
48kD OPN by nearly 70% at 3d post-FPI (33.99±5.02, p<0.001), where, in WT cases, injury
failed to have an effect on expression of this OPN form. By the 21d postinjury interval, loss of
MMP9 did not produce a difference in 48kD OPN level vs sham controls (95.30±5.24).
Subsequent post hoc comparison revealed striking strain differences. Foremost, loss of MMP9
significantly reduced the 48kD RGD signaling fragment of OPN at 1, 3 and 7d after FPI when
compared with WT injured cases (p<0.01, 1,7d; p<0.001, 3d).

For the 32kD carboxy terminal OPN fragment, we found little evidence of MMP9 KO effect. At
1, 3 and 21d after FPI, 32kD OPN levels in MMP9 KOs were not different from WT injured
animals (111.72±18.87; 134.93±15.37; 86.45±15.07). The one exception was the MMP9 KO
normalization of peptide expression at 7d postinjury (84.49±12.64), where WT cases did show a
significant protein reduction versus sham control animals (Figure 4.3B). Nonetheless, post hoc
comparison failed to identify any strain differences between WT and MMP9 KO 32kD OPN.
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Figure 4.3 MMP9 KO alters OPN fragmentation after FPI
A. WB analysis revealed profound effect of MMP9 KO on 48kD OPN fragment expression 17d after FPI. Loss of MMP9 significantly attenuated WT injury-induced elevation of the
fragment (WT data replotted for comparison) at 1 and 7d, normalizing expression to sham
control levels. By contrast, loss of MMP9 significantly reduced 48kD OPN at 3d, to
approximately 40% of control values. At 21d, the effect of MMP9 KO was lost, and the Nterminal fragment was no different from shams. Post hoc testing validated the 1-7d WT/MMP9
KO differences. These results point to direct MMP9/OPN interaction after FPI and suggest that
at subacute time intervals when the enzyme is not elevated, its absence has a strong effect on the
expression of 48kD OPN. B. Expression of 32kD OPN fragment was much less affected by
MMP9 KO. It was not different from sham values at all four time points and no post hoc strain
differences were detected. MMP9 KO normalization of 7d 32kD OPN suggests loss of MMP9
reversed the reduction of 32kD OPN seen in 7d WT animals. Results are expressed as percent
of sham control relative optical density (100% dashed line). C. Representative blot images of
OPN, with cyclophilin A and β-actin load controls, are illustrated below. *p<0.05 Sham vs.
TBI, ***p<0.001 Sham vs. TBI, §§p<0.01 WT vs KO, §§§p<0.001 WT vs KO. N=4-6/group.
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These results mapping MMP9 KO effect on OPN fragment generation after FPI show that if the
contribution of MMP9 lytic activity is removed, then critical 48kD OPN signaling fragment
production is significantly attenuated during the subacute degenerative phases of recovery, which
must precede axon sprouting and synapse reformation at 21d. Overall, these data support our
hypothesis that MMP9 activation after FPI is instrumental in producing and regulating cleavage
of two critical inter-cellular signaling proteins.

MMP9 KO affects OPN protein localization
While a tissue immunobinding assay cannot discriminate between the 48 and 32kD forms of
OPN, our histological results did reveal MMP9 KO effects on cell labeling which matched WB
protein measures. IHC tissue staining supports the finding of attenuated OPN fragment
generation in MMP9 KO cases (Figure 4.4). Qualitative staining differences consistent with the
loss of 48kD OPN expression were observed in both mitral and tufted neurons, whose 3d
postinjury OPN label intensity was strikingly reduced in the absence of MMP9. Further, at 7d
after FPI, OPN labeling of the same cell populations in MMP9 KO mice was also visibly lower
than in WT cases, with a signal close to that of sham controls, and consistent with 7d WB OPN
fragment normalization. These morphological correlates support the hypothesis that MMP9 KO
attenuates postinjury OPN response in deafferented neurons of the OB, likely affecting synaptic
reinnervation of these cells.
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Figure 4.4 IHC of OB OPN distribution in MMP9 KO animals following FPI
A. Confocal imaging of OPN in WT sham animals showed selective cell body labeling of
tufted and mitral neurons (white arrows), which increased in intensity at 3d postinjury
(Reproduced from Figure 3.5). MMP9 KO visibly reduced this neuronal OPN signal (right
panel). B. Similar neuronal OPN staining is seen in 7d sham cases, with FPI induction of
heavy OPN signal in WT animals 7d postinjury. Again, loss of MMP9 notably attenuated
the OPN response. This IHC result is consistent with significant loss of 48kD OPN within
the injured MMP9 KO cases. Scale bar = 50µm. N=3-4/group.
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Loss of MMP9 fails to alter CD44 receptor expression after FPI
As for WT, we probed expression of OPN receptor protein CD44 in the OB of injured MMP9
KO animals. Overall, we found that loss of MMP9 failed to change the time course of OB CD44
protein expression after FPI (Figure 4.5). At 1 and 21d after injury, the level of CD44 protein in
FPI MMP9 KO mice was not different from sham controls (131.57±11.30; 90.29±10.32). As for
injured WT mice, expression of the OPN receptor in MMP9 KO at 3 and 7d postinjury intervals
was significantly elevated over sham injured cases (267.77±33.03, p<0.001; 247.68±35.95,
p<0.001). Nevertheless, post hoc tests failed to detect strain differences at any postinjury time
point. In general, these results suggest that MMP9 does not significantly contribute to the
postinjury signaling responsible for CD44 receptor elevation. Further, postinjury rise in cell
surface CD44 receptors appears not to be dependent upon the generation of specific MMP9/OPN
proteolytic signaling, which is reduced in the MMP9 KO mice. From these results we would
now posit that OB OPN signaling after FPI likely occurs through other receptor pathways (e.g.,
vitronectin, αvβ3 integrin receptors), or that there exists another, indirect CD44 ligand whose
signaling pathway compensates for the loss of MMP9 and OPN peptides, maintaining CD44
receptor expression after FPI. Further studies will be needed to clarify these possibilities.

MMP9 KO does not alter OB astrocyte reactivity
Given that we observed OB MMP9 to be associated with GFAP positive astrocytes (see again
Figure 3.2), and that these glia are highly integrated among the GL synapses of the OB, we
conducted IHC to determine if loss of MMP9 affects deafferentation-induced astrocyte
reactivity. Importantly, astrocytes can express surface receptors for OPN paracrine signaling,
raising the possibility that any manipulation altering OPN expression might affect cellular
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Figure 4.5 Loss of MMP9 does not affect CD44 expression after FPI
A. WB analysis of OB CD44 receptor expression in MMP9 KO showed no difference from WT
injured cases (WT data replotted for comparison). Significant elevation of CD44 protein at both
3 and 7d postinjury of WT cases was also seen in the MMP9 KO animals. Similarly, injury did
not significantly alter 1 or 21d CD44. These results suggest that loss of MMP9 has little
influence on postinjury CD44 expression. Results are expressed as percent of sham control
relative optical density (100% dashed line). B. Representative blot images of OPN, with
cyclophilin A and β-actin load controls, are illustrated below. *p<0.05 Sham vs. TBI,
***p<0.001 Sham vs. TBI. N=3-5/group.
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reactivity to FPI. Loss of MMP9 would be one such manipulation. Upon analysis of OB tissue
from injured MMP9 KO mice, we found that loss of MMP9 activity did not appreciably affect
GL astrocyte response (Figure 4.6). Although the glia appeared slightly less hypertrophic in
MMP9 KO cases at time points of 3 and 7d postinjury, when WT cellular reactivity was robust,
there was only a minimal effect of MMP9 loss on astrocyte morphology. While OB glial
reactivity and MMP mediated ECM disruption are critical to clearance of degenerating axons, as
well as induction of growth factors for synaptic regeneration, MMP9 function in this process
may be redundant with other OB ECM enzymes, resulting in a compensation for the loss of
MMP9 function and little change in astrocyte reactivity.

Loss of MMP9 alters molecular markers of OB synaptic plasticity
We next profiled the expression of several proteins linked to synaptic stability and maturity
(OMP, Synapsin-I, Synapsin-II) and establishment of axonal outgrowth (GAP-43) to track
synaptic changes in MMP9 KOs subjected to FPI. The temporal pattern of postinjury OMP
expression was dramatically altered as a result of MMP9 KO. While OMP level in the MMP9
KO was no longer different from that of sham injured controls at 3d (70.97±9.83), OMP
expression was persistently reduced to 58% and 65% of sham control values at days 7
(58.94±9.44, p<0.05) and 21 (65.02±7.32, p<0.05), respectively (Figure 4.7). Similar to WT
cases, 1d OMP levels were equal to controls (97.29±9.41). Notably, comparison of strain effect
on OMP expression showed that the 7 and 21d return to sham control levels in WT cases, a shift
associated with onset of axon outgrowth and synapse reformation, failed to occur in the MMP9
KO, where OMP protein remained significantly reduced relative to WT sham cases (p<0.05 at
7d; p<0.01 at 21d). These results indicate that MMP9 activity contributes to the time-dependent
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Figure 4.6 IHC of OB astrocytes in MMP9 KO mice subjected to FPI
A. Confocal imaging of GFAP staining in 3d MMP9 KO samples was similar to WT injured
cases (Reproduced from Figure 2.2), with astrocytes displaying only minimal change in process
hypertrophy. Thus, loss of the gelatinase did not have an appreciable effect on astrocyte
reactivity assessed by GFAP staining. B. As for the 3d interval, the 7d MMP9 KO animals
subjected to FPI also showed little change in astrocyte reactivity relative to WT injured cases.
GFAP labeling in 7d MMP9 KO OB exhibited a labeling pattern consistent with WT injured,
slightly attenuated glomerular astrocyte reactivity relative to 3d postinjury. Scale bar = 50µm.
N=3-4/group.
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Figure 4.7 MMP9 KO causes persistent attenuation of OMP expression after FPI
A. WB analysis revealed that MMP9 KO had significant effect on OMP expression. While
MMP9 KO did not alter 1d OMP expression relative to sham controls, the 3, 7, and 21d
intervals were affected. WT 3d decrease in OMP (WT data replotted for comparison) was
attenuated with loss of MMP9, no longer statistically differ from sham controls. WT restoration
of OMP at 7 and 21d failed to occur in the MMP9 KO cases, with OMP now significantly
reduced relative to sham controls at each of the two time points. These results suggest that loss
of MMP9 compromised progression toward synaptic recovery and retarded reinnervation.
Results are expressed as percent of sham control relative optical density (100% dashed line). B.
Representative blot images of OMP with β-actin as a load control. *p<0.05 Sham vs. TBI,
§p<0.05 WT vs KO, §§p<0.01 WT vs KO. N=4-6/group.
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Figure 4.8 IHC of OB OMP distribution in MMP9 KO animals following FPI
OB distribution of OMP in postinjury MMP9 KO animals showed changes consistent with WB
shifts in OMP protein expression. A. Sham control (Reproduced from Figure 2.4) shows high
OMP signal in the ONL and in ORN axons penetrating the glomeruli (GL; arrow). At 3d
postinjury, MMP9 KO OMP tissue distribution was similar to the sham control, heavily staining
the ONL and labeling pre-synaptic ORN axons throughout the GL (arrow). B. By 7d, a marked
loss of OMP could be detected within the deafferented GL (arrow), consistent with the
persistent reduction of OB OMP seen in WB analysis. These results, further show that loss of
MMP9 has a real effect on the progression of pre-synaptic reinnervation within the deafferented
OB. Scale bar = 50µm. N=3-4/group.
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onset of ORN axon reinnervation after FPI, possibly involving cell pathways mediated by 7d
MMP9 generation of OPN cell signaling fragments.

To confirm the identity of the cell regions exhibiting change of OMP expression in MMP9 KO
animals, we performed IHC for the protein within the deafferented OB. As reported in Chapter
2, WT sham injured cases showed heavy localization of OMP protein in the surface ON layer of
the OB, and along axon processes within glomeruli (Figure 4.8). As previously described for 3
and 7d postinjury WT cases, OMP protein remained high in the ON layer, however, its presence
along 7d axon aggregates in the GL was of lower intensity, consistent with the WB reduction in
OMP protein expression (see again Figure 2.3). Interestingly, 3d postinjury MMP9 KO mice no
longer exhibited reduction in OB glomerular labeling, with signal intensity similar to that of
sham controls and mimicking the shift toward control OMP expression seen in MMP9 KO WB
experiments. ORN axon processes showed strong OMP signal within the GL region. These IHC
data show consistency of MMP9 KO effects across outcome measures.

While our results support the hypothesis that loss of MMP9 produces a detectable effect on
expression of those proteins associated with ORN-specific regeneration, however, changes in
more general pre-synaptic markers were modest. Although MMP9 KO did not have a large
effect on Synapsin-I and II expression, we did observe two modest time-dependent changes in
protein expression following FPI. The 80kD form of Synapsin-I (Figure 4.9A), expressed as a
percent of sham injured controls, showed a reduction of mean OB level relative to injured WT
animals at 3d postinjury (96.30±6.84 vs 122.58±8.88, p<0.05). We also found that MMP9 KO
slightly increased 21d expression of 72kD sham normalized Synapsin-II (Figure 4.10A) in the
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deafferented OB, compared to WT cases (110.53±6.38 vs 87.62±5.84, p<0.05). However,
MMP9 KO 1, 7, and 21d 80kD OB Synapsin-I levels, relative to sham controls (95.19±6.36;
95.87±10.34; 101.13±5.15), were not different from WT values, nor were any of the analyzed
time point measures in the MMP9 KO 70kD Synapsin-I (100.59±13.38; 103.39±20.87;
90.53±15.41; 91.22±10.57) (Figure 4.9B). Further, loss of MMP9 failed to alter sham
normalized 72kD Synapsin-II expression relative to WT in 1, 3, 7 d postinjury cases
(108.21±7.33; 104.92±6.85; 90.86±5.55). As for Synapsin-I, measures of the lower 58kD
Synapsin-II signal also did not show differences from WT values (119.70±20.73; 89.44±8.75;
137.07±25.95; 102.71±4.97). (Figure 4.10B) Interestingly, this rather modest effect of MMP9
KO on two synapsins occurred at postinjury time points where WT MMP9 activity was not
different from sham controls (see again Figure 3.1), suggesting that the gelatinase is less likely
to be associated with regulation of these proteins during OB reactive synaptogenesis.

In genetically modified MMP9 KO mice, overall GAP-43 protein expression relative to sham
control cases was similar to injured WT, with only one detectable strain difference. Foremost,
FPI in MMP9 KOs produced an elevation in 21d protein level similar to that of WT,
(362.09±31.06 vs 297.19±58.77), each of which was significantly higher than sham controls
(p<0.001; Figure 4.11). As in WT mice, levels of GAP-43 in MMP9 KO cases were also no
different from sham controls at 1 or 7d postinjury (85.44±25.56; 145.59±27.22). Interestingly,
we did find a shift to approximately 47% of uninjured control GAP-43 levels for the 3d
postinjury MMP9 KO cases (47.16±4.38), but this reduction failed to reach significance.
Nevertheless, post hoc analysis did reveal strain differences between WT and MMP9 KO values
at this time point (p<0.05). In general, these results indicate that MMP9 KO does not
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Figure 4.9 MMP9 KO does not affect OB Synapsin-I expression after FPI
A. WB analysis of 80kD Synapsin-I in MMP9 KO subjected to FPI failed to show any timedependent effects on protein expression relative to sham control animals. Post hoc analysis
detected only one strain related difference in this isoform, a reduction to control level at 3d in
the MMP9 KO cases (WT data replotted for comparison). B. 70kD Synapsin-I expression was
unaffected by the loss of MMP9 at each time point postinjury and no strain differences were
observed. Results are expressed as percent of sham control relative optical density (100%
dashed line). C. Representative blot images of 80kD and 70kD Synapsin-I with β-actin as a
load control. §p<0.05 WT vs KO. N=4-5/group.
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Figure 4.10 MMP9 KO does not affect OB Synapsin-II expression after FPI
A. Similar to Synapsin-I, WB probe of the larger 72kD Synapsin-II isoform did not show any
time-dependent effects of injury in the MMP9 KO compared with sham controls. Post hoc
analysis detected only one strain related difference in this isoform, a small, but significant
increase at 21d in the MMP9 KO cases (WT data replotted for comparison). B. As for
Synapsin-I, the lower, 58kD Synapsin-II isoform did not show injury effect relative to paired
shams, nor did it have detectable strain differences compared with WT cases. Results are
expressed as percent of sham control relative optical density (100% dashed line). C.
Representative blot images of 72kD and 58kD Synapsin-II with cyclophilin A as a load control.
§p<0.05 WT vs KO. N=4-6/group.
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substantively alter the postinjury pattern of OB GAP-43 expression. However, it is intriguing
that MMP9 KO shows a downward trend in GAP-43 protein at 3d, the same postinjury time
when KO OMP expression increases toward sham control levels. An opposite, but inverse
relationship between GAP-43 and OMP expression was also found in the WT cases at the same
3d survival interval. From these data we then speculate that these GAP-43/OMP protein changes
are related to the posited inverse regulatory interaction between GAP-43 and OMP (Holtmaat et
al., 1995; Margolis et al., 1991; Verhaagen et al., 1989; Verhaagen et al., 1990), and that MMP9
has an impact on such interaction.

Ultrastructure of OB glomerular synapses show effects of MMP9 KO
At 21d postinjury, our WB analysis of MMP9 KO OB showed a persistent reduction in OMP
protein, contrary to the injured WT cases, where OMP returned to control levels. We reasoned
that persistent attenuation of the ORN axon marker protein might represent aberrant progress
toward synaptic reorganization in the MMP9 KO animals. To probe for this possibility, we
performed TEM analysis of MMP9 KO OB tissues 21d after FPI (Figure 4.12). The
ultrastructure of WT glomeruli showed re-emergence of normal morphology 21d after injury,
with healthy ORN axon/dendritic synapses exhibiting multiple junctional sites and thick postsynaptic densities (Figure 4.12A). By contrast, glomeruli of the 21d postinjury MMP9 KO
cases had fewer of these healthy synaptic profiles (Figure 4.12B). The identifiable ORN
terminal synapses were poorly developed, with less mature post-synaptic density structure.
Moreover, the 21d MMP9 KO contained frequent areas of persistent tissue degeneration, which
correlated with a OMP loss at 21d, a time when synaptic regeneration and OMP reemergence
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Figure 4.11 MMP9 KO does not affect OB GAP-43 expression after injury
A. WB analysis of GAP-43 response to injury in MMP9 KO animals was not significantly
different from sham controls at 1, 3, or 7d postinjury. FPI caused a similar elevation of 21d
GAP-43 in MMP9 KO (4-fold vs 3-fold in WT injured), and 7d MMP9 KO GAP-43 trended
higher than in paired WT cases. Post hoc analysis confirmed a reduction in GAP-43 within the
3d MMP9 KO animals, although the 50% reduction failed to show statistical difference from
sham controls. While major effects of MMP9 loss were not observed, effects at 3d suggest a
potential role for GAP-43 attenuation during the acute postinjury phase. Results are expressed
as percent of sham control relative optical density (100% dashed line). B. Representative blot
images of GAP-43 with β-actin as a load control. ***p<0.001 Sham vs. TBI, §p<0.05 WT vs
KO. N=4-6/group.
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Figure 4.12 OB ultrastructure in MMP9 KO shows persistent damage after FPI
A. Micrographs of ultrathin sections (600Å) at 21d after FPI show normal reorganization of
synapses. Active pre-synaptic ORN axon terminals, containing aggregates of synaptic vesicles
(v; white arrows), form defined synaptic junctions with post-synaptic dendrites, exhibiting thick
post-synaptic densities (black arrows). B. In the MMP9 KO animals, 21d postinjury synaptic
morphology is less well developed. Synaptic junctions are loosely formed (black arrows), with
pre-synaptic vesicles more diffusely distributed along the axon membranes and sites of active
degeneration still present (red arrow). Inset: ORN axons form immature synaptic structure
along dendritic shafts (black arrows). These qualitative differences further support the
attenuated progression of OB synaptogenesis in the absence of MMP9 and the importance of
subacute postinjury MMP9 activity in promoting successful synaptic repair. Bar =1µm. N=23/group.
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should occur. Taken together, these cytoarchitectural features were consistent with MMP9 KO
causing a disruption of the degeneration/regeneration cycle in the deafferented OB.

DISCUSSION
MMP9 has several established roles in CNS synaptic plasticity. Supportive evidence comes
from studies showing enzyme regulation of different aspects of synaptic organization, including
critical plasticity proteins (Phillips et al., 2014). For example, during brain development, MMP9
activity influences the evolution of spine morphology (Ethell and Ethell, 2007) and spine shape
(Kelly et al., 2015). It also directs axon sprouting through growth factor processing (Shubayev
and Myers, 2004; Sternlicht and Werb, 2001) and can affect structure, as well as membrane
mobility, of predominant excitatory receptors like NMDAR (van der Kooij et al., 2014; Kelly et
al., 2015). By modification of post-synaptic membranes, MMP9 is positively linked to efficacy
of synaptic functional activity (Szepesi et al., 2013) and, more recently, to a supportive role in
postinjury reactive synaptogenesis after CNS deafferentation of sensory pathways (Kaliszewska
et al., 2012; Kelly et al., 2015). Traditionally, MMP9 investigation under conditions of CNS
insult (e.g., spinal cord injury, TBI and stroke) has focused on the negative effects of postinjury
enzyme activation, which generate tissue necrosis, blood brain/spinal cord barrier disruption, and
excessive immune activation (Zhang et al., 2011; Hsu et al., 2008; Wang et al., 2000; Suofu et
al., 2012; Noble et al., 2002; Lo et al., 2004; Ziebell and Morganti-Kossmann, 2010; Woodcock
and Morganti-Kossmann, 2013). Nevertheless, our laboratory and others have provided
evidence that MMPs can play a positive role over the course of CNS synaptic repair (Costanzo
and Perrino, 2008; Hsu et al., 2006; Kaliszewska et al., 2012; Kelly et al., 2015; reviewed in
Phillips et al., 2014). Only a few of these studies, however, have focused on MMP9 activity
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during OB synaptic repair (Costanzo et al., 2006; Bakos et al., 2010), leaving its role in the
molecular regulation of sensory plasticity after TBI relatively unexplored.

In Chapters 2 and 3, results mapping OB response to FPI showed that postinjury MMP9 enzyme
activity increases in a time-dependent manner, correlated with acute/subacute degenerative
phases of reactive synaptogenesis. More importantly, enzyme elevation was temporally
associated with the production of OPN fragments capable of binding to cell surface receptors,
like αvβ3 and CD44, to direct critical cell to cell signaling. MMP9 upregulation was also shown
in deafferented zones populated with processes of glomerular neurons, as well as within reactive
glia surrounding deafferented OB glomeruli during these same early stages of reactive
synaptogenesis. In order to test whether these correlations were mechanistically dependent, we
utilized our laboratory colony of MMP9 KO mice to see if the loss of MMP9 altered cellular and
molecular components of the OB response to FPI. Based on the findings in Chapters 2 and 3, we
hypothesized that MMP9 KO animals subjected to FPI will fail to show time dependent
postinjury increases in cell signaling OPN fragments, along with reduced induction of CD44
receptor protein. We also posited that the reduction or absence of these molecular changes will
attenuate ORN axon regeneration (tracked by OMP signal) and alter the expression of proteins
critical to axonal growth (GAP-43) and synaptic function (Synapsins I and II). Results from
these MMP9 KO experiments will further confirm the role of the MMP9/OPN/CD44 signaling
pathway as a regulator of OB glomerular synaptic plasticity after TBI.

Overall, our results support the hypothesis that MMP9/OPN interaction is critical to the effective
progression of OB reactive synaptogenesis following FPI. First, strain comparison with WT
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mice showed that loss of MMP9 completely reversed time dependent generation of the 48kD
OPN signaling fragment, pointing to specific OB enzyme/substrate interaction after brain injury.
OB tissue staining for OPN in the MMP9 KO cases showed large signal reduction in both tufted
and mitral neurons. More importantly, MMP9 KO animals revealed a persistent reduction in the
ORN axon marker protein OMP at both 7 and 21d. This is in direct contrast to WT injured
cases, where diffuse FPI deafferentation resulted in a postinjury OMP normalization toward
control levels by 7d. Our parallel IHC results also support a glomerular reduction in OMP in the
MMP9 KO. Thus, the transition between axonal loss and regeneration (Schwob et al., 1999) was
disrupted without MMP9. Interestingly, WT vs. MMP9 KO comparison failed to show any
effect on expression of CD44, not supporting our hypothesis that the OPN receptor protein
induction is mediated through upstream MMP9/OPN interaction. Similarly, we found only
minimal strain differences with respect to GAP-43 expression, which did not occur at the 21d
postinjury interval where both strains remained equally and maximally elevated. As in the WT
condition, MMP9 KO animals also failed to show significant change in Synapsin-I and
Synapsin-II protein expression relative to control cases. From these data we conclude that a
MMP9/OPN mediated response to FPI occurs during the early degenerative phase and has a
direct correlation with the timing of initial ORN axon regeneration after injury. While it remains
to be determined if OPN affects CD44 expression through alternative pathways not tested here,
we can infer that MMP9 either does not directly affect downstream CD44 and synaptic protein
expression, or other MMPs compensate for the loss of MMP9, producing the signals required to
induce their postinjury response.
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Loss of MMP9 reverses FPI generation of OPN proteolytic fragments
As described above, MMP9 could play multiple roles during repair of injured OB synapses.
Since we observed significant correlation between MMP9 activity and production of OPN cell
signaling peptides, we first assessed the effect of MMP9 KO on OB OPN protein expression
following FPI. The same postinjury intervals focusing on acute/subacute degenerative and early
regenerative phases sampled in Chapters 2 and 3 were examined here. As for WT cases, FPI
failed to alter the expression of full length 66kD OPN in MMP9 KO mice when compared to
uninjured controls. This result reinforces the interpretation that the diffuse level of axotomy
produced by FPI is not sufficient to elevate OPN protein expression, in contrast to the increase of
OPN in other brain regions subjected to deafferentation (Chan et al., 2014). Moreover, it
suggests that MMP9 proteolytic activity does not significantly affect OB transcription processes,
which would alter expression of nascent OPN. A very different result was observed for the
48kD OPN, where loss of MMP9 eliminated 1 and 7d postinjury elevation of the fragment seen
in WT cases, which was no longer different from sham controls. Interestingly, MMP9 KO mice
also revealed a vulnerability for large reductions in 48kD OPN at 3d after FPI, a time point
where OPN did not change in WT cases. Parallel IHC of MMP9 KO animals confirmed a
profound loss of OPN tissue signal in both tufted and mitral neurons, consistent with the
significant drop in fragment generation. While other proteases, notably thrombin, can also lyse
OPN (Scatena et al., 2007), the fact that increased generation of OB 48kD OPN no longer
occurred in the absence of MMP9 strongly supports our hypothesis that critical RGD integrin
cell signaling is mediated by MMP9/OPN interaction after FPI, and suggests this reduced OPN
processing may occur within deafferented neurons. MMP9 KO also had an effect on 7d 32kD
OPN expression, where loss of enzyme reversed WT reduction of this carboxy terminal fragment
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to a level no longer different from sham controls. Since WT MMP9 activity is greatest at 7d,
affecting OB expression of both 48 and 32kD OPN signaling peptides, and loss of MMP9
normalizes this response, we conclude that MMP9 targeting of OPN is principally responsible
for generating critical cell to cell signaling fragments just prior to onset of synaptic regeneration.
Such MMP9 influence on the process of synaptic repair is novel, in that the majority of CNS
insults reveal induction of MMP9 expression and activity acutely, usually peaking well before 7d
postinjury (Costanzo and Perrino, 2008; Phillips et al., 2014; Rosenberg, 1995; Zhang et al.,
2010). Most of these studies show significant decline in MMP9 protein by the10d post-lesion
period, when the evidence of axon regeneration occurs. To our knowledge, no other studies with
CNS models have tested OPN fragment generation in MMP9 KO mice, however, at least one
model of ureteral obstruction kidney disease shows that MMP2/9 inhibitor and MMP9 antibody
do significantly reduce the generation of MMP9-cleaved OPN (Tan et al., 2013).

Loss of MMP9 fails to change FPI induction of CD44 receptor protein
A reduction in OPN signaling fragments with MMP9 KO would suggest that upregulated
expression of cell surface receptors targeted by these fragments might be attenuated without
MMP9. In fact, we failed to observe such an effect. FPI induction of CD44 at 3 and 7d
postinjury, while trending lower, was not significantly altered in the MMP9 KO animals. This
result reinforces the importance of CD44 signaling in response to OB deafferentation and
suggests that it is independent of MMP9 during the subacute degenerative phase of synaptic
recovery. In Chapter 3, we posited that CD44/MMP9 membrane interaction could mediate local
enzyme activity around affected synapses. Since MMP9 KO failed to change OB CD44 peptide,
we now suggest that the receptor is likely regulated by alternative molecular signals, not directly
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affected by MMP9. First, it remains possible that developmental loss of MMP9 allowed
compensation by other homologous MMPs to maintain the CD44 response. In fact, it has been
shown that membrane bound MT-1 MMP targets membrane tethered CD44 in glioma cells,
cleaving its intracellular domain to function as a transcription factor for upregulation of CD44
transcript (Okamoto et al., 2001). However, a more plausible explanation of our results may be
found in non-CNS cell models. For example, over expression of full length OPN can lead to
increased membrane deposition of CD44 and potentially MMP9/OPN interaction on the cell
surface of migrating prostate cancer cells (Desai et al., 2007). Further, this same group has
reported increased membrane-associated activity of CD44 bound MMP9 linked to this OPN
interaction (Desai et al., 2009). Such findings point to an alternative interpretation of our MMP9
KO results for CD44, suggesting that a steady 66kD OPN expression in the OB supports
induction and maintenance of CD44 signal after FPI, even in the absence of MMP9. This
possibility points to CD44 signaling and its OPN regulation occurring mainly within injured
neurons of the OB, given that IHC principally localizes OPN in tufted and mitral cells. In the
present studies, we did not perform CD44 IHC, but prior experiments in our lab do show CD44
expression in both neurons and glia (Powell and Doperalski, unpublished results). Since glia can
also signal postinjury activation through CD44 receptors (Jones et al., 2000; Shin et al., 2005;
Kang et al., 2008), our histological observations that WT OB astrocyte and microglial reactivity
is not altered by MMP9 KO would be consistent with a maintained glial receptor level as well,
even though these cells did not appear to contain significant OPN. However, it must also be
considered that the phenotypic cellular changes we see in the OB glia could involve CD44
maintenance by local injury-induced release of inflammatory cytokines like TNFα and IL1β
(Campo et al., 2012; Leir et al., 2003; Webb et al., 1990). Alternatively, OPN 48 and 32kD
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fragments may act through other receptors (e.g., vitronectin integrin receptor) in response to FPI,
a pathway we predict would be affected by MMP9 KO. Taken together, our results indicate that
postinjury OPN receptor response is complex within the OB, involving multiple molecular
mechanisms of regulation, potentially utilizing stable full length and elevated cleaved fragment
OPN forms. It will be quite important to map αvβ3 receptor expression and binding to OPN after
FPI in order to fully explain the role of these complex MMP9/OPN interactions.

Loss of MMP9 persistently reduces olfactory marker protein after FPI
In Chapter 2, we utilized OMP to identify ORN axons targeting OB glomeruli, confirming that
FPI induced significant loss of this pre-synaptic sensory input. This loss supported the
production of diffuse axotomy and deafferentation in our OB model. OMP loss was attenuated
relative to more severe olfactory nerve insults (Cummings et al., 2000; Costanzo et al., 2006;
Bakos et al., 2010) and occurred only at 3d postinjury. To clarify whether or not MMP9/OPN
signaling might impact ORN terminal loss, we probed for OMP protein expression in MMP9 KO
animals subjected to FPI. In WT animals, OMP returned to control levels by 7d postinjury,
supporting a diffuse, milder FPI deafferentation and accelerated ORN axon regeneration. That
loss of OMP was not temporally correlated with elevated MMP9 activity or 48kD OPN increase.
However, our results in Chapter 4 showed the loss of MMP9 caused a persistent reduction of OB
OMP protein, extending into the 7 and 21d postinjury intervals, where even severe ORN lesion
models show protein recovery (Bakos et al., 2010; Costanzo et al., 2006; Cummings et al., 2000;
Holbrook et al., 2014). More importantly, the persistent 7d loss of OMP was directly correlated
with reduced 48kD OPN fragment generation, suggesting OPN cell signaling at that postinjury
interval is critical to OMP normalization and onset of reinnervation.
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These associated effects of MMP9 KO on OMP might be explained in two ways. First, loss of
MMP9-generated OPN fragments, which activate local glia, could significantly attenuate
removal of degenerative debris associated with ORN deafferentation, affecting ECM
reorganization and prolonging or blunting ORN reinnervation. This OPN related glial activation
has been documented after ischemia (Kang et al., 2008), cortical stab wound (Shin et al., 2005)
and hippocampal deafferentation (Chan et al., 2014). In addition, MMPs can modify the ECM
structure by targeting molecules that stabilize synaptic junctions (Ethell and Ethell, 2007; Monea
et al., 2006; Warren et al., 2012) and vascular endothelium (Muradashvili et al., 2011). Loss of
MMP9 likely interferes with this process, delaying clearance of degenerative debris from local
OB synaptic environments. Alternatively, axonal growth and synapse regeneration could be
reduced due to loss of MMP9/OPN generated signaling, resulting in a delayed return of OMP
expression, as reinnervation occurs at a slower pace. Relative to ORN axon reinnervation, OPN
expression is associated with increased CNS cell migration, principally shown in glioma (Lu et
al., 2012) and astrocytoma (Ding et al., 2002) models. Loss of OPN at a critical axonal
migration interval could delay reappearance of OMP+ ORN axons. Further, PC12 in vitro
studies also link MMP9 to organization of α-tubulin in growing neurites, implying a role in
axonal elongation (Shubayev and Myers, 2004). We also found evidence that loss of MMP9
causes a trend toward OMP protein increase at 3d, no longer different from uninjured controls.
Although this result did not show strain difference, it may be related to the significant loss of
48kD OPN we observed at 3d in the MMP9 KO animals. At the least, this observation points to
MMP9 influencing the stable expression of 48kD OPN level at 3d, which, in turn, may affect the
extent of OMP loss. Notably, IHC of the MMP9 KO OB shows OMP tissue distribution
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consistent with our protein measures, further validating a MMP9 role in the ORN axon
degeneration/regeneration cycle after FPI. Together, these MMP9 KO results support our
hypothesis that MMP9 generated 48kD OPN signal influences time course of ORN axon
sprouting and glomerular synaptic plasticity. While we could find no prior studies of TBI
plasticity using MMP9 KO mice to examine MMP9/OPN interaction, models of cortical barrel
field and monocular deprivation have assessed sensory axonal plasticity in MMP9 KO mice.
Their results support our OB findings. Kaliszewska et al. (2012) reported that loss of MMP9
caused significant decrease in experience-dependent synaptic plasticity within cortical layers IIIV, assessed by [14C]-2-deoxyglucose and c-Fos mapping. In a second study of monocular
deprivation, ocular dominance plasticity was mapped in MMP9 KO mice, with results showing a
clear reduction of spine and synapse density in visual cortex (Kelly et al., 2015). Interestingly,
very limited histological change in reactive microglial morphology was also observed in that
study, consistent with our findings in the OB.

Loss of MMP9 only minimally affects OB synaptic markers
In the characterization of our FPI OB model (Chapter 2), we examined the postinjury change in
two pre-synaptic proteins critical to vesicular organization and transmitter release, Synapsins I
and II. This approach was based on the fact that Synapsin reduction has been reported in several
models of CNS insult, including ischemia (Kitagawa, 1992), deafferentation (Chan et al., 2014),
and TBI (hippocampus and cortex; Ansari et al., 2008a, b). Over the first three weeks postinjury,
FPI did not alter WT expression of either Synapsin-I or II relative to paired sham controls. Each
of these proteins is localized to OB, with Synapsin-II most concentrated in the glomerular layer
(Stone et al., 1994). Overall, in the MMP9 KO subjected to FPI, we failed to find any significant
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changes in Synapsin-I or II expression relative to uninjured controls. Within strains, both
isoforms of each protein were unaffected by MMP9 loss. This indicated that OB postinjury
Synapsin stability was not dependent on MMP9 and reinforced our earlier conclusion that OB
sampling procedure may have prevented detection of effect in a diffuse population of injured
ORN axons. Nevertheless, post hoc analysis did identify two cases where small, but
significantly different strain differences could be detected. In Synapsin-I 80kD, the small WT
rise above controls at 3d was normalized in the MMP9 KO, and in Synapsin-II 72kD, a 21d shift
from just below control in WT, to just above control level without MMP9, also achieved
statistical significance. While these strain differences are difficult to interpret, and we could not
find reported links between MMP9 and Synapsin protein expression, our results do raise
interesting questions about MMP9 role in both the acute degenerative and regenerative phases of
OB synaptic repair. In the MMP9 KO, 3d postinjury 80kD Synapsin-I trended toward
normalization, correlating with a similar shift toward normalization of OMP protein. This
relationship, although counterintuitive for the acute degenerative period, does suggest that loss of
MMP9 may indirectly influence some aspect of axon stabilization, slowing ORN axon loss and
reorganization. For Synapsin-II 72kD, MMP9 loss resulted in a trend toward increased
expression at 21d, which correlated with GAP-43 increase relative to controls at that same
postinjury interval (discussed below).

One explanation for these paired shifts might relate to Synapsin-II concentration in glomeruli
and its involvement in the synchronization of GABA vesicular trafficking/release, controlling
OB synaptic signaling (Medrihan et al., 2015). From this, we can speculate that loss of MMP9
may release some capacity for increase of local growth factors (e.g., GAP-43) to drive axon
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regeneration and allow re-emergence of critical pre-synaptic terminal proteins. Additional
experiments focusing on more accurate assessment of these proteins within deafferented OB
glomeruli will be needed to determine if such MMP9 roles are valid.

Loss of MMP9 only minimally affects OB GAP-43 expression
Sprouting of new axon after CNS injury has long been characterized by growth factor induction
(Benowitz and Routtenberg, 1997). Such neuroplasticity in the olfactory system is consistently
associated with the upregulation of GAP-43. Whether induced by OE lesion or target
bulbectomy, regenerating ORN axons have been marked by elevated GAP-43 expression, which
is reduced upon synaptic contact and synapse formation with their OB targets (Verhaagen et al.,
1990; Cizkova et al., 1995). In Chapter 2, we showed that WT mice subjected to FPI
deafferentation exhibit a nearly 3-fold upregulation of OB GAP-43 at 21d, marking the active
period of axonal regeneration into glomeruli. No change in WT GAP-43 was detected at any
other postinjury time point. This finding suggests that the growth factor marked regenerating
ORN axons are invading the OB, consistent with reported immuno-localization of GAP-43 in
pre-terminal axons of the mouse olfactory bulb (Ramakers et al., 1992). Here, loss of MMP9
produced only minor effects on this GAP-43 response to FPI. While the 21d 3-fold upregulation
of GAP-43 was essentially not different between the strains, MMP9 KO mice did show a trend
toward increase. As discussed above, this trend was accompanied by a slight increase in 72kD
Synapsin-II, which, together, may indicate progression toward synapse repair. Interestingly, we
did see a strain difference at the 3d postinjury time point, a strong trend toward reduced GAP-43
in the MMP9 KO. While this decrease was not significantly different from uninjured controls,
the nearly 50% reduction in GAP-43 was different from WT cases. The more straightforward
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interpretation of these results would be that, overall, MMP9 does not substantively affect GAP43 induction during onset of axon regeneration. In vitro studies using PC12 cells support this
view, showing that NGF-induced increase in GAP-43 was not altered by MMP9 treatment or
inhibition (Shubayev and Meyers, 2004). Nevertheless, MMP9 KO strain differences at 3d raise
the interesting possibility that MMP9 may indirectly contribute to growth factor regulation
during the early, subacute degenerative phase. With the loss of MMP9, OMP returns to a level
not different from controls (discussed above), in tandem with a precipitous drop of GAP-43
protein. If MMP9 presence contributes to the decrease of WT ORN OMP at 3d, and this
contribution is lost, then OMP levels might be abnormally maintained in MMP9 KO, driving a
reduction in FPI induced GAP-43. This type of reciprocal OMP/GAP-43 expression has been
described during postnatal development of the olfactory system (Verhaagen et al., 1989), and
posited as a mechanism by which OMP null mice can increase immature ORN axon sprouting
(Griff et al., 2000). Additional studies designed to map the tissue distribution of OMP and GAP43 are needed to confirm whether this reciprocal relationship occurs in the OB following FPI.

Loss of MMP9 attenuates OB synaptic reorganization following FPI
In our biochemical analysis of MMP9 KOs subjected to FPI, OPN fragments were reduced
across time, and OMP levels were persistently low, even into the period of axon regeneration.
Together, these findings suggest a blunted postinjury synaptic recovery in the MMP9 KO vs. WT
animals. As in Chapter 2, we used TEM ultrastructural analysis of the OB glomeruli to
determine if such differences might be revealed in abnormal synaptic structure. Here we focused
on the 21d time point, reasoning that the reversal of OPN fragment signaling at the onset of
regeneration and abnormally low level of OMP well into active synaptic reinnervation phase
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would have a maximal impact on synaptic structure at this postinjury interval. Overall,
qualitative glomerular ultrastructure was consistent with the observed changes in OPN and OMP
expression within the MMP9 KO, where synaptic architecture was clearly less organized at 21d
after injury. Fine structure of ORN synapses revealed poorly organized junctions in the MMP9
KO mice. ORN terminal cytoskeleton appeared disrupted and pre-synaptic vesicles more
diffusely distributed. Post-synaptic densities were also thinner and less defined. This was in
contrast to WT 21d cases which had well organized synaptic structure, more like control OB
glomeruli. There, pre-synaptic vesicles were easy to identify, seen within ORN axon terminals
opposed to synaptic junctions containing thick post-synaptic densities. The latter WT profile is
similar to the normal ultrastructure reported for ORN/mitral and ORN/tufted excitatory synaptic
junctions (Kasowski et al., 1999; Kosaka et al., 2001). This same pattern of asymmetric vesiclecontaining ORN terminals was reported after unilateral olfactory nerve transection in the
hamster, where transneuronal tracer WGA-HRP labeled post-synaptic glomerular layers,
confirming synaptic reinnervation (Morrison and Costanzo, 1995). In the only MMP9 KO
mouse study with ORN transection, loss of MMP9 did not alter the time-dependent response of
the other principal gelatinase, MMP2, which is highly expressed during glomerular reinnervation
(Costanzo and Perrino, 2008). While no TEM was performed in that study, the time course of
reinnervation was not affected by loss of MMP9, suggesting that OB reinnervation after full
ORN axotomy does not show the same vulnerability to MMP9 KO as does FPI. As further
evidence of poor recovery in our data, MMP9 KO glomeruli at 21d postinjury also contained
sites of ongoing cellular degeneration. Membrane debris from either degenerating axons or postsynaptic dendrites was clearly visible. We interpret these TEM findings as evidence that loss of
MMP9 significantly alters the time-dependent progress of terminal degeneration and ORN
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synaptic reinnervation after FPI. Such attenuation of degenerative debris clearance and
impairment of ORN axon reinnervation would be expected to correlate with persistently low
OMP levels. Loss of OPN signaling is posited to reduce local clearance of damaged ORN axon
terminals, as well as attenuate other cell signaling pathways required for onset of OB
reinnervation.

Summary
Taken together, our results in MMP9 KO mice confirms our hypothesis that the gelatinase
MMP9 is critical to postinjury timing of the degenerative and regenerative phases of OB reactive
synaptogenesis following FPI. Further, this role appears to be mediated through acute and
subacute proteolysis of OPN, in particular the generation of the 48kD RGD containing cell
signaling fragment. Loss of this fragment likely impairs clearance of injury generated debris and
the maturation of regenerating ORN axons. A delayed increase of OMP during the regeneration
phase and TEM evidence of poor synaptic recovery supports this interpretation. Surprisingly,
loss of MMP9 does not alter FPI induction of the OPN receptor CD44 or growth factor GAP-43,
the latter of which would be predicted given the altered time course for regeneration onset in the
MMP9 KO. This suggests that FPI OPN signaling may be mediated through alternative integrin
receptor pathways, quite possibly αvβ3. It also points to upregulation of GAP-43 through a
MMP9-independent pathway, which is consistent with published studies (Fredrich and Illing,
2011; Shubayev and Myers, 2004).
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CHAPTER 5

GENERAL DISCUSSION
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SUMMARY OF STUDY AND FINDINGS
This is the first study documenting synaptic changes in the mouse OB resulting from mild
diffuse brain injury induced with the fluid percussion model. We successfully demonstrated that
the injury delivered over the sagittal suture adjacent to the cortex can distort brain tissue as distal
as the OB. We hypothesized that TBI would cause axonal damage to ORNs, deafferenting
synapses of the GL of the OB and activating molecular mechanisms that elicit a cellular response
to induce reactive synaptogenesis. This process, we posited, would involve cellular signaling
initiated by integrin and CD44 receptor binding of OPN fragments predominantly cleaved by
MMP9. Our investigation of αII-spectrin proteolysis and TEM analysis, coupled with
exploration of ORN specific marker OMP, supports FPI induction of reactive synaptogenesis in
the OB. Assessment of the postinjury time course of glial activation, MMP9 activity, OPN
fragmentation, and CD44 expression revealed a complex, interactive role of these proteins in OB
reinnervation. Subsequent MMP9 KO experiments confirmed strong influence of MMP9 on
OPN fragment generation and ORN axon recovery, marked by OMP expression. Together, our
studies support the critical role of MMP9/OPN interaction in promoting OB ECM reorganization
for synaptic repair.

In Chapters 2 and 3, we demonstrated that FPI was sufficient to cause ORN axotomy, leading to
disruption and deafferentation of OB synapses, as well as onset of a temporal sequence of ECM
associated cellular and molecular changes supporting OB synaptic recovery. We characterized
FPI influence on OB using several markers of axonal injury and regeneration. First αII-spectrin
was tested. This cytoskeletal protein is cleaved upon axonal injury and is used to measure
degree of axotomy. In the OB, the calpain-cleaved 150kD αII-spectrin fragment was elevated
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almost 4-fold at 3d postinjury, showing that axon degeneration occurs within injured OB at this
subacute injury interval. To further characterize axonal damage, we assayed pre-synaptic protein
markers. In our mild injury paradigm, analysis of Synapsins, which are vesicle associated
proteins expressed in neuronal pre-synaptic terminals, did not reveal any WT postinjury change.
We next focused on profiling the postinjury change in OMP expression, a protein serving as a
marker of the ORN axon degeneration/regeneration cycle. The reduction of this mature sensory
neuron marker at 3d after FPI, with a gradual return to normal levels by 21d, was consistent with
the published time course of OB synaptic reinnervation in other models of ORN deafferentation.
Importantly, spectrin proteolysis coincided with OMP loss at 3d, supporting this subacute
interval as a critical period of axon degradation in the diffusely injured OB, and showing that
axon breakdown is correlated with loss of mature ORN marker. In parallel with these molecular
findings, IHC was used to map morphological changes in OB glia after FPI. Robust OB
astrocyte hypertrophy and increase in the number of amoeboid microglia at the 3d postinjury,
pointed to the reactive glia as potential sources of MMP9 for OPN signal processing, which we
posit directs removal of axon break down products. Moreover, TEM analyses showed OB glial
phagocytosis is underway at 7d postinjury, supporting the predicted role for reactive glia in
tissue debris clearance of GL synaptic regions. These phenotypic changes of astrocytes and
microglia also indicate that FPI initiates an OB immune response, and GFAP labeling of
astrocyte processes reveals an intimate association between these glia and synapses of the injured
GL. From this we conclude that both glia are active in response to OB deafferentation, but GL
astrocytes are likely to play a larger role in postinjury degenerative/regenerative stages. To
explore the regenerative phase of OB synaptogenesis, the growth associated protein GAP-43 was
employed to confirm the onset of ORN reinnervation at 21d after FPI. GAP-43 showed over 3-

245

fold elevation at that time point, yet was unchanged from control at the three earlier postinjury
intervals, further supporting induction of synaptic reinnervation after FPI. Upregulation of GAP43 also fits with WT TEM analyses, which demonstrated that evidence of damaged pre-synaptic
terminals is almost completely removed by 21d, when more mature synapses begin to reappear.
These data supported the use of our mild FPI model to induce OB reactive synaptogenesis,
allowing the exploration of how ECM molecules might mediate the process of ORN synaptic
recovery after TBI.

In Chapters 3 and 4, our results confirmed a time-dependent association between ECM molecular
change and OB response to ORN deafferentation and dysfunction. Gelatinases are critical
mediators of postinjury degradation and ECM modification, facilitating synapse recovery. While
the full extent of MMP9 role in OB reactive synaptogenesis is open to further study, data from
our experiments show that enzyme interaction with OPN, a MMP substrate, results in elevation
of cleaved OPN fragments. These peptides can be released into the ECM, bind cell surface
receptors and affect key cell signaling pathways in the injured OB. However, our study does
reveal that this postinjury MMP9/OPN interaction is complex in the OB, with time-dependent
change in OPN fragments representing distinct phases of reactive synaptogenesis. Interestingly,
both MMP9 activity and OPN fragment expression were elevated at 1d after FPI, the acute
degenerative phase, consistent with MMP9 response in other CNS insults. MMP9 activity is
reduced to sham level at 3d postinjury, again similar to the predicted acute postinjury response
pattern of this gelatinase. A novel finding in our study was the subsequent peak elevation of OB
MMP9 activity at 7d after FPI, which was also associated with significant rise in OPN fragment
processing (producing both elevated 48 and reduced 32kD proteins). The timing of this peak in
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MMP9 lysis suggests that the enzyme serves a second functional role in facilitating OPN cell
signaling at the late degenerative phase, perhaps aiding in the promotion of ORN axon growth
associated with the 21d postinjury interval. While elevated MMP9 protein was found in the GL
and EPL neuropil, as well as within reactive astrocytes at 7d postinjury, OPN was restricted to
neuronal subtypes from 3-21d after FPI. Localization of OPN within deafferented mitral and
tufted cells and the time-dependent upregulation of this neuronal OPN suggests a post-synaptic
production and secretion of OPN into the ECM, priming cells in the local environment to prepare
the synaptic site for reorganization. It remains possible, however, that glial expression of OPN
may occur earlier, at 1d postinjury, a time interval which we did not examine with IHC. As OPN
effects cellular reactivity through interaction with cell surface receptors, we probed hyaluronan
receptor CD44, reported to bind with OPN. Robust upregulation of OB CD44 occurred at 3d and
was sustained through 7d. Since this receptor is highly expressed on reactive microglia and
astrocytes in the CNS, and reactive glia promote the stages of reactive synaptogenesis, we
posited that OPN/CD44 interaction would be temporally correlated in the injured OB.
Interestingly, we failed to see paired elevation of OPN and CD44 protein, but found time shifted
peaks in the two, suggesting that OPN fragment rise at 1d may serve to signal a 3d increase of
CD44 transcription and facilitate later positioning of CD44 within cell membranes for signaling
purposes. Taken together, mapping of MMP9 activity, OPN fragment expression, OMP marking
of ORN axon loss, and GAP-43 induction for axon growth, all point to a complex, multicellular
interaction within the ECM that directs successful OB synaptic plasticity after FPI. In order to
fully understand MMP9 role in the complex process, we conducted a second analysis of these
proteins in MMP9 KO animals subjected to FPI.
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Our studies utilizing MMP9 KO animals suggest that MMP9 activity is critical for the
production of OPN signaling fragments at multiple points during the process of OB reactive
synaptogenesis. Most notably, loss of MMP9 delayed reappearance of ORN axon marker
protein OMP over time postinjury and significantly reduced OPN fragmentation at acute and
subacute time points (up to one week postinjury). Interestingly, MMP9 loss failed to alter the
time-dependent expression of OPN receptor CD44 after FPI, nor did it significantly change
overall response of Synapsin-I and II or GAP-43 growth factor. While post hoc tests on
measures of the latter three molecules did reveal interesting strain differences at some of the time
points, these differences were small and likely do not reflect the prominent MMP9 effects related
to OPN or OMP. Foremost, MMP9 KO effect on critical proteins marking efficacy of synaptic
recovery suggests that MMP9 plays an important role in degeneration/regeneration of OB
synapses after FPI. The limited effect of MMP9 activity on Synapsin expression, injury-induced
astrocyte phenotype, as well as GAP-43 expression, all point to a more complex, indirect
interaction of these molecules with the enzyme. The significant difference in OPN
fragmentation between WT and MMP9 KO animals, however, indicates a strong association with
acute, critical cell mediated signaling and later, a mediation of ORN axon growth and
synaptogenesis. At 1d, when early cell activation is required to initiate ECM reorganization and
debris removal, loss of MMP9 significantly reduces the 48kD OPN RGD fragment. This would
potentially curtail this early activation of local glomerular glia. As noted above, we did not assay
in vivo glial reactivity at 1d postinjury, however, we did conduct pilot in vitro assay of OB
MMP9 KO glia. Results showed a more ramified microglial profile, consistent with attenuated
OPN signaling between OB glia (Appendix B.1). At 7d postinjury, closer to the
degeneration/regeneration transition phase, MMP9 production of 48kD OPN correlated with
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high levels of CD44, suggesting MMP9/OPN interaction is important in this period of the
recovery process. In the WT injured mice, it is this interval when MMP9 activity, OPN
proteolysis and CD44 expression are concurrently high, and where OMP level starts to approach
controls, pointing to onset of the reparative process. By contrast, MMP9 loss prevented
elevation of 48kD OPN and attenuated reduction of 32kD OPN, as well as delayed the
stabilization of OMP expression, which continued into the 21d time point. Additionally, OPN
distribution within mitral and tufted cells was reduced in MMP9 KO animals, and TEM showed
evidence of protracted damage to GL synapses, further confirming a significant role for MMP9
in mediating successful synapse recovery.

Overall, these results show that FPI induces OB injury sufficient to deafferent GL synapses, and
MMP9 is an integral part of subsequent reactive synaptogenesis. Our data point to early OPN
fragmentation induced by an acute immune response, which likely contributes to 3d CD44
upregulation and OB glial activation to mediate clearance of ORN axons/OMP protein.
Regenerative processes may begin as early as 7d, when WT MMP9 peaks, OPN fragmentation is
high, and OMP moves toward control levels, indicative of synaptic reorganization. This process
is clearly delayed in MMP9 KO mice, pointing to a significant role for MMP9/OPN interaction
in modulating cell biological processes for ORN reinnervation. This novel data for OB response
to FPI details a mechanism that is consistent with published reports on more severe OB
deafferentation and MMP9/OPN response to TBI. These studies offer new insight into
gelatinase function in the OB following ORN axotomy.
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FPI INDUCES ORN AXOTOMY AND SYNAPTIC REPAIR
Neurogenesis within the OE is well described (Moulton, 1974). ORNs exhibit continuous
turnover, cycling through degeneration and replacement by OE basal stem cells. They extend
their axons from the epithelium, through the cribriform plate and directly into the OB. This
process of continuous OB reinnervation shows that GL environment supports synaptogenesis,
making the region ideal for exploring post-traumatic synaptic plasticity. Mechanical forces and
secondary injury mechanisms induced by head trauma can lead to ORN axonal injury and loss of
GL synaptic input, resulting in loss of olfactory function (Costanzo et al., 2012; Sumner, 1964;
Costanzo and Zasler, 1991; Hagan, 1967). Despite the ORN regenerative capacity, anosmia can
persist in TBI patients, which could result from glial scar formation (Costanzo, 2005; Kobayashi
and Costanzo, 2009) and/or aberrant synaptogenesis, with axons projecting to incorrect
glomeruli, partially reinnervating the GL (Costanzo, 2005; Morrison and Costanzo, 1995).
Recently developed animal models of OB insult with TBI do show that severe closed head injury
can reduce OB size, causing significant olfactory deficits up to 12 weeks postinjury (Siopi et al.,
2012). However, it remains unknown how such functional loss relates to synaptic repair or
whether similar OB effects could be generated with diffuse TBI. In order to address this
question, we first established that our model of mild mouse FPI causes ORN axon damage and
upregulates markers of OB deafferentation. This was important to show before testing the
hypothesis that ECM enzymes, substrates, and receptors mediate OB reactive synaptogenesis
induced by TBI. To do this, we probed for proteins associated with axonal damage (αII-spectrin)
and presence of ORN axons (OMP), as well as markers of axon growth (GAP-43) and presynaptic vesicle trafficking (Synapsin-I and Synapsin-II).
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After trauma, axolemmal Na+ and Na+/Ca2+ channels are disrupted causing uncontrolled calcium
influx and activating calcium-dependent caspases and calpains (Tuck and Cavalli, 2010). These
enzymes can cleave αII-spectrin, disrupting stability of membrane tethered ankyrin-G and actin
components of intact axons (Letourneau, 2009; Reeves et al., 2010), leading to disintegration of
the axon cytoskeleton. Lysis of αII-spectrin after diffuse and focal injury in cortex, corpus
callosum, and hippocampus has been documented (Pike et al., 1998; Reeves et al., 2010;
Saatman et al., 1996; Saatman et al., 2003). Robust increases in 150kD and 145kD αII-spectrin
fragments, as early as 2 hours and up to 4d postinjury, correlated with axotomy, particularly
during acute recovery periods. Our studies probing for protein expression of αII-spectrin in the
postinjury OB revealed a more limited amount of αII-spectrin breakdown, with only the calpaincleaved 150kD αII-spectrin fragment significantly increased nearly 4-fold over controls 3d
following injury, supporting an attenuated level of ORN axotomy with diffuse FPI. The fact that
the 150kD αII-spectrin peptide did not change for any other time point, and that calpaingenerated 145kD was unaffected, indicates that ORN axon degeneration in our model is less
robust relative to other brain regions and likely peaks at 3d postinjury. This result would be
predicted based upon the distance of OB from injury site and distribution of shearing forces
reaching cortical regions rostral to the FPI focus. Further, since the caspase-produced 120kD
αII-spectrin also did not change, we conclude that diffuse FPI does not generate αII-spectrin
commensurate with significant cell death in the OB. More specifically, the predominant increase
in calpain-cleaved αII-spectrin in our model suggests that calpain may be the more sensitive
enzyme in the OB subjected to diffuse TBI, cleaving αII-spectrin extensively when activated by
an indirect, diffuse injury.
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Given that the OB contains several neuronal subtypes whose axons are also susceptible to TBIinduced damage, it was important for our OB deafferentation model to confirm that elevated αIIspectrin lysis, indicative of axotomy, was associated with axonal damage sustained by the more
vulnerable ORN afferent axons. To identify injury-induced ORN loss, we probed OMP, a
cytosolic protein that is only expressed in the first order sensory neurons of the OB (MontiGraziadei et al., 1977). A mature ORN marker, OMP has been detected along the interface of
the OE and OB as early as E16 (Valverde et al., 1993). Moreover, Verhaagen and colleagues
(1989) documented OMP tissue distribution during a 6 month postnatal developmental period,
revealing that OB maturation is characterized by emergence of OMP signal as ORN axons move
from the OE to the ONL, approaching the target OB glomeruli. Since OMP expression marks
OB innervation by labeling mature ORNs, it has been used to track the process of OB
reinnervation after ORN damage. In models of OB deafferentation, OMP expression drops and
recovers over a time frame largely dependent on severity and type of denervation. For example,
when the ON is axotomized with knife transection, OMP is reduced 3-10d, decreasing and
returning to control levels within 15d (Costanzo et al., 2008), while complete nasal epithelial
loss, causes a later and more prolonged return of OMP to control levels, between 7-40d postlesion (Bakos et al., 2010; Nathan et al., 2001). Interestingly, loss of OMP after diffuse FPI was
consistent with the ON transection model, showing significant reduction at 3d after injury.
Given that insult to the ORN axons is most likely the primary mechanism by which the OB is
denervated after head injury, it is reasonable to predict a similar OMP expression pattern
between FPI and the knife lesion. However, in contrast to the knife transection, OMP level at 7d
postinjury was no longer different from controls, suggesting a more rapid restoration of mature
ORN axons than in models of complete axotomy. This pattern of OMP reduction at 3d and
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return to normal level by 7d suggests that, while diffuse FPI can cause axon damage and
deafferent the OB, the injury may also produce a less severe insult to a subset of ORN axons
which could be reversible. TEM analysis of the GL synaptic cytoarchitecture supports the
presence of both types of axon damage after FPI. First, we found evidence for the well described
progressive degenerative/regenerative response characteristic of OB reactive synaptogenesis:
disorganization of pre-synaptic ORN terminals surrounding post-synaptic dendrites at 3d;
shrunken, retracted terminals at 7d, with sites of glial phagocytosis; reemergence of normal
synaptic structure by 21d. However, we also observed disorganization of ORN axon
cytoskeleton and disruption of synaptic vesicle arrangement after FPI, which appeared to resolve
over time postinjury. The latter profile may represent a partial, reversible deafferentation or
remodeling without junctional separation in a subset of synapses. The revelation of a more
complex deafferentation profile is novel for TBI models. Future studies of OB synaptic
ultrastructure will be necessary to clarify the extent to which FPI generates different types of
ORN axon damage. In addition to our OMP analyses of axon damage, we assessed GAP-43
expression to verify the presence of growing axons and the induction of synaptic reinnervation.

Elevated growth factor GAP-43 is critical for synaptic sprouting, promoting neurite outgrowth
by guiding the reorganization of growth cone cytoskeletal structure (Benowitz and Routtenberg,
1997). These properties underlie the tight association of GAP-43 level and regeneration
(Sachdeva et al., 2016; Wang et al., 2014; Williams et al., 2015), as GAP-43 labels immature
neurons and increases within the CNS after several models of injury (Carmichael et al., 2005;
Christman et al., 1997; Park et al., 2013; Gorup et al., 2015; Goto et al., 1994; Hulsebosch et al.,
1998; Stroemer et al, 1993). Consequently, GAP-43 is high during periods of ORN axon growth

253

from the OE to the OB, then downregulated during ORN maturation and navigation toward OB
targets (Margolis et al., 1991; Rodriguez-Gil et al., 2015; Steuer et al., 2014). In our FPI model,
significant elevation in OB GAP-43 was not detected until 21d postinjury. This result is
reasonable since growth cones of newly formed GAP-43 expressing ORN axons begin to enter
and navigate the OB GL around this time after injury, moving toward their post-synaptic targets.
Mapping of OB synaptogenesis after more severe insults shows that up to 60d is required for the
process of reinnervation to be complete (Graziadei et al., 1978; Graziadei et al., 1979), making
the 21d postinjury interval an early phase of such synaptic reorganization, perhaps requiring high
levels of growth factor stimulation. Its significant elevation at 21d following FPI is also
reasonable considering GAP-43 may control axon response to intrinsic OB signals for synaptic
targeting (Holtmaat et al., 1995). In that context, strong upregulation of GAP-43 at 21d also
suggests that sprouting terminals can now navigate a modified ECM which provides a favorable
environment for ORN reinnervation (discussed below relative to MMP9 and its substrates).

Interestingly, OMP regulation of GAP-43 expression has been proposed (Griff et al., 2000;
Holtmaat et al., 1995; Margolis et al., 1991; Verhaagen et al., 1989; Verhaagen et al., 1990),
where low OMP expression, as in cases of OB injury, releases suppression of GAP-43, leading to
increased GAP-43 expression for growth within immature neurons and axons. A similar inverse
relationship between OMP and GAP-43 expression was recently reported in a new rodent model
of OB insult, where direct OB displacement stretches ORN axons against the cribriform plate
similar to human TBI (Steuer et al., 2014). Our results, however, show that robust GAP-43
increase is limited to 21d when OMP expression has returned to control level. On the surface,
this result is somewhat difficult to interpret. One simple explanation is that the proposed
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OMP/GAP-43 relationship is not expressed after diffuse FPI. Alternatively, intrinsic
neurogenesis of the olfactory system might contribute to GAP-43 rise at 21d in our samples of
whole OB, independent of OMP. For example, GAP-43 expression relative to ongoing
neurogenesis in deeper OB layers might predominate over GL GAP-43 change. During
development, the timing of OB entry for subventricular zone (SVZ)-generated progenitor cells is
approximately 15-30d (Petreanu and Alvarez-Buylla, 2002), which would be consistent with the
observed 21d GAP-43 peak expression in our study. Further, TBI studies mapping progenitor
generation do show increased postinjury neurogenesis in the SVZ (Sun, 2014), however, OB
targeting for these newly induced cells after brain injury has not been confirmed. While
progenitor contribution cannot be ruled out at this point, at least three lines of evidence suggest
that this pathway is not a major contributor to GAP-43 profile in our study. First, we see no
change in GAP-43 at other postinjury time points, during which ongoing neurogenesis would
presumably also affect growth factor expression. In addition, GAP-43 protein expression peaks
at the documented time point of ORN axon reentry. Further, more severe CNS injury models
can increase proliferation in the SVZ, yet they are reported to reduce neurogenesis in the OB,
suggesting migrating neuroblasts are diverted from the rostral migratory stream (RMS) to other
injured cortical areas (Radomski et al., 2013; Sundholm-Peters et al., 2005). Additional studies
are needed to clarify the relationship between OB OMP and GAP-43 after FPI. Mapping each
protein’s expression during later postinjury intervals could determine if GAP-43 is actually
reduced during synapse maturation and correlated with a surge in OMP level, indicating that the
two proteins interact to promote the successful reestablishment of stable GL synapses.
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In order to further verify trauma-induced degeneration of ORN axons, we probed for changes in
OB pre-synaptic vesicle markers after FPI. Synapsins are involved in the docking and release of
neurotransmitter vesicles, with Synapsin-I present throughout the OB core and Synapsin-II
localized to the GL (Melloni et al., 1993; Stone et al., 1994). Interestingly, improved spatial
memory is associated with increased 80kD Synapsin-I and 72kD Synapsin-II (John et al., 2009).
Further, 72kD Synapsin-II also regulates GABA inhibition by affecting glutamatergic synaptic
vesicle clustering and release (Medrihan et al., 2013; Orenbuch et al., 2012; Song and Augustine,
2015). Synapsin-II role in controlling the size of the synaptic vesicle reserve pool within
glutamatergic terminals (Gitler et al., 2008) could underlie its reported association with the GL,
where both ORNs and mitral cells transmit glutamate (Cave and Baker, 2009). After zinc
sulfate-induced OB deafferentation, OMP and Synapsin-II were not only co-localized in the GL,
but also reduced to a similar degree at 3-4d post-injury (Stone et al., 1994). This finding
suggests that ORN axon terminals can be marked by both OMP and expression of proteins
controlling their terminal vesicles. Since association between the two OB proteins appeared
strong, we predicted that FPI would show parallel reductions in the two proteins over time
postinjury. Surprisingly, we did not find this correlation in our studies, as OMP was
significantly reduced in WT animals at 3d relative to sham controls, but the 72 and 58kD
isoforms of Synapsin-II were not affected. One simple explanation for lack of Synapsin-II effect
could be a dilution of signal in our whole OB samples. It is possible that GL Synapsin-II
appeared unaltered by diffuse FPI as a result of its lower percentage expression within a larger,
heterogeneous OB population of pre-synaptic structures. This includes ORN axons as well as
GABAergic terminals of periglomerular and granule cells, which we posit are less vulnerable to
axotomy after TBI. Another possible interpretation of our result comes from GL TEM data.
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There, we found that synaptic vesicles could still be visualized within many of the disorganized
pre-synaptic terminals after FPI. This observation suggests that while some pre-synaptic ORN
axons degenerate, others are simply disorganized, retaining a population of terminal vesicles
with Synapsin-II protein.

We also measured protein expression of the 80 and 70kD isoforms of Synapsin-I after TBI, again
observing no difference from sham controls throughout the 21d recovery period. Since 80kD
Synapsin-I promotes GABA inhibition through synaptic vesicle trafficking (Song and Augustine,
2015), the failure to detect change in its expression might indicate limited FPI-induced damage
to inhibitory GABAergic interneurons. Even if some of these cells are affected by diffuse injury,
normal Synapsin-I expression within the intact periglomerular or granule cell terminals could
mask detection of a minimal Synapsin-I loss in the ORN axons. Nevertheless, we found mean
expression of both Synapsin-I isoforms trending lower during the 21d period of early synapse
regeneration, with post hoc tests supporting a clear reduction between 3d and both 7 and 21d
time points. Generally, in the context of CNS trauma, Synapsin-I expression is reduced acutely
following injury (Kitagawa, 1992; Chan et al., 2014; Ansari et al., 2008a, b), and increases later,
during postinjury recovery (Griesbach et al., 2004). Again, our OB data did not completely fit
this prediction, which we interpret to be due to the mild nature of the injury.

Overall, we conclude that even mild OB insult to the mouse brain, occurring distal to the focal
point of diffuse TBI, can set into motion neuroplasticity of ORN projecting axons, and induce
time-dependent production of molecules mediating synaptic reorganization. Our results
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documenting such reactive synaptogenesis supported further exploration of molecular
mechanisms underlying this OB reinnervation.

MMP9 IS ACTIVATED DURING POSTINJURY OB SYNAPTIC PLASTICITY
As modulators of ECM proteins, MMPs can promote both pathogenesis and recovery from
different CNS insults, with their time course of expression a function of injury type and brain
region (Abdul-Muneer et al., 2015; Montaner et al., 2001; Phillips et al., 2014). Interestingly,
aberrant MMP elevation has been observed with stroke, cerebral hemorrhage, Alzheimer’s
disease, and TBI (Abdul-Muneer et al., 2015; Van Hove et al., 2012; Verlegers et al., 2013).
This elevation contributes to evolution of excessive neuropathology by increasing glial activation
and further degrading the ECM. By contrast, time-dependent upregulation of several MMPs
promotes reactive synaptogenesis after neuronal injury (Chan et al., 2014; Kim et al., 2005; Falo
et al., 2006; Warren et al., 2012; Phillips and Reeves, 2001), where ordered processing of
targeted substrates support terminal sprouting, synapse formation, and synapse stabilization.
Acute rise in MMP 2, 3, and 9 expression is consistently detected after injury, where the
enzymes contribute to degenerative and regenerative processes involved with synaptic plasticity,
providing a rationale for exploring OB MMP9 in our study. For instance, OB deafferentation by
full ORN knife lesion induces acute (1d) elevation of MMP9 protein expression (Costanzo et al.,
2006), a response that gradually declines over a 20-60d recovery period. A second study by the
same group showed that direct MeBr gas ablation of ORNs in the OE also induced OB MMP9
expression, however, the peak protein was seen at 5d, not 1d postinjury, and rapidly decreased
between 5-10d after lesion (Bakos et al., 2010).
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In the present study, we did not assay MMP9 protein, but used zymography to measure
postinjury enzyme activity. Nevertheless, comparison of FPI OB MMP9 response to these prior
studies shows some interesting similarities and differences. For example, diffuse FPI to the OB
did produce a 1d rise in MMP9 activity, consistent with the elevated MMP9 protein reported
after full ORN transection. No such elevation of MMP9 protein was reported with OE insult.
This supports a common response to local ORN axotomy near the OB. At 3d postinjury, when
spectrin proteolysis peaked and OMP was lowest in our model, OB MMP9 activity was
essentially equal to control cases. Initially, this result was surprising, however, both ORN
transection and OE lesion were in line with such reduction. Interestingly, our data was most
consistent with the 3d baseline MMP9 protein level observed with OE lesion, whereas the ORN
transection model retained some MMP9 protein elevation at 3d after lesion. These model
similarities and differences point to an important, yet complex, role for MMP9 in the
deafferented OB. It suggests that ORN injury locus and type may differentially alter the time
course of ECM and cell signaling response in the distal synaptic regions targeted by these
neurons. After FPI, our data suggests that acute postinjury MMP9 activity serves to promote
clearance of degenerating axon terminals by locally activated glia, primed for their peak reactive
state at 3d. OB MMP9 activity would then return to control levels, concluding the acute phase
role. By 7d postinjury, we observed a second, more robust OB MMP9 activity, pointing to the
subsequent, critical role for increased MMP9 activity in ECM reorganization, just prior to axonal
regeneration. Notably, FPI causes axon degeneration and pre-synaptic terminal loss, as well as
acute inflammatory response (Abdul-Muneer et al., 2015; Erb and Povlishock, 1991; Werner and
Engelhard, 2007). Each pathway could drive MMP9 elevation, producing time-dependent
cleavage of inflammatory cell signaling proteins like OPN to program 3-7d glial reactivity
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detected in our studies. For example, elevated OPN at 1d may signal a spike in CD44 cell
surface receptors on activated glia at 3d (Desai et al., 2007), contributing to increased MMP9
activity at the 7d mark. Successful ECM clearance of ORN axonal debris through increased
microglial and astrocyte phagocytosis would result, preparing the local OB environment for
synaptic reinnervation. Our observation of extensive glial phagocytosis in the GL with TEM
analysis would further support this interpretation.

While both ORN transection and MeBr OE ablation show increase of MMP9 protein, only the
ablation model (Bakos et al. 2010) identifies the later MMP9 rise as a peak response to insult,
similar to our observations with FPI. This suggests that the 7d MMP9 peak activity after FPI
could reflect more substantive damage to ORN cells and their axons, generating a pattern of
response similar to deafferentation without major axotomy near the OB. It remains possible that
diffuse FPI also causes direct damage to ORNs within the OE, which would be consistent with
the timing of enzyme response after MeBr OE ablation. Whether from direct axotomy at the
cribriform plate or ORN damage within the OE, the 7d peak MMP9 activation appears to
represent important substrate processing during the transition from degenerative to regenerative
phases of recovery. Within the 21d recovery window, we saw no evidence of prolonged or
aberrant MMP9 activity which could lead to disorganized reorganization. This result differs
from those of maladaptive recovery models (Falo et al., 2006; Warren et al., 2012; Phillips et al.,
2014), where prolonged elevation of MMP activity leads to aberrant synaptic repair. In
summary, our data points to biphasic periods of OB enzyme increase after diffuse FPI,
suggesting a well-timed, beneficial role for MMP9 activation in the processing of substrates
critical to ECM reorganization and successful synaptic plasticity.
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Given that CNS trauma typically produces time-dependent elevation in both protein and
enzymatic activity of MMPs 2 and 9 (Costanzo et al., 2006; Costanzo and Perrino, 2008;
Horstmann et al., 2006; Hsu et al., 2006; Hsu et al., 2008; Phillips and Reeves, 2001; Wang et
al., 2000), we also assessed the effect of OB FPI on MMP2 activity. Despite similar effects on
ECM protein reorganization, it has been proposed that the two gelatinases mediate different
critical periods of synaptogenesis, principally due to the postinjury time course of their
expression/activation. For example, in the deafferented hippocampus and FPI corpus callosum,
our laboratory has documented single acute peak MMP9 elevation at 1d postinjury, while MMP2
increases during the 7-14d period (Phillips and Reeves, 2001; Phillips et al., 2014; unpublished
data). Similarly, in the ORN transection model, a 7d MMP2 peak protein expression in the OB
was reported (Costanzo and Perrino, 2008). In Chapter 3, we showed that OB MMP2 activity in
WT mice subjected to FPI peaked at the 7d postinjury interval, in tandem with the second peak
of MMP9 activity. However, MMP2 elevation above sham was much lower than that of MMP9
(130% vs. 280% of sham), suggesting a differential, and perhaps specific, role for each enzyme
during synaptic recovery. This observation of an increased gelatinase activity is consistent with
MMP role in regeneration, however, early MMP9 activation is usually followed by its decline in
tandem with later elevation of MMP2 (Goussev et al., 2003; Zuo et al., 1998; Hsu et al., 2006;
Costanzo and Perrino, 2008), implicating MMP9 mediation of the acute degenerative phase and
a MMP2 role in regeneration. This pattern was true for gelatinase protein expression following
OB deafferentation by ORN transection (Costanzo et al., 2006; Costanzo and Perrino, 2008),
where rise in MMP2 was not concurrent with MMP9 elevation. Interestingly, Bakos et al.
(2010) did report concurrent MMP9 and MMP2 elevation after OE ablation, at 5d rather than 7d
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postinjury, but with relative change in gelatinase level similar to what we observed for activity.
The similarity between gelatinase change after FPI and OE ablation further supports the
possibility that FPI may cause additional damage to ORNs, engaging a combined MMP9/MMP2
response greater than that predicted for ORN axon transection alone. From these data, we
interpret our 7d phase of gelatinase activation to mean that FPI to the OB enlists both MMP9 and
MMP2 in the pre-reinnervation stages of synaptic recovery. Peak 7d activity of both enzymes
also suggests similar roles for the two gelatinases during the OB regenerative phase, with MMP9
providing greater support than in other injury paradigms.

In summary, we observed a predicted, time-dependent increase in OB gelatinase activity
following FPI, consistent with a documented role for MMP9 in preparing the ECM for axon
degeneration and for MMP2 fostering the onset of synaptic reinnervation. Our results revealed a
novel 7d combined MMP9/MMP2 response to FPI, raising the possibility that distal injury to
ORNs may be influencing OB gelatinase activation in addition to local axotomy.

MMP9/OPN INTERACTION MARKS TIME COURSE OF OB PLASTICITY
In WT animals, time-dependent postinjury activation of MMP9 showed correlation with some,
but not all, of the selected molecular markers used to map OB reactive synaptogenesis.
Consistent with our hypothesis that a MMP9/OPN signaling mechanism is induced after OB
deafferentation, we found a direct temporal correlation between increased MMP9 activity and
generation of OPN 48kD RGD fragment at 1 and 7d after FPI. Further, at 7d peak in MMP9
activity, the 32kD OPN fragment, particularly vulnerable to MMP9 digestion (Takafuji et al.,
2007), was significantly reduced relative to sham controls. Moreover, during periods of control
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level MMP9 activity (3, 21d postinjury), no change in either OPN fragment was detected. We
interpret these data as evidence for a predominant interaction of OB MMP9 with OPN during
acute degenerative and subacute pre-regenerative phases, and that the RGD containing OPN
peptide is produced as a major mediator of critical cell surface signaling. Maximal MMP9
activation at 7d also likely drives significant breakdown of the non-RGD containing OPN
fragment, further supporting the important role for MMP9 at this postinjury interval.

We also found a temporal relationship between MMP9 and markers of axon degeneration in WT
cases, where acute 1d rise in MMP9 and 48kD OPN could generate cell signals to hasten ORN
axon degeneration. This process was positively identified at 3d postinjury by 150kD αII-spectrin
increase and OMP loss, as well as with TEM evidence of GL axon disruption. Interestingly,
other models of OB deafferentation document elevated MMP9 protein preceding OMP loss
(Bakos et al., 2010; Costanzo et al., 2006), which matches the relationship between increased 1d
MMP9 activity and reduced OMP observed in our studies. Alternatively, the 3d OMP loss may
be independent from 1d MMP9/OPN change, resulting from either the diffuse nature of OB
axotomy causing secondary injury, or a delay in response due to ORN damage in the OE,
requiring more than 24 hours for cell body injury signals to affect axons in the OB.
Interestingly, the same MMP9/OPN fragment relationship was found at 7d, where ORN axon
marker OMP shifted back to control levels. Although OB OMP returns to control levels much
faster with FPI than after ORN transection or OE ablation (Bakos et al., 2010; Costanzo et al.,
2006), each of the latter models fail to show MMP9 peak protein expression at the time of OMP
normalization. Taken together, we conclude that it is less likely a direct signaling interaction
between MMP9 derived OPN peptides causes the OMP restoration at 7d, but it cannot be ruled
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out that other, as yet unidentified, indirect signaling between MMP9/OPN and OMP could be
involved.

Our WT mouse results also pointed to no temporal correlation between elevated MMP9 activity
and either CD44 or GAP-43 protein increase. With respect to CD44, we interpret these results as
evidence of a complex signaling pathway controlling its OB postinjury expression. For example,
MMP9/CD44 interaction could be mediated through acute OPN signaling, generated by MMP9
activation at 1d after FPI. OPN is reported to influence both CD44 transcription and its insertion
within cell surface membrane (Desai et al., 2007). Membrane bound CD44 has potential to bind
and facilitate MMP9 activation at the cell surface (Desai et al., 2007; Desai et al., 2009), leaving
open the possibility that its peak at 3d postinjury contributes to later high MMP9 activity at the
7d time point. There was also no evidence for time-dependent OB MMP9 interaction with GAP43 after FPI. At the 21d time point of growth factor rise in response to OB deafferentation, no
change in MMP9 was found. This suggests that GAP-43 elevation is not time-matched by
MMP9-associated signaling and is linked with the regenerative phase of synaptogenesis after
FPI. Nevertheless, it remains possible that MMP9/OPN/CD44 stimulus of GAP-43 expression
could have occurred at an earlier time point, due to change in the pathway proteins. Although
less likely, the 1-7d increase in these proteins might influence long term glial activation to
produce maximal GAP-43 expression at 21d. Alternatively, significant elevation of the
MMP9/OPN/CD44 pathway may exist between 7 and 21d postinjury, an interval not measured in
this study.
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Finally, we did assess whether MMP2 activity showed temporal correlation with the molecules
of our proposed signaling pathway after FPI. Overall, MMP2 response showed little association
with acute changes in αII-spectrin, OMP, OPN or in the subsequent rise in expression of its
receptor CD44, nor did the enzyme activity match upregulation of GAP-43. Although we did
see a significant increase in MMP2 activity at 7d after FPI, this was the only interaction with the
MMP9/OPN/CD44 pathway found in our study. While OB MMP2 change in activity did occur
when MMP9 response was maximal, the proportional amount of MMP2 lysis was relatively
small. A later, regenerative associated role for MMP2 has been postulated in both knife
transection and MeBr OE ablation models (Bakos et al., 2010; Costanzo and Perrino, 2008),
which we conclude is also likely after FPI to the OB. Moreover, after cochlear ablation, the
presence of GAP-43 positive growth cones was required for MMP2 ECM redistribution during
reinnervation of the cochlear nucleus (Friedrich and Illing, 2011). It remains possible that at
postinjury intervals beyond 21d, after GAP-43 containing ORN axon invasion, MMP2 protein
and activity may be higher than observed here. Nevertheless, the rather modest 7d MMP2
activity in OB could be important to the onset of regeneration, but we conclude that its role is
secondary to that of MMP9 during the time periods we examined.

MMP9 KO ALTERS MARKERS OF OB SYNAPTIC PLASTICITY
While MMP9 KO mice have been used to explore postinjury tissue damage in both TBI and SCI
models (Noble et al., 2009; Wang et al., 2000), prior studies tested how removing MMP9 would
alter evolution of acute pathobiology and affect extent of functional recovery. These studies also
applied more severe forms of each injury paradigm, not examining how loss of MMP9 might
change synaptic reorganization. As discussed above, WT OB response to diffuse FPI does
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suggest that MMP9 plays a critical role in timing of synaptic recovery. We performed proof of
principal studies utilizing MMP9 KO mice to test whether MMP9 indeed mediates OB
synaptogenesis after TBI. Our findings provide strong evidence to support that conclusion. A
direct assessment of MMP9 influence on ORN reinnervation was made by mapping how MMP9
KO affected OMP in the deafferented OB. Loss of MMP9 attenuated the 3d OMP reduction of
WT mice, and also caused a persistent decrease in OMP expression at both 7 and 21d. The latter
change was in direct contrast to the WT injured animals, where 7 and 21d OMP levels were
equal to controls, indicative of movement toward OB sensory reinnervation. The attenuation of
OMP loss at 3d, coupled with persistent OMP reduction at 7 and 21d, further supports MMP9
involvement in both promoting cellular clearance of axon debris, as well as ORN axon
reinnervation of OB targets. These results were supported by 21d TEM analyses that revealed
persistent disruption of pre-synaptic terminal and post-synaptic density structure in the MMP9
KO animals, suggesting delayed reactive synaptogenesis.

In order to confirm how a delay in synaptic recovery might alter molecular markers of synaptic
organization, we again probed for change in Synapsins I and II in MMP9 KO animals subjected
to FPI. We discovered that loss of MMP9 had minimal effect on the amount and timing of
expression for each Synapsin, detectable only as small strain differences in select isoforms. For
example, at 3d, 80kD Synapsin-I was significantly reduced in the MMP9 KO mice relative to
WT injured animals, and 21d 72kD Synapsin-II in the MMP9 KO cases was elevated compared
to WT injured mice. Neither of these shifts in Synapsin expression were different from paired
sham controls. Overall, these results indicate that loss of MMP9 did not alter the stable
postinjury measures of Synapsin expression in the WT mice. Nevertheless, a potential
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regulatory role for MMP9 might be inferred from the two time-dependent strain differences we
found. Additional studies with more localized GL analysis are needed to determine if these
minor effects on Synapsin-Isoform expression are relevant to OB synaptic recovery.

As a third index of how MMP9 loss affects synaptic reinnervation, we mapped postinjury GAP43 expression within the injured MMP9 KO. Generally, GAP-43 and MMP9 expression in
neurons exhibit parallel response to CNS trauma (Juan et al., 2014; Keilhoff et al., 2016). In
regenerating nerves, MMP9 and GAP-43 colocalize (Shubayev and Myers, 2004), although a
direct link between the two proteins during reinnervation has not been established (Fredrich and
Illing, 2011; Shubayev and Myers, 2004). Thus, MMP9 and GAP-43 could play key, but
separate, roles in CNS regeneration. Surprisingly, following FPI of the OB, WT MMP9 activity
and GAP-43 expression did not map together over postinjury time. MMP9 activity was elevated
at 1 and 7d postinjury, when GAP-43 was not changed, and at 21d, when GAP-43 showed a 3fold elevation, MMP9 activity was equal to controls. Despite these differences, MMP9 KO
GAP-43 levels were reduced to nearly 50% of control at 3d postinjury, when degenerative
processes appear to peak and was different from WT GAP-43 expression. At 21d, peak GAP-43
in MMP9 KO mice did not show strain difference relative to WT cases, but there was a trend
toward higher growth factor expression in the absence of MMP9. It should be noted that we did,
however, find that reinnervation of GL synapse cytoarchitecture was hindered without the
enzyme, showing that MMP9 function plays a role in the full restoration and stabilization of OB
synapses following injury.
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These results suggest that MMP9 activity is not required for the induction of major OB GAP-43
expression during later stages of ORN axon growth. Several alternative pathways could
independently drive OB GAP-43 upregulation, including other MMPs such as the regenerationassociated MMP2, multiple injury-induced cytokines released to stimulate ORN growth factor
production, or GAP-43 production by reactive glia within deafferented GL. Thus, local OB
synaptic sprouting could continue to occur in the absence of MMP9, pointing to an indirect
relationship between MMP9 and GAP-43 during GL reinnervation.

As discussed above, several investigators have proposed a relationship between OMP and GAP43, where the growth factor is expressed in the absence of OMP (immature neurons), while
upregulation of OMP (when ORNs mature) suppresses GAP-43 (Griff et al., 2000; Holtmaat et
al., 1995; Margolis et al., 1991; Verhaagen et al., 1989; Verhaagen et al., 1990). Evaluation of
OMP and GAP-43 in MMP9 KO mice also revealed potential interaction between the two
proteins within the OB after FPI. This type of inverse expression was not observed in our
injured WT animals, however, MMP9 KO subjected to FPI had persistent OMP reduction,
revealing patterns of OMP/GAP-43 expression consistent with their inter-dependent regulation.
For example, at 3d postinjury, WT OMP was significantly reduced, with GAP-43 just trending
toward elevation over controls. Loss of MMP9 reversed that expression pattern, with a
normalization of OMP and a large reduction of GAP-43 signal, for which strain differences
could be detected. Similarly, sharp OMP reduction at 7 and 21d in the MMP9 KO was paired
with trends toward increased GAP-43 levels. While these patterns suggest that OMP could serve
as an inverse regulator of OB GAP-43, the WT 21d GAP-43 upregulation, with normal OMP
level, was not consistent with that interpretation. Clearly, MMP9 does influence the extent of
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detectable OMP/GAP-43 interaction, however, the relationship of the two proteins at 21d
postinjury argues that another pathway predominates for GAP-43 regulation in postinjury OB.

Finally, we did assay for postinjury change in MMP2 activity in response to loss of MMP9. As
predicted by a prior study using MMP9 KO in the knife transection model of OB deafferentation
(Costanzo and Perrino, 2008), we found no compensatory increase in MMP2 lysis and no
specific strain differences in MMP2 enzyme activity across time postinjury. However, loss of
MMP9 did reduce the 7d elevation of MMP2 activity to a level equivalent with sham controls,
suggesting that activation of MMP2 may be linked to MMP9 or its downstream effects within
the deafferented OB. For example, we found OMP persistently reduced at 7 and 21d in the
MMP9 KO mice, indicating a more protracted degenerative phase. If MMP2 serves to drive the
synapse regeneration, a blunted enzyme response would be predicted as the degenerative phase
lagged.

Overall, our studies in the deafferented OB support the hypothesis that MMP9 activity is
correlated with organized synaptic loss and axon degeneration following FPI. Data showing the
effect of MMP9 KO on ORN plasticity further demonstrates that MMP9 plays a critical role in
the temporal progression of OB postinjury synaptic repair.

MMP9/OPN INTERACTION FACILITATES OB SYNAPTIC RECOVERY
The studies presented here identify a complex enzyme/substrate interaction between MMP9 and
OPN that facilitates reactive synaptogenesis. Changes in level of MMP9 activity and OPN
expression over time postinjury are confirmed with multiple outcome measures, supporting our
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hypothesis that MMP9/OPN interaction mediates progression of early degradative processes and
the initiation of terminal sprouting for synapse reformation. Activated microglia and astrocytes
are a primary source of injury or disease-induced OPN expression (Albertsson et al., 2014;
Ellison et al., 1999; Neuman, et al., 2014; Silva et al., 2015; Tambuyzer et al., 2012). Upon
brain injury, these cells can upregulate OPN, which is then processed for binding to integrin
and/or CD44 receptors to promote reactive glial function. After FPI, such functions include
increasing pro-inflammatory cytokines and chemokines for a robust immune response, and
promoting cellular migration, proliferation, and cell adhesion, which can mediate synaptic repair.
Here, we also detected an increase of OPN in deafferented OB neurons 7d after injury, and posit
that this increase signals ECM modification promoting glial reactivity as well as navigation of
nascent synaptic sprouts toward their appropriate post-synaptic targets.
We have provided evidence that the interaction between MMP9 and OPN occurs during OB
deafferentation-induced synaptic plasticity. OPN signaling can precede and drive MMP9
expression (Caers et al., 2006; Lai et al., 2006; Liu et al., 2014; Wu et al., 2015; Yang et al.,
2011) to promote matrix remodeling. While OPN elevation would normally be followed by
MMP9 activity, parallel expression of OPN and MMP9 has also been reported in several
pathologies including MS and prostate cancer (Braitch et al., 2008; Castellano et al., 2008), as
well as in beneficial conditions such as periodontal tissue regeneration and cell adhesion (Lima
et al., 2008; Wang et al., 2014). While we failed to detect changes in full length 66kD OPN,
paired, time-dependent elevation of 48kD OPN and MMP9 activity was observed in WT
deafferented OB, consistent with correlated expression of the two proteins reported in the
literature. At 1d postinjury, MMP9 activity was significantly elevated along with peak 48kD
OPN RGD fragment production, suggesting the two proteins interact during acute postinjury
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phases to promote cell surface signaling, critical to effective glial clearance of degenerating presynaptic axons. The early 3d degenerative period is marked by peak activation of OB astrocytes
and microglia, increased 150kD αII-spectrin expression, OMP reduction and onset of GL
synaptic breakdown. Taken together with the rapid MMP9/OPN response, these cellular changes
suggest that OB reactive neuroglia are significant contributors to ECM reorganization required
for synaptogenesis, principally through OPN-mediated migration and phagocytosis of ORN
debris. In fact, the biphasic expression of OPN signaling fragments has been posited to mediate
time-dependent shifts in glial reactivity with other CNS insults. For example, OPN transcript is
also upregulated in a model of forebrain ischemia in a cell and time-dependent, biphasic pattern
(Choi et al., 2007). There, at 3d postinjury, OPN mRNA is detected in CD44+ microglia, while
protein interaction with integrin receptors is localized to astrocytes around 10d, suggesting timedependent production of OPN to mediate distinct cellular responses. Early microglial synthesis
of OPN might also occur in the injured OB, prior to the 1d postinjury interval, and could
contribute to the OPN RGD fragment pattern we detect across time intervals.

Interestingly, MMP9 activity and 48kD OPN level were not different from controls at the 3d
postinjury interval, when glia are most responsive. We interpret this shift in MMP9/OPN
response to mean that acute 1d rise in MMP9/OPN first serves to prime local glia in preparation
for active degenerative response at 3d, after which the two proteins return to normal
activity/expression. However, MMP9/OPN also show a second paired increase at 7d, suggesting
the two are subsequently upregulated to promote onset of repair processes at 21d. Thus,
MMP9/OPN show a biphasic pattern of response to OB deafferentation, indicating a dual role in
the synaptic repair process, regulating aspects of both degeneration and regeneration phases.
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Indeed, it is possible that the 21d GAP-43 increase associated with ORN axon growth and
reinnervation of the OB may be promoted by the cell and ECM changes signaled through
MMP9/OPN elevation two weeks earlier.

In order to confirm the importance of MMP9-mediated processing of OPN in OB plasticity, we
compared the effects of MMP9 loss in FPI induced synaptogenesis using MMP9 KO animals.
Concurrent robust elevation of MMP9 activity and 48kD OPN protein expression in WT animals
at 1 and 7d postinjury was lost in MMP9 KO animals subjected to FPI, and 3d expression of
48kD OPN was significantly reduced below control levels. Although thrombin and cathepsin-D
can cleave OPN and produce functional 48 and 32kD OPN proteolytic fragments (Christensen et
al., 2010; Denhardt et al., 2001), our results with MMP9 KO mice support the hypothesis that
MMP9 enzyme activity is responsible for the acute and subacute postinjury generation of OPN
cell signaling fragments in the deafferented OB. It also points to critical MMP9 role in driving
OPN fragment signaling pathways to regulate cytokine production, phagocytosis, and cell
migration through CD44 and integrin receptors.

A second major effect of MMP9 KO was the reversal of OMP protein expression 3-21d after OB
deafferentation. MMP9 KO attenuated the 3d postinjury peak of OMP loss, while at the same
time induced OMP reduction at 7 and 21d. Since OMP loss/return shift marks ORN axon
degeneration/regeneration cycling, our OMP data at 3 and 7d point to MMP9/OPN signaling as a
regulator of ORN plasticity after FPI. Surprisingly, OMP is significantly reduced by MMP9 KO
at the 21d mark relative to WT animals, but OPN is unaltered. This result suggests that MMP9
may be independently involved in fostering a shift to ORN reinnervation at that time point. Such
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a response could occur by MMP9 influence on the ECM for regrowth or through some role in the
maturation of the pre-synaptic OMP+ terminals as they reenter the GL. It also appears likely that
the importance of OPN fragment processing as signal for ORN OMP change is restricted to 1-7d
postinjury. This interpretation fits with the literature, since OPN has been identified as an acute
mediator of inflammation, eliciting its effect during early recovery periods. Overall, these
MMP9 KO data show that loss of MMP9 disrupts progress toward synapse reformation. They
further highlight a strong role for MMP9 in producing OPN fragments for postinjury
degeneration, in addition to processing, as yet unidentified, substrates important for ORN axon
maturation and stabilization of pre-synaptic terminals.

Since we posit that MMP9/OPN interaction promotes effective cell signaling for ECM clearance
during synaptogenesis, a second approach for proof of principle would be to test whether the
manipulation of OPN also changes OB response. In addition to assessing MMP9 KO-induced
changes in OPN fragmentation, we also conducted pilot experiments with OPN KO mice to look
for differences in OB MMP9 activity and OMP recovery after FPI (Appendix A). While loss of
MMP9 significantly reduced OPN fragment generation, we found that MMP9 activity actually
increased in OPN KO mice at 1 and 7d postinjury when compared with injured WT C57Bl/6
animals (OPN KO background strain). This result differs from change in MMP9 activity
reported for OPN KO mice after hippocampal denervation. Chan et al. (2014) showed that when
OPN is absent, MMP9 activity is significantly reduced to roughly half the level displayed at 2d
post-lesion. Given that we observed a tight temporal interaction between MMP9 and its OPN
substrate in the deafferented OB, it might be predicted that loss of this substrate would
downregulate enzyme production and gelatinase activity. For example, OPN protein may itself
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invoke cell transduction signaling to drive transcription factors that upregulate MMP9 after
injury. Since OPN binds receptors that initiate that transduction, loss of OPN would then
attenuate injury-induced MMP9 production and reduce MMP9 activity, as in deafferented
hippocampus. In the injured OB we observed the opposite result, a significant increase in
MMP9 activity (Appendix A.1). One explanation would be that loss of OPN may cause an
overexpression of other pro-inflammatory cytokines, resulting in a hyper-elevated MMP9
production and activity. Alternatively, the MMP9 rise could simply be due to the absence of
postinjury elevation in WT C57Bl/6 MMP9 activity (discussed further below). More OB studies
in the injured OPNKO mouse model will be required to test such possibilities, including a
detailed look at potential variation of FPI response due to mouse strain differences.
Based on our WT mouse data comparison between C57Bl/6 and FVB/NJ strains, we conclude
that differences exist in OB MMP9 response to FPI as a function of mouse strain. Unlike the
WT FVB/NJ mice, where we found clear time-dependent injury elevation of MMP9 activity, no
change in enzyme activity was seen in OB of C57Bl/6 injured mice (see again, Appendix A).
Similarly, we found WT strain differences in postinjury OMP expression when C57Bl/6 and
FVB/NJ mice were compared. For example, the 3d postinjury OMP reduction in WT FVB/NJ
cases was absent for the WT C57Bl/6 strain, and OMP expression was largely unaffected by
injury in OPN KO. Nevertheless, 7d protein trended toward reduction in the OPN KO,
consistent with 7d OMP reduction in our MMP9 KO data and potentially supporting
MMP9/OPN interaction in ORN recovery. Interestingly, strain differences in the extent of
pathology and inflammatory response following TBI have been reported (Witgen et al., 2006),
and our studies support these findings. Overall, our experiments with KO mice point to complex
interactions that are not easily defined by complete gene inactivation. A more targeted approach
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involving inducible knockout to control expression over time or conditional knockout mice with
either OPN or MMP9 gene ablation in specific cell types (microglia, astrocytes, or neurons)
could be used to help clarify whether specific cell sources of MMP9 or OPN protein are
responsible for the differences we see between WT strains and individual KO mice.

As OPN exhibits cytokine properties through binding of its fragments to cell membrane
receptors, we explored changes in principal OPN receptor expression. Both integrin and CD44
receptors are capable of recognizing amino acid sequences on OPN fragments, with 48kD OPN
expressing RGD and SVVYGLR sites primarily for binding integrin receptors (Scatena et al.,
2007; Smith and Giachelli, 1998), and carboxy terminal 32kD OPN binding CD44 in an RGDindependent manner (Weber et al., 2002). This interaction is not strict, however, with evidence
that CD44 also binds the 48kD amino terminal OPN fragment, inducing cell survival through
activation of the PI3K and Akt pathway (Lin and Yang-Yen, 2001). Such alternative binding is
consistent with our results, in that 48kD OPN expression at 1d postinjury may prompt the 3d
CD44 upregulation, increasing potential interaction between even normal levels of OPN and
CD44. We expect that if we had been able to probe for time-dependent correlations between
postinjury expression of 48kD OPN and the αvβ3 integrin receptor, we would have observed a
more robust interaction in the deafferented OB. Nevertheless, OPN co-localizes with CD44 in
some studies (Zohar et al., 2000), and we did find temporal correlations between CD44 receptor
and its 32kD OPN binding partner, as post hoc analysis showed 3d postinjury expression of both
proteins significantly higher than at 7d. While OPN/CD44 interaction may be important at 3d
postinjury, such interaction could also occur with control 32kD OPN levels, indicating that
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CD44 ligands other than 48kD OPN could more readily bind to the hyaluronan receptor to
promote OB reactive glial cell functions.

In line with our hypothesis, MMP9 KO caused significant changes in ORN recovery, as well as
OPN fragmentation, which could be mediated through activated OB glia. In MMP9 KO animals,
injury-induced OMP reduction was persistent throughout the early regenerative phases of OB
recovery, while 48 and 32kD OPN were attenuated 1-7d. By contrast, CD44 expression was not
different between WT and MMP9 KO cases at any time point. Notably, GFAP positive
astrocytes showed no obvious change in IHC assessed reactivity when MMP9 was genetically
ablated. Hsu et al. (2008) demonstrated that loss of MMP9 negatively impacted migration of
astrocytes, but not proliferation, which could explain why no apparent change in extent of OB
glial activation was observed in the GL of injured MMP9 KO animals. Although our IHC
showed that reactive OB astrocytes express MMP9 at 7d, which fits with other studies
documenting the same type of activation (Candelario-Jalil et al., 2009; Zhao et al., 2006), loss of
MMP9 did not drastically change astrocyte morphology, suggesting OB glial activation may be
less sensitive to loss of MMP9. This indicates that the MMP9/OPN interaction, while it likely
influences synaptic plasticity through an OPN receptor signaling mechanism, may not directly
alter astrocyte hypertrophic response during the first week of OB reactive synaptogenesis. One
explanation for this result would be that MMP9 and OPN more readily interact with OB
microglia (through CD44 receptor) during subacute (3, 7d) stages of synaptic repair. Other CNS
insult studies do support a biphasic, differential postinjury interaction between OPN and
CD44/integrin receptors (Choi et al., 2007; Kang et al., 2008; Shin et al., 2005). They provide
evidence for acute (3-4d) CD44 upregulation and OPN binding within reactive microglia, while
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OPN interaction with integrin receptors is delayed, occurring in reactive astrocytes at later
postinjury intervals (14-28d). Although we observed hypertrophic GL astrocytes at 21d and
ultrastructural evidence of continued astrocyte phagocytosis, the delayed time course of reactive
synaptogenesis within the injured OB suggests that we may possibly detect robust astrocyte
reactivity beyond our 21d time point. Such reactivity could correlate with elevated integrin
receptor expression. We suggest this possibility given that astrocytes significantly contribute to
growth factor production for axon guidance during synaptic reinnervation. In this case,
extending our time course and probing for integrin receptors could prove useful to determine
exact influence of processed OPN in OB astrocyte response to injury.

In the present study, we have focused on a molecular mechanism whereby MMP9 cleaves OPN
into signaling fragments that bind CD44/integrin cell surface receptors to induce signal
transduction and glial cell reactivity. There is evidence, however, that OPN can induce
formation of a CD44/MMP9 membranous complex to promote MMP9 activity at the cell surface
(Desai et al., 2007). In the injured OB, OPN increases at 1d postinjury and may foster
CD44/MMP9 interaction at 3d, where CD44 receptor protein peaks in the context of normal
MMP9 activity levels. If promotion of peak MMP9 activity is required for 7d OPN signaling,
then higher 3d cell surface complexing between elevated CD44 receptors and MMP9 could
enhance MMP9 activity, leading to the 7d peak we observed after FPI. This would support the
increased 7d OPN processing we see as both 48kD elevation and 32kD reduction. In addition,
Desai and colleagues (2007) suggest that OPN itself can direct an increase in CD44 production.
This interpretation is again plausible in our OB model since highest OPN 48kD elevation occurs
at 1d after FPI, just before CD44 protein peaks. Thus, enhanced OPN and CD44 receptor cell
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signaling permits increased cell reactivity to promote a more effective degenerative phase and
foster onset of orderly synaptic regeneration. Interestingly, MMP9 activity, OPN fragment
generation and CD44 expression all return to control levels by 21d postinjury, suggesting that
our posited role for these proteins in OB synaptogenesis is focused within the initial degenerative
and early ORN regenerative phases.

One interesting feature of OPN injury response in the OB is the apparent effect of FPI on
neuronal OPN expression. While reactive glia express OPN, several models of CNS insult
document OPN localization within neurons (Borges et al., 2008; Shin et al., 2005). In our FPI
model, cellular OPN was restricted to post-synaptic mitral and tufted neurons, where it is
increased 7d after insult, a finding consistent with our whole OB protein analyses. Interestingly,
only a subset of post-synaptic excitatory cells express OPN in our model, while interneurons like
the TH+ periglomerular cells surrounding GL synapses do not contain OPN. Few investigators
specify whether such postinjury OPN+ neurons are inhibitory or excitatory, but morphologically
these cells are pyramidal in shape, suggesting they are excitatory neurons. It is likely that these
are the neurons directly affected by loss of ORN input, in which OPN can drive autocrine or
paracrine signaling to implement local cell response to injury. This pattern is consistent with
strong OPN expression in dentate granule cells deafferented by entorhinal cortical lesion (Chan
et al., 2014). Developmentally, OPN is retained in neuronal soma, not only appearing during
differentiation and increasing with maturation in brainstem and cerebellum (Lee et al., 2001), but
also reappearing in injured neurons of adult brains (Borges et al., 2008; Shin et al., 2012). In
neurons, there is evidence for an intracellular form of the protein, OPNi, which is not secreted
but binds with microtubule-associated proteins 1A (MAP1A) and 1B (MAP1B). These MAP
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proteins act to stabilize microtubules of the cytoskeleton, which could introduce a role for OPN
in synapse formation, neurite outgrowth, and axonal transport (Chan et al., 2014; Long et al.,
2012). While we did not directly assess OPN/MAP1A/MAP1B binding, we did use IHC to
probe for OPN association with another microtubule-associated protein (MAP2), which has a
similar role in cytoskeletal stabilization as MAP1 (Huber and Matus, 1983), and is often used to
mark post-synaptic dendritic integrity. Expression of OPN was essentially limited to the cell
bodies of mitral and tufted cells, but also visible within a few primary dendrites. Importantly,
IHC failed to show co-localization of OPN and MAP2 in either neuronal cell bodies or within the
limited OPN positive dendrites. Given the strong cell soma localization of OPN and the lack of
OPN signal overlap with MAP2, we posit that the postinjury response in OB neurons likely
represents increase in production and secretion of the cell signaling form of OPN to promote OB
synaptic recovery.

One potential source of OPN upregulation could be the mechanical stress induced by FPI. This
stress may directly injure the post-synaptic neurons to promote their OPN expression. Further, it
is possible that distal deafferentation, rather than direct injury to the cell soma underlies the
elevation of mitral and tufted cell OPN, similar to OPN upregulation within neurons peripheral
to sites of experimental cryolesions (Shin et al., 2005). Alternatively, it may also be that OPN is
rapidly produced by glia during an acute immune response, and secreted from these reactive cells
too early for detection in our 3-21d IHC studies. Interestingly, we performed preliminary in
vitro studies of OB glia derived from P2 pups and did find OPN present in a subset of microglia,
but not in astrocytes (Appendix B). This OPN signal was reduced in microglia derived from
MMP9 KO mice, further supporting MMP9/OPN interaction in the OB. Since these experiments

279

suggest potential OPN production in OB glia, and we did not examine acute microglial IHC (<3d
after FPI), it remains possible that microglia activated 1d or earlier after injury could also express
OPN in the OB. Early (1d) in situ hybridization experiments, which would identify cells
responsible for synthesizing OPN through mRNA localization, could help clarify these
possibilities.

Another way FPI could lead to high neuronal OPN expression might be explained by the fact that
the injury generates an environment in which neurons are subject to excitotoxicity, excessive
calcium influx, and potential degeneration (see Chapter 1). Park et al. (2012) showed that OPN
interacts with calcium to bind the cell surface of degenerating neurons after transient focal brain
ischemia, leading to OPN-mediated phagocytosis, which could explain the presence of OPN in a
subset of mitral and tufted cells after FPI. Similarly, OPN appeared in degenerating neurons
after pilocarpine induction of status epilepticus, however, it failed to play a role in regulating cell
death (Borges, et al., 2008). Other studies show that OPN can be localized to mitochondria of
degenerating neurons, as well as within macrophages as phagocytosed particles (Kim et al.,
2015), suggesting OPN may mediate phagocytosis in damaged neurons. Although interesting,
the association of OPN with OB neuronal cell death seems less likely in our study since diffuse,
mild FPI appears to have little effect on OB neuronal ultrastructure. Rather, our results point to a
more prominent OPN role in post-synaptic cellular signaling of deafferented neurons, perhaps
for axon guidance during later postinjury phases, as reported in stab wound injury models
(Plantman et al., 2012). Finally, exactly how this neuronal OPN might be processed and directed
toward sites of regeneration is not yet clear. Based on the fact that the OPN antibody used in our
IHC recognized both full length and major OPN fragments, several possibilities might be
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considered: 1) OPN is both produced and cleaved within the neuron, as MMP9 has been detected
in dendrites (Konopacki et al., 2007; Gawlack et al., 2009; Wilczynski et al., 2008), then secreted
as signaling peptides, 2) full length OPN is produced in deafferented neurons, then secreted into
the ECM for signal peptide processing, or 3) OPN is transiently produced by acute glial
inflammatory response, secreted for cleavage by matrix MMPs, then taken up by injury affected
neurons. Future studies will be necessary to determine whether MMP9/OPN interaction occurs
in one or more of these potential locations in order to generate critical cell signaling proteins for
OB synaptogenesis.

MMP9/OPN DIRECT OB SYNAPTOGENESIS: A WORKING HYPOTHESIS
Our studies have highlighted a role for MMP9/OPN processing in postinjury reinnervation of the
OB. Acute changes in synaptic integrity and protein expression have revealed a novel role for
ECM modulators in FPI-induced OB reactive synaptogenesis. Here, we outline our working
hypothesis for MMP9 and OPN-mediated events leading to ORN repair following TBI
(illustrated in Figure 5.1).

We have defined a time course of critical cellular and molecular responses that contribute to OB
plasticity. Within the first 24 hours of injury, initiation of inflammatory processes and
membrane perturbation lead to axon damage. Given the diffuse nature of FPI, evidence of OB
axonal injury is not immediately apparent, however, the acute immune response activated by
head trauma upregulates MMP9 activity 2-fold 1d after injury. Moreover, MMP9 processes
OPN, contributing to an elevation of 48kD OPN. The RGD-containing 48kD, and to an extent,
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the carboxy-terminal 32kD OPN, are then available to bind integrin and CD44 receptors
localized to microglia and astrocytes, promoting glial activation and synaptic repair. Loss of the
enzyme caused a significant reduction in 48kD OPN, further confirming its role in OPN
fragmentation at the 1d postinjury interval.

During the 3d postinjury period, we have documented clear evidence of axon degeneration. Our
TEM analyses showed that synaptic vesicle reserve pools were disorganized and arrangement of
GL synapses was altered after injury. Additionally, calcium-dependent calpain caused an
elevation of spectrin breakdown products, while protein expression of ORN marker OMP
dropped significantly. These results suggest important molecular processes facilitating the
degradation of injured ORN terminals are underway. Although CD44 expression was
significantly upregulated 3d after TBI, both MMP9 activity and expression of 48kD OPN
returned to control levels, which could be a real temporal shift or, in part, reduced antibody
access due to high CD44 or integrin-bound OPN. Interestingly, OPN was localized to postsynaptic mitral and tufted cells, likely inducing both paracrine and autocrine signaling to presynaptic neurons and neuroglia. At the 3d interval, microglia were less ramified, increasing in
number with larger cell bodies and shorter processes, while astrocyte processes were
hypertrophied and thickened as fibrillary protein increased, both indicative of significant cell
reactivity. Their activated states promote further cell migration, proliferation, and clearance of
tissue debris from the GL and EPL matrix through phagocytosis. Surprisingly, MMP9 KO did
not attenuate CD44 elevation or glial reactivity. We posit that, in absence of OPN fragment
elevation, cytokines and other ligands compensate, maintaining both CD44 and glial response.
OMP loss was, by contrast, attenuated by MMP9 KO, suggesting degradative processes
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mediated by 48kD OPN were inhibited or delayed without MMP9. Overall, there is strong
evidence of an acute 3d period of axonal degradation mediated by MMP9/OPN interaction,
directing downstream cellular responses to facilitate FPI-induced synaptogenesis.

One week after FPI appears to mark a transition phase between degenerative and regenerative
phases. OMP expression approaches control level, pointing to the onset of ORN axon recovery
in the GL. CD44 receptor protein is reduced, suggesting a less important role for the cell surface
receptor at the 7d time point. Increases in 48kD OPN and a 50% reduction in 32kD OPN
fragment expression can be attributed to significantly elevated MMP9 activity at this same time.
High levels of OPN protein in mitral and tufted neurons points to a direct effect of FPI
deafferentation on these cells, which is confirmed with their increased IHC signal for OPN at 7d.
This could potentially indicate both direct response to deafferentation and increased expression
due to cell signaling through CD44. Notably, MMP9 protein was detected in astrocytes at 7d
postinjury. The cellular distribution of MMP9 and OPN suggests they could be produced within
cells and secreted for interaction in the OB matrix. However, MMP9 also heavily labeled the GL
and EPL neuropil, pointing to the possibility that the enzyme may be present in post-synaptic
dendrites, where MMP9/OPN interaction might also occur. TEM analyses revealed that removal
of degenerating tissue was underway, indicating that OB glia remained active and play a pivotal
role in modifying the ECM for new synapse formation.

We also predict that time course of ORN reinnervation is significantly affected by MMP9, as
OMP reduction failed to normalize 7d after injury in MMP9 KOs subject to FPI, specifically
correlated with reduced 48kD OPN production. By contrast, CD44 and glial morphology were
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no different between WT and MMP9 KO animals, suggesting other cytokines, enzymes, and
ECM proteins compensate for absence of increase in OPN fragments. Finally, since MMP2 is
normalized in 7d postinjury MMP9 KO mice, its potential role in synaptic regeneration is likely
attenuated with loss of MMP9, pointing to clear interaction between the two gelatinases in OB
response to FPI.

The 21d postinjury period is marked by onset of OB reinnervation, where the predominant effect
of FPI is the significantly upregulated GAP-43, supporting reentry of immature ORN terminals.
In tandem, OMP continues to rise, slightly exceeding control signal. IHC staining at 21d
suggests that microglia and astrocytes no longer exhibit reactive profiles. TEM analysis at 21d
postinjury shows a reduction in glial phagocytosis, indicating that critical glial-mediated
degeneration is nearing completion. At the same time, synaptic structure is reorganizing, paired
with control level of MMP9 activity and OPN fragment expression. Since loss of MMP9
persistently inhibits OMP recovery and has no effect on OPN fragment generation, we posit that
an additional MMP9-dependent mechanism, independent of the MMP9/OPN interaction, can
affect the timing of ORN reinnervation. Beyond 21d, when OB reinnervation persists, we
predict that GAP-43 expression would return to normal levels as ORNs continue to mature and
synapses are stabilized.

FUTURE DIRECTIONS
The studies of this dissertation provide support for the hypothesis that MMP9/OPN interaction
mediates the progress of OB reactive synaptogenesis following FPI. We addressed gelatinase
processing of OPN to promote OB plasticity over the first 3 weeks postinjury using molecular
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Figure 5.1 Working hypothesis for ECM-mediated synaptic change in the OB after TBI
Illustrated are four panels representing the time-dependent postinjury changes in the OB
microenvironment during deafferentation and reinnervation of an OB glomerlus. Alpha IIspectrin labeling shows the breakdown and reemergence of pre-synaptic OMP+ axons. Late
appearance of GAP-43+ growth cones marks entry of nascent synaptic terminals. Concurrently,
changes in astrocyte and microglial activation are shown, as well as representative levels of
MMP2 and MMP9 activity, OPN protein levels, and CD44 receptor expression at each
respective time point. Specific ECM interactions and influence on glial reactivity and synaptic
morphology are detailed within the text.
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and structural endpoints, and have considered additional experiments that would complement our
results and enhance understanding of this complex plasticity process.

Here we focused on acute molecular interactions (1-21d after injury). As OB reinnervation
typically requires up to 60d, extending the studies to cover the entire recovery interval would
provide a better understanding of MMP9/OPN role in the GL regeneration process. In addition,
our whole OB protein extracts do not permit assay within the GL alone, where synaptic
reinnervation occurs. Enriching our extracts for the synaptic-rich GL would allow us to confirm
whether our whole OB gelatin zymography and Western blot analyses are reproduced in that
target layer. Such enriched samples would clarify how much the GL contributes to the large OB
GAP-43 change at 21d postinjury. Given that we failed to find postinjury changes in OB
Synapsins, a more precise GL dissection might clarify presence of injury effect. We could also
add analysis of other synaptic marker proteins in OB and GL extracts. One good choice would
be synaptophysin, which is localized to a majority of pre-synaptic terminals (Wiedenmann and
Franke, 1985) and co-expressed with OMP in the OB (Kasowski et al., 1999). Finally, since the
48kD RGD fragment of OPN primarily binds the αvβ3 receptor, probing for either αv or β3 in the
injured OB and GL would help clarify the signaling pathway through which OPN might regulate
OB synaptogenesis. It is possible that such OPN/integrin receptor interaction will promote glial
growth factor production for guidance of ORN axons to their synaptic sites. Each of these more
refined assays could be used in studies comparing WT with MMP9 KO and OPN KO mice.

The use of genetically modified animals is a powerful tool, which we have already applied to
understand MMP9/OPN interaction in the deafferented OB. Loss of MMP9 alters both OPN
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fragmentation and postinjury recovery of OMP expression. We also piloted studies in OPN KO
mice, revealing interesting postinjury differences from MMP9 KOs. Adding samples for later
survival intervals and filling in critical acute postinjury time points in each KO are needed to
complete the proof of principle analysis for MMP9/OPN interaction. Comparison of additional
synaptic markers, glial reactivity, and synaptic cytoarchitecture in both MMP9 KO and OPN KO
animals will help to determine the relative contribution of each protein to ORN reinnervation.
Ideally, we could also generate double MMP9/OPN knockouts or double conditional knockout
mice, to more accurately assess the postinjury consequences of their interaction.

Additional mapping of tissue protein and mRNA would provide new and important molecular
data. Expanding our IHC time course to include the 1d time point would reveal more detail
regarding acute glial changes. Both IHC at 1d and in situ hybridization at each postinjury time
point would allow identification of OPN synthesizing cells and the level of postinjury transcript
induction. To characterize the OPN+ cells in our current studies, we could employ the use of
mitral and tufted cell markers such as T-box brain protein 1 (Tbr1) and Tbr2 (Bulfone et al.,
1998; Imamura and Greer, 2013; Mizuguchi et al., 2012) and cholecystokinin, or CCK (Ma et
al., 2013; Nagayama et al., 2014). IHC probe for OB CD44 and αvβ3 in the OB would identify
cells responsible for their injury-induced elevation, as the receptors are found on both neuroglia
and neurons. We can also probe for GAP-43 in OB tissue sections, which would label and
identify the cells responsible for the 21d upregulation.

It remains unclear whether OB deafferentation induced by FPI produces reversible behavioral
deficits or how MMP9 KO and OPN KO affect olfactory function. A few models of OB injury
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have addressed these questions. In zebrafish, amino acid administration provided clues about
olfactory function after OB deafferentation (Paskin and Byrd-Jacobs, 2012), while behavioral
analyses were also utilized to determine the effect of growth factors on rat OB reinnervation
(Herzog and Otto, 2002). Interestingly, olfactory discrimination tests were administered and
deficits revealed in a focal, cortical injury model (CCI), but Radomski and colleagues (2013)
focused their study on the effects of injury on OB neurogenesis and granule cell formation rather
than ORN recovery. These observations suggest we could apply olfactory functional testing to
assay mild-severe forms of FPI. Electrophysiological assessment of OB synaptic function is also
used to measure extent of OB injury/recovery. That approach is feasible in our FPI model,
however, interpretation of results could be difficult given new synapses may show normal postsynaptic potentials even with aberrant perception of smell. While testing olfaction in mildmoderate FPI will likely require a more sensitive assay, experiments addressing specific effects
on olfactory function would make our study much more comprehensive.

Our study provides novel information about a molecular pathway that could identify therapeutic
targets to improve recovery of OB synaptic circuits after head injury. Nasal steroid sprays are
commonly prescribed for treatment of clinical anosmia (Costanzo et al., 2012), reducing
inflammation associated with glial scarring that inhibits OB reinnervation after injury (Costanzo,
2005; Kobayashi and Costanzo, 2009). In the context of our link between OPN and successful
OB reinnervation, intranasal OPN has been applied to improve cortical function and recovery
after CNS trauma (Albertsson et al, 2014; Doyle et al., 2008; Jin et al., 2016; Joachim et al.,
2014; Topkoru et al., 2013). This would support future experiments designed to test whether
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intranasal OPN treatment might induce greater OB reinnervation after TBI and if that effect is
altered in MMP9 KO or OPN KO mice.

FINAL REMARKS
In conclusion, the studies in this dissertation reveal an important molecular mechanism involved
in OB reactive synaptogenesis. Using the FPI model, our data support the hypothesis that the
OB is deafferented after injury, and ORN reinnervation of the GL can be mediated through
proteolytic processing of cytokine OPN by MMP9. We successfully documented a postinjury
time course of altered synaptic morphology and OMP expression, local glial activation, and
increased production of critical matrix and synaptic components supporting reinnervation. In
conclusion, the findings presented not only offer insight regarding OB recovery after head
trauma, but also reveal a potential neuroplasticity mechanism that may be targeted to facilitate
repair of other brain regions where CNS insult disrupts synaptic circuits.

290

List of References

291

List of References
Abdul-Muneer, P. M., Pfister, B. J., Haorah, J., & Chandra, N. (2015). Role of matrix
metalloproteinases in the pathogenesis of traumatic brain injury. Molecular Neurobiology,
doi:10.1007/s12035-015-9520-8 [doi]
Abdul-Muneer, P. M., Schuetz, H., Wang, F., Skotak, M., Jones, J., Gorantla, S., . . . Haorah,
J. (2013). Induction of oxidative and nitrosative damage leads to cerebrovascular inflammation
in an animal model of mild traumatic brain injury induced by primary blast. Free Radical
Biology & Medicine, 60, 282-291. doi:10.1016/j.freeradbiomed.2013.02.029 [doi]
Abumiya, T., Lucero, J., Heo, J. H., Tagaya, M., Koziol, J. A., Copeland, B. R., & del Zoppo,
G. J. (1999). Activated microvessels express vascular endothelial growth factor and integrin
alpha(v)beta3 during focal cerebral ischemia. Journal of Cerebral Blood Flow and Metabolism :
Official Journal of the International Society of Cerebral Blood Flow and Metabolism, 19(9),
1038-1050. doi:10.1097/00004647-199909000-00012 [doi]
Adams, J. H., Doyle, D., Ford, I., Gennarelli, T. A., Graham, D. I., & McLellan, D. R. (1989).
Diffuse axonal injury in head injury: Definition, diagnosis and grading. Histopathology, 15(1),
49-59.
Adams, J. H., Doyle, D., Graham, D. I., Lawrence, A. E., McLellan, D. R., Gennarelli, T. A., .
. . Sakamoto, T. (1985). The contusion index: A reappraisal in human and experimental nonmissile head injury. Neuropathology and Applied Neurobiology, 11(4), 299-308.
Adams, J. H., Graham, D. I., Murray, L. S., & Scott, G. (1982). Diffuse axonal injury due to
nonmissile head injury in humans: An analysis of 45 cases. Annals of Neurology, 12(6), 557563. doi:10.1002/ana.410120610 [doi]
Agnihotri, R., Crawford, H. C., Haro, H., Matrisian, L. M., Havrda, M. C., & Liaw, L. (2001).
Osteopontin, a novel substrate for matrix metalloproteinase-3 (stromelysin-1) and matrix
metalloproteinase-7 (matrilysin). The Journal of Biological Chemistry, 276(30), 28261-28267.
doi:10.1074/jbc.M103608200 [doi]
Agrawal, S. K., & Fehlings, M. G. (1996). Mechanisms of secondary injury to spinal cord
axons in vitro: Role of na+, na(+)-K(+)-ATPase, the na(+)-H+ exchanger, and the na(+)-Ca2+
exchanger. The Journal of Neuroscience : The Official Journal of the Society for Neuroscience,
16(2), 545-552.
Aguado, F., Carmona, M. A., Pozas, E., Aguilo, A., Martinez-Guijarro, F. J., Alcantara, S., . . .
Soriano, E. (2003). BDNF regulates spontaneous correlated activity at early developmental

292

stages by increasing synaptogenesis and expression of the K+/Cl- co-transporter KCC2.
Development (Cambridge, England), 130(7), 1267-1280.
Aiba, T., Sugiura, M., Mori, J., Matsumoto, K., Tomiyama, K., Okuda, F., & Nakai, Y. (1998).
Effect of zinc sulfate on sensorineural olfactory disorder. Acta OtoLaryngologica.Supplementum, 538, 202-204.
Aigner, L., & Caroni, P. (1995). Absence of persistent spreading, branching, and adhesion in
GAP-43-depleted growth cones. The Journal of Cell Biology, 128(4), 647-660.
Aiguo, W., Zhe, Y., & Gomez-Pinilla, F. (2010). Vitamin E protects against oxidative damage
and learning disability after mild traumatic brain injury in rats. Neurorehabilitation and Neural
Repair, 24(3), 290-298. doi:10.1177/1545968309348318 [doi]
Aikman, J., O'Steen, B., Silver, X., Torres, R., Boslaugh, S., Blackband, S., . . . Pineda, J.
(2006). Alpha-II-spectrin after controlled cortical impact in the immature rat brain.
Developmental Neuroscience, 28(4-5), 457-465. doi:94171 [pii]
Ailane, S., Long, P., Jenner, P., & Rose, S. (2013). Expression of integrin and CD44 receptors
recognising osteopontin in the normal and LPS-lesioned rat substantia nigra. The European
Journal of Neuroscience, 38(3), 2468-2476. doi:10.1111/ejn.12231 [doi]
Albertsson, A. M., Zhang, X., Leavenworth, J., Bi, D., Nair, S., Qiao, L., . . . Wang, X.
(2014). The effect of osteopontin and osteopontin-derived peptides on preterm brain injury.
Journal of Neuroinflammation, 11, 197-014-0197-0. doi:10.1186/s12974-014-0197-0 [doi]
Alessandri, B., Rice, A. C., Levasseur, J., DeFord, M., Hamm, R. J., & Bullock, M. R. (2002).
Cyclosporin A improves brain tissue oxygen consumption and learning/memory performance
after lateral fluid percussion injury in rats. Journal of Neurotrauma, 19(7), 829-841.
doi:10.1089/08977150260190429 [doi]
Allen, F. J. (1896). The mechanism of contre-coup and of certain other forms of intracranial
injury. British Medical Journal, 1(1846), 1196-1197.
Almolda, B., Villacampa, N., Manders, P., Hidalgo, J., Campbell, I. L., Gonzalez, B., &
Castellano, B. (2014). Effects of astrocyte-targeted production of interleukin-6 in the mouse on
the host response to nerve injury. Glia, 62(7), 1142-1161. doi:10.1002/glia.22668 [doi]
Anil, S. P., Laxmi, T. R., Kutty, B. M., & Raju, T. R. (2012). Olfactory tract transection in
neonatal rats: Evidence for mitral cell regeneration and restoration of functional connectivity
with its targets. Indian Journal of Experimental Biology, 50(11), 755-764.
Annegers, J. F., Hauser, W. A., Coan, S. P., & Rocca, W. A. (1998). A population-based
study of seizures after traumatic brain injuries. The New England Journal of Medicine, 338(1),
20-24. doi:10.1056/NEJM199801013380104 [doi]

293

Ansari, M. A., Roberts, K. N., & Scheff, S. W. (2008). Oxidative stress and modification of
synaptic proteins in hippocampus after traumatic brain injury. Free Radical Biology &
Medicine, 45(4), 443-452. doi:10.1016/j.freeradbiomed.2008.04.038 [doi]
Ansari, M. A., Roberts, K. N., & Scheff, S. W. (2008). A time course of contusion-induced
oxidative stress and synaptic proteins in cortex in a rat model of TBI. Journal of Neurotrauma,
25(5), 513-526. doi:10.1089/neu.2007.0451 [doi]
Arundine, M., & Tymianski, M. (2004). Molecular mechanisms of glutamate-dependent
neurodegeneration in ischemia and traumatic brain injury. Cellular and Molecular Life Sciences
: CMLS, 61(6), 657-668. doi:10.1007/s00018-003-3319-x [doi]
Asahina, M., Yoshiyama, Y., & Hattori, T. (2001). Expression of matrix metalloproteinase-9
and urinary-type plasminogen activator in alzheimer's disease brain. Clinical Neuropathology,
20(2), 60-63.
Ashkar, S., Teplow, D. B., Glimcher, M. J., & Saavedra, R. A. (1993). In vitro
phosphorylation of mouse osteopontin expressed in E. coli. Biochemical and Biophysical
Research Communications, 191(1), 126-133. doi:S0006-291X(83)71193-9 [pii]
Ashkar, S., Weber, G. F., Panoutsakopoulou, V., Sanchirico, M. E., Jansson, M., Zawaideh, S.,
. . . Cantor, H. (2000). Eta-1 (osteopontin): An early component of type-1 (cell-mediated)
immunity. Science (New York, N.Y.), 287(5454), 860-864. doi:8232 [pii]
Asikainen, I., Kaste, M., & Sarna, S. (1998). Predicting late outcome for patients with traumatic
brain injury referred to a rehabilitation programme: A study of 508 finnish patients 5 years or
more after injury. Brain Injury, 12(2), 95-107.
Atanasova, B., Graux, J., El Hage, W., Hommet, C., Camus, V., & Belzung, C. (2008).
Olfaction: A potential cognitive marker of psychiatric disorders. Neuroscience and
Biobehavioral Reviews, 32(7), 1315-1325. doi:10.1016/j.neubiorev.2008.05.003;
10.1016/j.neubiorev.2008.05.003
Aungst, S. L., Kabadi, S. V., Thompson, S. M., Stoica, B. A., & Faden, A. I. (2014).
Repeated mild traumatic brain injury causes chronic neuroinflammation, changes in hippocampal
synaptic plasticity, and associated cognitive deficits. Journal of Cerebral Blood Flow and
Metabolism : Official Journal of the International Society of Cerebral Blood Flow and
Metabolism, 34(7), 1223-1232. doi:10.1038/jcbfm.2014.75 [doi]
Bahler, M., & Greengard, P. (1987). Synapsin-I bundles F-actin in a phosphorylation-dependent
manner. Nature, 326(6114), 704-707. doi:10.1038/326704a0 [doi]
Bailey, M. S., & Shipley, M. T. (1993). Astrocyte subtypes in the rat olfactory bulb:
Morphological heterogeneity and differential laminar distribution. The Journal of Comparative
Neurology, 328(4), 501-526. doi:10.1002/cne.903280405 [doi]
Baines, A. J., & Bennett, V. (1985). Synapsin-I is a spectrin-binding protein immunologically
related to erythrocyte protein 4.1. Nature, 315(6018), 410-413.
294

Baines, A. J., & Bennett, V. (1986). Synapsin-I is a microtubule-bundling protein. Nature,
319(6049), 145-147. doi:10.1038/319145a0 [doi]
Bakos, S. R., Schwob, J. E., & Costanzo, R. M. (2010). Matrix metalloproteinase-9 and -2
expression in the olfactory bulb following methyl bromide gas exposure. Chemical Senses,
35(8), 655-661. doi:10.1093/chemse/bjq056; 10.1093/chemse/bjq056
Bandtlow, C. E., & Zimmermann, D. R. (2000). Proteoglycans in the developing brain: New
conceptual insights for old proteins. Physiological Reviews, 80(4), 1267-1290.
Barry, S. T., Ludbrook, S. B., Murrison, E., & Horgan, C. M. (2000). Analysis of the
alpha4beta1 integrin-osteopontin interaction. Experimental Cell Research, 258(2), 342-351.
doi:10.1006/excr.2000.4941 [doi]
Bartfai, T., Sanchez-Alavez, M., Andell-Jonsson, S., Schultzberg, M., Vezzani, A., Danielsson,
E., & Conti, B. (2007). Interleukin-1 system in CNS stress: Seizures, fever, and neurotrauma.
Annals of the New York Academy of Sciences, 1113, 173-177. doi:annals.1391.022 [pii]
Bayless, K. J., & Davis, G. E. (2001). Identification of dual alpha 4beta1 integrin binding sites
within a 38 amino acid domain in the N-terminal thrombin fragment of human osteopontin. The
Journal of Biological Chemistry, 276(16), 13483-13489. doi:10.1074/jbc.M011392200 [doi]
Bayless, K. J., Meininger, G. A., Scholtz, J. M., & Davis, G. E. (1998). Osteopontin is a
ligand for the alpha4beta1 integrin. Journal of Cell Science, 111 ( Pt 9)(Pt 9), 1165-1174.
Bechade, C., Cantaut-Belarif, Y., & Bessis, A. (2013). Microglial control of neuronal activity.
Frontiers in Cellular Neuroscience, 7, 32. doi:10.3389/fncel.2013.00032 [doi]
Becker, K., Kindrick, D., Relton, J., Harlan, J., & Winn, R. (2001). Antibody to the alpha4
integrin decreases infarct size in transient focal cerebral ischemia in rats. Stroke; a Journal of
Cerebral Circulation, 32(1), 206-211.
Bejarano, P. A., Noelken, M. E., Suzuki, K., Hudson, B. G., & Nagase, H. (1988).
Degradation of basement membranes by human matrix metalloproteinase 3 (stromelysin). The
Biochemical Journal, 256(2), 413-419.
Bellander, B. M., Singhrao, S. K., Ohlsson, M., Mattsson, P., & Svensson, M. (2001).
Complement activation in the human brain after traumatic head injury. Journal of Neurotrauma,
18(12), 1295-1311. doi:10.1089/08977150152725605 [doi]
Benedictus, M. R., Spikman, J. M., & van der Naalt, J. (2010). Cognitive and behavioral
impairment in traumatic brain injury related to outcome and return to work. Archives of Physical
Medicine and Rehabilitation, 91(9), 1436-1441. doi:10.1016/j.apmr.2010.06.019 [doi]
Benowitz, L. I., Rodriguez, W. R., & Neve, R. L. (1990). The pattern of GAP-43
immunostaining changes in the rat hippocampal formation during reactive synaptogenesis. Brain
Research.Molecular Brain Research, 8(1), 17-23.

295

Benowitz, L. I., & Routtenberg, A. (1997). GAP-43: An intrinsic determinant of neuronal
development and plasticity. Trends in Neurosciences, 20(2), 84-91. doi:S0166-2236(96)100722 [pii]
Berkowicz, D. A., & Trombley, P. Q. (2000). Dopaminergic modulation at the olfactory nerve
synapse. Brain Research, 855(1), 90-99.
Berkowicz, D. A., Trombley, P. Q., & Shepherd, G. M. (1994). Evidence for glutamate as the
olfactory receptor cell neurotransmitter. Journal of Neurophysiology, 71(6), 2557-2561.
Bernheimer, H., Birkmayer, W., Hornykiewicz, O., Jellinger, K., & Seitelberger, F. (1973).
Brain dopamine and the syndromes of parkinson and huntington. clinical, morphological and
neurochemical correlations. Journal of the Neurological Sciences, 20(4), 415-455.
Bessis, A., Bechade, C., Bernard, D., & Roumier, A. (2007). Microglial control of neuronal
death and synaptic properties. Glia, 55(3), 233-238. doi:10.1002/glia.20459 [doi]
Bignami A. & Dahl D. (1976). The astroglial response to stabbing. Immunofluorescence studies
with antibodies to astrocyte-specific protein (GFA) in mammalian and submammalian
vertebrates. Neuropathol Appl Neurobiol. 2:99–110.
Bilimoria, P. M., & Stevens, B. (2015). Microglia function during brain development: New
insights from animal models. Brain Research, 1617, 7-17. doi:10.1016/j.brainres.2014.11.032
[doi]
Blinzinger, K., & Kreutzberg, G. (1968). Displacement of synaptic terminals from regenerating
motoneurons by microglial cells. Zeitschrift Fur Zellforschung Und Mikroskopische Anatomie
(Vienna, Austria : 1948), 85(2), 145-157.
Block, M. L., & Hong, J. S. (2005). Microglia and inflammation-mediated neurodegeneration:
Multiple triggers with a common mechanism. Progress in Neurobiology, 76(2), 77-98.
doi:S0301-0082(05)00067-5 [pii]
Block, M. L., & Hong, J. S. (2007). Chronic microglial activation and progressive
dopaminergic neurotoxicity. Biochemical Society Transactions, 35(Pt 5), 1127-1132.
doi:BST0351127 [pii]
Blomqvist, E. H., Lundblad, L., Bergstedt, H., & Stjarne, P. (2003). Placebo-controlled,
randomized, double-blind study evaluating the efficacy of fluticasone propionate nasal spray for
the treatment of patients with hyposmia/anosmia. Acta Oto-Laryngologica, 123(7), 862-868.
Book, A. A., Fischer, I., Yu, X. J., Iannuzzelli, P., & Murphy, E. H. (1996). Altered
expression of microtubule-associated proteins in cat trochlear motoneurons after peripheral and
central lesions of the trochlear nerve. Experimental Neurology, 138(2), 214-226. doi:S00144886(96)90060-6 [pii]
Bornsen, L., Khademi, M., Olsson, T., Sorensen, P. S., & Sellebjerg, F. (2011). Osteopontin
concentrations are increased in cerebrospinal fluid during attacks of multiple sclerosis. Multiple

296

Sclerosis (Houndmills, Basingstoke, England), 17(1), 32-42. doi:10.1177/1352458510382247
[doi]
Bourassa, B., Monaghan, S., & Rittling, S. R. (2004). Impaired anti-tumor cytotoxicity of
macrophages from osteopontin-deficient mice. Cellular Immunology, 227(1), 1-11.
doi:10.1016/j.cellimm.2004.01.001 [doi]
Bourguignon, L. Y., Gilad, E., Peyrollier, K., Brightman, A., & Swanson, R. A. (2007).
Hyaluronan-CD44 interaction stimulates Rac1 signaling and PKN gamma kinase activation
leading to cytoskeleton function and cell migration in astrocytes. Journal of Neurochemistry,
101(4), 1002-1017. doi:JNC4485 [pii]
Bower, J. H., Maraganore, D. M., Peterson, B. J., McDonnell, S. K., Ahlskog, J. E., & Rocca,
W. A. (2003). Head trauma preceding PD: A case-control study. Neurology, 60(10), 16101615.
Bradbury, E. J., Moon, L. D., Popat, R. J., King, V. R., Bennett, G. S., Patel, P. N., . . .
McMahon, S. B. (2002). Chondroitinase ABC promotes functional recovery after spinal cord
injury. Nature, 416(6881), 636-640. doi:10.1038/416636a [doi]
Braitch, M., Nunan, R., Niepel, G., Edwards, L. J., & Constantinescu, C. S. (2008). Increased
osteopontin levels in the cerebrospinal fluid of patients with multiple sclerosis. Archives of
Neurology, 65(5), 633-635. doi:10.1001/archneur.65.5.633 [doi]
Brakebusch, C., Seidenbecher, C. I., Asztely, F., Rauch, U., Matthies, H., Meyer, H., . . .
Fassler, R. (2002). Brevican-deficient mice display impaired hippocampal CA1 long-term
potentiation but show no obvious deficits in learning and memory. Molecular and Cellular
Biology, 22(21), 7417-7427.
Breder, C. D., Dinarello, C. A., & Saper, C. B. (1988). Interleukin-1 immunoreactive
innervation of the human hypothalamus. Science (New York, N.Y.), 240(4850), 321-324.
Brew, K., Dinakarpandian, D., & Nagase, H. (2000). Tissue inhibitors of metalloproteinases:
Evolution, structure and function. Biochimica Et Biophysica Acta, 1477(1-2), 267-283.
doi:S0167-4838(99)00279-4 [pii]
Bronner-Fraser, M. (1986). An antibody to a receptor for fibronectin and laminin perturbs
cranial neural crest development in vivo. Developmental Biology, 117(2), 528-536. doi:00121606(86)90320-9 [pii]
Bronner-Fraser, M. (1994). Neural crest cell formation and migration in the developing embryo.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental
Biology, 8(10), 699-706.
Bruckner, G., Brauer, K., Hartig, W., Wolff, J. R., Rickmann, M. J., Derouiche, A., . . .
Reichenbach, A. (1993). Perineuronal nets provide a polyanionic, glia-associated form of
microenvironment around certain neurons in many parts of the rat brain. Glia, 8(3), 183-200.
doi:10.1002/glia.440080306 [doi]
297

Bruno, M. A., & Cuello, A. C. (2006). Activity-dependent release of precursor nerve growth
factor, conversion to mature nerve growth factor, and its degradation by a protease cascade.
Proceedings of the National Academy of Sciences of the United States of America, 103(17),
6735-6740. doi:0510645103 [pii]
Bruns, J.,Jr, & Hauser, W. A. (2003). The epidemiology of traumatic brain injury: A review.
Epilepsia, 44 Suppl 10, 2-10. doi:10003 [pii]
Buck, L., & Axel, R. (1991). A novel multigene family may encode odorant receptors: A
molecular basis for odor recognition. Cell, 65(1), 175-187.
Buiakova, O. I., Baker, H., Scott, J. W., Farbman, A., Kream, R., Grillo, M., . . . Margolis, F.
L. (1996). Olfactory marker protein (OMP) gene deletion causes altered physiological activity
of olfactory sensory neurons. Proceedings of the National Academy of Sciences of the United
States of America, 93(18), 9858-9863.
Buki, A., Siman, R., Trojanowski, J. Q., & Povlishock, J. T. (1999). The role of calpainmediated spectrin proteolysis in traumatically induced axonal injury. Journal of Neuropathology
and Experimental Neurology, 58(4), 365-375.
Bulfone, A., Wang, F., Hevner, R., Anderson, S., Cutforth, T., Chen, S., . . . Rubenstein, J. L.
(1998). An olfactory sensory map develops in the absence of normal projection neurons or
GABAergic interneurons. Neuron, 21(6), 1273-1282. doi:S0896-6273(00)80647-9 [pii]
Bullock, R., Zauner, A., Woodward, J. J., Myseros, J., Choi, S. C., Ward, J. D., . . . Young,
H. F. (1998). Factors affecting excitatory amino acid release following severe human head
injury. Journal of Neurosurgery, 89(4), 507-518. doi:10.3171/jns.1998.89.4.0507 [doi]
Buommino, E., De Filippis, A., Gaudiello, F., Balato, A., Balato, N., Tufano, M. A., & Ayala, F.
(2012). Modification of osteopontin and MMP-9 levels in patients with psoriasis on anti-TNFalpha therapy. Archives of Dermatological Research, 304(6), 481-485. doi:10.1007/s00403012-1251-3 [doi]
Bye, N., Habgood, M. D., Callaway, J. K., Malakooti, N., Potter, A., Kossmann, T., &
Morganti-Kossmann, M. C. (2007). Transient neuroprotection by minocycline following
traumatic brain injury is associated with attenuated microglial activation but no changes in cell
apoptosis or neutrophil infiltration. Experimental Neurology, 204(1), 220-233. doi:S00144886(06)00596-6 [pii]
Byrnes, K. R., Garay, J., Di Giovanni, S., De Biase, A., Knoblach, S. M., Hoffman, E. P., . . .
Faden, A. I. (2006). Expression of two temporally distinct microglia-related gene clusters after
spinal cord injury. Glia, 53(4), 420-433. doi:10.1002/glia.20295 [doi]
Byrnes, K. R., Stoica, B., Riccio, A., Pajoohesh-Ganji, A., Loane, D. J., & Faden, A. I. (2009).
Activation of metabotropic glutamate receptor 5 improves recovery after spinal cord injury in
rodents. Annals of Neurology, 66(1), 63-74. doi:10.1002/ana.21673 [doi]

298

Cacci, E., Ajmone-Cat, M. A., Anelli, T., Biagioni, S., & Minghetti, L. (2008). In vitro
neuronal and glial differentiation from embryonic or adult neural precursor cells are differently
affected by chronic or acute activation of microglia. Glia, 56(4), 412-425.
doi:10.1002/glia.20616; 10.1002/glia.20616
Caers, J., Gunthert, U., De Raeve, H., Van Valckenborgh, E., Menu, E., Van Riet, I., . . .
Vanderkerken, K. (2006). The involvement of osteopontin and its receptors in multiple
myeloma cell survival, migration and invasion in the murine 5T33MM model. British Journal of
Haematology, 132(4), 469-477. doi:BJH5886 [pii]
Cafferty, W. B., Yang, S. H., Duffy, P. J., Li, S., & Strittmatter, S. M. (2007). Functional
axonal regeneration through astrocytic scar genetically modified to digest chondroitin sulfate
proteoglycans. The Journal of Neuroscience : The Official Journal of the Society for
Neuroscience, 27(9), 2176-2185. doi:27/9/2176 [pii]
Campo, G. M., Avenoso, A., D'Ascola, A., Scuruchi, M., Prestipino, V., Calatroni, A., &
Campo, S. (2012). Hyaluronan in part mediates IL-1beta-induced inflammation in mouse
chondrocytes by up-regulating CD44 receptors. Gene, 494(1), 24-35.
doi:10.1016/j.gene.2011.11.064 [doi]
Carbonell, W. S., Maris, D. O., McCall, T., & Grady, M. S. (1998). Adaptation of the fluid
percussion injury model to the mouse. Journal of Neurotrauma, 15(3), 217-229.
doi:10.1089/neu.1998.15.217 [doi]
Carbonell, W. S., Murase, S., Horwitz, A. F., & Mandell, J. W. (2005). Migration of
perilesional microglia after focal brain injury and modulation by CC chemokine receptor 5: An
in situ time-lapse confocal imaging study. The Journal of Neuroscience : The Official Journal of
the Society for Neuroscience, 25(30), 7040-7047. doi:25/30/7040 [pii]
Carleton, A., Petreanu, L. T., Lansford, R., Alvarez-Buylla, A., & Lledo, P. M. (2003).
Becoming a new neuron in the adult olfactory bulb. Nature Neuroscience, 6(5), 507-518.
doi:10.1038/nn1048
Carmichael, S. T., Archibeque, I., Luke, L., Nolan, T., Momiy, J., & Li, S. (2005). Growthassociated gene expression after stroke: Evidence for a growth-promoting region in peri-infarct
cortex. Experimental Neurology, 193(2), 291-311. doi:S0014-4886(05)00010-5 [pii]
Castellano, G., Malaponte, G., Mazzarino, M. C., Figini, M., Marchese, F., Gangemi, P., . . .
Libra, M. (2008). Activation of the osteopontin/matrix metalloproteinase-9 pathway correlates
with prostate cancer progression. Clinical Cancer Research : An Official Journal of the
American Association for Cancer Research, 14(22), 7470-7480. doi:10.1158/1078-0432.CCR08-0870 [doi]
Catalan, V., Gomez-Ambrosi, J., Rodriguez, A., Ramirez, B., Silva, C., Rotellar, F., . . .
Fruhbeck, G. (2009). Increased adipose tissue expression of lipocalin-2 in obesity is related to
inflammation and matrix metalloproteinase-2 and metalloproteinase-9 activities in humans.
Journal of Molecular Medicine (Berlin, Germany), 87(8), 803-813. doi:10.1007/s00109-0090486-8 [doi]
299

Cave, J. W., & Baker, H. (2009). Dopamine systems in the forebrain. Advances in
Experimental Medicine and Biology, 651, 15-35.
Celio, M. R., Spreafico, R., De Biasi, S., & Vitellaro-Zuccarello, L. (1998). Perineuronal nets:
Past and present. Trends in Neurosciences, 21(12), 510-515. doi:S0166-2236(98)01298-3 [pii]
Chabas, D., Baranzini, S. E., Mitchell, D., Bernard, C. C., Rittling, S. R., Denhardt, D. T., . . .
Steinman, L. (2001). The influence of the proinflammatory cytokine, osteopontin, on
autoimmune demyelinating disease. Science (New York, N.Y.), 294(5547), 1731-1735.
doi:10.1126/science.1062960 [doi]
Chamak, B., Dobbertin, A., & Mallat, M. (1995). Immunohistochemical detection of
thrombospondin in microglia in the developing rat brain. Neuroscience, 69(1), 177-187.
doi:030645229500236C [pii]
Chan, J. L., Reeves, T. M., & Phillips, L. L. (2014). Osteopontin expression in acute immune
response mediates hippocampal synaptogenesis and adaptive outcome following cortical brain
injury. Experimental Neurology, 261, 757-771. doi:10.1016/j.expneurol.2014.08.015 [doi]
Chang, C. Y., Chien, H. F., Jiangshieh, Y. F., & Wu, C. H. (2003). Microglia in the olfactory
bulb of rats during postnatal development and olfactory nerve injury with zinc sulfate: A lectin
labeling and ultrastrucutural study. Neuroscience Research, 45(3), 325-333.
doi:S0168010202002365 [pii]
Chang, M. C., Park, J. M., Pelkey, K. A., Grabenstatter, H. L., Xu, D., Linden, D. J., . . .
Worley, P. F. (2010). Narp regulates homeostatic scaling of excitatory synapses on
parvalbumin-expressing interneurons. Nature Neuroscience, 13(9), 1090-1097.
doi:10.1038/nn.2621 [doi]
Chao, C. C., Hu, S., Molitor, T. W., Shaskan, E. G., & Peterson, P. K. (1992). Activated
microglia mediate neuronal cell injury via a nitric oxide mechanism. Journal of Immunology
(Baltimore, Md.: 1950), 149(8), 2736-2741.
Chao, T. I., Kasa, P., & Wolff, J. R. (1997). Distribution of astroglia in glomeruli of the rat
main olfactory bulb: Exclusion from the sensory subcompartment of neuropil. The Journal of
Comparative Neurology, 388(2), 191-210.
Charriaut-Marlangue, C., Margaill, I., Represa, A., Popovici, T., Plotkine, M., & Ben-Ari, Y.
(1996). Apoptosis and necrosis after reversible focal ischemia: An in situ DNA fragmentation
analysis. Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International
Society of Cerebral Blood Flow and Metabolism, 16(2), 186-194. doi:10.1097/00004647199603000-00002 [doi]
Chen, W., Ma, Q., Suzuki, H., Hartman, R., Tang, J., & Zhang, J. H. (2011). Osteopontin
reduced hypoxia-ischemia neonatal brain injury by suppression of apoptosis in a rat pup model.
Stroke; a Journal of Cerebral Circulation, 42(3), 764-769.
doi:10.1161/STROKEAHA.110.599118 [doi]

300

Chintala, S. K., Zhang, X., Austin, J. S., & Fini, M. E. (2002). Deficiency in matrix
metalloproteinase gelatinase B (MMP-9) protects against retinal ganglion cell death after optic
nerve ligation. The Journal of Biological Chemistry, 277(49), 47461-47468.
doi:10.1074/jbc.M204824200 [doi]
Chodobski, A., Zink, B. J., & Szmydynger-Chodobska, J. (2011). Blood-brain barrier
pathophysiology in traumatic brain injury. Translational Stroke Research, 2(4), 492-516.
doi:10.1007/s12975-011-0125-x [doi]
Choi, B. Y., Jang, B. G., Kim, J. H., Lee, B. E., Sohn, M., Song, H. K., & Suh, S. W. (2012).
Prevention of traumatic brain injury-induced neuronal death by inhibition of NADPH oxidase
activation. Brain Research, 1481, 49-58. doi:10.1016/j.brainres.2012.08.032 [doi]
Choi, J. S., Cha, J. H., Park, H. J., Chung, J. W., Chun, M. H., & Lee, M. Y. (2004).
Transient expression of osteopontin mRNA and protein in amoeboid microglia in developing rat
brain. Experimental Brain Research, 154(3), 275-280. doi:10.1007/s00221-003-1657-4 [doi]
Christensen, B., Schack, L., Klaning, E., & Sorensen, E. S. (2010). Osteopontin is cleaved at
multiple sites close to its integrin-binding motifs in milk and is a novel substrate for plasmin and
cathepsin D. The Journal of Biological Chemistry, 285(11), 7929-7937.
doi:10.1074/jbc.M109.075010 [doi]
Christman, C. W., Salvant, J. B.,Jr, Walker, S. A., & Povlishock, J. T. (1997).
Characterization of a prolonged regenerative attempt by diffusely injured axons following
traumatic brain injury in adult cat: A light and electron microscopic immunocytochemical study.
Acta Neuropathologica, 94(4), 329-337.
Christopherson, K. S., Ullian, E. M., Stokes, C. C., Mullowney, C. E., Hell, J. W., Agah, A., .
. . Barres, B. A. (2005). Thrombospondins are astrocyte-secreted proteins that promote CNS
synaptogenesis. Cell, 120(3), 421-433. doi:S0092-8674(04)01245-0 [pii]
Cizkova, D., Sekerkova, G., Oestreicher, A. B., Gispen, W. H., & Zigova, T. (1995).
Distribution of growth associated protein (B-50/GAP-43) and glial fibrillary acidic protein
(GFAP) immunoreactivity in rat homotopic olfactory bulb transplants. Archives Italiennes De
Biologie, 133(4), 237-250.
Clark, R. S., Kochanek, P. M., Adelson, P. D., Bell, M. J., Carcillo, J. A., Chen, M., . . .
Graham, S. H. (2000). Increases in bcl-2 protein in cerebrospinal fluid and evidence for
programmed cell death in infants and children after severe traumatic brain injury. The Journal of
Pediatrics, 137(2), 197-204. doi:S0022-3476(00)59601-2 [pii]
Clegg, D. O., Wingerd, K. L., Hikita, S. T., & Tolhurst, E. C. (2003). Integrins in the
development, function and dysfunction of the nervous system. Frontiers in Bioscience : A
Journal and Virtual Library, 8, d723-50.
Coburn, K. (1992). Traumatic brain injury: The silent epidemic. AACN Clinical Issues in
Critical Care Nursing, 3(1), 9-18.

301

Cohen-Cory, S., & Fraser, S. E. (1995). Effects of brain-derived neurotrophic factor on optic
axon branching and remodelling in vivo. Nature, 378(6553), 192-196. doi:10.1038/378192a0
[doi]
Cole, G. J., & Halfter, W. (1996). Agrin: An extracellular matrix heparan sulfate proteoglycan
involved in cell interactions and synaptogenesis. Perspectives on Developmental Neurobiology,
3(4), 359-371.
Colley, B. S., Phillips, L. L., & Reeves, T. M. (2010). The effects of cyclosporin-A on axonal
conduction deficits following traumatic brain injury in adult rats. Experimental Neurology,
224(1), 241-251. doi:10.1016/j.expneurol.2010.03.026 [doi]
Colton, C., & Wilcock, D. M. (2010). Assessing activation states in microglia. CNS &
Neurological Disorders Drug Targets, 9(2), 174-191. doi:BSP/CDTCNSND/E-Pub/00025 [pii]
Colton, C. A. (2009). Heterogeneity of microglial activation in the innate immune response in
the brain. Journal of Neuroimmune Pharmacology : The Official Journal of the Society on
NeuroImmune Pharmacology, 4(4), 399-418. doi:10.1007/s11481-009-9164-4 [doi]
Colton, C. A., & Gilbert, D. L. (1987). Production of superoxide anions by a CNS
macrophage, the microglia. FEBS Letters, 223(2), 284-288. doi:0014-5793(87)80305-8 [pii]
Colton, C. A., Mott, R. T., Sharpe, H., Xu, Q., Van Nostrand, W. E., & Vitek, M. P. (2006).
Expression profiles for macrophage alternative activation genes in AD and in mouse models of
AD. Journal of Neuroinflammation, 3, 27. doi:1742-2094-3-27 [pii]
Comi, C., Carecchio, M., Chiocchetti, A., Nicola, S., Galimberti, D., Fenoglio, C., . . .
Dianzani, U. (2010). Osteopontin is increased in the cerebrospinal fluid of patients with
alzheimer's disease and its levels correlate with cognitive decline. Journal of Alzheimer's
Disease : JAD, 19(4), 1143-1148. doi:10.3233/JAD-2010-1309 [doi]
Conti, A. C., Raghupathi, R., Trojanowski, J. Q., & McIntosh, T. K. (1998). Experimental
brain injury induces regionally distinct apoptosis during the acute and delayed post-traumatic
period. The Journal of Neuroscience : The Official Journal of the Society for Neuroscience,
18(15), 5663-5672.
Copin, J. C., Goodyear, M. C., Gidday, J. M., Shah, A. R., Gascon, E., Dayer, A., . . .
Gasche, Y. (2005). Role of matrix metalloproteinases in apoptosis after transient focal cerebral
ischemia in rats and mice. The European Journal of Neuroscience, 22(7), 1597-1608.
doi:EJN4367 [pii]
Coronado, V. G., McGuire, L. C., Sarmiento, K., Bell, J., Lionbarger, M. R., Jones, C. D., . .
. Xu, L. (2012). Trends in traumatic brain injury in the U.S. and the public health response:
1995-2009. Journal of Safety Research, 43(4), 299-307. doi:10.1016/j.jsr.2012.08.011 [doi]
Corps, K. N., Roth, T. L., & McGavern, D. B. (2015). Inflammation and neuroprotection in
traumatic brain injury. JAMA Neurology, 72(3), 355-362. doi:10.1001/jamaneurol.2014.3558
[doi]
302

Correale, J. (2014). The role of microglial activation in disease progression. Multiple Sclerosis
(Houndmills, Basingstoke, England), 20(10), 1288-1295. doi:10.1177/1352458514533230 [doi]
Costanzo, R. M. (1985). Neural regeneration and functional reconnection following olfactory
nerve transection in hamster. Brain Research, 361(1-2), 258-266. doi:0006-8993(85)91297-1
[pii]
Costanzo, R. M. (2005). Regeneration and rewiring the olfactory bulb. Chemical Senses, 30
Suppl 1, i133-4. doi:10.1093/chemse/bjh150
Costanzo, R. M. & Becker, D. P. (1986). Smell and taste disorders in head injury and
neurosurgery patients. In: Meiselman, H. L. & Rivlin, R.S. (Eds.), Clinical Measurements of
Taste and Smell (pp. 565-578). New York: MacMillian Publishing Company.
Costanzo, R. M., & Perrino, L. A. (2008). Peak in matrix metaloproteinases-2 levels observed
during recovery from olfactory nerve injury. Neuroreport, 19(3), 327-331.
doi:10.1097/WNR.0b013e3282f50c7b; 10.1097/WNR.0b013e3282f50c7b
Costanzo, R. M., Perrino, L. A., & Kobayashi, M. (2006). Response of matrix
metalloproteinase-9 to olfactory nerve injury. Neuroreport, 17(17), 1787-1791.
doi:10.1097/WNR.0b013e32800fef87
Costanzo, R. M., Reiter, E. R., & Yelverton, J. C. (2012). Smell and Taste. In: Zasler, N., Katz,
D. L., & Zafonte, R. D. (Eds.), Brain Injury Medicine: Principles and Practice (2nd ed.). New
York, NY: Demos Medical Publishing, LLC.
Costanzo R. M. & Zasler N. D. (1991). Head Trauma. In: Getchell T. V., Doty R. L., Bartoshuk
L. M. & Snow J. B. Jr. Smell and Taste in Health and Disease, (pp. 711–730). New York: Raven
Press.
Cousin, B., Leloup, C., Penicaud, L., & Price, J. (1997). Developmental changes in integrin
beta-subunits in rat cerebral cortex. Neuroscience Letters, 234(2-3), 161-165.
Crawford, H. C., Matrisian, L. M., & Liaw, L. (1998). Distinct roles of osteopontin in host
defense activity and tumor survival during squamous cell carcinoma progression in vivo. Cancer
Research, 58(22), 5206-5215.
Csuka, E., Morganti-Kossmann, M. C., Lenzlinger, P. M., Joller, H., Trentz, O., & Kossmann,
T. (1999). IL-10 levels in cerebrospinal fluid and serum of patients with severe traumatic brain
injury: Relationship to IL-6, TNF-alpha, TGF-beta1 and blood-brain barrier function. Journal of
Neuroimmunology, 101(2), 211-221. doi:S0165572899001484 [pii]
Cummings, D. M., Emge, D. K., Small, S. L., & Margolis, F. L. (2000). Pattern of olfactory
bulb innervation returns after recovery from reversible peripheral deafferentation. The Journal
of Comparative Neurology, 421(3), 362-373. doi:10.1002/(SICI)10969861(20000605)421:3<362::AID-CNE5>3.0.CO;2-8 [pii]

303

Cuschieri, A., & Bannister, L. H. (1975). The development of the olfactory mucosa in the
mouse: Electron microscopy. Journal of Anatomy, 119(Pt 3), 471-498.
Dahiya, S., Givvimani, S., Bhatnagar, S., Qipshidze, N., Tyagi, S. C., & Kumar, A. (2011).
Osteopontin-stimulated expression of matrix metalloproteinase-9 causes cardiomyopathy in the
mdx model of duchenne muscular dystrophy. Journal of Immunology (Baltimore, Md.: 1950),
187(5), 2723-2731. doi:10.4049/jimmunol.1101342 [doi]
Dahiya, S., Givvimani, S., Bhatnagar, S., Qipshidze, N., Tyagi, S. C., & Kumar, A. (2011).
Osteopontin-stimulated expression of matrix metalloproteinase-9 causes cardiomyopathy in the
mdx model of duchenne muscular dystrophy. Journal of Immunology (Baltimore, Md.: 1950),
187(5), 2723-2731. doi:10.4049/jimmunol.1101342 [doi]
Davis, A. E. (2000). Mechanisms of traumatic brain injury: Biomechanical, structural and
cellular considerations. Critical Care Nursing Quarterly, 23(3), 1-13.
de Castro, F. (2009). Wiring olfaction: The cellular and molecular mechanisms that guide the
development of synaptic connections from the nose to the cortex. Frontiers in Neuroscience, 3,
52. doi:10.3389/neuro.22.004.2009; 10.3389/neuro.22.004.2009
de Castro, R. C.,Jr, Burns, C. L., McAdoo, D. J., & Romanic, A. M. (2000).
Metalloproteinase increases in the injured rat spinal cord. Neuroreport, 11(16), 3551-3554.
De la Monte, S. M., Federoff, H. J., Ng, S. C., Grabczyk, E., & Fishman, M. C. (1989). GAP43 gene expression during development: Persistence in a distinctive set of neurons in the mature
central nervous system. Brain Research.Developmental Brain Research, 46(2), 161-168.
De Rosa, E., Hasselmo, M. E., & Baxter, M. G. (2001). Contribution of the cholinergic basal
forebrain to proactive interference from stored odor memories during associative learning in rats.
Behavioral Neuroscience, 115(2), 314-327.
Del Bigio, M. R. (2000). Calcium-mediated proteolytic damage in white matter of
hydrocephalic rats? Journal of Neuropathology and Experimental Neurology, 59(11), 946-954.
Deller, T., Del Turco, D., Rappert, A., & Bechmann, I. (2007). Structural reorganization of the
dentate gyrus following entorhinal denervation: Species differences between rat and mouse.
Progress in Brain Research, 163, 501-528. doi:S0079-6123(07)63027-1 [pii]
Deller, T., Del Turco, D., Rappert, A., & Bechmann, I. (2007). Structural reorganization of the
dentate gyrus following entorhinal denervation: Species differences between rat and mouse.
Progress in Brain Research, 163, 501-528. doi:S0079-6123(07)63027-1 [pii]
Denhardt, D. T., Giachelli, C. M., & Rittling, S. R. (2001). Role of osteopontin in cellular
signaling and toxicant injury. Annual Review of Pharmacology and Toxicology, 41, 723-749.
doi:41/1/723 [pii]

304

Denhardt, D. T., & Guo, X. (1993). Osteopontin: A protein with diverse functions. FASEB
Journal : Official Publication of the Federation of American Societies for Experimental Biology,
7(15), 1475-1482.
Denning, S. M., Le, P. T., Singer, K. H., & Haynes, B. F. (1990). Antibodies against the
CD44 p80, lymphocyte homing receptor molecule augment human peripheral blood T cell
activation. Journal of Immunology (Baltimore, Md.: 1950), 144(1), 7-15.
Dent, E. W., & Meiri, K. F. (1998). Distribution of phosphorylated GAP-43 (neuromodulin) in
growth cones directly reflects growth cone behavior. Journal of Neurobiology, 35(3), 287-299.
doi:10.1002/(SICI)1097-4695(19980605)35:3<287::AID-NEU6>3.0.CO;2-V [pii]
Desai, B., Ma, T., Zhu, J., & Chellaiah, M. A. (2009). Characterization of the expression of
variant and standard CD44 in prostate cancer cells: Identification of the possible molecular
mechanism of CD44/MMP9 complex formation on the cell surface. Journal of Cellular
Biochemistry, 108(1), 272-284. doi:10.1002/jcb.22248 [doi]
Desai, B., Rogers, M. J., & Chellaiah, M. A. (2007). Mechanisms of osteopontin and CD44 as
metastatic principles in prostate cancer cells. Molecular Cancer, 6, 18. doi:1476-4598-6-18
[pii]
Dietrich, W. D., Alonso, O., & Halley, M. (1994). Early microvascular and neuronal
consequences of traumatic brain injury: A light and electron microscopic study in rats. Journal
of Neurotrauma, 11(3), 289-301. doi:10.1089/neu.1994.11.289 [doi]
Ding, Q., Stewart, J.,Jr, Prince, C. W., Chang, P. L., Trikha, M., Han, X., . . . Gladson, C. L.
(2002). Promotion of malignant astrocytoma cell migration by osteopontin expressed in the
normal brain: Differences in integrin signaling during cell adhesion to osteopontin versus
vitronectin. Cancer Research, 62(18), 5336-5343.
Diniz, L. P., Almeida, J. C., Tortelli, V., Vargas Lopes, C., Setti-Perdigao, P., Stipursky, J., . .
. Gomes, F. C. (2012). Astrocyte-induced synaptogenesis is mediated by transforming growth
factor beta signaling through modulation of D-serine levels in cerebral cortex neurons. The
Journal of Biological Chemistry, 287(49), 41432-41445. doi:10.1074/jbc.M112.380824 [doi]
Dityatev, A., Dityateva, G., Sytnyk, V., Delling, M., Toni, N., Nikonenko, I., . . . Schachner,
M. (2004). Polysialylated neural cell adhesion molecule promotes remodeling and formation of
hippocampal synapses. The Journal of Neuroscience : The Official Journal of the Society for
Neuroscience, 24(42), 9372-9382. doi:24/42/9372 [pii]
Dityatev, A., & Fellin, T. (2008). Extracellular matrix in plasticity and epileptogenesis. Neuron
Glia Biology, 4(3), 235-247. doi:10.1017/S1740925X09000118 [doi]
Dityatev, A., Frischknecht, R., & Seidenbecher, C. I. (2006). Extracellular matrix and synaptic
functions. Results and Problems in Cell Differentiation, 43, 69-97.
Dityatev, A., & Schachner, M. (2006). The extracellular matrix and synapses. Cell and Tissue
Research, 326(2), 647-654. doi:10.1007/s00441-006-0217-1 [doi]
305

Dityatev, A., Schachner, M., & Sonderegger, P. (2010). The dual role of the extracellular
matrix in synaptic plasticity and homeostasis. Nature Reviews.Neuroscience, 11(11), 735-746.
doi:10.1038/nrn2898 [doi]
Dixon, C. E., Bramlett, H. M., Dietrich, W. D., Shear, D. A., Yan, H. Q., Deng-Bryant, Y., . .
. Kochanek, P. M. (2016). Cyclosporine treatment in traumatic brain injury: Operation brain
trauma therapy. Journal of Neurotrauma, 33(6), 553-566. doi:10.1089/neu.2015.4122 [doi]
Dixon, C. E., Lyeth, B. G., Povlishock, J. T., Findling, R. L., Hamm, R. J., Marmarou, A., . .
. Hayes, R. L. (1987). A fluid percussion model of experimental brain injury in the rat.
Journal of Neurosurgery, 67(1), 110-119. doi:10.3171/jns.1987.67.1.0110
Dobbertin, A., Rhodes, K. E., Garwood, J., Properzi, F., Heck, N., Rogers, J. H., . . . Faissner,
A. (2003). Regulation of RPTPbeta/phosphacan expression and glycosaminoglycan epitopes in
injured brain and cytokine-treated glia. Molecular and Cellular Neurosciences, 24(4), 951-971.
doi:S1044743103002574 [pii]
Doty, R. L. (2012). Olfactory dysfunction in parkinson disease. Nature Reviews.Neurology,
8(6), 329-339. doi:10.1038/nrneurol.2012.80; 10.1038/nrneurol.2012.80
Doty, R. L., Shaman, P., Kimmelman, C. P., & Dann, M. S. (1984). University of
pennsylvania smell identification test: A rapid quantitative olfactory function test for the clinic.
The Laryngoscope, 94(2 Pt 1), 176-178.
Doty, R. L., Yousem, D. M., Pham, L. T., Kreshak, A. A., Geckle, R., & Lee, W. W. (1997).
Olfactory dysfunction in patients with head trauma. Archives of Neurology, 54(9), 1131-1140.
Doyle, K. P., Yang, T., Lessov, N. S., Ciesielski, T. M., Stevens, S. L., Simon, R. P., . . .
Stenzel-Poore, M. P. (2008). Nasal administration of osteopontin peptide mimetics confers
neuroprotection in stroke. Journal of Cerebral Blood Flow and Metabolism : Official Journal of
the International Society of Cerebral Blood Flow and Metabolism, 28(6), 1235-1248.
doi:10.1038/jcbfm.2008.17 [doi]
Drummond, M., Douglas, J., & Olver, J. (2013). 'If I haven't got any smell ... I'm out of work':
Consequences of olfactory impairment following traumatic brain injury. Brain Injury : [BI],
27(3), 332-345. doi:10.3109/02699052.2012.750743; 10.3109/02699052.2012.750743
Du, C., Hu, R., Csernansky, C. A., Hsu, C. Y., & Choi, D. W. (1996). Very delayed infarction
after mild focal cerebral ischemia: A role for apoptosis? Journal of Cerebral Blood Flow and
Metabolism : Official Journal of the International Society of Cerebral Blood Flow and
Metabolism, 16(2), 195-201. doi:10.1097/00004647-199603000-00003 [doi]
Duchossoy, Y., Horvat, J. C., & Stettler, O. (2001). MMP-related gelatinase activity is strongly
induced in scar tissue of injured adult spinal cord and forms pathways for ingrowing neurites.
Molecular and Cellular Neurosciences, 17(6), 945-956. doi:10.1006/mcne.2001.0986 [doi]
Duggal, N., Schmidt-Kastner, R., & Hakim, A. M. (1997). Nestin expression in reactive
astrocytes following focal cerebral ischemia in rats. Brain Research, 768(1-2), 1-9.
306

Dumin, J. A., Dickeson, S. K., Stricker, T. P., Bhattacharyya-Pakrasi, M., Roby, J. D.,
Santoro, S. A., & Parks, W. C. (2001). Pro-collagenase-1 (matrix metalloproteinase-1) binds
the alpha(2)beta(1) integrin upon release from keratinocytes migrating on type I collagen. The
Journal of Biological Chemistry, 276(31), 29368-29374. doi:10.1074/jbc.M104179200 [doi]
Dziembowska, M., & Wlodarczyk, J. (2012). MMP9: A novel function in synaptic plasticity.
The International Journal of Biochemistry & Cell Biology, 44(5), 709-713.
doi:10.1016/j.biocel.2012.01.023; 10.1016/j.biocel.2012.01.023
Ekdahl, C. T., Kokaia, Z., & Lindvall, O. (2009). Brain inflammation and adult neurogenesis:
The dual role of microglia. Neuroscience, 158(3), 1021-1029.
doi:10.1016/j.neuroscience.2008.06.052 [doi]
Ellison, J. A., Barone, F. C., & Feuerstein, G. Z. (1999). Matrix remodeling after stroke. de
novo expression of matrix proteins and integrin receptors. Annals of the New York Academy of
Sciences, 890, 204-222.
Ellison, J. A., Velier, J. J., Spera, P., Jonak, Z. L., Wang, X., Barone, F. C., & Feuerstein, G.
Z. (1998). Osteopontin and its integrin receptor alpha(v)beta3 are upregulated during formation
of the glial scar after focal stroke. Stroke; a Journal of Cerebral Circulation, 29(8), 1698-706;
discussion 1707.
Engel, S., Schluesener, H., Mittelbronn, M., Seid, K., Adjodah, D., Wehner, H. D., &
Meyermann, R. (2000). Dynamics of microglial activation after human traumatic brain injury
are revealed by delayed expression of macrophage-related proteins MRP8 and MRP14. Acta
Neuropathologica, 100(3), 313-322.
Ennis, M., Zhou, F. M., Ciombor, K. J., Aroniadou-Anderjaska, V., Hayar, A., Borrelli, E., . . .
Shipley, M. T. (2001). Dopamine D2 receptor-mediated pre-synaptic inhibition of olfactory
nerve terminals. Journal of Neurophysiology, 86(6), 2986-2997.
Erb, D. E., & Povlishock, J. T. (1988). Axonal damage in severe traumatic brain injury: An
experimental study in cat. Acta Neuropathologica, 76(4), 347-358.
Erb, D. E., & Povlishock, J. T. (1991). Neuroplasticity following traumatic brain injury: A
study of GABAergic terminal loss and recovery in the cat dorsal lateral vestibular nucleus.
Experimental Brain Research, 83(2), 253-267.
Ethell, I. M., & Ethell, D. W. (2007). Matrix metalloproteinases in brain development and
remodeling: Synaptic functions and targets. Journal of Neuroscience Research, 85(13), 28132823. doi:10.1002/jnr.21273 [doi]
Ethell, I. M., & Yamaguchi, Y. (1999). Cell surface heparan sulfate proteoglycan syndecan-2
induces the maturation of dendritic spines in rat hippocampal neurons. The Journal of Cell
Biology, 144(3), 575-586.

307

EVANS, J. P., & SCHEINKER, I. M. (1946). Histologic studies of the brain following head
trauma; post-traumatic petechial and massive intracerebral hemorrhage. Journal of
Neurosurgery, 3, 101-113. doi:10.3171/jns.1946.3.2.0101 [doi]
Evans, J. P., & Scheinker, I. M. (1944). Histologic studies of the brain following head trauma.
Journal of Neurosurgery, 1(5), 306-320. doi:10.3171/jns.1944.1.5.0306
Ezeh, P. I., Wellis, D. P., & Scott, J. W. (1993). Organization of inhibition in the rat olfactory
bulb external plexiform layer. Journal of Neurophysiology, 70(1), 263-274.
Faden, A. I. (2011). Microglial activation and traumatic brain injury. Annals of Neurology,
70(3), 345-346. doi:10.1002/ana.22555 [doi]
Faden, A. I., Demediuk, P., Panter, S. S., & Vink, R. (1989). The role of excitatory amino
acids and NMDA receptors in traumatic brain injury. Science (New York, N.Y.), 244(4906), 798800.
Falo, M. C., Reeves, T. M., & Phillips, L. L. (2008). Agrin expression during synaptogenesis
induced by traumatic brain injury. Journal of Neurotrauma, 25(7), 769-783.
doi:10.1089/neu.2008.0511 [doi]
Farhy Tselnicker, I., Boisvert, M. M., & Allen, N. J. (2014). The role of neuronal versus
astrocyte-derived heparan sulfate proteoglycans in brain development and injury. Biochemical
Society Transactions, 42(5), 1263-1269. doi:10.1042/BST20140166 [doi]
Fasen, K., Elger, C. E., & Lie, A. A. (2003). Distribution of alpha and beta integrin subunits in
the adult rat hippocampus after pilocarpine-induced neuronal cell loss, axonal reorganization and
reactive astrogliosis. Acta Neuropathologica, 106(4), 319-322. doi:10.1007/s00401-003-0733-y
[doi]
Faul, M., Xu, L., & Sasser, S. M. (2016). Hospitalized traumatic brain injury: Low trauma
center utilization and high interfacility transfers among older adults. Prehospital Emergency
Care : Official Journal of the National Association of EMS Physicians and the National
Association of State EMS Directors, 20(5), 594-600. doi:10.3109/10903127.2016.1149651 [doi]
Faul, M. D., Xu, L., Wald, M. M., & Coronado, V. G. (2010). Traumatic brain injury in the
United States: Emergency department visits, hospitalizations, and deaths et al., 2002–2006.
Atlanta, GA: Centers for Disease Control and Prevention, National Center for Injury Prevention
and Control.
Fawcett, J. (2009). Molecular control of brain plasticity and repair. Progress in Brain
Research, 175, 501-509. doi:10.1016/S0079-6123(09)17534-9 [doi]
Fehlings, M. G., & Agrawal, S. (1995). Role of sodium in the pathophysiology of secondary
spinal cord injury. Spine, 20(20), 2187-2191.

308

Ferguson, P. L., Smith, G. M., Wannamaker, B. B., Thurman, D. J., Pickelsimer, E. E., &
Selassie, A. W. (2010). A population-based study of risk of epilepsy after hospitalization for
traumatic brain injury. Epilepsia, 51(5), 891-898. doi:10.1111/j.1528-1167.2009.02384.x [doi]
Ferrer, I., Krupinski, J., Goutan, E., Marti, E., Ambrosio, S., & Arenas, E. (2001). Brainderived neurotrophic factor reduces cortical cell death by ischemia after middle cerebral artery
occlusion in the rat. Acta Neuropathologica, 101(3), 229-238.
Field, P., Li, Y., & Raisman, G. (2003). Ensheathment of the olfactory nerves in the adult rat.
Journal of Neurocytology, 32(3), 317-324. doi:10.1023/B:NEUR.0000010089.37032.48
Fisher, L. W., Torchia, D. A., Fohr, B., Young, M. F., & Fedarko, N. S. (2001). Flexible
structures of SIBLING proteins, bone sialoprotein, and osteopontin. Biochemical and
Biophysical Research Communications, 280(2), 460-465. doi:10.1006/bbrc.2000.4146 [doi]
Fiske, B. K., & Brunjes, P. C. (2000). Microglial activation in the developing rat olfactory
bulb. Neuroscience, 96(4), 807-815. doi:S0306452299006016 [pii]
Fitch, M. T., & Silver, J. (1997). Glial cell extracellular matrix: Boundaries for axon growth in
development and regeneration. Cell and Tissue Research, 290(2), 379-384.
Fleminger, S., Oliver, D. L., Lovestone, S., Rabe-Hesketh, S., & Giora, A. (2003). Head injury
as a risk factor for alzheimer's disease: The evidence 10 years on; a partial replication. Journal
of Neurology, Neurosurgery, and Psychiatry, 74(7), 857-862.
Fluiter, K., Opperhuizen, A. L., Morgan, B. P., Baas, F., & Ramaglia, V. (2014). Inhibition of
the membrane attack complex of the complement system reduces secondary neuroaxonal loss
and promotes neurologic recovery after traumatic brain injury in mice. Journal of Immunology
(Baltimore, Md.: 1950), 192(5), 2339-2348. doi:10.4049/jimmunol.1302793 [doi]
Fox, M. A. (2008). Novel roles for collagens in wiring the vertebrate nervous system. Current
Opinion in Cell Biology, 20(5), 508-513. doi:10.1016/j.ceb.2008.05.003 [doi]
Frangogiannis, N. G. (2012). Matricellular proteins in cardiac adaptation and disease.
Physiological Reviews, 92(2), 635-688. doi:10.1152/physrev.00008.2011 [doi]
Fredrich, M., & Illing, R. B. (2011). Deafferentation-induced redistribution of MMP-2, but not
of MMP-9, depends on the emergence of GAP-43 positive axons in the adult rat cochlear
nucleus. Neural Plasticity, 2011, 859359. doi:10.1155/2011/859359 [doi]
Freeman, L. R., Zhang, L., Nair, A., Dasuri, K., Francis, J., Fernandez-Kim, S. O., . . . Keller,
J. N. (2013). Obesity increases cerebrocortical reactive oxygen species and impairs brain
function. Free Radical Biology & Medicine, 56, 226-233.
doi:10.1016/j.freeradbiomed.2012.08.577 [doi]
Frey, L. C. (2003). Epidemiology of posttraumatic epilepsy: A critical review. Epilepsia, 44
Suppl 10, 11-17. doi:10004 [pii]

309

Frischknecht, R., & Gundelfinger, E. D. (2012). The brain's extracellular matrix and its role in
synaptic plasticity. Advances in Experimental Medicine and Biology, 970, 153-171.
doi:10.1007/978-3-7091-0932-8_7 [doi]
Frotscher, M., Heimrich, B., & Deller, T. (1997). Sprouting in the hippocampus is layerspecific. Trends in Neurosciences, 20(5), 218-223. doi:S0166-2236(96)01018-1 [pii]
Frotscher, M., Heimrich, B., & Deller, T. (1997). Sprouting in the hippocampus is layerspecific. Trends in Neurosciences, 20(5), 218-223. doi:S0166-2236(96)01018-1 [pii]
Frugier, T., Morganti-Kossmann, M. C., O'Reilly, D., & McLean, C. A. (2010). In situ
detection of inflammatory mediators in post mortem human brain tissue after traumatic injury.
Journal of Neurotrauma, 27(3), 497-507. doi:10.1089/neu.2009.1120 [doi]
Frugier, T., Morganti-Kossmann, M. C., O'Reilly, D., & McLean, C. A. (2010). In situ
detection of inflammatory mediators in post mortem human brain tissue after traumatic injury.
Journal of Neurotrauma, 27(3), 497-507. doi:10.1089/neu.2009.1120 [doi]
Fujita, M., Oda, Y., Wei, E. P., & Povlishock, J. T. (2011). The combination of either tempol
or FK506 with delayed hypothermia: Implications for traumatically induced microvascular and
axonal protection. Journal of Neurotrauma, 28(7), 1209-1218. doi:10.1089/neu.2011.1852 [doi]
Gallant, P. E. (1992). The direct effects of graded axonal compression on axoplasm and fast
axoplasmic transport. Journal of Neuropathology and Experimental Neurology, 51(2), 220-230.
Gao, Y. A., Agnihotri, R., Vary, C. P., & Liaw, L. (2004). Expression and characterization of
recombinant osteopontin peptides representing matrix metalloproteinase proteolytic fragments.
Matrix Biology : Journal of the International Society for Matrix Biology, 23(7), 457-466.
doi:S0945-053X(04)00114-3 [pii]
Gavrieli, Y., Sherman, Y., & Ben-Sasson, S. A. (1992). Identification of programmed cell
death in situ via specific labeling of nuclear DNA fragmentation. The Journal of Cell Biology,
119(3), 493-501.
Gawlak, M., Gorkiewicz, T., Gorlewicz, A., Konopacki, F. A., Kaczmarek, L., & Wilczynski,
G. M. (2009). High resolution in situ zymography reveals matrix metalloproteinase activity at
glutamatergic synapses. Neuroscience, 158(1), 167-176.
doi:10.1016/j.neuroscience.2008.05.045 [doi]
Geissler, M., Gottschling, C., Aguado, A., Rauch, U., Wetzel, C. H., Hatt, H., & Faissner, A.
(2013). Primary hippocampal neurons, which lack four crucial extracellular matrix molecules,
display abnormalities of synaptic structure and function and severe deficits in perineuronal net
formation. The Journal of Neuroscience : The Official Journal of the Society for Neuroscience,
33(18), 7742-7755. doi:10.1523/JNEUROSCI.3275-12.2013 [doi]
Gennarelli, T. A. (1993). Mechanisms of brain injury. The Journal of Emergency Medicine, 11
Suppl 1, 5-11.

310

Gennarelli, T. A., & Graham, D. I. (1998). Neuropathology of the head injuries. Seminars in
Clinical Neuropsychiatry, 3(3), 160-175. doi:00300160 [pii]
Gennarelli, T. A., Thibault, L. E., Adams, J. H., Graham, D. I., Thompson, C. J., &
Marcincin, R. P. (1982). Diffuse axonal injury and traumatic coma in the primate. Annals of
Neurology, 12(6), 564-574. doi:10.1002/ana.410120611 [doi]
Gentleman, S. M., Leclercq, P. D., Moyes, L., Graham, D. I., Smith, C., Griffin, W. S., &
Nicoll, J. A. (2004). Long-term intracerebral inflammatory response after traumatic brain
injury. Forensic Science International, 146(2-3), 97-104. doi:S0379-0738(04)00398-6 [pii]
Gerrow, K., & El-Husseini, A. (2006). Cell adhesion molecules at the synapse. Frontiers in
Bioscience : A Journal and Virtual Library, 11, 2400-2419. doi:1978 [pii]
Giachelli, C. M., & Steitz, S. (2000). Osteopontin: A versatile regulator of inflammation and
biomineralization. Matrix Biology : Journal of the International Society for Matrix Biology,
19(7), 615-622. doi:S0945-053X(00)00108-6 [pii]
Gitler, D., Cheng, Q., Greengard, P., & Augustine, G. J. (2008). Synapsin-IIa controls the
reserve pool of glutamatergic synaptic vesicles. The Journal of Neuroscience : The Official
Journal of the Society for Neuroscience, 28(43), 10835-10843. doi:10.1523/JNEUROSCI.092408.2008 [doi]
Gliem, M., Krammes, K., Liaw, L., van Rooijen, N., Hartung, H. P., & Jander, S. (2015).
Macrophage-derived osteopontin induces reactive astrocyte polarization and promotes reestablishment of the blood brain barrier after ischemic stroke. Glia, 63(12), 2198-2207.
doi:10.1002/glia.22885 [doi]
Goggio, A. F. (1941). The mechanism of contre-coup injury. Journal of Neurology and
Psychiatry, 4(1), 11-22.
Goldman, S. M., Tanner, C. M., Oakes, D., Bhudhikanok, G. S., Gupta, A., & Langston, J. W.
(2006). Head injury and parkinson's disease risk in twins. Annals of Neurology, 60(1), 65-72.
doi:10.1002/ana.20882 [doi]
Goldshmit, Y., & Bourne, J. (2010). Upregulation of EphA4 on astrocytes potentially mediates
astrocytic gliosis after cortical lesion in the marmoset monkey. Journal of Neurotrauma, 27(7),
1321-1332. doi:10.1089/neu.2010.1294 [doi]
Goldstein, L. E., Fisher, A. M., Tagge, C. A., Zhang, X. L., Velisek, L., Sullivan, J. A., . . .
McKee, A. C. (2012). Chronic traumatic encephalopathy in blast-exposed military veterans and
a blast neurotrauma mouse model. Science Translational Medicine, 4(134), 134ra60.
doi:10.1126/scitranslmed.3003716 [doi]
Goldstein, M. (1990). Traumatic brain injury: A silent epidemic. Annals of Neurology, 27(3),
327. doi:10.1002/ana.410270315 [doi]

311

Gonzalez, M. L., & Silver, J. (1994). Axon-glia interactions regulate ECM patterning in the
postnatal rat olfactory bulb. The Journal of Neuroscience : The Official Journal of the Society
for Neuroscience, 14(10), 6121-6131.
Goodison, S., Urquidi, V., & Tarin, D. (1999). CD44 cell adhesion molecules. Molecular
Pathology : MP, 52(4), 189-196.
Gordon-Weeks, P. R., & Fischer, I. (2000). MAP1B expression and microtubule stability in
growing and regenerating axons. Microscopy Research and Technique, 48(2), 63-74.
doi:10.1002/(SICI)1097-0029(20000115)48:2<63::AID-JEMT2>3.0.CO;2-1 [pii]
Gorup, D., Bohacek, I., Milicevic, T., Pochet, R., Mitrecic, D., Kriz, J., & Gajovic, S. (2015).
Increased expression and colocalization of GAP43 and CASP3 after brain ischemic lesion in
mouse. Neuroscience Letters, 597, 176-182. doi:10.1016/j.neulet.2015.04.042 [doi]
Goto, S., Yamada, K., Inoue, N., Nagahiro, S., & Ushio, Y. (1994). Increased expression of
growth-associated protein GAP-43/B-50 following cerebral hemitransection or striatal ischemic
injury in the substantia nigra of adult rats. Brain Research, 647(2), 333-339. doi:00068993(94)91332-3 [pii]
Goussev, S., Hsu, J. Y., Lin, Y., Tjoa, T., Maida, N., Werb, Z., & Noble-Haeusslein, L. J.
(2003). Differential temporal expression of matrix metalloproteinases after spinal cord injury:
Relationship to revascularization and wound healing. Journal of Neurosurgery, 99(2 Suppl),
188-197.
Grady, M. S., Jane, J. A., & Steward, O. (1989). Synaptic reorganization within the human
central nervous system following injury. Journal of Neurosurgery, 71(4), 534-537.
doi:10.3171/jns.1989.71.4.0534 [doi]
Graziadei, G. A., & Graziadei, P. P. (1979). Neurogenesis and neuron regeneration in the
olfactory system of mammals. II. degeneration and reconstitution of the olfactory sensory
neurons after axotomy. Journal of Neurocytology, 8(2), 197-213.
Graziadei, P. P., Levine, R. R., & Graziadei, G. A. (1978). Regeneration of olfactory axons
and synapse formation in the forebrain after bulbectomy in neonatal mice. Proceedings of the
National Academy of Sciences of the United States of America, 75(10), 5230-5234.
Graziadei, P. P., Levine, R. R., & Monti Graziadei, G. A. (1979). Plasticity of connections of
the olfactory sensory neuron: Regeneration into the forebrain following bulbectomy in the
neonatal mouse. Neuroscience, 4(6), 713-727. doi:0306-4522(79)90002-2 [pii]
Graziadei, P. P., & Monti Graziadei, G. A. (1980). Neurogenesis and neuron regeneration in
the olfactory system of mammals. III. deafferentation and reinnervation of the olfactory bulb
following section of the fila olfactoria in rat. Journal of Neurocytology, 9(2), 145-162.
Graziadei, P. P., & Okano, M. (1979). Neuronal degeneration and regeneration in the olfactory
epithelium of pigeon following transection of the first cranial nerve. Acta Anatomica, 104(2),
220-236.
312

Green, P. M., Ludbrook, S. B., Miller, D. D., Horgan, C. M., & Barry, S. T. (2001).
Structural elements of the osteopontin SVVYGLR motif important for the interaction with
alpha(4) integrins. FEBS Letters, 503(1), 75-79. doi:S0014-5793(01)02690-4 [pii]
Greenwald, R. M., Chu, J. J., Beckwith, J. G., & Crisco, J. J. (2012). A proposed method to
reduce underreporting of brain injury in sports. Clinical Journal of Sport Medicine : Official
Journal of the Canadian Academy of Sport Medicine, 22(2), 83-85.
doi:10.1097/JSM.0b013e31824cc5d3 [doi]
Griesbach, G. S., Gomez-Pinilla, F., & Hovda, D. A. (2004). The upregulation of plasticityrelated proteins following TBI is disrupted with acute voluntary exercise. Brain Research,
1016(2), 154-162. doi:10.1016/j.brainres.2004.04.079 [doi]
Griesbach, G. S., Gomez-Pinilla, F., & Hovda, D. A. (2007). Time window for voluntary
exercise-induced increases in hippocampal neuroplasticity molecules after traumatic brain injury
is severity dependent. Journal of Neurotrauma, 24(7), 1161-1171. doi:10.1089/neu.2006.0255
[doi]
Griesbach, G. S., Hovda, D. A., Molteni, R., Wu, A., & Gomez-Pinilla, F. (2004). Voluntary
exercise following traumatic brain injury: Brain-derived neurotrophic factor upregulation and
recovery of function. Neuroscience, 125(1), 129-139. doi:10.1016/j.neuroscience.2004.01.030
[doi]
Griesbach, G. S., Sutton, R. L., Hovda, D. A., Ying, Z., & Gomez-Pinilla, F. (2009).
Controlled contusion injury alters molecular systems associated with cognitive performance.
Journal of Neuroscience Research, 87(3), 795-805. doi:10.1002/jnr.21893 [doi]
Griff, E. R., Greer, C. A., Margolis, F., Ennis, M., & Shipley, M. T. (2000). Ultrastructural
characteristics and conduction velocity of olfactory receptor neuron axons in the olfactory
marker protein-null mouse. Brain Research, 866(1-2), 227-236. doi:S0006-8993(00)02291-5
[pii]
Grooms, S. Y., Terracio, L., & Jones, L. S. (1993). Anatomical localization of beta 1 integrinlike immunoreactivity in rat brain. Experimental Neurology, 122(2), 253-259. doi:S00144886(83)71125-8 [pii]
Grumet, M., Flaccus, A., & Margolis, R. U. (1993). Functional characterization of chondroitin
sulfate proteoglycans of brain: Interactions with neurons and neural cell adhesion molecules.
The Journal of Cell Biology, 120(3), 815-824.
Guell, K., & Bix, G. J. (2014). Brain endothelial cell specific integrins and ischemic stroke.
Expert Review of Neurotherapeutics, 14(11), 1287-1292. doi:10.1586/14737175.2014.964210
[doi]
Gueye, Y., Ferhat, L., Sbai, O., Bianco, J., Ould-Yahoui, A., Bernard, A., . . . Khrestchatisky,
M. (2011). Trafficking and secretion of matrix metalloproteinase-2 in olfactory ensheathing
glial cells: A role in cell migration? Glia, 59(5), 750-770. doi:10.1002/glia.21146 [doi]

313

Gunther, M., Plantman, S., Davidsson, J., Angeria, M., Mathiesen, T., & Risling, M. (2015).
COX-2 regulation and TUNEL-positive cell death differ between genders in the secondary
inflammatory response following experimental penetrating focal brain injury in rats. Acta
Neurochirurgica, 157(4), 649-659. doi:10.1007/s00701-014-2331-2 [doi]
Hadass, O., Tomlinson, B. N., Gooyit, M., Chen, S., Purdy, J. J., Walker, J. M., . . . Gu, Z.
(2013). Selective inhibition of matrix metalloproteinase-9 attenuates secondary damage
resulting from severe traumatic brain injury. PloS One, 8(10), e76904.
doi:10.1371/journal.pone.0076904 [doi]
Hagan, P. J. (1967). Posttraumatic anosmia. Archives of Otolaryngology (Chicago, Ill.: 1960),
85(1), 85-89.
Hall, E. D., Sullivan, P. G., Gibson, T. R., Pavel, K. M., Thompson, B. M., & Scheff, S. W.
(2005). Spatial and temporal characteristics of neurodegeneration after controlled cortical
impact in mice: More than a focal brain injury. Journal of Neurotrauma, 22(2), 252-265.
doi:10.1089/neu.2005.22.252 [doi]
Hanisch, U. K. (2002). Microglia as a source and target of cytokines. Glia, 40(2), 140-155.
doi:10.1002/glia.10161 [doi]
Hanisch, U. K., & Kettenmann, H. (2007). Microglia: Active sensor and versatile effector cells
in the normal and pathologic brain. Nature Neuroscience, 10(11), 1387-1394. doi:nn1997 [pii]
Haorah, J., Ramirez, S. H., Schall, K., Smith, D., Pandya, R., & Persidsky, Y. (2007).
Oxidative stress activates protein tyrosine kinase and matrix metalloproteinases leading to bloodbrain barrier dysfunction. Journal of Neurochemistry, 101(2), 566-576. doi:JNC4393 [pii]
Harris, A. S., & Morrow, J. S. (1988). Proteolytic processing of human brain alpha spectrin
(fodrin): Identification of a hypersensitive site. The Journal of Neuroscience : The Official
Journal of the Society for Neuroscience, 8(7), 2640-2651.
Harris, J. L., Reeves, T. M., & Phillips, L. L. (2011). Phosphacan and receptor protein
tyrosine phosphatase beta expression mediates deafferentation-induced synaptogenesis.
Hippocampus, 21(1), 81-92. doi:10.1002/hipo.20725 [doi]
Harris, N. G., Carmichael, S. T., Hovda, D. A., & Sutton, R. L. (2009). Traumatic brain
injury results in disparate regions of chondroitin sulfate proteoglycan expression that are
temporally limited. Journal of Neuroscience Research, 87(13), 2937-2950.
doi:10.1002/jnr.22115 [doi]
Harris, N. G., Mironova, Y. A., Hovda, D. A., & Sutton, R. L. (2010). Chondroitinase ABC
enhances pericontusion axonal sprouting but does not confer robust improvements in behavioral
recovery. Journal of Neurotrauma, 27(11), 1971-1982. doi:10.1089/neu.2010.1470 [doi]
Hashimoto, M., Sun, D., Rittling, S. R., Denhardt, D. T., & Young, W. (2007). Osteopontindeficient mice exhibit less inflammation, greater tissue damage, and impaired locomotor
recovery from spinal cord injury compared with wild-type controls. The Journal of
314

Neuroscience : The Official Journal of the Society for Neuroscience, 27(13), 3603-3611.
doi:27/13/3603 [pii]
Hayes, R. L., Jenkins, L. W., & Lyeth, B. G. (1992). Neurotransmitter-mediated mechanisms
of traumatic brain injury: Acetylcholine and excitatory amino acids. Journal of Neurotrauma, 9
Suppl 1, S173-87.
Hayes, R. L., Jenkins, L. W., Lyeth, B. G., Balster, R. L., Robinson, S. E., Clifton, G. L., . .
. Young, H. F. (1988). Pretreatment with phencyclidine, an N-methyl-D-aspartate antagonist,
attenuates long-term behavioral deficits in the rat produced by traumatic brain injury. Journal of
Neurotrauma, 5(4), 259-274. doi:10.1089/neu.1988.5.259 [doi]
Heikkinen, A., Pihlajaniemi, T., Faissner, A., & Yuzaki, M. (2014). Neural ECM and
synaptogenesis. Progress in Brain Research, 214, 29-51. doi:10.1016/B978-0-444-634863.00002-5 [doi]
Hellewell, S., Semple, B. D., & Morganti-Kossmann, M. C. (2016). Therapies negating
neuroinflammation after brain trauma. Brain Research, 1640(Pt A), 36-56.
doi:10.1016/j.brainres.2015.12.024 [doi]
Hernandez-Ontiveros, D. G., Tajiri, N., Acosta, S., Giunta, B., Tan, J., & Borlongan, C. V.
(2013). Microglia activation as a biomarker for traumatic brain injury. Frontiers in Neurology,
4, 30. doi:10.3389/fneur.2013.00030 [doi]
Herrmann, J. E., Imura, T., Song, B., Qi, J., Ao, Y., Nguyen, T. K., . . . Sofroniew, M. V.
(2008). STAT3 is a critical regulator of astrogliosis and scar formation after spinal cord injury.
The Journal of Neuroscience : The Official Journal of the Society for Neuroscience, 28(28),
7231-7243. doi:10.1523/JNEUROSCI.1709-08.2008 [doi]
Herzog, C. D., & Otto, T. (2002). Administration of transforming growth factor-alpha
enhances anatomical and behavioral recovery following olfactory nerve transection.
Neuroscience, 113(3), 569-580. doi:S0306452202002038 [pii]
Heywood, W. E., Galimberti, D., Bliss, E., Sirka, E., Paterson, R. W., Magdalinou, N. K., . . .
Mills, K. (2015). Identification of novel CSF biomarkers for neurodegeneration and their
validation by a high-throughput multiplexed targeted proteomic assay. Molecular
Neurodegeneration, 10, 64-015-0059-y. doi:10.1186/s13024-015-0059-y [doi]
Higashida, T., Kreipke, C. W., Rafols, J. A., Peng, C., Schafer, S., Schafer, P., . . . Ding, Y.
(2011). The role of hypoxia-inducible factor-1alpha, aquaporin-4, and matrix metalloproteinase9 in blood-brain barrier disruption and brain edema after traumatic brain injury. Journal of
Neurosurgery, 114(1), 92-101. doi:10.3171/2010.6.JNS10207 [doi]
Hirata, K., Kanemaru, T., Minohara, M., Togo, A., & Kira, J. (2008). Accumulation of stressrelated proteins within the glomeruli of the rat olfactory bulb following damage to olfactory
receptor neurons. Archives of Histology and Cytology, 71(4), 265-277.

315

Hirose, T., Matsumoto, N., Tasaki, O., Nakamura, H., Akagaki, F., & Shimazu, T. (2013).
Delayed progression of edema formation around a hematoma expressing high levels of VEGF
and mmp-9 in a patient with traumatic brain injury: Case report. Neurologia Medico-Chirurgica,
53(9), 609-612. doi:DN/JST.JSTAGE/nmc/cr2012-0342 [pii]
Hoehn, B. D., Palmer, T. D., & Steinberg, G. K. (2005). Neurogenesis in rats after focal
cerebral ischemia is enhanced by indomethacin. Stroke; a Journal of Cerebral Circulation,
36(12), 2718-2724. doi:10.1161/01.STR.0000190020.30282.cc
Hofman, F. M., Hinton, D. R., Johnson, K., & Merrill, J. E. (1989). Tumor necrosis factor
identified in multiple sclerosis brain. The Journal of Experimental Medicine, 170(2), 607-612.
Holbrook, E. H., Iwema, C. L., Peluso, C. E., & Schwob, J. E. (2014). The regeneration of P2
olfactory sensory neurons is selectively impaired following methyl bromide lesion. Chemical
Senses, 39(7), 601-616. doi:10.1093/chemse/bju033 [doi]
Holmin, S., & Mathiesen, T. (1999). Long-term intracerebral inflammatory response after
experimental focal brain injury in rat. Neuroreport, 10(9), 1889-1891.
Holtmaat, A. J., Dijkhuizen, P. A., Oestreicher, A. B., Romijn, H. J., Van der Lugt, N. M.,
Berns, A., . . . Verhaagen, J. (1995). Directed expression of the growth-associated protein B50/GAP-43 to olfactory neurons in transgenic mice results in changes in axon morphology and
extraglomerular fiber growth. The Journal of Neuroscience : The Official Journal of the Society
for Neuroscience, 15(12), 7953-7965.
Homsi, S., Federico, F., Croci, N., Palmier, B., Plotkine, M., Marchand-Leroux, C., & JafarianTehrani, M. (2009). Minocycline effects on cerebral edema: Relations with inflammatory and
oxidative stress markers following traumatic brain injury in mice. Brain Research, 1291, 122132. doi:10.1016/j.brainres.2009.07.031 [doi]
Horstmann, S., Su, Y., Koziol, J., Meyding-Lamade, U., Nagel, S., & Wagner, S. (2006).
MMP-2 and MMP-9 levels in peripheral blood after subarachnoid hemorrhage. Journal of the
Neurological Sciences, 251(1-2), 82-86. doi:S0022-510X(06)00382-0 [pii]
Horton, M. A., Nesbit, M. A., & Helfrich, M. H. (1995). Interaction of osteopontin with
osteoclast integrins. Annals of the New York Academy of Sciences, 760, 190-200.
Hou, P., Troen, T., Ovejero, M. C., Kirkegaard, T., Andersen, T. L., Byrjalsen, I., . . .
Delaisse, J. M. (2004). Matrix metalloproteinase-12 (MMP-12) in osteoclasts: New lesson on
the involvement of MMPs in bone resorption. Bone, 34(1), 37-47. doi:S8756328203003363
[pii]
Hsu, J. Y., Bourguignon, L. Y., Adams, C. M., Peyrollier, K., Zhang, H., Fandel, T., . . .
Noble-Haeusslein, L. J. (2008). Matrix metalloproteinase-9 facilitates glial scar formation in
the injured spinal cord. The Journal of Neuroscience : The Official Journal of the Society for
Neuroscience, 28(50), 13467-13477. doi:10.1523/JNEUROSCI.2287-08.2008 [doi]

316

Hsu, J. Y., McKeon, R., Goussev, S., Werb, Z., Lee, J. U., Trivedi, A., & Noble-Haeusslein, L.
J. (2006). Matrix metalloproteinase-2 facilitates wound healing events that promote functional
recovery after spinal cord injury. The Journal of Neuroscience : The Official Journal of the
Society for Neuroscience, 26(39), 9841-9850. doi:26/39/9841 [pii]
Huang, E. J., & Reichardt, L. F. (2001). Neurotrophins: Roles in neuronal development and
function. Annual Review of Neuroscience, 24, 677-736. doi:10.1146/annurev.neuro.24.1.677
[doi]
Hubert, T., Grimal, S., Carroll, P., & Fichard-Carroll, A. (2009). Collagens in the developing
and diseased nervous system. Cellular and Molecular Life Sciences : CMLS, 66(7), 1223-1238.
doi:10.1007/s00018-008-8561-9 [doi]
Huet, S., Groux, H., Caillou, B., Valentin, H., Prieur, A. M., & Bernard, A. (1989). CD44
contributes to T cell activation. Journal of Immunology (Baltimore, Md.: 1950), 143(3), 798801.
Hulsebosch, C. E., DeWitt, D. S., Jenkins, L. W., & Prough, D. S. (1998). Traumatic brain
injury in rats results in increased expression of gap-43 that correlates with behavioral recovery.
Neuroscience Letters, 255(2), 83-86. doi:S0304-3940(98)00712-5 [pii]
Hunter, A. J., & Murray, T. K. (1989). Cholinergic mechanisms in a simple test of olfactory
learning in the rat. Psychopharmacology, 99(2), 270-275.
Huntley, G. W. (2012). Synaptic circuit remodelling by matrix metalloproteinases in health and
disease. Nature Reviews.Neuroscience, 13(11), 743-757. doi:10.1038/nrn3320 [doi]
Hwang, I. K., Yoo, K. Y., Kim, D. W., Li, H., Park, O. K., Lee, C. H., . . . Won, M. H.
(2008). AlphaII-spectrin breakdown product increases in principal cells in the gerbil main
olfactory bulb following transient ischemia. Neuroscience Letters, 435(3), 251-256.
doi:10.1016/j.neulet.2008.02.050 [doi]
Hyder, A. A., Wunderlich, C. A., Puvanachandra, P., Gururaj, G., & Kobusingye, O. C.
(2007). The impact of traumatic brain injuries: A global perspective. Neurorehabilitation,
22(5), 341-353.
Iaffaldano, P., Ruggieri, M., Viterbo, R. G., Mastrapasqua, M., & Trojano, M. (2014). The
improvement of cognitive functions is associated with a decrease of plasma osteopontin levels in
natalizumab treated relapsing multiple sclerosis. Brain, Behavior, and Immunity, 35, 176-181.
doi:10.1016/j.bbi.2013.08.009 [doi]
Iczkiewicz, J., Broom, L., Cooper, J. D., Wong, A. M., Rose, S., & Jenner, P. (2010). The
RGD-containing peptide fragment of osteopontin protects tyrosine hydroxylase positive cells
against toxic insult in primary ventral mesencephalic cultures and in the rat substantia nigra.
Journal of Neurochemistry, 114(6), 1792-1804. doi:10.1111/j.1471-4159.2010.06896.x [doi]
Iczkiewicz, J., Jackson, M. J., Smith, L. A., Rose, S., & Jenner, P. (2006). Osteopontin
expression in substantia nigra in MPTP-treated primates and in parkinson's disease. Brain
Research, 1118(1), 239-250. doi:S0006-8993(06)02422-X [pii]
317

Iczkiewicz, J., Rose, S., & Jenner, P. (2005). Increased osteopontin expression following
intranigral lipopolysaccharide injection in the rat. The European Journal of Neuroscience, 21(7),
1911-1920. doi:EJN4009 [pii]
Ikeda, K., Sakurada, T., Takasaka, T., Okitsu, T., & Yoshida, S. (1995). Anosmia following
head trauma: Preliminary study of steroid treatment. The Tohoku Journal of Experimental
Medicine, 177(4), 343-351.
Imai, F., Sawada, M., Suzuki, H., Zlokovic, B. V., Kojima, J., Kuno, S., . . . Kanno, T. (1999).
Exogenous microglia enter the brain and migrate into ischaemic hippocampal lesions.
Neuroscience Letters, 272(2), 127-130. doi:S0304-3940(99)00592-3 [pii]
Imai, K., Shikata, H., & Okada, Y. (1995). Degradation of vitronectin by matrix
metalloproteinases-1, -2, -3, -7 and -9. FEBS Letters, 369(2-3), 249-251. doi:00145793(95)00752-U [pii]
Imamura, F., & Greer, C. A. (2013). Pax6 regulates Tbr1 and Tbr2 expressions in olfactory
bulb mitral cells. Molecular and Cellular Neurosciences, 54, 58-70.
doi:10.1016/j.mcn.2013.01.002 [doi]
Inamitsu, M., Nakashima, T., & Uemura, T. (1990). Immunopathology of olfactory mucosa
following injury to the olfactory bulb. The Journal of Laryngology and Otology, 104(12), 959964.
Jadhav, V., Yamaguchi, M., Obenaus, A., & Zhang, J. H. (2008). Matrix metalloproteinase
inhibition attenuates brain edema after surgical brain injury. Acta Neurochirurgica.Supplement,
102, 357-361.
Jafek, B. W., Eller, P. M., Esses, B. A., & Moran, D. T. (1989). Post-traumatic anosmia.
ultrastructural correlates. Archives of Neurology, 46(3), 300-304.
Jalkanen, S., & Jalkanen, M. (1992). Lymphocyte CD44 binds the COOH-terminal heparinbinding domain of fibronectin. The Journal of Cell Biology, 116(3), 817-825.
Jalkanen, S. T., Bargatze, R. F., Herron, L. R., & Butcher, E. C. (1986). A lymphoid cell
surface glycoprotein involved in endothelial cell recognition and lymphocyte homing in man.
European Journal of Immunology, 16(10), 1195-1202. doi:10.1002/eji.1830161003 [doi]
Jansson, M., Panoutsakopoulou, V., Baker, J., Klein, L., & Cantor, H. (2002). Cutting edge:
Attenuated experimental autoimmune encephalomyelitis in eta-1/osteopontin-deficient mice.
Journal of Immunology (Baltimore, Md.: 1950), 168(5), 2096-2099.
Janz, P., & Illing, R. B. (2014). A role for microglial cells in reshaping neuronal circuitry of
the adult rat auditory brainstem after its sensory deafferentation. Journal of Neuroscience
Research, 92(4), 432-445. doi:10.1002/jnr.23334 [doi]
Jaoude, J., & Koh, Y. (2016). Matrix metalloproteinases in exercise and obesity. Vascular
Health and Risk Management, 12, 287-295. doi:10.2147/VHRM.S103877 [doi]

318

Jellinger, K. A. (2001). The pathology of parkinson's disease. Advances in Neurology, 86, 5572.
Jennings, R. A., Hambright Keiger, C. J., & Walker, J. C. (1995). Time course of
reinnervation of the olfactory bulb after transection of the primary olfactory nerve in the pigeon.
Brain Research, 683(2), 159-163. doi:000689939500361S [pii]
Jia, F., Pan, Y. H., Mao, Q., Liang, Y. M., & Jiang, J. Y. (2010). Matrix metalloproteinase-9
expression and protein levels after fluid percussion injury in rats: The effect of injury severity
and brain temperature. Journal of Neurotrauma, 27(6), 1059-1068. doi:10.1089/neu.2009.1067
[doi]
Jiang, R. S., Wu, S. H., Liang, K. L., Shiao, J. Y., Hsin, C. H., & Su, M. C. (2010). Steroid
treatment of posttraumatic anosmia. European Archives of Oto-Rhino-Laryngology : Official
Journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : Affiliated
with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 267(10), 15631567. doi:10.1007/s00405-010-1240-0; 10.1007/s00405-010-1240-0
Jin, Y., Kim, I. Y., Kim, I. D., Lee, H. K., Park, J. Y., Han, P. L., . . . Lee, J. K. (2014).
Biodegradable gelatin microspheres enhance the neuroprotective potency of osteopontin via
quick and sustained release in the post-ischemic brain. Acta Biomaterialia, 10(7), 3126-3135.
doi:10.1016/j.actbio.2014.02.045 [doi]
John, J. P., Sunyer, B., Hoger, H., Pollak, A., & Lubec, G. (2009). Hippocampal SynapsinIsoform levels are linked to spatial memory enhancement by SGS742. Hippocampus, 19(8),
731-738. doi:10.1002/hipo.20553 [doi]
John, N., Krugel, H., Frischknecht, R., Smalla, K. H., Schultz, C., Kreutz, M. R., . . .
Seidenbecher, C. I. (2006). Brevican-containing perineuronal nets of extracellular matrix in
dissociated hippocampal primary cultures. Molecular and Cellular Neurosciences, 31(4), 774784. doi:S1044-7431(06)00008-X [pii]
Johnson, B. A., Woo, C. C., Ninomiya-Tsuboi, K., & Leon, M. (1996). Synaptophysin-like
immunoreactivity in the rat olfactory bulb during postnatal development and after restricted early
olfactory experience. Brain Research.Developmental Brain Research, 92(1), 24-30.
doi:0165380695001972 [pii]
Johnson, E. M., Traver, K. L., Hoffman, S. W., Harrison, C. R., & Herman, J. P. (2013).
Environmental enrichment protects against functional deficits caused by traumatic brain injury.
Frontiers in Behavioral Neuroscience, 7, 44. doi:10.3389/fnbeh.2013.00044;
10.3389/fnbeh.2013.00044
Johnson, J. L. (1972). Glutamic acid as a synaptic transmitter in the nervous system. A review.
Brain Research, 37(1), 1-19. doi:0006-8993(72)90343-5 [pii]
Jones, L. L., Liu, Z., Shen, J., Werner, A., Kreutzberg, G. W., & Raivich, G. (2000).
Regulation of the cell adhesion molecule CD44 after nerve transection and direct trauma to the

319

mouse brain. The Journal of Comparative Neurology, 426(3), 468-492. doi:10.1002/10969861(20001023)426:3<468::AID-CNE9>3.0.CO;2-I [pii]
Jones, L. L., Yamaguchi, Y., Stallcup, W. B., & Tuszynski, M. H. (2002). NG2 is a major
chondroitin sulfate proteoglycan produced after spinal cord injury and is expressed by
macrophages and oligodendrocyte progenitors. The Journal of Neuroscience : The Official
Journal of the Society for Neuroscience, 22(7), 2792-2803. doi:20026258 [doi]
Jones, L. S. (1996). Integrins: Possible functions in the adult CNS. Trends in Neurosciences,
19(2), 68-72. doi:0166-2236(96)89623-8 [pii]
Kaliszewska, A., Bijata, M., Kaczmarek, L., & Kossut, M. (2012). Experience-dependent
plasticity of the barrel cortex in mice observed with 2-DG brain mapping and c-fos: Effects of
MMP-9 KO. Cerebral Cortex (New York, N.Y.: 1991), 22(9), 2160-2170.
doi:10.1093/cercor/bhr303 [doi]
Kandel, E. R., Schwartz, J. H., Jessell, T. M., Siegelbaum, S. A., & Hudspeth, A. J.
(2013). Principles of Neural Science (5th ed.). United States: McGraw Hill.
Kang, W. S., Choi, J. S., Shin, Y. J., Kim, H. Y., Cha, J. H., Lee, J. Y., . . . Lee, M. Y.
(2008). Differential regulation of osteopontin receptors, CD44 and the alpha(v) and beta(3)
integrin subunits, in the rat hippocampus following transient forebrain ischemia. Brain
Research, 1228, 208-216. doi:10.1016/j.brainres.2008.06.106 [doi]
Kasowski, H. J., Kim, H., & Greer, C. A. (1999). Compartmental organization of the olfactory
bulb glomerulus. The Journal of Comparative Neurology, 407(2), 261-274.
Kass, M. D., Moberly, A. H., Rosenthal, M. C., Guang, S. A., & McGann, J. P. (2013).
Odor-specific, olfactory marker protein-mediated sparsening of primary olfactory input to the
brain after odor exposure. The Journal of Neuroscience : The Official Journal of the Society for
Neuroscience, 33(15), 6594-6602. doi:10.1523/JNEUROSCI.1442-12.2013 [doi]
Katagiri, Y. U., Sleeman, J., Fujii, H., Herrlich, P., Hotta, H., Tanaka, K., . . . Uede, T.
(1999). CD44 variants but not CD44s cooperate with beta1-containing integrins to permit cells
to bind to osteopontin independently of arginine-glycine-aspartic acid, thereby stimulating cell
motility and chemotaxis. Cancer Research, 59(1), 219-226.
Kazanecki, C. C., Kowalski, A. J., Ding, T., Rittling, S. R., & Denhardt, D. T. (2007).
Characterization of anti-osteopontin monoclonal antibodies: Binding sensitivity to posttranslational modifications. Journal of Cellular Biochemistry, 102(4), 925-935.
doi:10.1002/jcb.21487 [doi]
Keller, A., & Margolis, F. L. (1976). Isolation and characterization of rat olfactory marker
protein. The Journal of Biological Chemistry, 251(20), 6232-6237.
Kelly, E. A., Russo, A. S., Jackson, C. D., Lamantia, C. E., & Majewska, A. K. (2015).
Proteolytic regulation of synaptic plasticity in the mouse primary visual cortex: Analysis of
matrix metalloproteinase 9 deficient mice. Frontiers in Cellular Neuroscience, 9, 369.
doi:10.3389/fncel.2015.00369 [doi]
320

Kern, R. C., Quinn, B., Rosseau, G., & Farbman, A. I. (2000). Post-traumatic olfactory
dysfunction. The Laryngoscope, 110(12), 2106-2109. doi:10.1097/00005537-200012000-00025
[doi]
Kernie, S. G., & Parent, J. M. (2010). Forebrain neurogenesis after focal ischemic and
traumatic brain injury. Neurobiology of Disease, 37(2), 267-274.
doi:10.1016/j.nbd.2009.11.002 [doi]
Kettenmann, H., Kirchhoff, F., & Verkhratsky, A. (2013). Microglia: New roles for the synaptic
stripper. Neuron, 77(1), 10-18. doi:10.1016/j.neuron.2012.12.023 [doi]
Kim, H. J., Fillmore, H. L., Reeves, T. M., & Phillips, L. L. (2005). Elevation of
hippocampal MMP-3 expression and activity during trauma-induced synaptogenesis.
Experimental Neurology, 192(1), 60-72. doi:S0014-4886(04)00424-8 [pii]
Kim, I. J., Beck, H. N., Lein, P. J., & Higgins, D. (2002). Interferon gamma induces
retrograde dendritic retraction and inhibits synapse formation. The Journal of Neuroscience :
The Official Journal of the Society for Neuroscience, 22(11), 4530-4539. doi:20026431 [doi]
Kim, J. M., Lee, K. H., Jeon, Y. J., Oh, J. H., Jeong, S. Y., Song, I. S., . . . Kim, N. S.
(2006). Identification of genes related to parkinson's disease using expressed sequence tags.
DNA Research : An International Journal for Rapid Publication of Reports on Genes and
Genomes, 13(6), 275-286. doi:dsl016 [pii]
Kim, M. D., Cho, H. J., & Shin, T. (2004). Expression of osteopontin and its ligand, CD44, in
the spinal cords of lewis rats with experimental autoimmune encephalomyelitis. Journal of
Neuroimmunology, 151(1-2), 78-84. doi:10.1016/j.jneuroim.2004.02.014 [doi]
Kishi, K. (1987). Golgi studies on the development of granule cells of the rat olfactory bulb
with reference to migration in the subependymal layer. The Journal of Comparative Neurology,
258(1), 112-124. doi:10.1002/cne.902580109
Kitagawa, K., Matsumoto, M., Sobue, K., Tagaya, M., Okabe, T., Niinobe, M., . . . Mikoshiba,
K. (1992). The Synapsin-I brain distribution in ischemia. Neuroscience, 46(2), 287-299.
Knapek, S., Gerber, B., & Tanimoto, H. (2010). Synapsin-Is selectively required for anesthesiasensitive memory. Learning & Memory (Cold Spring Harbor, N.Y.), 17(2), 76-79.
doi:10.1101/lm.1661810 [doi]
Knoblach, S. M., & Faden, A. I. (1998). Interleukin-10 improves outcome and alters
proinflammatory cytokine expression after experimental traumatic brain injury. Experimental
Neurology, 153(1), 143-151. doi:S0014-4886(98)96877-7 [pii]
Knyihar-Csillik, E., Csillik, B., & Oestreicher, A. B. (1992). Light and electron microscopic
localization of B-50 (GAP43) in the rat spinal cord during transganglionic degenerative atrophy
and regeneration. Journal of Neuroscience Research, 32(1), 93-109. doi:10.1002/jnr.490320112
[doi]

321

Kobal, G., Hummel, T., Sekinger, B., Barz, S., Roscher, S., & Wolf, S. (1996). "Sniffin' sticks":
Screening of olfactory performance. Rhinology, 34(4), 222-226.
Kobayashi, M., & Costanzo, R. M. (2009). Olfactory nerve recovery following mild and severe
injury and the efficacy of dexamethasone treatment. Chemical Senses, 34(7), 573-580.
doi:10.1093/chemse/bjp038; 10.1093/chemse/bjp038
Kobayashi, M., Tamari, K., Miyamura, T., & Takeuchi, K. (2013). Blockade of interleukin-6
receptor suppresses inflammatory reaction and facilitates functional recovery following olfactory
system injury. Neuroscience Research, 76(3), 125-132. doi:10.1016/j.neures.2013.03.015 [doi]
Kochlamazashvili, G., Henneberger, C., Bukalo, O., Dvoretskova, E., Senkov, O., Lievens, P.
M., . . . Dityatev, A. (2010). The extracellular matrix molecule hyaluronic acid regulates
hippocampal synaptic plasticity by modulating post-synaptic L-type ca(2+) channels. Neuron,
67(1), 116-128. doi:10.1016/j.neuron.2010.05.030 [doi]
Koh, A., da Silva, A. P., Bansal, A. K., Bansal, M., Sun, C., Lee, H., . . . Zohar, R. (2007).
Role of osteopontin in neutrophil function. Immunology, 122(4), 466-475. doi:IMM2682 [pii]
Konopacki, F. A., Rylski, M., Wilczek, E., Amborska, R., Detka, D., Kaczmarek, L., &
Wilczynski, G. M. (2007). Synaptic localization of seizure-induced matrix metalloproteinase-9
mRNA. Neuroscience, 150(1), 31-39. doi:S0306-4522(07)01055-X [pii]
Konopka, A., Grajkowska, W., Ziemianska, K., Roszkowski, M., Daszkiewicz, P., Rysz, A., . . .
Dzwonek, J. (2013). Matrix metalloproteinase-9 (MMP-9) in human intractable epilepsy caused
by focal cortical dysplasia. Epilepsy Research, 104(1-2), 45-58.
doi:10.1016/j.eplepsyres.2012.09.018 [doi]
Kosaka, K., Aika, Y., Toida, K., Heizmann, C. W., Hunziker, W., Jacobowitz, D. M., . . .
Kosaka, T. (1995). Chemically defined neuron groups and their subpopulations in the
glomerular layer of the rat main olfactory bulb. Neuroscience Research, 23(1), 73-88.
Kosaka, K., Aika, Y., Toida, K., & Kosaka, T. (2001). Structure of intraglomerular dendritic
tufts of mitral cells and their contacts with olfactory nerve terminals and calbindinimmunoreactive type 2 periglomerular neurons. The Journal of Comparative Neurology, 440(3),
219-235. doi:10.1002/cne.1381
Kosaka, K., Toida, K., Aika, Y., & Kosaka, T. (1998). How simple is the organization of the
olfactory glomerulus?: The heterogeneity of so-called periglomerular cells. Neuroscience
Research, 30(2), 101-110.
Koster, N. L., & Costanzo, R. M. (1996). Electrophysiological characterization of the
olfactory bulb during recovery from sensory deafferentation. Brain Research, 724(1), 117-120.
doi:0006-8993(96)00281-8 [pii]
Kotapka, M. J., Graham, D. I., Adams, J. H., Doyle, D., & Gennarelli, T. A. (1993).
Hippocampal damage in fatal paediatric head injury. Neuropathology and Applied
Neurobiology, 19(2), 128-133.
322

Kremlev, S. G., & Palmer, C. (2005). Interleukin-10 inhibits endotoxin-induced proinflammatory cytokines in microglial cell cultures. Journal of Neuroimmunology, 162(1-2), 7180. doi:S0165-5728(05)00016-0 [pii]
Kumar, A., & Loane, D. J. (2012). Neuroinflammation after traumatic brain injury:
Opportunities for therapeutic intervention. Brain, Behavior, and Immunity, 26(8), 1191-1201.
doi:10.1016/j.bbi.2012.06.008 [doi]
Lafrenaye, A. D., Todani, M., Walker, S. A., & Povlishock, J. T. (2015). Microglia processes
associate with diffusely injured axons following mild traumatic brain injury in the micro pig.
Journal of Neuroinflammation, 12, 186-015-0405-6. doi:10.1186/s12974-015-0405-6 [doi]
Lai, C. F., Seshadri, V., Huang, K., Shao, J. S., Cai, J., Vattikuti, R., . . . Towler, D. A.
(2006). An osteopontin-NADPH oxidase signaling cascade promotes pro-matrix
metalloproteinase 9 activation in aortic mesenchymal cells. Circulation Research, 98(12), 14791489. doi:01.RES.0000227550.00426.60 [pii]
Lander, C., Zhang, H., & Hockfield, S. (1998). Neurons produce a neuronal cell surfaceassociated chondroitin sulfate proteoglycan. The Journal of Neuroscience : The Official Journal
of the Society for Neuroscience, 18(1), 174-183.
Langlois, J. A., Rutland-Brown, W., & Wald, M. M. (2006). The epidemiology and impact of
traumatic brain injury: A brief overview. The Journal of Head Trauma Rehabilitation, 21(5),
375-378. doi:00001199-200609000-00001 [pii]
Latchney, S. E., Masiulis, I., Zaccaria, K. J., Lagace, D. C., Powell, C. M., McCasland, J. S.,
& Eisch, A. J. (2014). Developmental and adult GAP-43 deficiency in mice dynamically alters
hippocampal neurogenesis and mossy fiber volume. Developmental Neuroscience, 36(1), 44-63.
doi:10.1159/000357840 [doi]
Latefi, N. S., Pedraza, L., Schohl, A., Li, Z., & Ruthazer, E. S. (2009). N-cadherin prodomain
cleavage regulates synapse formation in vivo. Developmental Neurobiology, 69(8), 518-529.
doi:10.1002/dneu.20718 [doi]
Lathia, J. D., Chigurupati, S., Thundyil, J., Selvaraj, P. K., Mughal, M. R., Woodruff, T. M., .
. . Arumugam, T. V. (2010). Pivotal role for beta-1 integrin in neurovascular remodelling
after ischemic stroke. Experimental Neurology, 221(1), 107-114.
doi:10.1016/j.expneurol.2009.10.007 [doi]
Lazarini, F., Gabellec, M. M., Torquet, N., & Lledo, P. M. (2012). Early activation of
microglia triggers long-lasting impairment of adult neurogenesis in the olfactory bulb. The
Journal of Neuroscience : The Official Journal of the Society for Neuroscience, 32(11), 36523664. doi:10.1523/JNEUROSCI.6394-11.2012; 10.1523/JNEUROSCI.6394-11.2012
Lazarini, F., & Lledo, P. M. (2011). Is adult neurogenesis essential for olfaction? Trends in
Neurosciences, 34(1), 20-30. doi:10.1016/j.tins.2010.09.006; 10.1016/j.tins.2010.09.006

323

Lee, A. C., He, J., & Ma, M. (2011). Olfactory marker protein is critical for functional
maturation of olfactory sensory neurons and development of mother preference. The Journal of
Neuroscience : The Official Journal of the Society for Neuroscience, 31(8), 2974-2982.
doi:10.1523/JNEUROSCI.5067-10.2011 [doi]
Lee, S. R., Tsuji, K., Lee, S. R., & Lo, E. H. (2004). Role of matrix metalloproteinases in
delayed neuronal damage after transient global cerebral ischemia. The Journal of Neuroscience :
The Official Journal of the Society for Neuroscience, 24(3), 671-678.
doi:10.1523/JNEUROSCI.4243-03.2004 [doi]
Lefcort, F., Venstrom, K., McDonald, J. A., & Reichardt, L. F. (1992). Regulation of
expression of fibronectin and its receptor, alpha 5 beta 1, during development and regeneration
of peripheral nerve. Development (Cambridge, England), 116(3), 767-782.
Leir, S. H., Holgate, S. T., & Lackie, P. M. (2003). Inflammatory cytokines can enhance CD44mediated airway epithelial cell adhesion independently of CD44 expression. American Journal
of Physiology.Lung Cellular and Molecular Physiology, 285(6), L1305-11.
doi:10.1152/ajplung.00255.2002 [doi]
Lenzlinger, P. M., Morganti-Kossmann, M. C., Laurer, H. L., & McIntosh, T. K. (2001). The
duality of the inflammatory response to traumatic brain injury. Molecular Neurobiology, 24(13), 169-181. doi:MN:24:1-3:169 [pii]
Letourneau, P. C. (2009). Actin in axons: Stable scaffolds and dynamic filaments. Results and
Problems in Cell Differentiation, 48, 65-90. doi:10.1007/400_2009_15 [doi]
Levin, H. S. (1995). Prediction of recovery from traumatic brain injury. Journal of
Neurotrauma, 12(5), 913-922. doi:10.1089/neu.1995.12.913 [doi]
Lewen, A., Matz, P., & Chan, P. H. (2000). Free radical pathways in CNS injury. Journal of
Neurotrauma, 17(10), 871-890.
Liaw, L., Birk, D. E., Ballas, C. B., Whitsitt, J. S., Davidson, J. M., & Hogan, B. L. (1998).
Altered wound healing in mice lacking a functional osteopontin gene (spp1). The Journal of
Clinical Investigation, 101(7), 1468-1478. doi:10.1172/JCI2131 [doi]
Liaw, L., Skinner, M. P., Raines, E. W., Ross, R., Cheresh, D. A., Schwartz, S. M., &
Giachelli, C. M. (1995). The adhesive and migratory effects of osteopontin are mediated via
distinct cell surface integrins. role of alpha v beta 3 in smooth muscle cell migration to
osteopontin in vitro. The Journal of Clinical Investigation, 95(2), 713-724.
doi:10.1172/JCI117718 [doi]
Lima, L. L., Goncalves, P. F., Sallum, E. A., Casati, M. Z., & Nociti, F. H.,Jr. (2008).
Guided tissue regeneration may modulate gene expression in periodontal intrabony defects: A
human study. Journal of Periodontal Research, 43(4), 459-464. doi:10.1111/j.16000765.2008.01094.x [doi]

324

Lindsey, M. L., Zouein, F. A., Tian, Y., Padmanabhan Iyer, R., & de Castro Bras, L. E.
(2015). Osteopontin is proteolytically processed by matrix metalloproteinase 9. Canadian
Journal of Physiology and Pharmacology, 93(10), 879-886. doi:10.1139/cjpp-2015-0019 [doi]
Linster, C., & Cleland, T. A. (2002). Cholinergic modulation of sensory representations in the
olfactory bulb. Neural Networks : The Official Journal of the International Neural Network
Society, 15(4-6), 709-717.
Liou, A. K., Clark, R. S., Henshall, D. C., Yin, X. M., & Chen, J. (2003). To die or not to die
for neurons in ischemia, traumatic brain injury and epilepsy: A review on the stress-activated
signaling pathways and apoptotic pathways. Progress in Neurobiology, 69(2), 103-142.
doi:S0301008203000054 [pii]
Liu, H., Chen, A., Guo, F., & Yuan, L. (2010). A short-hairpin RNA targeting osteopontin
downregulates MMP-2 and MMP-9 expressions in prostate cancer PC-3 cells. Cancer Letters,
295(1), 27-37. doi:10.1016/j.canlet.2010.02.012 [doi]
Liu, J., Liu, Q., Wan, Y., Zhao, Z., Yu, H., Luo, H., & Tang, Z. (2014). Osteopontin promotes
the progression of gastric cancer through the NF-kappaB pathway regulated by the MAPK and
PI3K. International Journal of Oncology, 45(1), 282-290. doi:10.3892/ijo.2014.2393 [doi]
Liu, Y., Que, H., Ma, Z., Yang, S., Ni, Y., Luo, Z., . . . Liu, S. (2013). Transcription factor
SCIRR69 involved in the activation of brain-derived neurotrophic factor gene promoter II in
mechanically injured neurons. Neuromolecular Medicine, 15(3), 605-622. doi:10.1007/s12017013-8245-y [doi]
Liu, Z., Fan, Y., Won, S. J., Neumann, M., Hu, D., Zhou, L., . . . Liu, J. (2007). Chronic
treatment with minocycline preserves adult new neurons and reduces functional impairment after
focal cerebral ischemia. Stroke; a Journal of Cerebral Circulation, 38(1), 146-152.
doi:01.STR.0000251791.64910.cd [pii]
Liuzzi, F. J., & Lasek, R. J. (1987). Astrocytes block axonal regeneration in mammals by
activating the physiological stop pathway. Science (New York, N.Y.), 237(4815), 642-645.
Lledo, P. M., Alonso, M., & Grubb, M. S. (2006). Adult neurogenesis and functional plasticity
in neuronal circuits. Nature Reviews.Neuroscience, 7(3), 179-193. doi:10.1038/nrn1867
Lo, E. H., Wang, X., & Cuzner, M. L. (2002). Extracellular proteolysis in brain injury and
inflammation: Role for plasminogen activators and matrix metalloproteinases. Journal of
Neuroscience Research, 69(1), 1-9. doi:10.1002/jnr.10270 [doi]
Loane, D. J., & Faden, A. I. (2010). Neuroprotection for traumatic brain injury: Translational
challenges and emerging therapeutic strategies. Trends in Pharmacological Sciences, 31(12),
596-604. doi:10.1016/j.tips.2010.09.005 [doi]
Loane, D. J., Kumar, A., Stoica, B. A., Cabatbat, R., & Faden, A. I. (2014). Progressive
neurodegeneration after experimental brain trauma: Association with chronic microglial

325

activation. Journal of Neuropathology and Experimental Neurology, 73(1), 14-29.
doi:10.1097/NEN.0000000000000021 [doi]
Loane, D. J., Stoica, B. A., Byrnes, K. R., Jeong, W., & Faden, A. I. (2013). Activation of
mGluR5 and inhibition of NADPH oxidase improves functional recovery after traumatic brain
injury. Journal of Neurotrauma, 30(5), 403-412. doi:10.1089/neu.2012.2589 [doi]
Loh, K. P., Huang, S. H., De Silva, R., Tan, B. K., & Zhu, Y. Z. (2006). Oxidative stress:
Apoptosis in neuronal injury. Current Alzheimer Research, 3(4), 327-337.
Long, P., Samnakay, P., Jenner, P., & Rose, S. (2012). A yeast two-hybrid screen reveals that
osteopontin associates with MAP1A and MAP1B in addition to other proteins linked to
microtubule stability, apoptosis and protein degradation in the human brain. The European
Journal of Neuroscience, 36(6), 2733-2742. doi:10.1111/j.1460-9568.2012.08189.x [doi]
Lotocki, G., de Rivero Vaccari, J. P., Perez, E. R., Sanchez-Molano, J., Furones-Alonso, O.,
Bramlett, H. M., & Dietrich, W. D. (2009). Alterations in blood-brain barrier permeability to
large and small molecules and leukocyte accumulation after traumatic brain injury: Effects of
post-traumatic hypothermia. Journal of Neurotrauma, 26(7), 1123-1134.
doi:10.1089/neu.2008.0802 [doi]
Lozano, D., Gonzales-Portillo, G. S., Acosta, S., de la Pena, I., Tajiri, N., Kaneko, Y., &
Borlongan, C. V. (2015). Neuroinflammatory responses to traumatic brain injury: Etiology,
clinical consequences, and therapeutic opportunities. Neuropsychiatric Disease and Treatment,
11, 97-106. doi:10.2147/NDT.S65815 [doi]
Lu, D. Y., Yeh, W. L., Huang, S. M., Tang, C. H., Lin, H. Y., & Chou, S. J. (2012).
Osteopontin increases heme oxygenase-1 expression and subsequently induces cell migration
and invasion in glioma cells. Neuro-Oncology, 14(11), 1367-1378. doi:10.1093/neuonc/nos262
[doi]
Luo, J. (2005). The role of matrix metalloproteinases in the morphogenesis of the cerebellar
cortex. Cerebellum (London, England), 4(4), 239-245. doi:N51454277XV16745 [pii]
Luskin, M. B. (1993). Restricted proliferation and migration of postnatally generated neurons
derived from the forebrain subventricular zone. Neuron, 11(1), 173-189.
Luxenhofer, G., Breer, H., & Strotmann, J. (2008). Differential reaction of outgrowing
olfactory neurites monitored in explant culture. The Journal of Comparative Neurology, 509(6),
580-593. doi:10.1002/cne.21766; 10.1002/cne.21766
Lyeth, B. G., Dixon, C. E., Hamm, R. J., Jenkins, L. W., Young, H. F., Stonnington, H. H., &
Hayes, R. L. (1988). Effects of anticholinergic treatment on transient behavioral suppression
and physiological responses following concussive brain injury to the rat. Brain Research,
448(1), 88-97. doi:0006-8993(88)91104-3 [pii]

326

Lyeth, B. G., Ray, M., Hamm, R. J., Schnabel, J., Saady, J. J., Poklis, A., . . . Hayes, R. L.
(1992). Postinjury scopolamine administration in experimental traumatic brain injury. Brain
Research, 569(2), 281-286. doi:0006-8993(92)90640-U [pii]
Lynch, G., Gall, C., Rose, G., & Cotman, C. (1976). Changes in the distribution of the dentate
gyrus associational system following unilateral or bilateral entorhinal lesions in the adult rat.
Brain Research, 110(1), 57-71. doi:0006-8993(76)90208-0 [pii]
Ma, D., Connors, T., Nothias, F., & Fischer, I. (2000). Regulation of the expression and
phosphorylation of microtubule-associated protein 1B during regeneration of adult dorsal root
ganglion neurons. Neuroscience, 99(1), 157-170. doi:S0306-4522(00)00141-X [pii]
Ma, J., Dankulich-Nagrudny, L., & Lowe, G. (2013). Cholecystokinin: An excitatory modulator
of mitral/tufted cells in the mouse olfactory bulb. PloS One, 8(5), e64170.
doi:10.1371/journal.pone.0064170 [doi]
Maas, A. I., Steyerberg, E. W., Butcher, I., Dammers, R., Lu, J., Marmarou, A., . . . Murray,
G. D. (2007). Prognostic value of computerized tomography scan characteristics in traumatic
brain injury: Results from the IMPACT study. Journal of Neurotrauma, 24(2), 303-314.
doi:10.1089/neu.2006.0033 [doi]
Madinier, A., Bertrand, N., Mossiat, C., Prigent-Tessier, A., Beley, A., Marie, C., & Garnier, P.
(2009). Microglial involvement in neuroplastic changes following focal brain ischemia in rats.
PloS One, 4(12), e8101. doi:10.1371/journal.pone.0008101 [doi]
Maeda, K., Takahashi, K., Takahashi, F., Tamura, N., Maeda, M., Kon, S., . . . Fukuchi, Y.
(2001). Distinct roles of osteopontin fragments in the development of the pulmonary
involvement in sarcoidosis. Lung, 179(5), 279-291. doi:10.1007/s004080000068 [doi]
Maetzler, W., Berg, D., Schalamberidze, N., Melms, A., Schott, K., Mueller, J. C., . . . Nitsch,
C. (2007). Osteopontin is elevated in parkinson's disease and its absence leads to reduced
neurodegeneration in the MPTP model. Neurobiology of Disease, 25(3), 473-482. doi:S09699961(06)00282-8 [pii]
Mahmood, A., Wu, H., Qu, C., Mahmood, S., Xiong, Y., Kaplan, D. L., & Chopp, M. (2014).
Suppression of neurocan and enhancement of axonal density in rats after treatment of traumatic
brain injury with scaffolds impregnated with bone marrow stromal cells. Journal of
Neurosurgery, 120(5), 1147-1155. doi:10.3171/2013.12.JNS131362 [doi]
Malnic, B., Hirono, J., Sato, T., & Buck, L. B. (1999). Combinatorial receptor codes for odors.
Cell, 96(5), 713-723.
Marcoli, M., Agnati, L. F., Benedetti, F., Genedani, S., Guidolin, D., Ferraro, L., . . . Fuxe, K.
(2015). On the role of the extracellular space on the holistic behavior of the brain. Reviews in
the Neurosciences, 26(5), 489-506. doi:10.1515/revneuro-2015-0007 [doi]

327

Margolis, F. L., Verhaagen, J., Biffo, S., Huang, F. L., & Grillo, M. (1991). Regulation of
gene expression in the olfactory neuroepithelium: A neurogenetic matrix. Progress in Brain
Research, 89, 97-122.
Marmarou, C. R., & Povlishock, J. T. (2006). Administration of the immunophilin ligand
FK506 differentially attenuates neurofilament compaction and impaired axonal transport in
injured axons following diffuse traumatic brain injury. Experimental Neurology, 197(2), 353362. doi:S0014-4886(05)00357-2 [pii]
Matsumoto-Miyai, K., Sokolowska, E., Zurlinden, A., Gee, C. E., Luscher, D., Hettwer, S., . . .
Sonderegger, P. (2009). Coincident pre- and post-synaptic activation induces dendritic filopodia
via neurotrypsin-dependent agrin cleavage. Cell, 136(6), 1161-1171.
doi:10.1016/j.cell.2009.02.034 [doi]
Matsuura, M., Suzuki, T., Suzuki, M., Tanaka, R., Ito, E., & Saito, T. (2011). Statin-mediated
reduction of osteopontin expression induces apoptosis and cell growth arrest in ovarian clear cell
carcinoma. Oncology Reports, 25(1), 41-47.
Matthews, M. A., St Onge, M. F., Faciane, C. L., & Gelderd, J. B. (1979). Axon sprouting
into segments of rat spinal cord adjacent to the site of a previous transection. Neuropathology
and Applied Neurobiology, 5(3), 181-196.
Matthews, M. A., St Onge, M. F., Faciane, C. L., & Gelderd, J. B. (1979). Spinal cord
transection: A quantitative analysis of elements of the connective tissue matrix formed within the
site of lesion following administration of piromen, cytoxan or trypsin. Neuropathology and
Applied Neurobiology, 5(3), 161-180.
Maxwell, W. L. (2015). Development of concepts in the pathology of traumatic axonal and
traumatic brain injury. In F. H. Kobeissy (Ed.), Brain neurotrauma: Molecular,
neuropsychological, and rehabilitation aspects (). Boca Raton (FL): by Taylor & Francis Group,
LLC. doi:NBK299201 [bookaccession]
Maxwell, W. L., Watt, C., Graham, D. I., & Gennarelli, T. A. (1993). Ultrastructural evidence
of axonal shearing as a result of lateral acceleration of the head in non-human primates. Acta
Neuropathologica, 86(2), 136-144.
McAllister, A. K., Lo, D. C., & Katz, L. C. (1995). Neurotrophins regulate dendritic growth
in developing visual cortex. Neuron, 15(4), 791-803. doi:0896-6273(95)90171-X [pii]
McKee, A. C., Cantu, R. C., Nowinski, C. J., Hedley-Whyte, E. T., Gavett, B. E., Budson, A.
E., . . . Stern, R. A. (2009). Chronic traumatic encephalopathy in athletes: Progressive
tauopathy after repetitive head injury. Journal of Neuropathology and Experimental Neurology,
68(7), 709-735. doi:10.1097/NEN.0b013e3181a9d503 [doi]
Medrihan, L., Cesca, F., Raimondi, A., Lignani, G., Baldelli, P., & Benfenati, F. (2013).
Synapsin-II desynchronizes neurotransmitter release at inhibitory synapses by interacting with
pre-synaptic calcium channels. Nature Communications, 4, 1512. doi:10.1038/ncomms2515
[doi]
328

Medrihan, L., Ferrea, E., Greco, B., Baldelli, P., & Benfenati, F. (2015). Asynchronous GABA
release is a key determinant of tonic inhibition and controls neuronal excitability: A study in the
Synapsin-II-/- mouse. Cerebral Cortex (New York, N.Y.: 1991), 25(10), 3356-3368.
doi:10.1093/cercor/bhu141 [doi]
Meerovitch, K., Bergeron, F., Leblond, L., Grouix, B., Poirier, C., Bubenik, M., . . . Attardo, G.
(2003). A novel RGD antagonist that targets both alphavbeta3 and alpha5beta1 induces
apoptosis of angiogenic endothelial cells on type I collagen. Vascular Pharmacology, 40(2), 7789. doi:S1537189102003397 [pii]
Meller, R., Stevens, S. L., Minami, M., Cameron, J. A., King, S., Rosenzweig, H., . . .
Stenzel-Poore, M. P. (2005). Neuroprotection by osteopontin in stroke. Journal of Cerebral
Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood
Flow and Metabolism, 25(2), 217-225. doi:9600022 [pii]
Melloni, R. H.,Jr, Hemmendinger, L. M., Hamos, J. E., & DeGennaro, L. J. (1993).
Synapsin-I gene expression in the adult rat brain with comparative analysis of mRNA and
protein in the hippocampus. The Journal of Comparative Neurology, 327(4), 507-520.
doi:10.1002/cne.903270404 [doi]
Menco, B. P., Bruch, R. C., Dau, B., & Danho, W. (1992). Ultrastructural localization of
olfactory transduction components: The G protein subunit golf alpha and type III adenylyl
cyclase. Neuron, 8(3), 441-453.
Mendelow, A. D., & Teasdale, G. M. (1983). Pathophysiology of head injuries. The British
Journal of Surgery, 70(11), 641-650.
Menet, V., Prieto, M., Privat, A., & Gimenez y Ribotta, M. (2003). Axonal plasticity and
functional recovery after spinal cord injury in mice deficient in both glial fibrillary acidic protein
and vimentin genes. Proceedings of the National Academy of Sciences of the United States of
America, 100(15), 8999-9004. doi:10.1073/pnas.1533187100 [doi]
Mi, T., Nie, B., Zhang, C., & Zhou, H. (2011). The elevated expression of osteopontin and NFkappaB in human aortic aneurysms and its implication. Journal of Huazhong University of
Science and Technology.Medical Sciences = Hua Zhong Ke Ji Da Xue Xue Bao.Yi Xue Ying De
Wen Ban = Huazhong Keji Daxue Xuebao.Yixue Yingdewen Ban, 31(5), 602-607.
doi:10.1007/s11596-011-0568-z [doi]
Michaluk, P., Mikasova, L., Groc, L., Frischknecht, R., Choquet, D., & Kaczmarek, L. (2009).
Matrix metalloproteinase-9 controls NMDA receptor surface diffusion through integrin beta1
signaling. The Journal of Neuroscience : The Official Journal of the Society for Neuroscience,
29(18), 6007-6012. doi:10.1523/JNEUROSCI.5346-08.2009 [doi]
Mierzwa, A. J., Marion, C. M., Sullivan, G. M., McDaniel, D. P., & Armstrong, R. C. (2015).
Components of myelin damage and repair in the progression of white matter pathology after mild
traumatic brain injury. Journal of Neuropathology and Experimental Neurology, 74(3), 218-232.
doi:10.1097/NEN.0000000000000165 [doi]

329

Miller, J. D., Becker, D. P., Ward, J. D., Sullivan, H. G., Adams, W. E., & Rosner, M. J.
(1977). Significance of intracranial hypertension in severe head injury. Journal of
Neurosurgery, 47(4), 503-516. doi:10.3171/jns.1977.47.4.0503 [doi]
Miller, L. P., Lyeth, B. G., Jenkins, L. W., Oleniak, L., Panchision, D., Hamm, R. J., . . .
Hayes, R. L. (1990). Excitatory amino acid receptor subtype binding following traumatic brain
injury. Brain Research, 526(1), 103-107. doi:0006-8993(90)90254-9 [pii]
Milner, R., Relvas, J. B., Fawcett, J., & ffrench-Constant, C. (2001). Developmental regulation
of alphav integrins produces functional changes in astrocyte behavior. Molecular and Cellular
Neurosciences, 18(1), 108-118. doi:10.1006/mcne.2001.1003 [doi]
Miyamoto, A., Wake, H., Moorhouse, A. J., & Nabekura, J. (2013). Microglia and synapse
interactions: Fine tuning neural circuits and candidate molecules. Frontiers in Cellular
Neuroscience, 7, 70. doi:10.3389/fncel.2013.00070; 10.3389/fncel.2013.00070
Miyazaki, K., Okada, Y., Yamanaka, O., Kitano, A., Ikeda, K., Kon, S., . . . Saika, S. (2008).
Corneal wound healing in an osteopontin-deficient mouse. Investigative Ophthalmology &
Visual Science, 49(4), 1367-1375. doi:10.1167/iovs.07-1007 [doi]
Mizoguchi, H., Nakade, J., Tachibana, M., Ibi, D., Someya, E., Koike, H., . . . Yamada, K.
(2011). Matrix metalloproteinase-9 contributes to kindled seizure development in
pentylenetetrazole-treated mice by converting pro-BDNF to mature BDNF in the hippocampus.
The Journal of Neuroscience : The Official Journal of the Society for Neuroscience, 31(36),
12963-12971. doi:10.1523/JNEUROSCI.3118-11.2011 [doi]
Mizuguchi, R., Naritsuka, H., Mori, K., Mao, C. A., Klein, W. H., & Yoshihara, Y. (2012).
Tbr2 deficiency in mitral and tufted cells disrupts excitatory-inhibitory balance of neural
circuitry in the mouse olfactory bulb. The Journal of Neuroscience : The Official Journal of the
Society for Neuroscience, 32(26), 8831-8844. doi:10.1523/JNEUROSCI.5746-11.2012 [doi]
Moller, J. C., Klein, M. A., Haas, S., Jones, L. L., Kreutzberg, G. W., & Raivich, G. (1996).
Regulation of thrombospondin in the regenerating mouse facial motor nucleus. Glia, 17(2), 121132. doi:10.1002/(SICI)1098-1136(199606)17:2<121::AID-GLIA4>3.0.CO;2-5 [pii]
Monea, S., Jordan, B. A., Srivastava, S., DeSouza, S., & Ziff, E. B. (2006). Membrane
localization of membrane type 5 matrix metalloproteinase by AMPA receptor binding protein
and cleavage of cadherins. The Journal of Neuroscience : The Official Journal of the Society for
Neuroscience, 26(8), 2300-2312. doi:26/8/2300 [pii]
Montaner, J., Alvarez-Sabin, J., Molina, C., Angles, A., Abilleira, S., Arenillas, J., . . .
Monasterio, J. (2001). Matrix metalloproteinase expression after human cardioembolic stroke:
Temporal profile and relation to neurological impairment. Stroke; a Journal of Cerebral
Circulation, 32(8), 1759-1766.
Monti-Graziadei, G. A., Margolis, F. L., Harding, J. W., & Graziadei, P. P. (1977).
Immunocytochemistry of the olfactory marker protein. The Journal of Histochemistry and
Cytochemistry : Official Journal of the Histochemistry Society, 25(12), 1311-1316.
330

Moran, L. B., & Graeber, M. B. (2004). The facial nerve axotomy model. Brain
Research.Brain Research Reviews, 44(2-3), 154-178. doi:10.1016/j.brainresrev.2003.11.004
[doi]
Morrison, E. E., & Costanzo, R. M. (1992). Morphology of olfactory epithelium in humans
and other vertebrates. Microscopy Research and Technique, 23(1), 49-61.
doi:10.1002/jemt.1070230105
Morrison, E. E., & Costanzo, R. M. (1995). Regeneration of olfactory sensory neurons and
reconnection in the aging hamster central nervous system. Neuroscience Letters, 198(3), 213217.
Mortimer, J. A., French, L. R., Hutton, J. T., & Schuman, L. M. (1985). Head injury as a risk
factor for alzheimer's disease. Neurology, 35(2), 264-267.
Moulton, D. G. (1974). Dynamics of cell populations in the olfactory epithelium. Annals of the
New York Academy of Sciences, 237(0), 52-61.
Mouzon, B. C., Bachmeier, C., Ferro, A., Ojo, J. O., Crynen, G., Acker, C. M., . . . Crawford,
F. (2014). Chronic neuropathological and neurobehavioral changes in a repetitive mild
traumatic brain injury model. Annals of Neurology, 75(2), 241-254. doi:10.1002/ana.24064
[doi]
Mueller, C. A., & Hummel, T. (2009). Recovery of olfactory function after nine years of posttraumatic anosmia: A case report. Journal of Medical Case Reports, 3, 9283-1947-3-9283.
doi:10.4076/1752-1947-3-9283; 10.4076/1752-1947-3-9283
Muir, E. M., Adcock, K. H., Morgenstern, D. A., Clayton, R., von Stillfried, N., Rhodes, K., . .
. Rogers, J. H. (2002). Matrix metalloproteases and their inhibitors are produced by
overlapping populations of activated astrocytes. Brain Research.Molecular Brain Research,
100(1-2), 103-117. doi:S0169328X02001328 [pii]
Muller, H. D., Hanumanthiah, K. M., Diederich, K., Schwab, S., Schabitz, W. R., & Sommer,
C. (2008). Brain-derived neurotrophic factor but not forced arm use improves long-term
outcome after photothrombotic stroke and transiently upregulates binding densities of excitatory
glutamate receptors in the rat brain. Stroke; a Journal of Cerebral Circulation, 39(3), 10121021. doi:10.1161/STROKEAHA.107.495069 [doi]
Murabe, Y., & Sano, Y. (1982). Morphological studies on neuroglia. V. microglial cells in the
cerebral cortex of the rat, with special reference to their possible involvement in synaptic
function. Cell and Tissue Research, 223(3), 493-506.
Muradashvili, N., Benton, R. L., Saatman, K. E., Tyagi, S. C., & Lominadze, D. (2015).
Ablation of matrix metalloproteinase-9 gene decreases cerebrovascular permeability and
fibrinogen deposition post traumatic brain injury in mice. Metabolic Brain Disease, 30(2), 411426. doi:10.1007/s11011-014-9550-3 [doi]

331

Muradashvili, N., Tyagi, N., Tyagi, R., Munjal, C., & Lominadze, D. (2011). Fibrinogen alters
mouse brain endothelial cell layer integrity affecting vascular endothelial cadherin. Biochemical
and Biophysical Research Communications, 413(4), 509-514. doi:10.1016/j.bbrc.2011.07.133
[doi]
Mutinati, M., Pantaleo, M., Roncetti, M., Piccinno, M., Rizzo, A., & Sciorsci, R. L. (2014).
Oxidative stress in neonatology: A review. Reproduction in Domestic Animals = Zuchthygiene,
49(1), 7-16. doi:10.1111/rda.12230 [doi]
Myer, D. J., Gurkoff, G. G., Lee, S. M., Hovda, D. A., & Sofroniew, M. V. (2006). Essential
protective roles of reactive astrocytes in traumatic brain injury. Brain : A Journal of Neurology,
129(Pt 10), 2761-2772. doi:awl165 [pii]
Nagamoto-Combs, K., McNeal, D. W., Morecraft, R. J., & Combs, C. K. (2007). Prolonged
microgliosis in the rhesus monkey central nervous system after traumatic brain injury. Journal
of Neurotrauma, 24(11), 1719-1742. doi:10.1089/neu.2007.0377 [doi]
Nagase, H., Visse, R., & Murphy, G. (2006). Structure and function of matrix
metalloproteinases and TIMPs. Cardiovascular Research, 69(3), 562-573. doi:S00086363(05)00565-1 [pii]
Nagayama, S., Homma, R., & Imamura, F. (2014). Neuronal organization of olfactory bulb
circuits. Frontiers in Neural Circuits, 8, 98. doi:10.3389/fncir.2014.00098 [doi]
Nagy, V., Bozdagi, O., Matynia, A., Balcerzyk, M., Okulski, P., Dzwonek, J., . . . Huntley, G.
W. (2006). Matrix metalloproteinase-9 is required for hippocampal late-phase long-term
potentiation and memory. The Journal of Neuroscience : The Official Journal of the Society for
Neuroscience, 26(7), 1923-1934. doi:26/7/1923 [pii]
Nakase, T., Takaoka, K., Hirakawa, K., Hirota, S., Takemura, T., Onoue, H., . . . Nomura, S.
(1994). Alterations in the expression of osteonectin, osteopontin and osteocalcin mRNAs during
the development of skeletal tissues in vivo. Bone and Mineral, 26(2), 109-122.
Nathan, B. P., Nisar, R., Randall, S., Short, J., Sherrow, M., Wong, G. K., & Struble, R. G.
(2001). Apolipoprotein E is upregulated in olfactory bulb glia following peripheral receptor
lesion in mice. Experimental Neurology, 172(1), 128-136. doi:10.1006/exnr.2001.7762 [doi]
Negoias, S., Croy, I., Gerber, J., Puschmann, S., Petrowski, K., Joraschky, P., & Hummel, T.
(2010). Reduced olfactory bulb volume and olfactory sensitivity in patients with acute major
depression. Neuroscience, 169(1), 415-421. doi:10.1016/j.neuroscience.2010.05.012;
10.1016/j.neuroscience.2010.05.012
Nesher, E., Koman, I., Gross, M., Tikhonov, T., Bairachnaya, M., Salmon-Divon, M., . . .
Pinhasov, A. (2015). Synapsin-IIb as a functional marker of submissive behavior. Scientific
Reports, 5, 10287. doi:10.1038/srep10287 [doi]

332

Neumann, C., Garreis, F., Paulsen, F., Hammer, C. M., Birke, M. T., & Scholz, M. (2014).
Osteopontin is induced by TGF-beta2 and regulates metabolic cell activity in cultured human
optic nerve head astrocytes. PloS One, 9(4), e92762. doi:10.1371/journal.pone.0092762 [doi]
Newcomb, J. K., Kampfl, A., Posmantur, R. M., Zhao, X., Pike, B. R., Liu, S. J., . . . Hayes,
R. L. (1997). Immunohistochemical study of calpain-mediated breakdown products to alphaspectrin following controlled cortical impact injury in the rat. Journal of Neurotrauma, 14(6),
369-383. doi:10.1089/neu.1997.14.369 [doi]
Ng, S. Y., Semple, B. D., Morganti-Kossmann, M. C., & Bye, N. (2012). Attenuation of
microglial activation with minocycline is not associated with changes in neurogenesis after focal
traumatic brain injury in adult mice. Journal of Neurotrauma, 29(7), 1410-1425.
doi:10.1089/neu.2011.2188 [doi]
Nikonenko, I., Toni, N., Moosmayer, M., Shigeri, Y., Muller, D., & Sargent Jones, L. (2003).
Integrins are involved in synaptogenesis, cell spreading, and adhesion in the postnatal brain.
Brain Research.Developmental Brain Research, 140(2), 185-194. doi:S0165380602005904 [pii]
Noble, L. J., Donovan, F., Igarashi, T., Goussev, S., & Werb, Z. (2002). Matrix
metalloproteinases limit functional recovery after spinal cord injury by modulation of early
vascular events. The Journal of Neuroscience : The Official Journal of the Society for
Neuroscience, 22(17), 7526-7535. doi:22/17/7526 [pii]
Nomura, S., Wills, A. J., Edwards, D. R., Heath, J. K., & Hogan, B. L. (1989). Expression of
genes for non-collagenous proteins during embryonic bone formation. Connective Tissue
Research, 21(1-4), 31-5; discussion 36-9.
O'Brien, R. J., Xu, D., Petralia, R. S., Steward, O., Huganir, R. L., & Worley, P. (1999).
Synaptic clustering of AMPA receptors by the extracellular immediate-early gene product narp.
Neuron, 23(2), 309-323. doi:S0896-6273(00)80782-5 [pii]
Oda, Y., Gao, G., Wei, E. P., & Povlishock, J. T. (2011). Combinational therapy using
hypothermia and the immunophilin ligand FK506 to target altered pial arteriolar reactivity,
axonal damage, and blood-brain barrier dysfunction after traumatic brain injury in rat. Journal
of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of
Cerebral Blood Flow and Metabolism, 31(4), 1143-1154. doi:10.1038/jcbfm.2010.208 [doi]
Ogier, C., Bernard, A., Chollet, A. M., LE Diguardher, T., Hanessian, S., Charton, G., . . .
Rivera, S. (2006). Matrix metalloproteinase-2 (MMP-2) regulates astrocyte motility in
connection with the actin cytoskeleton and integrins. Glia, 54(4), 272-284.
doi:10.1002/glia.20349 [doi]
Oh, L. Y., Larsen, P. H., Krekoski, C. A., Edwards, D. R., Donovan, F., Werb, Z., & Yong, V.
W. (1999). Matrix metalloproteinase-9/gelatinase B is required for process outgrowth by
oligodendrocytes. The Journal of Neuroscience : The Official Journal of the Society for
Neuroscience, 19(19), 8464-8475.

333

Okada, Y., Nagase, H., & Harris, E. D.,Jr. (1987). Matrix metalloproteinases 1, 2, and 3 from
rheumatoid synovial cells are sufficient to destroy joints. The Journal of Rheumatology, 14 Spec
No, 41-42.
Okamoto, I., Kawano, Y., Murakami, D., Sasayama, T., Araki, N., Miki, T., . . . Saya, H.
(2001). Proteolytic release of CD44 intracellular domain and its role in the CD44 signaling
pathway. The Journal of Cell Biology, 155(5), 755-762. doi:10.1083/jcb.200108159 [doi]
Okere, C. O., & Kaba, H. (2000). Heterogenous immunohistochemical expression of
microglia-specific ionized calcium binding adaptor protein (Iba1) in the mouse olfactory bulb.
Brain Research, 877(1), 85-90.
Okuda, T., Yu, L. M., Cingolani, L. A., Kemler, R., & Goda, Y. (2007). Beta-catenin regulates
excitatory post-synaptic strength at hippocampal synapses. Proceedings of the National
Academy of Sciences of the United States of America, 104(33), 13479-13484. doi:0702334104
[pii]
Oldberg, A., Franzen, A., & Heinegard, D. (1986). Cloning and sequence analysis of rat bone
sialoprotein (osteopontin) cDNA reveals an arg-gly-asp cell-binding sequence. Proceedings of
the National Academy of Sciences of the United States of America, 83(23), 8819-8823.
Oldberg, A., Franzen, A., & Heinegard, D. (1988). The primary structure of a cell-binding bone
sialoprotein. The Journal of Biological Chemistry, 263(36), 19430-19432.
Oley, N., DeHan, R. S., Tucker, D., Smith, J. C., & Graziadei, P. P. (1975). Recovery of
structure and function following transection of the primary olfactory nerves in pigeons. Journal
of Comparative and Physiological Psychology, 88(2), 477-495.
Olson, M. W., Gervasi, D. C., Mobashery, S., & Fridman, R. (1997). Kinetic analysis of the
binding of human matrix metalloproteinase-2 and -9 to tissue inhibitor of metalloproteinase
(TIMP)-1 and TIMP-2. The Journal of Biological Chemistry, 272(47), 29975-29983.
O'Regan, A. (2003). The role of osteopontin in lung disease. Cytokine & Growth Factor
Reviews, 14(6), 479-488. doi:S1359610103000558 [pii]
O'Regan, A. W., Hayden, J. M., & Berman, J. S. (2000). Osteopontin augments CD3mediated interferon-gamma and CD40 ligand expression by T cells, which results in IL-12
production from peripheral blood mononuclear cells. Journal of Leukocyte Biology, 68(4), 495502.
O'Regan, A. W., Nau, G. J., Chupp, G. L., & Berman, J. S. (2000). Osteopontin (eta-1) in
cell-mediated immunity: Teaching an old dog new tricks. Immunology Today, 21(10), 475-478.
doi:S0167-5699(00)01715-1 [pii]
Orenbuch, A., Shalev, L., Marra, V., Sinai, I., Lavy, Y., Kahn, J., . . . Gitler, D. (2012).
Synapsin selectively controls the mobility of resting pool vesicles at hippocampal terminals. The
Journal of Neuroscience : The Official Journal of the Society for Neuroscience, 32(12), 39693980. doi:10.1523/JNEUROSCI.5058-11.2012 [doi]
334

Otto, V. I., Stahel, P. F., Rancan, M., Kariya, K., Shohami, E., Yatsiv, I., . . . MorgantiKossmann, M. C. (2001). Regulation of chemokines and chemokine receptors after
experimental closed head injury. Neuroreport, 12(9), 2059-2064.
Pagano, P. J., & Haurani, M. J. (2006). Vascular cell locomotion: Osteopontin, NADPH
oxidase, and matrix metalloproteinase-9. Circulation Research, 98(12), 1453-1455.
doi:98/12/1453 [pii]
Park, E., Liu, E., Shek, M., Park, A., & Baker, A. J. (2007). Heavy neurofilament accumulation
and alpha-spectrin degradation accompany cerebellar white matter functional deficits following
forebrain fluid percussion injury. Experimental Neurology, 204(1), 49-57. doi:S00144886(06)00551-6 [pii]
Park, H., & Poo, M. M. (2013). Neurotrophin regulation of neural circuit development and
function. Nature Reviews.Neuroscience, 14(1), 7-23. doi:10.1038/nrn3379 [doi]
Park, J. H., Min, J., Baek, S. R., Kim, S. W., Kwon, I. K., & Jeon, S. R. (2013). Enhanced
neuroregenerative effects by scaffold for the treatment of a rat spinal cord injury with Wnt3asecreting fibroblasts. Acta Neurochirurgica, 155(5), 809-816. doi:10.1007/s00701-013-1663-7
[doi]
Parrish-Aungst, S., Shipley, M. T., Erdelyi, F., Szabo, G., & Puche, A. C. (2007). Quantitative
analysis of neuronal diversity in the mouse olfactory bulb. The Journal of Comparative
Neurology, 501(6), 825-836. doi:10.1002/cne.21205
Pellman, E. J., Viano, D. C., & National Football League's Committee on Mild Traumatic Brain
Injury. (2006). Concussion in professional football: Summary of the research conducted by the
national football league's committee on mild traumatic brain injury. Neurosurgical Focus, 21(4),
E12. doi:210412 [pii]
Peng, H., Wu, Y., Duan, Z., Ciborowski, P., & Zheng, J. C. (2012). Proteolytic processing of
SDF-1alpha by matrix metalloproteinase-2 impairs CXCR4 signaling and reduces neural
progenitor cell migration. Protein & Cell, 3(11), 875-882. doi:10.1007/s13238-012-2092-8
[doi]
Penkowa, M., Giralt, M., Carrasco, J., Hadberg, H., & Hidalgo, J. (2000). Impaired
inflammatory response and increased oxidative stress and neurodegeneration after brain injury in
interleukin-6-deficient mice. Glia, 32(3), 271-285. doi:10.1002/10981136(200012)32:3<271::AID-GLIA70>3.0.CO;2-5 [pii]
Petreanu, L., & Alvarez-Buylla, A. (2002). Maturation and death of adult-born olfactory bulb
granule neurons: Role of olfaction. The Journal of Neuroscience : The Official Journal of the
Society for Neuroscience, 22(14), 6106-6113. doi:20026588 [doi]
Petrucci, T. C., & Morrow, J. S. (1987). Synapsin-I: An actin-bundling protein under
phosphorylation control. The Journal of Cell Biology, 105(3), 1355-1363.

335

Pettus, E. H., Christman, C. W., Giebel, M. L., & Povlishock, J. T. (1994). Traumatically
induced altered membrane permeability: Its relationship to traumatically induced reactive axonal
change. Journal of Neurotrauma, 11(5), 507-522. doi:10.1089/neu.1994.11.507 [doi]
Phillips, L. L., Chan, J. L., Doperalski, A. E., & Reeves, T. M. (2014). Time dependent
integration of matrix metalloproteinases and their targeted substrates directs axonal sprouting
and synaptogenesis following central nervous system injury. Neural Regeneration Research,
9(4), 362-376. doi:10.4103/1673-5374.128237 [doi]
Phillips, L. L., Lyeth, B. G., Hamm, R. J., & Povlishock, J. T. (1994). Combined fluid
percussion brain injury and entorhinal cortical lesion: A model for assessing the interaction
between neuroexcitation and deafferentation. Journal of Neurotrauma, 11(6), 641-656.
doi:10.1089/neu.1994.11.641 [doi]
Phillips, L. L., & Reeves, T. M. (2001). Interactive pathology following traumatic brain injury
modifies hippocampal plasticity. Restorative Neurology and Neuroscience, 19(3-4), 213-235.
Phillips, S., & Woessner, D. (2015). Sports-related traumatic brain injury. Primary Care,
42(2), 243-248. doi:10.1016/j.pop.2015.01.010 [doi]
Piani, D., Frei, K., Do, K. Q., Cuenod, M., & Fontana, A. (1991). Murine brain macrophages
induced NMDA receptor mediated neurotoxicity in vitro by secreting glutamate. Neuroscience
Letters, 133(2), 159-162.
Pike, B. R., Zhao, X., Newcomb, J. K., Posmantur, R. M., Wang, K. K., & Hayes, R. L.
(1998). Regional calpain and caspase-3 proteolysis of alpha-spectrin after traumatic brain injury.
Neuroreport, 9(11), 2437-2442.
Pinching, A. J., & Powell, T. P. (1971). The neuron types of the glomerular layer of the
olfactory bulb. Journal of Cell Science, 9(2), 305-345.
Pinching, A. J., & Powell, T. P. (1971). The neuropil of the glomeruli of the olfactory bulb.
Journal of Cell Science, 9(2), 347-377.
Pinching, A. J., & Powell, T. P. (1972). The termination of centrifugal fibres in the glomerular
layer of the olfactory bulb. Journal of Cell Science, 10(3), 621-635.
Pinkstaff, J. K., Detterich, J., Lynch, G., & Gall, C. (1999). Integrin subunit gene expression is
regionally differentiated in adult brain. The Journal of Neuroscience : The Official Journal of
the Society for Neuroscience, 19(5), 1541-1556.
Pinkstaff, J. K., Lynch, G., & Gall, C. M. (1998). Localization and seizure-regulation of
integrin beta 1 mRNA in adult rat brain. Brain Research.Molecular Brain Research, 55(2), 265276. doi:S0169328X98000072 [pii]
Pizzi, M. A., & Crowe, M. J. (2007). Matrix metalloproteinases and proteoglycans in axonal
regeneration. Experimental Neurology, 204(2), 496-511. doi:S0014-4886(06)00645-5 [pii]

336

Plantman, S. (2012). Osteopontin is upregulated after mechanical brain injury and stimulates
neurite growth from hippocampal neurons through beta1 integrin and CD44. Neuroreport,
23(11), 647-652. doi:10.1097/WNR.0b013e328355380e [doi]
Pokorny, J., & Yamamoto, T. (1981). Postnatal ontogenesis of hippocampal CA1 area in rats.
I. development of dendritic arborisation in pyramidal neurons. Brain Research Bulletin, 7(2),
113-120.
Ponomarev, E. D., Maresz, K., Tan, Y., & Dittel, B. N. (2007). CNS-derived interleukin-4 is
essential for the regulation of autoimmune inflammation and induces a state of alternative
activation in microglial cells. The Journal of Neuroscience : The Official Journal of the Society
for Neuroscience, 27(40), 10714-10721. doi:27/40/10714 [pii]
Poston, M. R., Bailey, M. S., Schwarcz, R., & Shipley, M. T. (1991). Differential
complementary localization of metabolic enzymes for quinolinic acid in olfactory bulb
astrocytes. The Journal of Comparative Neurology, 311(3), 367-374.
doi:10.1002/cne.903110307
Povlishock, J. T. (1992). Traumatically induced axonal injury: Pathogenesis and
pathobiological implications Brain Pathology (Zurich, Switzerland), 2(1), 1-12.
Povlishock, J. T., Becker, D. P., Cheng, C. L., & Vaughan, G. W. (1983). Axonal change in
minor head injury. Journal of Neuropathology and Experimental Neurology, 42(3), 225-242.
Povlishock, J. T., & Christman, C. W. (1995). The pathobiology of traumatically induced
axonal injury in animals and humans: A review of current thoughts. Journal of Neurotrauma,
12(4), 555-564. doi:10.1089/neu.1995.12.555 [doi]
Povlishock, J. T., & Katz, D. I. (2005). Update of neuropathology and neurological recovery
after traumatic brain injury. The Journal of Head Trauma Rehabilitation, 20(1), 76-94.
doi:00001199-200501000-00008 [pii]
Pozzo-Miller, L. D., Gottschalk, W., Zhang, L., McDermott, K., Du, J., Gopalakrishnan, R., . .
. Lu, B. (1999). Impairments in high-frequency transmission, synaptic vesicle docking, and
synaptic protein distribution in the hippocampus of BDNF knockout mice. The Journal of
Neuroscience : The Official Journal of the Society for Neuroscience, 19(12), 4972-4983.
Price, J. L., & Powell, T. P. (1970). An experimental study of the origin and the course of the
centrifugal fibres to the olfactory bulb in the rat. Journal of Anatomy, 107(Pt 2), 215-237.
Pun, P. B., Lu, J., & Moochhala, S. (2009). Involvement of ROS in BBB dysfunction. Free
Radical Research, 43(4), 348-364. doi:10.1080/10715760902751902 [doi]
Purves, D., Augustine, G. J., Fitzpatrick, D., Hall, W. C., LaMantia, A. S., McNamara, J. O., &
White, L. E. (2008). Neuroscience (4th ed.). Sunderland, MA: Sinauer Associates, Inc.

337

Radomski, K. L., Zhou, Q., Yi, K. J., & Doughty, M. L. (2013). Cortical contusion injury
disrupts olfactory bulb neurogenesis in adult mice. BMC Neuroscience, 14, 142-2202-14-142.
doi:10.1186/1471-2202-14-142 [doi]
Raghupathi, R., Graham, D. I., & McIntosh, T. K. (2000). Apoptosis after traumatic brain
injury. Journal of Neurotrauma, 17(10), 927-938. doi:10.1089/neu.2000.17.927 [doi]
Raisman, G. (2001). Olfactory ensheathing cells - another miracle cure for spinal cord injury?
Nature Reviews.Neuroscience, 2(5), 369-375. doi:10.1038/35072576 [doi]
Rajagopalan, S., Meng, X. P., Ramasamy, S., Harrison, D. G., & Galis, Z. S. (1996). Reactive
oxygen species produced by macrophage-derived foam cells regulate the activity of vascular
matrix metalloproteinases in vitro. implications for atherosclerotic plaque stability. The Journal
of Clinical Investigation, 98(11), 2572-2579. doi:10.1172/JCI119076 [doi]
Ralay Ranaivo, H., Zunich, S. M., Choi, N., Hodge, J. N., & Wainwright, M. S. (2011). Mild
stretch-induced injury increases susceptibility to interleukin-1beta-induced release of matrix
metalloproteinase-9 from astrocytes. Journal of Neurotrauma, 28(9), 1757-1766.
doi:10.1089/neu.2011.1799 [doi]
Ramakers, G. J., Verhaagen, J., Oestreicher, A. B., Margolis, F. L., van Bergen en
Henegouwen, P. M., & Gispen, W. H. (1992). Immunolocalization of B-50 (GAP-43) in the
mouse olfactory bulb: Predominant presence in preterminal axons. Journal of Neurocytology,
21(12), 853-869.
Ramlackhansingh, A. F., Brooks, D. J., Greenwood, R. J., Bose, S. K., Turkheimer, F. E.,
Kinnunen, K. M., . . . Sharp, D. J. (2011). Inflammation after trauma: Microglial activation
and traumatic brain injury. Annals of Neurology, 70(3), 374-383. doi:10.1002/ana.22455 [doi]
Ramon-Cueto, A., & Avila, J. (1999). Two modes of microtubule-associated protein 1B
phosphorylation are differentially regulated during peripheral nerve regeneration. Brain
Research, 815(2), 213-226. doi:S0006-8993(98)01092-0 [pii]
Ramon-Cueto, A., & Nieto-Sampedro, M. (1992). Glial cells from adult rat olfactory bulb:
Immunocytochemical properties of pure cultures of ensheathing cells. Neuroscience, 47(1), 213220.
Rangaswami, H., Bulbule, A., & Kundu, G. C. (2004). Nuclear factor-inducing kinase plays a
crucial role in osteopontin-induced MAPK/IkappaBalpha kinase-dependent nuclear factor
kappaB-mediated promatrix metalloproteinase-9 activation. The Journal of Biological
Chemistry, 279(37), 38921-38935. doi:10.1074/jbc.M404674200 [doi]
Rangaswami, H., Bulbule, A., & Kundu, G. C. (2006). Osteopontin: Role in cell signaling and
cancer progression. Trends in Cell Biology, 16(2), 79-87. doi:S0962-8924(05)00313-2 [pii]
Rangaswami, H., & Kundu, G. C. (2007). Osteopontin stimulates melanoma growth and lung
metastasis through NIK/MEKK1-dependent MMP-9 activation pathways. Oncology Reports,
18(4), 909-915.
338

Ranscht, B. (2000). Cadherins: Molecular codes for axon guidance and synapse formation.
International Journal of Developmental Neuroscience : The Official Journal of the International
Society for Developmental Neuroscience, 18(7), 643-651. doi:S0736-5748(00)00030-7 [pii]
Ravel, N., Elaagouby, A., & Gervais, R. (1994). Scopolamine injection into the olfactory bulb
impairs short-term olfactory memory in rats. Behavioral Neuroscience, 108(2), 317-324.
Reden, J., Lill, K., Zahnert, T., Haehner, A., & Hummel, T. (2012). Olfactory function in
patients with postinfectious and posttraumatic smell disorders before and after treatment with
vitamin A: A double-blind, placebo-controlled, randomized clinical trial. The Laryngoscope,
122(9), 1906-1909. doi:10.1002/lary.23405; 10.1002/lary.23405
Redondo-Munoz, J., Ugarte-Berzal, E., Garcia-Marco, J. A., del Cerro, M. H., Van den Steen,
P. E., Opdenakker, G., . . . Garcia-Pardo, A. (2008). Alpha4beta1 integrin and 190-kDa
CD44v constitute a cell surface docking complex for gelatinase B/MMP-9 in chronic leukemic
but not in normal B cells. Blood, 112(1), 169-178. doi:10.1182/blood-2007-08-109249 [doi]
Reeves, T. M., Greer, J. E., Vanderveer, A. S., & Phillips, L. L. (2010). Proteolysis of
submembrane cytoskeletal proteins ankyrin-G and alphaII-spectrin following diffuse brain
injury: A role in white matter vulnerability at nodes of ranvier. Brain Pathology (Zurich,
Switzerland), 20(6), 1055-1068. doi:10.1111/j.1750-3639.2010.00412.x [doi]
Reeves, T. M., Prins, M. L., Zhu, J., Povlishock, J. T., & Phillips, L. L. (2003). Matrix
metalloproteinase inhibition alters functional and structural correlates of deafferentation-induced
sprouting in the dentate gyrus. The Journal of Neuroscience : The Official Journal of the Society
for Neuroscience, 23(32), 10182-10189. doi:23/32/10182 [pii]
Reichardt, L. F., & Tomaselli, K. J. (1991). Extracellular matrix molecules and their receptors:
Functions in neural development. Annual Review of Neuroscience, 14, 531-570.
doi:10.1146/annurev.ne.14.030191.002531 [doi]
Reines, A., Bernier, L. P., McAdam, R., Belkaid, W., Shan, W., Koch, A. W., . . . Dhaunchak,
A. S. (2012). N-cadherin prodomain processing regulates synaptogenesis. The Journal of
Neuroscience : The Official Journal of the Society for Neuroscience, 32(18), 6323-6334.
doi:10.1523/JNEUROSCI.0916-12.2012 [doi]
Ringger, N. C., O'Steen, B. E., Brabham, J. G., Silver, X., Pineda, J., Wang, K. K., . . . Papa,
L. (2004). A novel marker for traumatic brain injury: CSF alphaII-spectrin breakdown product
levels. Journal of Neurotrauma, 21(10), 1443-1456. doi:10.1089/neu.2004.21.1443 [doi]
Rittling, S. R., & Singh, R. (2015). Osteopontin in immune-mediated diseases. Journal of
Dental Research, 94(12), 1638-1645. doi:10.1177/0022034515605270 [doi]
Rivera, S., Khrestchatisky, M., Kaczmarek, L., Rosenberg, G. A., & Jaworski, D. M. (2010).
Metzincin proteases and their inhibitors: Foes or friends in nervous system physiology? The
Journal of Neuroscience : The Official Journal of the Society for Neuroscience, 30(46), 1533715357. doi:10.1523/JNEUROSCI.3467-10.2010 [doi]

339

Roberts, D. J., Jenne, C. N., Leger, C., Kramer, A. H., Gallagher, C. N., Todd, S., . . . Zygun,
D. A. (2013). A prospective evaluation of the temporal matrix metalloproteinase response after
severe traumatic brain injury in humans. Journal of Neurotrauma, 30(20), 1717-1726.
doi:10.1089/neu.2012.2841 [doi]
Rodan, G. A. (1995). Osteopontin overview. Annals of the New York Academy of Sciences,
760, 1-5.
Rodriguez-Gil, D. J., Bartel, D. L., Jaspers, A. W., Mobley, A. S., Imamura, F., & Greer, C.
A. (2015). Odorant receptors regulate the final glomerular coalescence of olfactory sensory
neuron axons. Proceedings of the National Academy of Sciences of the United States of
America, 112(18), 5821-5826. doi:10.1073/pnas.1417955112 [doi]
Romanic, A. M., White, R. F., Arleth, A. J., Ohlstein, E. H., & Barone, F. C. (1998). Matrix
metalloproteinase expression increases after cerebral focal ischemia in rats: Inhibition of matrix
metalloproteinase-9 reduces infarct size. Stroke; a Journal of Cerebral Circulation, 29(5), 10201030.
Rombaux, P., Huart, C., Deggouj, N., Duprez, T., & Hummel, T. (2012). Prognostic value of
olfactory bulb volume measurement for recovery in postinfectious and posttraumatic olfactory
loss. Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of
Otolaryngology-Head and Neck Surgery, 147(6), 1136-1141. doi:10.1177/0194599812459704;
10.1177/0194599812459704
Romme Christensen, J., Bornsen, L., Khademi, M., Olsson, T., Jensen, P. E., Sorensen, P. S., &
Sellebjerg, F. (2013). CSF inflammation and axonal damage are increased and correlate in
progressive multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England), 19(7),
877-884. doi:10.1177/1352458512466929 [doi]
Rosenberg, G. A. (1995). Matrix metalloproteinases in brain injury. Journal of Neurotrauma,
12(5), 833-842. doi:10.1089/neu.1995.12.833 [doi]
Ross, D. T., Graham, D. I., & Adams, J. H. (1993). Selective loss of neurons from the
thalamic reticular nucleus following severe human head injury. Journal of Neurotrauma, 10(2),
151-165. doi:10.1089/neu.1993.10.151 [doi]
Roth, T. L., Nayak, D., Atanasijevic, T., Koretsky, A. P., Latour, L. L., & McGavern, D. B.
(2014). Transcranial amelioration of inflammation and cell death after brain injury. Nature,
505(7482), 223-228. doi:10.1038/nature12808 [doi]
Rothman, B. L., Blue, M. L., Kelley, K. A., Wunderlich, D., Mierz, D. V., & Aune, T. M.
(1991). Human T cell activation by OKT3 is inhibited by a monoclonal antibody to CD44.
Journal of Immunology (Baltimore, Md.: 1950), 147(8), 2493-2499.
Rothman, S. M., & Olney, J. W. (1986). Glutamate and the pathophysiology of hypoxic-ischemic brain damage. Annals of Neurology, 19(2), 105-111. doi:10.1002/ana.410190202 [doi]

340

Rothwell, N. J., & Luheshi, G. N. (2000). Interleukin 1 in the brain: Biology, pathology and
therapeutic target. Trends in Neurosciences, 23(12), 618-625. doi:S0166-2236(00)01661-1 [pii]
Roux, L., Benchenane, K., Rothstein, J. D., Bonvento, G., & Giaume, C. (2011). Plasticity of
astroglial networks in olfactory glomeruli. Proceedings of the National Academy of Sciences of
the United States of America, 108(45), 18442-18446. doi:10.1073/pnas.1107386108;
10.1073/pnas.1107386108
Rutland-Brown, W., Langlois, J. A., Thomas, K. E., & Xi, Y. L. (2006). Incidence of
traumatic brain injury in the united states, 2003. The Journal of Head Trauma Rehabilitation,
21(6), 544-548.
Saatman, K. E., Abai, B., Grosvenor, A., Vorwerk, C. K., Smith, D. H., & Meaney, D. F.
(2003). Traumatic axonal injury results in biphasic calpain activation and retrograde transport
impairment in mice. Journal of Cerebral Blood Flow and Metabolism : Official Journal of the
International Society of Cerebral Blood Flow and Metabolism, 23(1), 34-42.
Saatman, K. E., Bozyczko-Coyne, D., Marcy, V., Siman, R., & McIntosh, T. K. (1996).
Prolonged calpain-mediated spectrin breakdown occurs regionally following experimental brain
injury in the rat. Journal of Neuropathology and Experimental Neurology, 55(7), 850-860.
Sachdeva, R., Theisen, C. C., Ninan, V., Twiss, J. L., & Houle, J. D. (2016). Exercise
dependent increase in axon regeneration into peripheral nerve grafts by propriospinal but not
sensory neurons after spinal cord injury is associated with modulation of regeneration-associated
genes. Experimental Neurology, 276, 72-82. doi:10.1016/j.expneurol.2015.09.004 [doi]
Sadanandappa, M. K., Blanco Redondo, B., Michels, B., Rodrigues, V., Gerber, B.,
VijayRaghavan, K., . . . Ramaswami, M. (2013). Synapsin function in GABA-ergic
interneurons is required for short-term olfactory habituation. The Journal of Neuroscience : The
Official Journal of the Society for Neuroscience, 33(42), 16576-16585.
doi:10.1523/JNEUROSCI.3142-13.2013 [doi]
Saglietti, L., Dequidt, C., Kamieniarz, K., Rousset, M. C., Valnegri, P., Thoumine, O., . . .
Passafaro, M. (2007). Extracellular interactions between GluR2 and N-cadherin in spine
regulation. Neuron, 54(3), 461-477. doi:S0896-6273(07)00291-7 [pii]
Sanchez-Aguilar, M., Tapia-Perez, J. H., Sanchez-Rodriguez, J. J., Vinas-Rios, J. M.,
Martinez-Perez, P., de la Cruz-Mendoza, E., . . . Gordillo-Moscoso, A. (2013). Effect of
rosuvastatin on cytokines after traumatic head injury. Journal of Neurosurgery, 118(3), 669-675.
doi:10.3171/2012.12.JNS121084 [doi]
Sato, M., Chang, E., Igarashi, T., & Noble, L. J. (2001). Neuronal injury and loss after
traumatic brain injury: Time course and regional variability. Brain Research, 917(1), 45-54.
doi:S0006-8993(01)02905-5 [pii]
Sato, W., Tomita, A., Ichikawa, D., Lin, Y., Kishida, H., Miyake, S., . . . Yamamura, T.
(2012). CCR2(+)CCR5(+) T cells produce matrix metalloproteinase-9 and osteopontin in the

341

pathogenesis of multiple sclerosis. Journal of Immunology (Baltimore, Md.: 1950), 189(10),
5057-5065. doi:10.4049/jimmunol.1202026 [doi]
Saulle, M., & Greenwald, B. D. (2012). Chronic traumatic encephalopathy: A review.
Rehabilitation Research and Practice, 2012, 816069. doi:10.1155/2012/816069 [doi]
Scatena, M., Liaw, L., & Giachelli, C. M. (2007). Osteopontin: A multifunctional molecule
regulating chronic inflammation and vascular disease. Arteriosclerosis, Thrombosis, and
Vascular Biology, 27(11), 2302-2309. doi:ATVBAHA.107.144824 [pii]
Scheff, S. W., & Sullivan, P. G. (1999). Cyclosporin A significantly ameliorates cortical
damage following experimental traumatic brain injury in rodents. Journal of Neurotrauma,
16(9), 783-792. doi:10.1089/neu.1999.16.783 [doi]
Scherbel, U., Raghupathi, R., Nakamura, M., Saatman, K. E., Trojanowski, J. Q., Neugebauer,
E., . . . McIntosh, T. K. (1999). Differential acute and chronic responses of tumor necrosis
factor-deficient mice to experimental brain injury. Proceedings of the National Academy of
Sciences of the United States of America, 96(15), 8721-8726.
Scholz, M., Cinatl, J., Schadel-Hopfner, M., & Windolf, J. (2007). Neutrophils and the bloodbrain barrier dysfunction after trauma. Medicinal Research Reviews, 27(3), 401-416.
doi:10.1002/med.20064 [doi]
Schousboe, A., & Waagepetersen, H. S. (2005). Role of astrocytes in glutamate homeostasis:
Implications for excitotoxicity. Neurotoxicity Research, 8(3-4), 221-225.
Schwob, J. E., Youngentob, S. L., Ring, G., Iwema, C. L., & Mezza, R. C. (1999).
Reinnervation of the rat olfactory bulb after methyl bromide-induced lesion: Timing and extent
of reinnervation. The Journal of Comparative Neurology, 412(3), 439-457.
doi:10.1002/(SICI)1096-9861(19990927)412:3<439::AID-CNE5>3.0.CO;2-H [pii]
Scolnick, J. A., Cui, K., Duggan, C. D., Xuan, S., Yuan, X. B., Efstratiadis, A., & Ngai, J.
(2008). Role of IGF signaling in olfactory sensory map formation and axon guidance. Neuron,
57(6), 847-857. doi:10.1016/j.neuron.2008.01.027; 10.1016/j.neuron.2008.01.027
Seidenbecher, C. I., Richter, K., Rauch, U., Fassler, R., Garner, C. C., & Gundelfinger, E. D.
(1995). Brevican, a chondroitin sulfate proteoglycan of rat brain, occurs as secreted and cell
surface glycosylphosphatidylinositol-anchored isoforms. The Journal of Biological Chemistry,
270(45), 27206-27212.
Seidenbecher, C. I., Smalla, K. H., Fischer, N., Gundelfinger, E. D., & Kreutz, M. R. (2002).
Brevican isoforms associate with neural membranes. Journal of Neurochemistry, 83(3), 738746. doi:1183 [pii]
Seipel, D., Oliveira, B. C., Resende, T. L., Schuindt, S. H., Pimentel, P. M., Kanashiro, M.
M., & Arnholdt, A. C. (2010). Toxoplasma gondii infection positively modulates the
macrophages migratory molecular complex by increasing matrix metalloproteinases, CD44 and

342

alpha v beta 3 integrin. Veterinary Parasitology, 169(3-4), 312-319.
doi:10.1016/j.vetpar.2009.12.042 [doi]
Senger, D. R., Perruzzi, C. A., Papadopoulos-Sergiou, A., & Van de Water, L. (1994).
Adhesive properties of osteopontin: Regulation by a naturally occurring thrombin-cleavage in
close proximity to the GRGDS cell-binding domain. Molecular Biology of the Cell, 5(5), 565574.
Serbest, G., Burkhardt, M. F., Siman, R., Raghupathi, R., & Saatman, K. E. (2007). Temporal
profiles of cytoskeletal protein loss following traumatic axonal injury in mice. Neurochemical
Research, 32(12), 2006-2014. doi:10.1007/s11064-007-9318-9 [doi]
Shang, J. L., Cheng, Q., Yang, W. F., Zhang, M., Cui, Y., & Wang, Y. F. (2014). Possible
roles of COX-1 in learning and memory impairment induced by traumatic brain injury in mice.
Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas
Medicas e Biologicas / Sociedade Brasileira De Biofisica ...[Et Al.], 47(12), 1050-1056.
doi:S0100-879X2014001201050 [pii]
Shen, Y., Mani, S., Donovan, S. L., Schwob, J. E., & Meiri, K. F. (2002). Growth-associated
protein-43 is required for commissural axon guidance in the developing vertebrate nervous
system. The Journal of Neuroscience : The Official Journal of the Society for Neuroscience,
22(1), 239-247. doi:22/1/239 [pii]
Shepherd, G. M. (1972). Synaptic organization of the mammalian olfactory bulb.
Physiological Reviews, 52(4), 864-917.
Sherriff, F. E., Bridges, L. R., & Sivaloganathan, S. (1994). Early detection of axonal injury
after human head trauma using immunocytochemistry for beta-amyloid precursor protein. Acta
Neuropathologica, 87(1), 55-62.
Shevde, L. A., & Samant, R. S. (2014). Role of osteopontin in the pathophysiology of cancer.
Matrix Biology : Journal of the International Society for Matrix Biology, 37, 131-141.
doi:10.1016/j.matbio.2014.03.001 [doi]
Shigematsu, K., & McGeer, P. L. (1992). Accumulation of amyloid precursor protein in
damaged neuronal processes and microglia following intracerebral administration of aluminum
salts. Brain Research, 593(1), 117-123. doi:0006-8993(92)91272-G [pii]
Shigemori, Y., Katayama, Y., Mori, T., Maeda, T., & Kawamata, T. (2006). Matrix
metalloproteinase-9 is associated with blood-brain barrier opening and brain edema formation
after cortical contusion in rats. Acta Neurochirurgica.Supplement, 96, 130-133.
Shin, T. (2012). Osteopontin as a two-sided mediator in acute neuroinflammation in rat models.
Acta Histochemica, 114(8), 749-754. doi:10.1016/j.acthis.2012.08.004 [doi]
Shin, T., Ahn, M., Kim, H., Moon, C., Kang, T. Y., Lee, J. M., . . . Hyun, J. W. (2005).
Temporal expression of osteopontin and CD44 in rat brains with experimental cryolesions.
Brain Research, 1041(1), 95-101. doi:S0006-8993(05)00236-2 [pii]
343

Shin, Y. J., Kim, H. L., Choi, J. S., Choi, J. Y., Cha, J. H., & Lee, M. Y. (2011).
Osteopontin: Correlation with phagocytosis by brain macrophages in a rat model of stroke. Glia,
59(3), 413-423. doi:10.1002/glia.21110 [doi]
Shohami, E., Gallily, R., Mechoulam, R., Bass, R., & Ben-Hur, T. (1997). Cytokine production
in the brain following closed head injury: Dexanabinol (HU-211) is a novel TNF-alpha inhibitor
and an effective neuroprotectant. Journal of Neuroimmunology, 72(2), 169-177. doi:S01655728(96)00181-6 [pii]
Shohami, E., Novikov, M., Bass, R., Yamin, A., & Gallily, R. (1994). Closed head injury
triggers early production of TNF alpha and IL-6 by brain tissue. Journal of Cerebral Blood
Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and
Metabolism, 14(4), 615-619. doi:10.1038/jcbfm.1994.76 [doi]
Shubayev, V. I., & Myers, R. R. (2004). Matrix metalloproteinase-9 promotes nerve growth
factor-induced neurite elongation but not new sprout formation in vitro. Journal of Neuroscience
Research, 77(2), 229-239. doi:10.1002/jnr.20160 [doi]
Siddiqui, S., Horvat-Broecker, A., & Faissner, A. (2009). Comparative screening of glial cell
types reveals extracellular matrix that inhibits retinal axon growth in a chondroitinase ABCresistant fashion. Glia, 57(13), 1420-1438. doi:10.1002/glia.20860 [doi]
Sierra, A., Encinas, J. M., Deudero, J. J., Chancey, J. H., Enikolopov, G., Overstreet-Wadiche,
L. S., . . . Maletic-Savatic, M. (2010). Microglia shape adult hippocampal neurogenesis
through apoptosis-coupled phagocytosis. Cell Stem Cell, 7(4), 483-495.
doi:10.1016/j.stem.2010.08.014; 10.1016/j.stem.2010.08.014
Sifringer, M., Stefovska, V., Zentner, I., Hansen, B., Stepulak, A., Knaute, C., . . . Ikonomidou,
C. (2007). The role of matrix metalloproteinases in infant traumatic brain injury. Neurobiology
of Disease, 25(3), 526-535. doi:S0969-9961(06)00287-7 [pii]
Silva, K., Hope-Lucas, C., White, T., Hairston, T. K., Rameau, T., & Brown, A. (2015).
Cortical neurons are a prominent source of the proinflammatory cytokine osteopontin in HIVassociated neurocognitive disorders. Journal of Neurovirology, 21(2), 174-185.
doi:10.1007/s13365-015-0317-3 [doi]
Silver, J., & Miller, J. H. (2004). Regeneration beyond the glial scar. Nature
Reviews.Neuroscience, 5(2), 146-156. doi:10.1038/nrn1326 [doi]
Simpson, K. L. & Sweazey, R. D. (2013). Smell and Taste In: D. E. Haines (4), Fundamental
Neuroscience for Basic and Clinical Applications, (pp. 313-323). Philadelphia, PA: Elsevier
Saunders.
Simoes, D. C., Xanthou, G., Petrochilou, K., Panoutsakopoulou, V., Roussos, C., & Gratziou, C.
(2009). Osteopontin deficiency protects against airway remodeling and hyperresponsiveness in
chronic asthma. American Journal of Respiratory and Critical Care Medicine, 179(10), 894902. doi:10.1164/rccm.200807-1081OC [doi]

344

Singh, M., Ananthula, S., Milhorn, D. M., Krishnaswamy, G., & Singh, K. (2007).
Osteopontin: A novel inflammatory mediator of cardiovascular disease. Frontiers in Bioscience:
A Journal and Virtual Library, 12, 214-221. doi:2059 [pii]
Singh, M., Foster, C. R., Dalal, S., & Singh, K. (2010). Osteopontin: Role in extracellular
matrix deposition and myocardial remodeling post-MI. Journal of Molecular and Cellular
Cardiology, 48(3), 538-543. doi:10.1016/j.yjmcc.2009.06.015 [doi]
Siopi, E., Calabria, S., Plotkine, M., Marchand-Leroux, C., & Jafarian-Tehrani, M. (2012).
Minocycline restores olfactory bulb volume and olfactory behavior after traumatic brain injury in
mice. Journal of Neurotrauma, 29(2), 354-361. doi:10.1089/neu.2011.2055;
10.1089/neu.2011.2055
Siopi, E., Llufriu-Daben, G., Cho, A. H., Vidal-Lletjos, S., Plotkine, M., Marchand-Leroux, C.,
& Jafarian-Tehrani, M. (2013). Etazolate, an alpha-secretase activator, reduces
neuroinflammation and offers persistent neuroprotection following traumatic brain injury in
mice. Neuropharmacology, 67, 183-192. doi:10.1016/j.neuropharm.2012.11.009;
10.1016/j.neuropharm.2012.11.009
Sivanandam, T. M., & Thakur, M. K. (2012). Traumatic brain injury: A risk factor for
alzheimer's disease. Neuroscience and Biobehavioral Reviews, 36(5), 1376-1381.
doi:10.1016/j.neubiorev.2012.02.013 [doi]
Smith, C., Gentleman, S. M., Leclercq, P. D., Murray, L. S., Griffin, W. S., Graham, D. I., &
Nicoll, J. A. (2013). The neuroinflammatory response in humans after traumatic brain injury.
Neuropathology and Applied Neurobiology, 39(6), 654-666. doi:10.1111/nan.12008 [doi]
Smith, L. L., Cheung, H. K., Ling, L. E., Chen, J., Sheppard, D., Pytela, R., & Giachelli, C. M.
(1996). Osteopontin N-terminal domain contains a cryptic adhesive sequence recognized by
alpha9beta1 integrin. The Journal of Biological Chemistry, 271(45), 28485-28491.
Smith, L. L., & Giachelli, C. M. (1998). Structural requirements for alpha 9 beta 1-mediated
adhesion and migration to thrombin-cleaved osteopontin. Experimental Cell Research, 242(1),
351-360. doi:S0014-4827(98)94108-8 [pii]
Smithson, L. J., & Kawaja, M. D. (2010). Microglial/macrophage cells in mammalian
olfactory nerve fascicles. Journal of Neuroscience Research, 88(4), 858-865.
doi:10.1002/jnr.22254; 10.1002/jnr.22254
Smithson, L. J., & Kawaja, M. D. (2010). Microglial/macrophage cells in mammalian
olfactory nerve fascicles. Journal of Neuroscience Research, 88(4), 858-865.
doi:10.1002/jnr.22254 [doi]
Sodek, J., Ganss, B., & McKee, M. D. (2000). Osteopontin. Critical Reviews in Oral Biology
and Medicine : An Official Publication of the American Association of Oral Biologists, 11(3),
279-303.

345

Sofroniew, M. V. (2005). Reactive astrocytes in neural repair and protection. The
Neuroscientist : A Review Journal Bringing Neurobiology, Neurology and Psychiatry, 11(5),
400-407. doi:11/5/400 [pii]
Stahel, P. F., Kossmann, T., Joller, H., Trentz, O., & Morganti-Kossmann, M. C. (1998).
Increased interleukin-12 levels in human cerebrospinal fluid following severe head trauma.
Neuroscience Letters, 249(2-3), 123-126.
Starkov, A. A., Chinopoulos, C., & Fiskum, G. (2004). Mitochondrial calcium and oxidative
stress as mediators of ischemic brain injury. Cell Calcium, 36(3-4), 257-264.
doi:10.1016/j.ceca.2004.02.012 [doi]
Stellwagen, D., & Malenka, R. C. (2006). Synaptic scaling mediated by glial TNF-alpha.
Nature, 440(7087), 1054-1059. doi:nature04671 [pii]
Sternlicht, M. D., & Werb, Z. (2001). How matrix metalloproteinases regulate cell behavior.
Annual Review of Cell and Developmental Biology, 17, 463-516.
doi:10.1146/annurev.cellbio.17.1.463 [doi]
Steuer, E., Schaefer, M. L., & Belluscio, L. (2014). Using the olfactory system as an in vivo
model to study traumatic brain injury and repair. Journal of Neurotrauma, 31(14), 1277-1291.
doi:10.1089/neu.2013.3296 [doi]
Steward, O. (1976). Reinnervation of dentate gyrus by homologous afferents following
entorhinal cortical lesions in adult rats. Science (New York, N.Y.), 194(4263), 426-428.
Steward, O. (1989). Reorganization of neuronal connections following CNS trauma: Principles
and experimental paradigms. Journal of Neurotrauma, 6(2), 99-152. doi:10.1089/neu.1989.6.99
[doi]
Steward, O., Davis, L., Dotti, C., Phillips, L. L., Rao, A., & Banker, G. (1988). Protein
synthesis and processing in cytoplasmic microdomains beneath post-synaptic sites on CNS
neurons. A mechanism for establishing and maintaining a mosaic post-synaptic receptive
surface. Molecular Neurobiology, 2(4), 227-261.
Steward, O., & Falk, P. M. (1986). Protein-synthetic machinery at post-synaptic sites during
synaptogenesis: A quantitative study of the association between polyribosomes and developing
synapses. The Journal of Neuroscience : The Official Journal of the Society for Neuroscience,
6(2), 412-423.
Steward, O., & Vinsant, S. L. (1978). Collateral projections of cells in the surviving entorhinal
area which reinnervate the dentate gyrus of the rat following unilateral entorhinal lesions. Brain
Research, 149(1), 216-222. doi:0006-8993(78)90601-7 [pii]
Steward, O., White, C. W., Cotman, C. W., & Lynch, G. (1976). Potentiation of excitatory
synaptic transmission in the normal and in the reinnervated dentate gyrus of the rat Experimental
Brain Research, 26(4), 423-441.

346

Stone, L. M., Browning, M. D., & Finger, T. E. (1994). Differential distribution of the
synapsins in the rat olfactory bulb. The Journal of Neuroscience : The Official Journal of the
Society for Neuroscience, 14(1), 301-309.
Stroemer, R. P., Kent, T. A., & Hulsebosch, C. E. (1993). Acute increase in expression of
growth associated protein GAP-43 following cortical ischemia in rat. Neuroscience Letters,
162(1-2), 51-54.
Stute, J., Pourmotabbed, T., & Tschesche, H. (2003). Kinetic analysis of the binding of
hemopexin-like domain of gelatinase B cloned and expressed in pichia pastoris to tissue inhibitor
of metalloproteinases-1. Journal of Protein Chemistry, 22(6), 509-514.
Stylli, S. S., Kaye, A. H., & Novak, U. (2000). Induction of CD44 expression in stab wounds
of the brain: Long term persistence of CD44 expression. Journal of Clinical Neuroscience :
Official Journal of the Neurosurgical Society of Australasia, 7(2), 137-140.
doi:10.1054/jocn.1999.0187 [doi]
Su, Z., Chen, J., Qiu, Y., Yuan, Y., Zhu, F., Zhu, Y., . . . He, C. (2013). Olfactory ensheathing
cells: The primary innate immunocytes in the olfactory pathway to engulf apoptotic olfactory
nerve debris. Glia, 61(4), 490-503. doi:10.1002/glia.22450; 10.1002/glia.22450
Sudhof, T. C., & Jahn, R. (1991). Proteins of synaptic vesicles involved in exocytosis and
membrane recycling. Neuron, 6(5), 665-677. doi:0896-6273(91)90165-V [pii]
Sullivan, P. G., Bruce-Keller, A. J., Rabchevsky, A. G., Christakos, S., Clair, D. K., Mattson,
M. P., & Scheff, S. W. (1999). Exacerbation of damage and altered NF-kappaB activation in
mice lacking tumor necrosis factor receptors after traumatic brain injury. The Journal of
Neuroscience : The Official Journal of the Society for Neuroscience, 19(15), 6248-6256.
SUMNER, D. (1964). Post-traumatic anosmia. Brain : A Journal of Neurology, 87, 107-120.
Sun, D. (2014). The potential of endogenous neurogenesis for brain repair and regeneration
following traumatic brain injury. Neural Regeneration Research, 9(7), 688-692.
doi:10.4103/1673-5374.131567 [doi]
Suofu, Y., Clark, J. F., Broderick, J. P., Kurosawa, Y., Wagner, K. R., & Lu, A. (2012).
Matrix metalloproteinase-2 or -9 deletions protect against hemorrhagic transformation during
early stage of cerebral ischemia and reperfusion. Neuroscience, 212, 180-189.
doi:10.1016/j.neuroscience.2012.03.036 [doi]
Sutton, R. L., Lescaudron, L., & Stein, D. G. (1993). Unilateral cortical contusion injury in the
rat: Vascular disruption and temporal development of cortical necrosis. Journal of Neurotrauma,
10(2), 135-149. doi:10.1089/neu.1993.10.135 [doi]

347

Suzuki, H., Ayer, R., Sugawara, T., Chen, W., Sozen, T., Hasegawa, Y., . . . Zhang, J. H.
(2010). Protective effects of recombinant osteopontin on early brain injury after subarachnoid
hemorrhage in rats. Critical Care Medicine, 38(2), 612-618.
doi:10.1097/CCM.0b013e3181c027ae [doi]
Suzuki, H., Hasegawa, Y., Ayer, R., Sugawara, T., Chen, W., Sozen, T., . . . Zhang, J. H.
(2011). Effects of recombinant osteopontin on blood-brain barrier disruption after subarachnoid
hemorrhage in rats. Acta Neurochirurgica.Supplement, 111, 231-236. doi:10.1007/978-3-70910693-8_39 [doi]
Szepesi, Z., Bijata, M., Ruszczycki, B., Kaczmarek, L., & Wlodarczyk, J. (2013). Matrix
metalloproteinases regulate the formation of dendritic spine head protrusions during chemically
induced long-term potentiation. PloS One, 8(5), e63314. doi:10.1371/journal.pone.0063314
[doi]
Takafuji, V., Forgues, M., Unsworth, E., Goldsmith, P., & Wang, X. W. (2007). An
osteopontin fragment is essential for tumor cell invasion in hepatocellular carcinoma. Oncogene,
26(44), 6361-6371. doi:1210463 [pii]
Takahashi, K., Takahashi, F., Tanabe, K. K., Takahashi, H., & Fukuchi, Y. (1998). The
carboxyl-terminal fragment of osteopontin suppresses arginine-glycine-asparatic acid-dependent
cell adhesion. Biochemistry and Molecular Biology International, 46(6), 1081-1092.
Tambuyzer, B. R., Casteleyn, C., Vergauwen, H., Van Cruchten, S., & Van Ginneken, C.
(2012). Osteopontin alters the functional profile of porcine microglia in vitro. Cell Biology
International, 36(12), 1233-1238. doi:10.1042/CBI20120172 [doi]
Tan, T. K., Zheng, G., Hsu, T. T., Lee, S. R., Zhang, J., Zhao, Y., . . . Harris, D. C. (2013).
Matrix metalloproteinase-9 of tubular and macrophage origin contributes to the pathogenesis of
renal fibrosis via macrophage recruitment through osteopontin cleavage. Laboratory
Investigation; a Journal of Technical Methods and Pathology, 93(4), 434-449.
doi:10.1038/labinvest.2013.3 [doi]
Tan, T. K., Zheng, G., Hsu, T. T., Lee, S. R., Zhang, J., Zhao, Y., . . . Harris, D. C. (2013).
Matrix metalloproteinase-9 of tubular and macrophage origin contributes to the pathogenesis of
renal fibrosis via macrophage recruitment through osteopontin cleavage. Laboratory
Investigation; a Journal of Technical Methods and Pathology, 93(4), 434-449.
doi:10.1038/labinvest.2013.3 [doi]
Teasdale, G., & Jennett, B. (1974). Assessment of coma and impaired consciousness. A
practical scale. Lancet (London, England), 2(7872), 81-84. doi:S0140-6736(74)91639-0 [pii]
Teasdale, G., & Jennett, B. (1976). Assessment and prognosis of coma after head injury. Acta
Neurochirurgica, 34(1-4), 45-55.
Tepavcevic, V., Lazarini, F., Alfaro-Cervello, C., Kerninon, C., Yoshikawa, K., Garcia-Verdugo,
J. M., . . . Baron-Van Evercooren, A. (2011). Inflammation-induced subventricular zone
dysfunction leads to olfactory deficits in a targeted mouse model of multiple sclerosis. The
348

Journal of Clinical Investigation, 121(12), 4722-4734. doi:10.1172/JCI59145;
10.1172/JCI59145
Thompson, S. N., Gibson, T. R., Thompson, B. M., Deng, Y., & Hall, E. D. (2006).
Relationship of calpain-mediated proteolysis to the expression of axonal and synaptic plasticity
markers following traumatic brain injury in mice. Experimental Neurology, 201(1), 253-265.
doi:S0014-4886(06)00260-3 [pii]
Thored, P., Heldmann, U., Gomes-Leal, W., Gisler, R., Darsalia, V., Taneera, J., . . . Lindvall,
O. (2009). Long-term accumulation of microglia with proneurogenic phenotype concomitant
with persistent neurogenesis in adult subventricular zone after stroke. Glia, 57(8), 835-849.
doi:10.1002/glia.20810; 10.1002/glia.20810
Togashi, H., Abe, K., Mizoguchi, A., Takaoka, K., Chisaka, O., & Takeichi, M. (2002).
Cadherin regulates dendritic spine morphogenesis. Neuron, 35(1), 77-89.
doi:S0896627302007481 [pii]
Topkoru, B. C., Altay, O., Duris, K., Krafft, P. R., Yan, J., & Zhang, J. H. (2013). Nasal
administration of recombinant osteopontin attenuates early brain injury after subarachnoid
hemorrhage. Stroke; a Journal of Cerebral Circulation, 44(11), 3189-3194.
doi:10.1161/STROKEAHA.113.001574 [doi]
Treggiari, M. M., Schutz, N., Yanez, N. D., & Romand, J. A. (2007). Role of intracranial
pressure values and patterns in predicting outcome in traumatic brain injury: A systematic
review. Neurocritical Care, 6(2), 104-112. doi:10.1007/s12028-007-0012-1 [doi]
Treloar, H. B., Ray, A., Dinglasan, L. A., Schachner, M., & Greer, C. A. (2009). Tenascin-C
is an inhibitory boundary molecule in the developing olfactory bulb. The Journal of
Neuroscience : The Official Journal of the Society for Neuroscience, 29(30), 9405-9416.
doi:10.1523/JNEUROSCI.2356-09.2009 [doi]
Trombley, P. Q., & Shepherd, G. M. (1993). Synaptic transmission and modulation in the
olfactory bulb. Current Opinion in Neurobiology, 3(4), 540-547.
Tsen, G., Halfter, W., Kroger, S., & Cole, G. J. (1995). Agrin is a heparan sulfate
proteoglycan. The Journal of Biological Chemistry, 270(7), 3392-3399.
Tsukatani, T., Fillmore, H. L., Hamilton, H. R., Holbrook, E. H., & Costanzo, R. M. (2003).
Matrix metalloproteinase expression in the olfactory epithelium. Neuroreport, 14(8), 1135-1140.
doi:10.1097/01.wnr.0000075306.76650.bb [doi]
Tuck, E., & Cavalli, V. (2010). Roles of membrane trafficking in nerve repair and regeneration.
Communicative & Integrative Biology, 3(3), 209-214.
Uhm, J. H., Dooley, N. P., Oh, L. Y., & Yong, V. W. (1998). Oligodendrocytes utilize a
matrix metalloproteinase, MMP-9, to extend processes along an astrocyte extracellular matrix.
Glia, 22(1), 53-63. doi:10.1002/(SICI)1098-1136(199801)22:1<53::AID-GLIA5>3.0.CO;2-9
[pii]
349

Urban, N. N. (2002). Lateral inhibition in the olfactory bulb and in olfaction. Physiology &
Behavior, 77(4-5), 607-612.
Vaillant, C., Meissirel, C., Mutin, M., Belin, M. F., Lund, L. R., & Thomasset, N. (2003).
MMP-9 deficiency affects axonal outgrowth, migration, and apoptosis in the developing
cerebellum. Molecular and Cellular Neurosciences, 24(2), 395-408. doi:S1044743103001969
[pii]
Valverde, F., & Lopez-Mascaraque, L. (1991). Neuroglial arrangements in the olfactory
glomeruli of the hedgehog. The Journal of Comparative Neurology, 307(4), 658-674.
doi:10.1002/cne.903070411
Van den Steen, P. E., Dubois, B., Nelissen, I., Rudd, P. M., Dwek, R. A., & Opdenakker, G.
(2002). Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9
(MMP-9). Critical Reviews in Biochemistry and Molecular Biology, 37(6), 375-536.
doi:10.1080/10409230290771546 [doi]
van der Kooij, M. A., Fantin, M., Rejmak, E., Grosse, J., Zanoletti, O., Fournier, C., . . . Sandi,
C. (2014). Role for MMP-9 in stress-induced downregulation of nectin-3 in hippocampal CA1
and associated behavioural alterations. Nature Communications, 5, 4995.
doi:10.1038/ncomms5995 [doi]
Van Hove, I., Lemmens, K., Van de Velde, S., Verslegers, M., & Moons, L. (2012). Matrix
metalloproteinase-3 in the central nervous system: A look on the bright side. Journal of
Neurochemistry, 123(2), 203-216. doi:10.1111/j.1471-4159.2012.07900.x [doi]
Van Hove, I., Verslegers, M., Buyens, T., Delorme, N., Lemmens, K., Stroobants, S., . . .
Moons, L. (2012). An aberrant cerebellar development in mice lacking matrix
metalloproteinase-3. Molecular Neurobiology, 45(1), 17-29. doi:10.1007/s12035-011-8215-z
[doi]
van Velthoven, C. T., Heijnen, C. J., van Bel, F., & Kavelaars, A. (2011). Osteopontin
enhances endogenous repair after neonatal hypoxic-ischemic brain injury. Stroke; a Journal of
Cerebral Circulation, 42(8), 2294-2301. doi:10.1161/STROKEAHA.110.608315 [doi]
VanSaun, M., & Werle, M. J. (2000). Matrix metalloproteinase-3 removes agrin from synaptic
basal lamina. Journal of Neurobiology, 43(2), 140-149. doi:10.1002/(SICI)10974695(200005)43:2<140::AID-NEU4>3.0.CO;2-K [pii]
Verhaagen, J., Oestreicher, A. B., Gispen, W. H., & Margolis, F. L. (1989). The expression of
the growth associated protein B50/GAP43 in the olfactory system of neonatal and adult rats. The
Journal of Neuroscience : The Official Journal of the Society for Neuroscience, 9(2), 683-691.
Verhaagen, J., Oestreicher, A. B., Grillo, M., Khew-Goodall, Y. S., Gispen, W. H., &
Margolis, F. L. (1990). Neuroplasticity in the olfactory system: Differential effects of central
and peripheral lesions of the primary olfactory pathway on the expression of B-50/GAP43 and
the olfactory marker protein. Journal of Neuroscience Research, 26(1), 31-44.
doi:10.1002/jnr.490260105 [doi]
350

Verhaagen, J., Zhang, Y., Hamers, F. P., & Gispen, W. H. (1993). Elevated expression of B50 (GAP-43)-mRNA in a subpopulation of olfactory bulb mitral cells following axotomy.
Journal of Neuroscience Research, 35(2), 162-169. doi:10.1002/jnr.490350206 [doi]
Verslegers, M., Lemmens, K., Van Hove, I., & Moons, L. (2013). Matrix metalloproteinase-2
and -9 as promising benefactors in development, plasticity and repair of the nervous system.
Progress in Neurobiology, 105, 60-78. doi:10.1016/j.pneurobio.2013.03.004 [doi]
von Gertten, C., Flores Morales, A., Holmin, S., Mathiesen, T., & Nordqvist, A. C. (2005).
Genomic responses in rat cerebral cortex after traumatic brain injury. BMC Neuroscience, 6, 69.
doi:1471-2202-6-69 [pii]
Vu, T. H., Shipley, J. M., Bergers, G., Berger, J. E., Helms, J. A., Hanahan, D., . . . Werb, Z.
(1998). MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of
hypertrophic chondrocytes. Cell, 93(3), 411-422. doi:S0092-8674(00)81169-1 [pii]
Wang, G. H., Jiang, Z. L., Li, Y. C., Li, X., Shi, H., Gao, Y. Q., . . . Chen, J. (2011). Freeradical scavenger edaravone treatment confers neuroprotection against traumatic brain injury in
rats. Journal of Neurotrauma, 28(10), 2123-2134. doi:10.1089/neu.2011.1939 [doi]
Wang, H., Lynch, J. R., Song, P., Yang, H. J., Yates, R. B., Mace, B., . . . Laskowitz, D. T.
(2007). Simvastatin and atorvastatin improve behavioral outcome, reduce hippocampal
degeneration, and improve cerebral blood flow after experimental traumatic brain injury.
Experimental Neurology, 206(1), 59-69. doi:S0014-4886(07)00137-9 [pii]
Wang, J., & Tsirka, S. E. (2005). Neuroprotection by inhibition of matrix metalloproteinases in
a mouse model of intracerebral haemorrhage. Brain : A Journal of Neurology, 128(Pt 7), 16221633. doi:awh489 [pii]
Wang, K. K. (2000). Calpain and caspase: Can you tell the difference? Trends in
Neurosciences, 23(1), 20-26. doi:S0166-2236(99)01479-4 [pii]
Wang, K. W., Wang, H. K., Chen, H. J., Liliang, P. C., Liang, C. L., Tsai, Y. D., . . . Lu, K.
(2014). Simvastatin combined with antioxidant attenuates the cerebral vascular endothelial
inflammatory response in a rat traumatic brain injury. BioMed Research International, 2014,
910260. doi:10.1155/2014/910260 [doi]
Wang, K. X., & Denhardt, D. T. (2008). Osteopontin: Role in immune regulation and stress
responses. Cytokine & Growth Factor Reviews, 19(5-6), 333-345.
doi:10.1016/j.cytogfr.2008.08.001 [doi]
Wang, S. H., Celic, I., Choi, S. Y., Riccomagno, M., Wang, Q., Sun, L. O., . . . Kolodkin, A.
L. (2014). Dlg5 regulates dendritic spine formation and synaptogenesis by controlling
subcellular N-cadherin localization. The Journal of Neuroscience : The Official Journal of the
Society for Neuroscience, 34(38), 12745-12761. doi:10.1523/JNEUROSCI.1280-14.2014 [doi]
Wang, S. L., Shi, X. H., Yang, Z., Zhang, Y. M., Shen, L. R., Lei, Z. Y., . . . Fan, D. L.
(2014). Osteopontin (OPN) is an important protein to mediate improvements in the
351

biocompatibility of C ion-implanted silicone rubber. PloS One, 9(6), e98320.
doi:10.1371/journal.pone.0098320 [doi]
Wang, X., Jung, J., Asahi, M., Chwang, W., Russo, L., Moskowitz, M. A., . . . Lo, E. H.
(2000). Effects of matrix metalloproteinase-9 gene knock-out on morphological and motor
outcomes after traumatic brain injury. The Journal of Neuroscience : The Official Journal of the
Society for Neuroscience, 20(18), 7037-7042. doi:20/18/7037 [pii]
Wang, X., & Lo, E. H. (2003). Triggers and mediators of hemorrhagic transformation in
cerebral ischemia. Molecular Neurobiology, 28(3), 229-244. doi:MN:28:3:229 [pii]
Wang, X., Louden, C., Ohlstein, E. H., Stadel, J. M., Gu, J. L., & Yue, T. L. (1996).
Osteopontin expression in platelet-derived growth factor-stimulated vascular smooth muscle
cells and carotid artery after balloon angioplasty. Arteriosclerosis, Thrombosis, and Vascular
Biology, 16(11), 1365-1372.
Wang, X., Xu, L., Wang, H., Zhan, Y., Pure, E., & Feuerstein, G. Z. (2002). CD44 deficiency
in mice protects brain from cerebral ischemia injury. Journal of Neurochemistry, 83(5), 11721179. doi:1225 [pii]
Wang, X. B., Bozdagi, O., Nikitczuk, J. S., Zhai, Z. W., Zhou, Q., & Huntley, G. W. (2008).
Extracellular proteolysis by matrix metalloproteinase-9 drives dendritic spine enlargement and
long-term potentiation coordinately. Proceedings of the National Academy of Sciences of the
United States of America, 105(49), 19520-19525. doi:10.1073/pnas.0807248105 [doi]
Wang, Y. C., Xia, Q. J., Ba, Y. C., Wang, T. Y., LiN, N., Zou, Y., . . . Qi, J. G. (2014).
Transplantation of olfactory ensheathing cells promotes the recovery of neurological functions in
rats with traumatic brain injury associated with downregulation of bad. Cytotherapy, 16(7),
1000-1010. doi:10.1016/j.jcyt.2013.12.009 [doi]
Warren, K. M., Reeves, T. M., & Phillips, L. L. (2012). MT5-MMP, ADAM-10, and Ncadherin act in concert to facilitate synapse reorganization after traumatic brain injury. Journal
of Neurotrauma, 29(10), 1922-1940. doi:10.1089/neu.2012.2383 [doi]
Webb, D. S., Shimizu, Y., Van Seventer, G. A., Shaw, S., & Gerrard, T. L. (1990). LFA-3,
CD44, and CD45: Physiologic triggers of human monocyte TNF and IL-1 release. Science (New
York, N.Y.), 249(4974), 1295-1297.
Weber, G. F., Ashkar, S., & Cantor, H. (1997). Interaction between CD44 and osteopontin as a
potential basis for metastasis formation. Proceedings of the Association of American Physicians,
109(1), 1-9.
Weber, G. F., Ashkar, S., Glimcher, M. J., & Cantor, H. (1996). Receptor-ligand interaction
between CD44 and osteopontin (eta-1). Science (New York, N.Y.), 271(5248), 509-512.
Weber, G. F., & Cantor, H. (1996). The immunology of eta-1/osteopontin. Cytokine & Growth
Factor Reviews, 7(3), 241-248. doi:S1359610196000305 [pii]

352

Weber, G. F., Zawaideh, S., Hikita, S., Kumar, V. A., Cantor, H., & Ashkar, S. (2002).
Phosphorylation-dependent interaction of osteopontin with its receptors regulates macrophage
migration and activation. Journal of Leukocyte Biology, 72(4), 752-761.
Weightman, M. M., Bolgla, R., McCulloch, K. L., & Peterson, M. D. (2010). Physical therapy
recommendations for service members with mild traumatic brain injury. The Journal of Head
Trauma Rehabilitation, 25(3), 206-218. doi:10.1097/HTR.0b013e3181dc82d3 [doi]
Weitz-Schmidt, G. (2002). Statins as anti-inflammatory agents. Trends in Pharmacological
Sciences, 23(10), 482-486. doi:S0165-6147(02)02077-1 [pii]
Werle, M. J., & VanSaun, M. (2003). Activity dependent removal of agrin from synaptic basal
lamina by matrix metalloproteinase 3. Journal of Neurocytology, 32(5-8), 905-913.
doi:10.1023/B:NEUR.0000020631.69804.f5 [doi]
Werner, C., & Engelhard, K. (2007). Pathophysiology of traumatic brain injury. British
Journal of Anaesthesia, 99(1), 4-9. doi:99/1/4 [pii]
White, L. E Jr. (1965). Olfactory bulb projections of the rat. The Anatomical Record, 152, 465–
80.
White, R. E., & Jakeman, L. B. (2008). Don't fence me in: Harnessing the beneficial roles of
astrocytes for spinal cord repair. Restorative Neurology and Neuroscience, 26(2-3), 197-214.
Wiedenmann, B., & Franke, W. W. (1985). Identification and localization of synaptophysin, an
integral membrane glycoprotein of mr 38,000 characteristic of pre-synaptic vesicles. Cell, 41(3),
1017-1028. doi:S0092-8674(85)80082-9 [pii]
Wilczynski, G. M., Konopacki, F. A., Wilczek, E., Lasiecka, Z., Gorlewicz, A., Michaluk, P., .
. . Kaczmarek, L. (2008). Important role of matrix metalloproteinase 9 in epileptogenesis. The
Journal of Cell Biology, 180(5), 1021-1035. doi:10.1083/jcb.200708213 [doi]
Wilhelmsson, U., Li, L., Pekna, M., Berthold, C. H., Blom, S., Eliasson, C., . . . Pekny, M.
(2004). Absence of glial fibrillary acidic protein and vimentin prevents hypertrophy of astrocytic
processes and improves post-traumatic regeneration. The Journal of Neuroscience : The Official
Journal of the Society for Neuroscience, 24(21), 5016-5021. doi:10.1523/JNEUROSCI.082004.2004 [doi]
Williams, R. R., Venkatesh, I., Pearse, D. D., Udvadia, A. J., & Bunge, M. B. (2015).
MASH1/Ascl1a leads to GAP43 expression and axon regeneration in the adult CNS. PloS One,
10(3), e0118918. doi:10.1371/journal.pone.0118918 [doi]
Wirths, O., Breyhan, H., Marcello, A., Cotel, M. C., Bruck, W., & Bayer, T. A. (2010).
Inflammatory changes are tightly associated with neurodegeneration in the brain and spinal cord
of the APP/PS1KI mouse model of alzheimer's disease. Neurobiology of Aging, 31(5), 747-757.
doi:10.1016/j.neurobiolaging.2008.06.011 [doi]

353

Witgen, B. M., Lifshitz, J., & Grady, M. S. (2006). Inbred mouse strains as a tool to analyze
hippocampal neuronal loss after brain injury: A stereological study. Journal of Neurotrauma,
23(9), 1320-1329. doi:10.1089/neu.2006.23.1320 [doi]
Wlodarczyk, J., Mukhina, I., Kaczmarek, L., & Dityatev, A. (2011). Extracellular matrix
molecules, their receptors, and secreted proteases in synaptic plasticity. Developmental
Neurobiology, 71(11), 1040-1053. doi:10.1002/dneu.20958 [doi]
Wolak, T. (2014). Osteopontin - a multi-modal marker and mediator in atherosclerotic vascular
disease. Atherosclerosis, 236(2), 327-337. doi:10.1016/j.atherosclerosis.2014.07.004 [doi]
Wolf, J. A., Stys, P. K., Lusardi, T., Meaney, D., & Smith, D. H. (2001). Traumatic axonal
injury induces calcium influx modulated by tetrodotoxin-sensitive sodium channels. The Journal
of Neuroscience : The Official Journal of the Society for Neuroscience, 21(6), 1923-1930.
doi:21/6/1923 [pii]
Woodcock, T., & Morganti-Kossmann, M. C. (2013). The role of markers of inflammation in
traumatic brain injury. Frontiers in Neurology, 4, 18. doi:10.3389/fneur.2013.00018 [doi]
Wu, A., Ying, Z., & Gomez-Pinilla, F. (2006). Dietary curcumin counteracts the outcome of
traumatic brain injury on oxidative stress, synaptic plasticity, and cognition. Experimental
Neurology, 197(2), 309-317. doi:S0014-4886(05)00327-4 [pii]
Wu, A., Ying, Z., & Gomez-Pinilla, F. (2011). The salutary effects of DHA dietary
supplementation on cognition, neuroplasticity, and membrane homeostasis after brain trauma.
Journal of Neurotrauma, 28(10), 2113-2122. doi:10.1089/neu.2011.1872 [doi]
Wu, B., Ma, Q., Suzuki, H., Chen, C., Liu, W., Tang, J., & Zhang, J. (2011). Recombinant
osteopontin attenuates brain injury after intracerebral hemorrhage in mice. Neurocritical Care,
14(1), 109-117. doi:10.1007/s12028-010-9372-z [doi]
Wu, H., Mahmood, A., Lu, D., Jiang, H., Xiong, Y., Zhou, D., & Chopp, M. (2010).
Attenuation of astrogliosis and modulation of endothelial growth factor receptor in lipid rafts by
simvastatin after traumatic brain injury. Journal of Neurosurgery, 113(3), 591-597.
doi:10.3171/2009.9.JNS09859 [doi]
Wu, L. Z., Liu, X. L., & Xie, Q. Z. (2015). Osteopontin facilitates invasion in human
trophoblastic cells via promoting matrix metalloproteinase-9 in vitro. International Journal of
Clinical and Experimental Pathology, 8(11), 14121-14130.
Wu, X., & Reddy, D. S. (2012). Integrins as receptor targets for neurological disorders.
Pharmacology & Therapeutics, 134(1), 68-81. doi:10.1016/j.pharmthera.2011.12.008 [doi]
Wung, J. K., Perry, G., Kowalski, A., Harris, P. L., Bishop, G. M., Trivedi, M. A., . . .
Atwood, C. S. (2007). Increased expression of the remodeling- and tumorigenic-associated
factor osteopontin in pyramidal neurons of the alzheimer's disease brain. Current Alzheimer
Research, 4(1), 67-72.

354

Xu, J., Xiao, N., & Xia, J. (2010). Thrombospondin 1 accelerates synaptogenesis in
hippocampal neurons through neuroligin 1. Nature Neuroscience, 13(1), 22-24.
doi:10.1038/nn.2459 [doi]
Xuan, W., Agrawal, T., Huang, L., Gupta, G. K., & Hamblin, M. R. (2015). Low-level laser
therapy for traumatic brain injury in mice increases brain derived neurotrophic factor (BDNF)
and synaptogenesis. Journal of Biophotonics, 8(6), 502-511. doi:10.1002/jbio.201400069 [doi]
Yaghmai, A., & Povlishock, J. (1992). Traumatically induced reactive change as visualized
through the use of monoclonal antibodies targeted to neurofilament subunits. Journal of
Neuropathology and Experimental Neurology, 51(2), 158-176.
Yakovlev, A. G., Knoblach, S. M., Fan, L., Fox, G. B., Goodnight, R., & Faden, A. I. (1997).
Activation of CPP32-like caspases contributes to neuronal apoptosis and neurological
dysfunction after traumatic brain injury. The Journal of Neuroscience : The Official Journal of
the Society for Neuroscience, 17(19), 7415-7424.
Yamaguchi, M., Jadhav, V., Obenaus, A., Colohan, A., & Zhang, J. H. (2007). Matrix
metalloproteinase inhibition attenuates brain edema in an in vivo model of surgically-induced
brain injury. Neurosurgery, 61(5), 1067-75; discussion 1075-6.
doi:10.1227/01.neu.0000303203.07866.18 [doi]
Yamaguchi, Y. (2000). Lecticans: Organizers of the brain extracellular matrix. Cellular and
Molecular Life Sciences : CMLS, 57(2), 276-289. doi:10.1007/PL00000690 [pii]
Yamaguchi, Y. (2001). Heparan sulfate proteoglycans in the nervous system: Their diverse
roles in neurogenesis, axon guidance, and synaptogenesis. Seminars in Cell & Developmental
Biology, 12(2), 99-106. doi:10.1006/scdb.2000.0238 [doi]
Yan, L., Borregaard, N., Kjeldsen, L., & Moses, M. A. (2001). The high molecular weight
urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and
neutrophil gelatinase-associated lipocalin (NGAL). modulation of MMP-9 activity by NGAL.
The Journal of Biological Chemistry, 276(40), 37258-37265. doi:10.1074/jbc.M106089200
[doi]
Yan, Y. P., Sailor, K. A., Lang, B. T., Park, S. W., Vemuganti, R., & Dempsey, R. J. (2007).
Monocyte chemoattractant protein-1 plays a critical role in neuroblast migration after focal
cerebral ischemia. Journal of Cerebral Blood Flow and Metabolism : Official Journal of the
International Society of Cerebral Blood Flow and Metabolism, 27(6), 1213-1224.
doi:10.1038/sj.jcbfm.9600432
Yan, Y. P., Sailor, K. A., Vemuganti, R., & Dempsey, R. J. (2006). Insulin-like growth
factor-1 is an endogenous mediator of focal ischemia-induced neural progenitor proliferation.
The European Journal of Neuroscience, 24(1), 45-54. doi:10.1111/j.1460-9568.2006.04872.x
Yang, G., Zhang, Y., Wu, J., Xiong, J., Deng, H., Wang, J., . . . Zhu, Z. (2011). Osteopontin
regulates growth and migration of human nasopharyngeal cancer cells. Molecular Medicine
Reports, 4(6), 1169-1173. doi:10.3892/mmr.2011.538 [doi]
355

Yang, P., Baker, K. A., & Hagg, T. (2005). A disintegrin and metalloprotease 21 (ADAM21) is
associated with neurogenesis and axonal growth in developing and adult rodent CNS. The
Journal of Comparative Neurology, 490(2), 163-179. doi:10.1002/cne.20659 [doi]
Yee, K. K., & Costanzo, R. M. (1995). Restoration of olfactory mediated behavior after
olfactory bulb deafferentation. Physiology & Behavior, 58(5), 959-968. doi:00319384(95)00159-G [pii]
Yee, K. K., & Costanzo, R. M. (1998). Changes in odor quality discrimination following
recovery from olfactory nerve transection. Chemical Senses, 23(5), 513-519.
Yee, K. K., & Rawson, N. E. (2000). Retinoic acid enhances the rate of olfactory recovery
after olfactory nerve transection. Brain Research.Developmental Brain Research, 124(1-2), 129132.
Yong, V. W., Power, C., Forsyth, P., & Edwards, D. R. (2001). Metalloproteinases in biology
and pathology of the nervous system. Nature Reviews.Neuroscience, 2(7), 502-511.
doi:10.1038/35081571 [doi]
Youngentob, S. L., & Margolis, F. L. (1999). OMP gene deletion causes an elevation in
behavioral threshold sensitivity. Neuroreport, 10(1), 15-19.
Youngentob, S. L., Margolis, F. L., & Youngentob, L. M. (2001). OMP gene deletion results
in an alteration in odorant quality perception. Behavioral Neuroscience, 115(3), 626-631.
Yousem, D. M., Geckle, R. J., Bilker, W. B., McKeown, D. A., & Doty, R. L. (1996).
Posttraumatic olfactory dysfunction: MR and clinical evaluation. AJNR.American Journal of
Neuroradiology, 17(6), 1171-1179.
Yu, F., Kamada, H., Niizuma, K., Endo, H., & Chan, P. H. (2008). Induction of mmp-9
expression and endothelial injury by oxidative stress after spinal cord injury. Journal of
Neurotrauma, 25(3), 184-195. doi:10.1089/neu.2007.0438 [doi]
Yu, X. Q., Nikolic-Paterson, D. J., Mu, W., Giachelli, C. M., Atkins, R. C., Johnson, R. J., &
Lan, H. Y. (1998). A functional role for osteopontin in experimental crescentic
glomerulonephritis in the rat. Proceedings of the Association of American Physicians, 110(1),
50-64.
Yui, S., Fujita, N., Chung, C. S., Morita, M., & Nishimura, R. (2014). Olfactory ensheathing
cells (OECs) degrade neurocan in injured spinal cord by secreting matrix metalloproteinase-2 in
a rat contusion model. The Japanese Journal of Veterinary Research, 62(4), 151-162.
Zhang, H., Adwanikar, H., Werb, Z., & Noble-Haeusslein, L. J. (2010). Matrix
metalloproteinases and neurotrauma: Evolving roles in injury and reparative processes. The
Neuroscientist : A Review Journal Bringing Neurobiology, Neurology and Psychiatry, 16(2),
156-170. doi:10.1177/1073858409355830 [doi]

356

Zhang, H., Trivedi, A., Lee, J. U., Lohela, M., Lee, S. M., Fandel, T. M., . . . NobleHaeusslein, L. J. (2011). Matrix metalloproteinase-9 and stromal cell-derived factor-1 act
synergistically to support migration of blood-borne monocytes into the injured spinal cord. The
Journal of Neuroscience : The Official Journal of the Society for Neuroscience, 31(44), 1589415903. doi:10.1523/JNEUROSCI.3943-11.2011 [doi]
Zhang, X., Chen, Y., Jenkins, L. W., Kochanek, P. M., & Clark, R. S. (2005). Bench-tobedside review: Apoptosis/programmed cell death triggered by traumatic brain injury. Critical
Care (London, England), 9(1), 66-75. doi:cc2950 [pii]
Zhang, X., Liu, F., Zhu, G., & Wang, Z. (2014). Recombinant osteopontin attenuates
hyperoxia-induced acute lung injury through inhibiting nuclear factor kappa B and matrix
metalloproteinases 2 and 9. Chinese Medical Journal, 127(23), 4025-4030.
Zhao, Z., Alam, S., Oppenheim, R. W., Prevette, D. M., Evenson, A., & Parsadanian, A.
(2004). Overexpression of glial cell line-derived neurotrophic factor in the CNS rescues
motoneurons from programmed cell death and promotes their long-term survival following
axotomy. Experimental Neurology, 190(2), 356-372. doi:S0014488604002353 [pii]
Zhou, X. H., Brakebusch, C., Matthies, H., Oohashi, T., Hirsch, E., Moser, M., . . . Fassler, R.
(2001). Neurocan is dispensable for brain development. Molecular and Cellular Biology,
21(17), 5970-5978.
Ziebell, J. M., Adelson, P. D., & Lifshitz, J. (2015). Microglia: Dismantling and rebuilding
circuits after acute neurological injury. Metabolic Brain Disease, 30(2), 393-400.
doi:10.1007/s11011-014-9539-y [doi]
Ziebell, J. M., & Morganti-Kossmann, M. C. (2010). Involvement of pro- and antiinflammatory cytokines and chemokines in the pathophysiology of traumatic brain injury.
Neurotherapeutics : The Journal of the American Society for Experimental NeuroTherapeutics,
7(1), 22-30. doi:10.1016/j.nurt.2009.10.016 [doi]
Zuo, J., Ferguson, T. A., Hernandez, Y. J., Stetler-Stevenson, W. G., & Muir, D. (1998).
Neuronal matrix metalloproteinase-2 degrades and inactivates a neurite-inhibiting chondroitin
sulfate proteoglycan. The Journal of Neuroscience : The Official Journal of the Society for
Neuroscience, 18(14), 5203-5211.
Zusho, H. (1982). Posttraumatic anosmia. Archives of Otolaryngology (Chicago, Ill.: 1960),
108(2), 90-92.

357

APPENDIX

358

Appendix A.1 MMP9 activity increases in OPN KO mice following FPI
C57/Bl6 WT mice and OPNKO mice (C57/Bl6 background strain) were subjected to the
identical FPI protocol as for FVB/NJ WT and MMP9KO mice and OB samples used for gelatin
zymography assay. Postinjury intervals of 1, 7 and 21d were sampled and MMP9 activity
measured as in Chapters 3 and 4. In contrast to WT FVB mice, we found no significant
increases in MMP9 activity at 1 or 7d postinjury relative to sham controls, but did find a solid
trend toward increased enzyme activity at 21d, which just missed significance (p=0.057). In
mice lacking OPN, the pattern of MMP9 activity was reversed. We found significant elevation
(2-3-fold over sham controls) at 1 and 7d after FPI. Post hoc tests confirmed that this MMP9
injury response differed between strains. These results make two important points: mild FPI
affects OB in the WT C57/Bl6 and FVB/NJ strains quite differently, and loss of OPN appears to
release MMP9 from some type of activity inhibition after C57/Bl6 brain injury. *p<0.05 Sham
vs. TBI; **p<0.01 Sham vs. TBI; §p<0.05 WT vs KO. N=3-4/group.
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Appendix A.2 OMP expression is not altered in OPN KO mice following FPI
C57/Bl6 WT mice and OPNKO mice (C57/Bl6 background strain) were subjected to the
identical FPI protocol as for FVB/NJ WT and MMP9KO mice and OB samples used for WB
probe for OMP expression as a metric of ORN axon damage. All four survival intervals
sampled in FVB/NJ experiments were used (1, 3, 7 and 21d postinjury). Surprisingly, we found
no effect of mild FPI on OMP expression in either WT or OPNKO cases for any time point
examined. All levels of OMP signal were not different from sham control cases. This result is
consistent with the absence of MMP9 activity in C57/Bl6 WT after FPI, which we posit is due to
attenuated OB injury in these mice relative to FVB/NJ animals. The reason for this difference is
not yet clear. Loss of OPN also had no effect on this lack of OMP response. These data support
further exploration to ascertain what appears to be significant differences in OB response to TBI
between the two mouse strains. N=4-5/group.
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Appendix B.1 MMP9 KO alters in vitro expression of OPN within OB microglia
Mixed neuronal/glial cultures derived from P2 olfactory bulbs of FVB/NJ WT or MMP9KO
mice were grown on MatTek dishes and subjected to confocal labeling for OPN (green) in
combination with microglial marker IBA-1 (red; A,D), astrocyte marker GFAP (red; B,E) or
neuronal marker TUJ1 (red; C,F). Loss of MMP9 failed to alter phenotype or lack of OPN
signal in OB astrocytes or neurons. Interestingly, OB microglia grown in vitro did show OPN
expression (unlike microglia from 3-21d in vivo). MMP9KO also did not change microglial
phenotype, but significantly reduced OPN expression in the glia. These results raise the
possibility that OB microglia may be a source of OPN, expressed at undetectable levels with
IHC, but detectable under the stress of in vitro conditions. Bar=20µm; N=2 separate cultures.
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Appendix C.1 MMP9 KO does not alter OB glomerular cytoarchitecture
A. TEM analysis of OB glomeruli from MMP9 KO naïve cases (n=2) showed axo-dendritic
structure matching that of FVB WT sham controls (compare with Figure 2.9). B. R.O.D.
volume measures from gelatin zymograms (n=3/strain) and WB probe (n=3-4/strain) of FVB
WT and MMP9 KO sham cases revealed no difference in either OB MMP2 activity or white
matter OPN 66kD protein (corpus callosum) between the two sham control groups. These
data support the choice of FVB WT sham as the control for the investigation of OB FVB WT
vs. MMP9 KO strain differences after FPI. Bar=4µm.
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Appendix C.2 Group n values for Chapters 2-4
Animal number for each group subjected to statistical analysis is shown for experiments in
Chapters 2-4.
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Sample sizes
Sham
Day Postinjury
1d 3d 7d 21d

TBI
Day Postinjury
1d 3d 7d 21d

Figure
Number

Experiment

2.1

Spectrin Breakdown Products
150 kD
145 kD
120 kD

7
8
8

4
5
5

4
4
4

5
6
6

7
6
7

8
8
8

5
5
4

4
5
5

2.3

OMP Protein

5

5

5

6

6

5

5

5

2.5

Synapsin-I 80 kD Protein
Synapsin-I 70 kD Protein

4
4

5
5

6
5

7
7

5
5

5
4

5
5

5
5

2.6

Synapsin-II 72 kD Protein
Synapsin-II 58 kD Protein

5
5

4
4

5
5

6
6

6
6

5
5

4
4

5
5

2.7

GAP43 Protein

4

4

6

4

6

5

5

5

3.1

MMP9 Activity
MMP2 Activity

7
5

5
5

4
4

7
7

10
7

5
5

7
8

5
5

3.3

OPN 66 kD Protein

5

4

4

5

5

5

7

4

3.4

OPN 48 kD Protein

5

5

4

5

6

5

5

5

OPN 32 kD Protein

3

5

4

5

5

5

6

5
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Notes:

Sample sizes
Figure
Number

Experiment

3.7

CD44 Protein

4.1
4.2
4.3

Sham
Day Postinjury
1d 3d 7d 21d
3

3

6

Notes:

5

3

5

5

MMP2 Protein (MMP9 KO mice)

3

5

4

4

WT mice as in Fig. 3.1

OPN 66 kD Protein (MMP9 KO
mice)

4

4

5

5

WT mice as in Fig. 3.3

5

5

4

6

WT mice as in Fig. 3.4

5

5

5

6

WT mice as in Fig. 3.4

OPN 48 kD Protein (MMP9 KO
mice)
OPN 32 kD Protein (MMP9 KO
mice)

6

TBI
Day Postinjury
1d 3d 7d 21d

4.5

CD44 Protein (MMP9 KO mice)

4

3

5

5

WT mice as in Fig. 3.7

4.7

OMP Protein (MMP9 KO mice)

5

5

4

4

WT mice as in Fig. 2.3

4

5

5

4

WT mice as in Fig. 2.5

5

4

5

4

WT mice as in Fig. 2.5

5

5

4

5

WT mice as in Fig. 2.6

5

5

5

4

WT mice as in Fig. 2.6

4

5

5

4

WT mice as in Fig. 2.7

4.9

4.10

4.11

Synapsin-I 80 kD Protein (MMP9
KO mice)
Synapsin-I 70 kD Protein (MMP9
KO mice)
Synapsin-II 72 kD Protein
(MMP9 KO mice)
Synapsin-II 58 kD Protein
(MMP9 KO mice)
GAP43 Protein (MMP9 KO mice)
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